Identification and functional analysis of molecular interaction partners of δ-protocadherin family members with putative roles in cancer by Billi, Eleonora
 
 
i 
 
 
 
 
 
 
Academic Year 2015-2016 
 
Ghent University-Faculty of Sciences 
Flanders Institute for Biotechnology 
Inflammation Research Center 
Medical Biotechnology Center 
 
 
 
IDENTIFICATION AND FUNCTIONAL ANALYSIS OF MOLECULAR INTERACTION PARTNERS 
OF ??PROTOCADHERIN FAMILY MEMBERS WITH PUTATIVE ROLES IN CANCER 
 
Eleonora Billi 
 
Thesis submitted in partially fulfilment of the requirements for the degree of 
Doctor of Science: Biochemistry and Biotechnology 
 
Promoters: 
Prof. Dr. Frans van Roy and Prof. Dr. Jan Tavernier 
 
  

iii 
 
 
Identification and functional analysis of molecular interaction partners 
of ??Protocadherin family members with putative roles in cancer 
 
Thesis submitted in partial fulfillment of the requirements for the degree of  
Doctor in Science: Biochemistry and Biotechnology 
 
By Eleonora Billi 
Molecular Cell biology Unit 
Inflammation Research Center (IRC), Ghent University 
Technologiepark 927 
B-9052 Ghent-Zwijnaarde 
 
Cytochine Receptor Lab (CRL) 
Medical Biotechnology Center (MBC), Ghent University 
Albert Baertsoenkaai 3 
B-9000 Ghent 
 
Promoters:         Prof. Dr. Frans van Roy (Ghent University, Belgium) 
Prof. Dr. Jan Tavernier (Ghent University) 
Examination committee: 
 
Chairman: Prof. Dr. Johan Grooten (Ghent University, Belgium) 
Secretary:  Prof. Dr. Geert Berx (Ghent University, Belgium) 
Members: Prof. Dr. Jean Christophe Marine (KU Leuven, Belgium) 
Prof. Dr. Marleen van Troys (Ghent University, Belgium) 
Dr. Irma Lemmens (Ghent University, Belgium) 
Dr. Karl Vandepoele (Ghent University Hospital, Belgium) 
 
  

 
 
v 
 
 
 
 
 
 
 
 
 
 
 
To Alessandro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Il corpo faccia quello che vuole. Io non sono il corpo: io sono la mente. 
 
The body does whatever it wants. I am not my body: I am my mind. 
 
 
 
 
 
Rita Levi Montalcini, 1909-2012, italian neurologist. 
vi 
So Mary, climb in.
 
 
vii 
 
 
Table of contents 
LIST OF ACRONYMS 1 
SUMMARY 5 
SAMENVATTING 7 
INTRODUCTION 11 
Chapter I. ?Protocadherins 13 
I.1 Protocadherins 15 
I.1.1 Overview 15 
I.1.2 History and Classification 18 
I.1.3 Molecular Evolution 20 
I.2 Clustered Protocadherins 22 
I.2.1 Genomic organization and protein structure of clustered protocadherin 22 
I.2.2 Gene expression and protein interactions 23 
I.3 ?Protocadherins 30 
I.3.1 Genomic organization and protein structure of ?PCDH 30 
I.3.2 Expression patterns 36 
I.3.3 ?Pcdhs and cell-cell adhesion 37 
I.3.4 Molecular Interaction Partners and Physiological functions 40 
I.3.4.1 ?1Pcdhs and PP1? 42 
I.3.4.2 ?Pcdhs and RYK 42 
I.3.4.3 Pcdh1 and SMAD3 43 
I.3.4.4 Pcdh7 and TAF1/Set 43 
I.3.4.5 Pcdh8 and TAO2? 44 
I.3.4.6 Pcdhs and NAP1 44 
I.3.4.7 Pcdh18 and DAB1 45 
I.3.4.8 Pcdhs and tissue morphogenesis 46 
I.3.4.9 Pcdhs and brain development 47 
I.3.5 Human diseases and ?Pcdhs 47 
I.3.5.1 ?Pcdhs in Cancer 50 
I.3.5.2 ?Pcdh in Neurological Disorders 52 
viii 
 
I.3.5.2.1 The Autism spectrum disorders (ASDs) and the Rett Syndrome 52 
I.3.5.2.2 Schizophrenia and bipolar disorders 55 
I.3.5.2.3 Epilepsy 55 
I.4 References 57 
 Chapter II. How to investigate Protein-Protein Interactions 71 
II.1 An introduction to Systems Biology and Interactomics 73 
II.2 Protein-protein Interactions (PPIs) 77 
II.2.1 Classification 77 
II.2.2 Posttranslational Modifications (PTM) 79 
II.2.3 Methods to study PPI 80 
II.2.3.1 Genetic methods 81 
II.2.3.1.1 Yeast Two-Hybrid (Y2H) 81 
General 81 
The Y2H method 82 
Pros and cons of the Y2H approach 83 
II.2.3.1.2 Variant Y2H methodologies 84 
II.2.3.1.3 Genetic Protein-Protein Interaction Methods in Prokaryotes: a quick overview 90 
II.2.3.1.4 Two-hybrid systems in mammalian cells 94 
M2H system 94 
Protein fragment complementation assays (PCA) 94 
The mammalian-membrane two-hybrid assay (MaMTH) 97 
Resonance energy transfer system 97 
MAPPIT 99 
II.2.3.2 Biochemical methods 106 
II.2.3.2.1 Coimmunoprecipitation (CoIP) 106 
II.2.3.2.2 Luciferase based CoIP methods 108 
II.2.3.2.3 Affinity Chromatography 109 
Tags 110 
II.2.3.2.4 Proximity-ligation assay (PLA) 111 
II.2.3.2.5 Other biochemical methods 113 
II.2.3.2.6 BioID 114 
II.3 Interactome mapping 116 
II.3.1 Yeast two-hybrid (Y2H) screening 116 
II.3.2 Affinity purification and mass spectrometry 118 
II.3.3 Virotrap and SFINX 120 
ix 
 
II.3.4 Protein fragment Complementation Assay (PCA) 122 
II.3.5 MAPPIT 122 
II.3.5.1 FACS-based approach 123 
II.3.5.2 Array MAPPIT 125 
II.3.5.3 A MAPPIT/MASPIT cell microarray screening platform 126 
II.3.5.4 Interactomics and MAPPIT 128 
II.3.6 Quality of the data 130 
II.3.7 PPIs Databases 132 
II.4 References 134 
  
Scientific problems addressed and Aims of the project 147 
References 151 
RESULTS AND DISCUSSION 153         
Chapter III. Identification of novel intracellular interaction partners of ?PCDH family members 155 
III.1 Introduction 157 
III.2 Materials and Methods 160 
III.2.1 Plasmids 160 
III.2.2 Transient MAPPIT experiment 160 
III.2.3 Array MAPPIT 161 
III.3 RESULTS: MAPPIT technology 162 
III.3.1 cDNA library MAPPIT experiments with PCDH cytoplasmic domains 162 
III.3.2 Array MAPPIT 164 
II.3.2.1 Array MAPPIT analysis for the PCDH11X cytoplasmic domain 165 
II.3.2.2 Array MAPPIT analysis for the PCDH10 cytoplasmic domain 170 
II.3.2.3 Array MAPPIT analysis for the PCDH9 cytoplasmic domain 172 
III.3.3 List of candidates: cross-test 174 
III.3.4 Analysis of the results 179 
II.3.5 Ingenuity Pathway Analysis 185 
III.4 Conclusions 191 
III.5 References 194 
Chapter IV. Biochemical Confirmation and Pathway Analysis 197 
IV.1 Biochemical pull down experiments 199 
x 
IV.1.1 Strategy and initial pilot experiments 199 
IV.1.2 Confirmation CoIP 201 
IV.1.2.1 Materials and methods 201 
IV.1.2.2 Results 202 
IV.2 Interaction candidates descriptions 206 
IV.2.1 MAX-MAD family 205 
IV.2.2 FHL2-FHL3 209 
IV.2.3 PDLIM7 210 
IV.2.4 USPs family 212 
IV.2.5 CUL5 & PMSC1 215 
IV.2.6 Actin-Related proteins 217 
IV.3 Conclusions 222 
IV.4 References 224 
Chapter V. Functional Studies  229 
V.1 Introduction 231 
V.2 Expression Analysis 232 
V.2.1 Background 232 
V.2.2 Methodology 233 
V.2.2.1 PCDH10 KO mice and genotyping 234 
V.2.2.2 Tissues and RNA extraction 235 
V.2.2.3 QRT-PCR 236 
V.2.2.4 RNA Sequencing 240 
V.2.3 Quantitative RT-PCR        241 
V.2.3.1 Pcdhs in brain and lung tissue     241 
V.2.3.2 Expression levels of the candidate ?Pcdh interactors 242 
Myc Target genes 242 
USPs related proteins 246 
FHL family members 246 
Other candidates 246 
V.2.3.3 Conclusions 247 
V.2.4 RNA Sequencing 251 
V.2.4.1 Report and raw data 251 
V.2.4.2 Pcdh10 exons in KO mice: validation of genotype in RNA Seq experiment 253 
V.2.4.3 Software analyses 253 
Ingenuity® Pathway Analysis 254 
xi 
 
MetaCore™ Analysis 264 
V.2.4.4 QPCR experiments on RNA Seq results 268 
V.2.4.5 Conclusions and discussion 271 
V.2.5 Nuclear localization 272 
V.3 USP Family Experiments 273 
V.3.1 Materials and methods 274 
V.3.2 Results 275 
V.4 MAX-MAD pathway 277 
V.5 Migration proliferation and adhesion 279 
V.5.1 Introduction 279 
V.5.2 Quantitative analysis of cell properties of cell lines with induced PCDHs expression 281 
V.5.2.1 Methodology 281 
V.5.2.1.1 Cells 281 
V.5.2.1.2 Cell exclusion zone migration assay and data analysis 282 
V.5.2.1.3 Cell proliferation assay 284 
V.5.2.1.4 Cell adhesion assay 284 
V.5.2.2 Results 285 
V.5.2.2.1 Properties of cell models used to investigate functional effects of PCDHs expression  285  
V.5.2.2.2 Effect of PCDHs expression on cell migration velocity 288 
V.5.2.2.3 Effect of PCDHs expression on cell growth 291 
V.5.2.2.4 Effect of expression of different PCDHs on cell adhesion on collagen 292 
V.5.2.3 Conclusions 293 
V.5.3 WAVE complex and cell migration 294 
V.6 References 296 
 
 CONCLUSIONS 301 
Concluding remarks 310 
References 311 
 
Curriculum vitae                                                                                                                                 315 
Acknowledgments                                                                                                                              317 
 

1 
 
List of acronyms   
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Summary 
The subject of this dissertation is the transmembrane protein family Delta-Protocadherin (?PCDH), 
belonging to the superfamily of cadherin. ?PCDH structure shows an extracellular domain related to 
E-cadherin and a unique intracellular domain. The functions of the members of the family are still
unclear. The family includes 10 members further divided in ??PCDH, ??PCDH and ??PCDH subgroups 
depending on their extracellular cadherin domains number and the presence (or absence, for
Pcdh20) of 2 or 3 conserved motifs (CM) in their cytoplasmic tail. Studies have shown that PCDHs are 
probably rather communicative than adhesive proteins and functional differences may exist
between long and short isoforms. PCDHs have been found mutated in several cancer types and
neurodegenerative diseases. In recent years, direct and indirect evidences have accumulated
indicating an important role for ?PCDHs during tumorigenesis and tumor suppression. Promoter
methylation and transcriptional silencing of ?PCDH genes have been shown to occur in numerous
epithelial cancer types and in multiple hematological malignancies, gliomas and medulloblastomas.
Moreover, loss of expression of various ?Pcdhs (PCDH1, PCDH9, PCDH10, PCDH17 and PCDH20)
often correlates with poor prognosis or with therapy resistance.  For some PCDHs, such as PCDH11Y,
an oncogenic role has been indicated: PCDH11Y expression correlates with the hormone-
independent growth of progressed prostate tumors. Also PCDH7 expression has been linked to
tumor progression rather than to suppression; PCDH7 is an upregulated gene in brain metastasis of
breast cancer models. PCDHs are expressed in high levels in brain so it is not surprising that many of
them are involved in neurological disorders such as autism, schizophrenia, epilepsy and Alzheimer’s
diseases. A role in mental diseases has been shown for PCDH7, PCDH10, PCDH8, PCDH17, PCDH11X
and PCDH11Y, and PCDH18, but the most convincing evidence comes from the correlation of
PCDH19 and epilepsy. PCDHs have been related to other kinds of disease as well, including asthma
and bronchial hyperresponsiveness. 
To investigate the functions of PCDHs, we performed studies of protein-protein interaction, in order 
to identify novel interaction partners of the members of the family. A screening of a collection of 
10000 ORFs was performed with Array mammalian protein-protein interaction trap (MAPPIT) 
technology for PCDH9, PCDH10 and PCDH11X. One-to-one binary MAPPIT assay and Ingenuity 
Pathway Analysis (IPA) were performed to obtain an experimental/literature-based priority list of 
candidate interaction partners for different members of the family. Co-Immunoprecipitation 
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experiments were performed as a biochemical confirmation of the interactions. Investigation of the 
functional relevance of those interactions was not straightforward and still requires additional 
studies. RNA expression levels of identified putative interaction partners and related proteins were 
investigated with qRT-PCR. The tests were performed in RNA extracted from cerebella or total brain 
of wild type (WT) and knock out (KO) mice for Pcdh10. For our experiments, we generated two 
different kinds of KO mice for Pcdh10: the first showing only the short isoforms of the protein 
(Pcdh10long KO), while in the second KO mouse all the isoforms were deleted (Pcdh10all KO). RNA 
from cerebellum has been used as well to perform RNA sequencing experiments: surprisingly the 
Pcdh10all KO mouse did not show change in RNA expression levels. Pcdh10long KO mouse for the 
long isoforms only shows differences in RNA expression levels for several genes if compared with the 
WT. We speculate that in Pcdh10all KO mice, compensation events from the other members of the 
family might occur while in Pcdh10long KO mice the short isoform inhibits the compensation 
mechanisms of the other PCDHs. In support of this we performed qRT-PCR analysis of both ???and 
???Pcdh family members in brain of Pcdh10all KO mice and it revealed an upregulation of Pcdh7, 
Pcdh8, Pcdh11, Pcdh17 and Pcdh18 transcript while none of the ?Pcdhs showed a change in the 
Pcdh10long KO mice. Results of RNA sequencing were analyzed via IPA and Metacore Analysis.  
Beside expression level investigations, studies of ubiquitination were performed, since a lot of 
candidate belongs to the ubiquitin family. We could show that PCDH10, PCDH11X, PCDH1 and 
PCDH7 can be ubiquitinated and that the novel interaction partners do not play a role in this 
mechanism. We also performed tests of protein stability to assess if it would change in presence of 
ubiquitin-proteasome system (UPS) proteins: we could define a range of turnover of about 20-36 
hours but we could not show difference in presence of UPSs. To check the relevance of another 
family of candidates we performed MYC-related tests such as MYC reporter assay and binary 
MAPPIT with doxorubicin to induce the p53 pathway but we could not show difference linked to the 
interaction with PCDHs. We then performed a quantitative analysis of cell properties in cell lines 
with induced PCDH expression: experiments on migration, proliferation and adhesion were carried 
out to investigate if PCDHs play a physiological role in these processes. Our preliminary results are 
promising: we established in vitro cell-based assay to evaluate the effect of PCDH10 or PCDH11X 
expression and this can be used in subsequent assays to test the relevance of the molecular partner 
interactions that we identified. Moreover, via the MAPPIT array we identified interesting proteins as 
putative interaction partners of PCDHs. In this dissertation we attempt to elucidate the relevance of 
these interactions aiming to identify the mechanisms of PCDHs in health and in pathological 
conditions.  
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Samenvatting 
Het onderwerp van deze doctoraatsthesis is de transmembraaneiwitfamilie Delta-Protocadherine 
(?PCDH), die behoort tot de cadherine-superfamilie. ?PCDHs worden gekenmerkt door een uniek 
intracellulair domein en een extracellulair domein dat gerelateerd is tot E-cadherine. Daarnaast is de 
functie van de leden van deze eiwitfamilie tot op heden onbekend. De ?PCDH-familie bevat 11 
leden. Deze zijn verder onderverdeeld in de subgroepen ??PCDH, ??PCDH en ??PCDH op basis van 
hun extracellulaire cadherine-domeinnummers en de aanwezigheid (of in het geval val Pcdh20 de 
afwezigheid) van twee of drie geconserveerde motieven (CM) in hun cytoplasmatische staart. 
Eerdere studies hebben aangetoond dat PCDHs eerder een communicatieve dan adhesieve 
eiwitfunctie hebben en dat er functionele verschillen bestaan tussen de lange en korte isovormen. 
Recent is zowel direct als indirect bewijs aangeleverd dat een belangrijke rol suggereert voor de 
?PCDHs tijdens tumorigenese en tumorsuppressie. Daarbij is aangetoond dat promotormethylatie 
en transcriptiesilencing van de ?PCDH genen in verschillende epitheliale kankertypes en 
hematologische maligniteiten, gliomen en medulloblastomen voorkomen. Bovendien is een 
expressieverlies van verschillende ?Pcdhs (PCDH1, PCDH9, PCDH10, PCDH17 en PCDH20) vaak 
gecorreleerd met therapieresistentie of een slechte prognose. Voor sommige PCDHs wordt er tevens 
een oncogene rol gesuggereerd. Zo is de expressie van PCDH11Y gecorreleerd met de 
hormoononafhankelijke groei van gevorderde prostaattumoren. Ook de expressie van PCDH7 wordt 
eerder gelinkt aan tumorprogressie dan suppressie, aangezien PCDH7 upgereguleerd is tijdens de 
metastasis in de hersenen en in borstkankermodellen. In de hersenen komt tevens een sterke 
expressie van PCDHs voor, waardoor het niet verrassend is dat vele PCDHs eveneens gecorreleerd 
zijn met neurologische storingen zoals autisme, schizofrenie, epilepsie en de ziekte van Alzheimer. 
Hierbij wordt er een belangrijke rol gesuggereerd voor PCDH7, PCDH10, PCDH8, PCDH17, PCDH11X 
and PCDH11Y en PCDH18; hoewel het sterkste bewijs is aangetoond voor de correlatie tussen 
PCDH19 en epilepsie. Verder zijn PCDHs ook in verband gebracht met andere ziektes zoals astma en 
bronchiale hyperreactiviteit.  
In deze doctoraatsthesis zijn de functies van PCDHs verder onderzocht. Meer specifiek zijn er nieuwe 
interactiepartners van de PCDH-familieleden geïdentificeerd met behulp van eiwit-eiwit 
interactieëxperimenten. Er werd een screening uitgevoerd op een collectie van 10000 ORFs met 
behulp van een Array mammalian protein-protein interaction trap (MAPPIT) voor PCDH9, PCDH10 en 
PCDH11X. Vervolgens werd er een prioriteitslijst opgesteld van potentiële interactiepartners voor de 
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verschillende eden van de PCDH-familie. Hiervoor werd gebruik gemaakt van één-op-één binaire 
MAPPIT assays en Ingenuity Pathway Analysis (IPA). Tevens werden er co-immunoprecipitatietesten 
uitgevoerd met als doel een biochemische confirmatie van de geïdentificeerde interacties te 
bekomen. Het bestuderen van de functionele relevantie van deze interacties is evenwel niet voor de 
hand liggend en vergt verder onderzoek. 
Vervolgens werden de RNA expressieniveaus van de geïdentificeerde vermeende interactiepartners 
en de gerelateerde eiwitten onderzocht aan de hand van qRT-PCR. Deze tests werden uitgevoerd 
met RNA geëxtraheerd van de cerebella of van de gehele hersenen van wild type (WT) en knock out 
(KO) muizen voor Pcdh10. Voor deze experimenten werden twee types van KO muizen voor PCDH10 
gebruikt. Het eerste type miste enkel de lange isovorm van het eiwit (Pcdh10long KO), terwijl bij het 
tweede type KO muis alle isovormen gedeletet werden (Pcdh10all KO). RNA van het cerebellum 
werd eveneens gebruikt voor RNA sequencing. Opmerkelijk werd hierbij aangetoond dat de 
Pcdh10all KO muizen geen verschil in RNA expressieniveaus vertoonden, terwijl voor de Pcdh10long 
KO muizen een lange lijst van up- en down-regulatie van genexpressie werd bekomen. Er werd 
daarom gespeculeerd dat in de Pcdh10all KO muizen compensatie-events plaatsvinden door andere 
leden van de PCDH-familie, terwijl voor de Pcdh10long KO muizen de korte isoform deze 
compensatiemechanismen verhindert. Deze hypothese werd bevestigd door de qRT-PCR analyses 
van zowel ?? en ?? Pcdh familieleden van de muizenhersenen. In het geval van Pcdh10all KO muizen 
werd een up-regulatie aangetoond van Pcdh7, Pcdh8, Pcdh11, Pcdh17 en Pcdh18 transcripts, terwijl 
de ?Pcdhs geen verandering vertoonden in de Pcdh10long KO muizen. De resultaten van de RNA 
sequencing werden overigens geanalyseerd via IPA en Metacore Analyses. 
Aangezien vele van de geïdentificeerde kandidaten tot de ubiquitine familie behoren, werd naast de 
expressieniveaus ook de ubiquitinatie bestudeerd. Meer specifiek werden daarbij experimenten 
uitgevoerd in Hek293T cellen tijdens transiënte transfectie. Eerst werd er gecontroleerd of de PCDHs 
geübiquitineerd waren met behulp van PCDH10, PCDH11X, PCDH1 and PCDH7. Zodra er 
ubiquitinatie van de PCDHs geobserveerd werd, werden de cellen gecotransfecteerd met een 
vermeende ubiquitine-gerelateerde interactiepartner. Deze experimenten konden evenwel geen 
verandering aantonen in de ubiquitinatieniveaus in de aanwezigheid van de geselecteerde 
kandidaten. Verder werd er gepostuleerd dat de ubiquitine-proteasome systeem (UPS) eiwitten 
eveneens kandidaat-interactiepartners zijn. Om deze reden werden er proteïnestabiliteitstesten 
uitgevoerd om te achterhalen of de proteïnestabiliteit zou wijzigen in de aanwezigheid van deze UPS 
eiwitten. Hoewel er een omzettingsrange van 20 tot 36 uur werd bekomen, konden er geen 
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verschillen worden vastgesteld tussen de condities met aan- en afwezigheid van de UPS. Om de 
relevantie van ook een andere familie van kandidaten te kunnen onderzoeken, werden eveneens 
MYC-gerelateerde testen uitgevoerd zoals MYC reporter assays en binaire MAPPIT met doxorubicine 
om de p53 pathway te induceren. Hierbij werden echter geen verschillen waargenomen die gelinkt 
zijn met een interactie met PCDHs. Vervolgens werd een kwantitatieve analyse van de 
celeigenschappen in de cellijnen uitgevoerd met behulp van geïnduceerde protocadherine expressie. 
Meer specifiek werden er experimenten uitgevoerd met betrekking tot migratie, proliferatie en 
adhesie, om op deze manier te kunnen onderzoeken of PCDHs een fysiologische rol spelen in deze 
processen. De bekomen preliminaire resultaten van deze thesis zijn veelbelovend. Er werd een in 
vitro cell-gebaseerde assay ontwikkeld om het effect van PCDH10- en PCDH11X-expressie te 
evalueren. Deze assay kan gebruikt worden voor navolgende assays om de relevantie te testen van 
de moleculaire partnerinteracties die in dit doctoraat geïdentificeerd werden. Bovendien werden 
met behulp van de MAPPIT array interessante proteïnen geïdentificeerd die als vermeende 
interactiepartners van PCDHs fungeren. Tenslotte is in deze doctoraatsthesis de relevantie van deze 
interacties verder opgehelderd om zo de mechanismen gerelateerd tot PCDHs in gezonde en 
pathologische omstandigheden te kunnen identificeren. 
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I.1 Protocadherins 
????? ?????????
The cadherin superfamily is a most interesting class of cell-cell adhesion molecules and the members 
are involved in creating and maintaining proper tissue architecture in embryonic development and 
tissue homeostasis1–3. Five major subfamilies form the cadherins superfamily, i.e. classical cadherins 
of type I, cadherins of type II, desmosomal cadherins, protocadherins, and cadherin-related 
molecules4,5. 
The classic cadherins show a single transmembrane domain and a cytoplasmic domain to which 
specific proteins bind collectively called catenins: p120-catenin (p120ctn) binds the cytoplasmic 
domain near the plasma membrane and ?-catenin near the C-terminus. The cadherin complex is 
linked to the actin cytoskeleton via the ?-catenin bind to ?-catenin (Figure 1)6. A mechanotension 
function due to the interaction of cadherin-linked ?-catenin/?-catenin complexes with the acto-
myosin cytoskeleton is a unique characteristic of classic cadherins, if compared with other cell-cell 
adhesion molecules or even other members of the cadherin superfamily. This interaction is 
important for the role played by classic cadherins at cellular junctions, where the generation of force 
contributes critically to morphogenetic and physiologic processes7,8.  
 
 
 
Figure 1 Cadherin domain structure. 
Classic cadherins in vertebrates show 5 extracellular cadherin (EC1-5) repeat domains with EC domain 
interfaces mediated by calcium binding sites. The common interaction with catenins in their cytoplasmic 
domain is shown: this regulates cadherin functions and mediates interaction with the cytoskeleton and 
signaling molecules. All classical cadherins are synthesized with a signal peptide (SP) and pro-region (pro), 
which are removed during protein processing (modified from 9). 
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Extracellular cadherin domains consist of calcium-binding repeats, referred to as ECs. The 
ectodomains of classical cadherins are responsible of their adhesive function as they mediate 
(generally homotypic) trans interactions between molecules on neighboring cells. Cis interactions 
can also occur via parallel interactions with like molecules on the same cell surface10.  
Cadherin-catenin complexes are dysregulated in various pathologies, notably cancer. In fact, the loss 
of function or decreased expression of any element of the cadherin-catenin-complex (CCC) leads to 
loss of the normal tissue architecture. Inappropriate regulation of their expression levels or 
functionality has been observed in human malignancies, in many cases leading to aggravated cancer 
cell invasion and metastasis11,12. 
The prototype cadherin is the Epithelial (E-)cadherin, a classical tumor suppressor that is generally 
downregulated in epithelial cancers leading to tumor growth and invasion13. It has been found to be 
mutated in lobular breast carcinoma and diffuse gastric carcinoma12. Different mechanisms 
depending on stage and type of tumor, can be responsible for the loss of E-cadherin expression, 
including genetic mutation but also hypermetylation of the promoter, silencing of the transcription, 
defective protein processing12. Another member of classic cadherin group, Neural cadherin (N-
cadherin), is generally expressed by mesenchymal cells including neural cells. It has been shown 
repeatedly that cancer cells derived from epithelia inappropriately express N-cadherin. During the 
so-called epithelial-to-mesenchymal transition (EMT) a “cadherin switching” process occurs, where 
the loss of E-cadherin is related to an induction of the expression of N-cadherin with functional 
significance in cancer progression. The disease-related expression of N-cadherin contributes to cell 
motility and invasion of the malignant cells9,12,14. Many more cadherins have meanwhile been 
identified and an increasing number of them have been implicated in cancer as putative tumor 
suppressor or as a proto-oncogenic protein, and in various neurological disorders6,11,15. 
The protocadherin (PCDH) family represents the largest subgroup of the cadherin superfamily5. In 
humans, out of ?110 cadherin superfamily members, 64 are protocadherins15. They are mainly but 
not exclusively expressed in the nervous system. PCDHs differ in various aspects from classic 
cadherins. The main differences with the cadherin family are the number of extracellular cadherin 
(EC) repeats (5 for cadherins and 6/7 for PCDHs) and the lack of conserved tryptophan residues, 
which are present at position 2 (W2) of the EC1 domain in classical type I cadherins, or at positions 2 
and 4 (W2 and W4) of the EC1 of the type II cadherins. Those residues are responsible in classical 
cadherins for the formation of a hydrophobic pocket involved in homophilic binding. Since the 
residues and consequently the pockets are not conserved in PCDHs this might play a role in their 
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inability of forming strong homophilic bonds16. PCDHs can be grouped in clustered PCDHs 
(subdivided in PCDH-?, -? and -?) and nonclustered PCDHs or ?-protocadherins4,5. The subfamily of 
nonclustered PCDHs is well conserved among vertebrates and comprises 10 members in humans. 
While evidence for cancer involvement of clustered PCDHs is sparse, accumulating evidence suggests 
that nonclustered PCDHs can function as tumor suppressors or proto-oncogenes in various non-
neuronal human tumors12. (Reviewed in van Roy, 2014)11.   
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????? ??????????????????????????
When the study of the cadherin superfamily was still at his infancy, attention was also given to the 
identification of cadherin-related molecules such as desmoglein, desmocollins and T-cadherin. In this 
context, for example, Mahoney and colleagues showed in 199117 that the so-called fat tumor 
suppressor gene of Drosophila encodes a cadherin-related protein, a novel big transmembrane 
protein member of the cadherin type. Different studies have been performed to investigate the 
characteristics of the family and it has been shown that the cadherins and cadherin-related proteins 
are expressed in a large number of tissues in different organisms17–19. 
In 1993, Sano et al.18 reported the first PCDH. They introduced the word proto- (from Greek ??????, 
“first”) to indicate them as “first cadherins”. The study was carried out with the aim of identifying 
new members of the cadherin (super) family. To this end, degenerate primers for the extracellular 
repeats of classical cadherins were used in PCR experiments. The newly identified cadherin 
ectodomains were different from the ones of classical cadherins and, since then, isolated in a wide 
range of vertebrates and invertebrates pointing at an ancient, primordial cadherin motif. The family 
was then defined by distinct cadherin repeats in the extracellular domain, which were related to the 
primordial cadherin motif18 (Figure 2A). 
This study aimed at investigating which other molecules could cooperate with classic cadherins in 
cell-cell contact mechanisms. Pc42 and pc43, today known as PCDH1 and PCDH ?C3, were identified 
first, but since then the number of the Pcdh family members increased dramatically: today more 
than 70 different PCDH genes are known in mammals. From this first study some peculiar 
characteristics of the members of the PCDH family were already disclosed. Quite typical is an overall 
structure similar to the one of the classic cadherins but with a completely different cytoplasmic 
domain. Moreover, despite the demonstration of Ca2+-dependent cell adhesion activity, like in the 
case of classic cadherins, it became clear that the adhesion activity of PCDHs is weak as compared 
with the other members of the superfamily.  
PCDHs resemble cadherins structurally: their ectodomains are composed of six or seven EC repeats, 
whereas classic cadherins have five. However, their cytoplasmic domains show no significant 
homology with those of classical cadherins. The family can be subdivided in two large groups based 
on the genomic structure and on sequence homologies: clustered (C) PCDHs (encoded by PCDH-?, -? 
and -? gene clusters) and non-clustered (NC) PCDHs (?PCDHs and PCDH12 (Figure 2B))4,5.?
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Figure 2 Structure and classification of the protocadherin family. 
(A) Schematic overview of structures of the non-clustered and clustered protocadherins compared to the classic 
cadherins. Clustered cadherins show 5 EC domains in the extracellular part and p120-catenin and ?-catenin 
binding sites in the intracellular domain. Protocadherins show 6 or 7 EC domains and the ?1 and ?2 subfamilies 
have 2 or 3 conserved motifs in the intracellular domain. 
(B) Simplified phylogenetic tree of protocadherins from Hulpiau and van Roy, 2009 5 . Figure adapted from 
refs.4,5. 
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????? ???????????????????
The superfamily of Pcdhs has been studied in different ways to disclose their evolutionary origin. 
Considering an Animalia phylogenetic tree, the appearance of a Pcdh has been shown already in 
Nematostella vectensis (NvPcdh) (Figure 3). Analyzing the complete tree leads us to conclude that 
despite the existence of a single NvPcdh, the family mostly evolved in the Deuterostomia branch of 
the evolutionary tree. However, evidence is mounting that among the Protostomians also the 
Lophotrochozoans (e.g. mollusks, annelids) express one to numerous protocadherins, whereas the 
Ecdysozoans (e.g. arthropods, nematodes) have apparently lost the Pcdh genes (5, and personal 
communication by Paco Hulpiau). In vertebrates, we see a maximum expansion of Pcdh genes, 
mainly due to generation of clustered Pcdh genes; in fact mammals, fishes and reptiles have 
between 60 and 80 Pcdh family members20 . 
Figure 3 Metazoan evolution of protocadherins from the sea anemone to man. 
(A) The cladogram shows relations among organisms for which protocadherin family members have been
described5,21. On the right representative examples are shown. NvFAT is the FAT-related ancestor. The blue
dotted lines show the internal deletion which reduce the number of EC domains from 7 to 6 in several modern
Pcdhs. (B) Amino acid alignment of the conserved binding motifs 1 (CM1) and 2 (CM2) in the cytoplasmic
domains of representative protocadherins. See text for more details (figure modified from21).
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To investigate the evolutionary origin of protocadherins, different protein domains from several 
evolutionarily relevant species were compared. For this purpose, Hulpiau & van Roy 21 compared 
four different ancestral Pcdhs: 2 from the lancelet Branchiostoma floridae (AmphiPcdh1 and 
AmphiPcdh2), one from the sea anemone Nematostella vectensis (NvPCDH) and one from the 
California sea hare, Aplysia californica. This study revealed that all 4 have seven EC repeats and also 
conserved cytoplasmic motifs (CMs), highly homologous to those identified in the long isoforms of 
vertebrate ?Pcdhs22. From the analysis of the ectodomain of these ancient Pcdhs, one could propose 
that this ectodomain evolved from the N-terminal ECs of NvFAT protein. Previous studies based on 
the EC1 domains confirmed the close evolutionary relationship between FAT and protocadherins5. 
The loss of part of EC5 and EC6 from a 7EC-Pcdh most likely is responsible for the arising of the 6EC-
Pcdh subfamily. Finally, it is conceivable that the numerous vertebrate C-Pcdhs with 6 EC domains 
were originating from ancestral NC-Pcdhs with 6EC-domains21. 
The molecular evolution of the cadherin superfamily (and consequently of the Pcdh family) has been 
analyzed by comparing the EC1 domains only (while confirmed in a EC1-to-EC7 analysis)5. A circular 
tree of the cadherin superfamily based on these EC1 sequence homologies was generated and 
showed a very clear dissection into two major branches in an evolutionary context 5. The so-called 
EC1 based cadherin major branch could again be subdivided into two groups: C-1 (which includes 
type I and type II cadherins, the desmogleins, the desmocollins and the 7D-cadherin family) and C-2 
(composed by type III cadherins, the FLAMINGO/CELSR cadherins and type IV cadherins). The second 
major branch is called EC1-based cadherin-related major branch (EC1-CrMB) and is composed of ten 
families including Protocadherins, which constitute the largest cadherin family, and has been 
annotated as the Cr-1a sub branch. C-Pcdh and NC-Pcdhs are taking obviously distinct positions in 
the EC1 based phylogenetic tree: Pcdh1, Pcdh7, Pcdh9, Pcdh11 (all delta1 Pcdhs) and Pcdh20 (?0) 
form a compact subbranch, while ?2Pcdhs are spread over different subbranches. Having 6 EC 
domains, they appear to be closer to C-Pcdhs than to ?1Pcdhs. Human PCDH10 and PCDH11 show 
an intriguing evolutionary position within the family members. In the analysis based on EC1 
domains, PCDH10 surprisingly localizes within the C-Pcdh subbranch, suggesting itself as a bridge 
between clustered and non-clustered Pcdhs. Concerning PCDH11, the X- and Y-linked genes which 
encode PCDH11X and PCDH11Y proteins, respectively, share up to 98.3% amino acid sequence 
identity, which means that they have evolutionarily diverged quite recently.  
Another analysis comparing cytoplasmic domains of protocadherins was performed showing, as 
expected, great homology between the three groups of C-Pcdh, and also within the NC-Pcdh 
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subgroup, but no homology at all between the cytoplasmic domain of, respectively, C- and NC 
Pcdhs5. Results are shown in the following circular phylogenetic trees (Figure 4):  
?
 
 
Figure 4 Circular phylogenetic trees of selected members of the protocadherin family. 
The analysis is based on homologies in the cytoplasmic domain. Left: C-Pcdhs, Right NC-Pcdhs (modified from5). 
 
I.2 Clustered Protocadherins 
With 50 members, clustered Pcdhs are the largest Pcdh group, and were first classified as cadherin 
neuronal receptor (CNR) gene family in mouse brain. The many clustered Pcdh genes have been 
found and analyzed in several vertebrate species, including rat, mouse, chicken, zebrafish and man. 
In mammals, the C-PCDH family is divided into three gene clusters: PCDH-?, -? and –?. The main 
characteristic of the C-PCDH gene clusters is a repetition of single large exons encoding multiple 
variants of the (ectodomain + TM + part of the cytoplasmic domain), in combination with shared 
smaller exons, encoding the remaining apart of the cytoplasmic domain (Figure 5). 
????? ??????????????????????????????????????????????????????????????????????
Concerning the genomic organization of C-Pcdh genes, the main characteristic is the presence of a 
region formed of a tandem array of variable exons and a constant region formed by a set of shared 
exons. This constant region (missing in the Pcdh-? subgroup) has been shown to be highly conserved 
among vertebrates. The variable exons are homologous among the Pcdh-?, -? and –? groups and 
encode each time for the six N-terminal EC-like domains, the transmembrane part and a short 
component of the cytoplasmic domain. The structural characterization of the protocadherin EC1 
domain revealed crucial variations including two specific motifs. The first one is a RGD (Arg-Gly-Asp) 
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motif well conserved in Pcdh-? proteins, PCDH17, PCDH19 and CDHR5. Such motif has been shown 
to be involved in integrin-dependent cell adhesion: it is recognized by integrins on their ligands, such 
as fibronectin, fibrinogen, von Willebrand factor and many other large glycoproteins23. The other 
very well conserved sequence in the EC1 domain is a Cys-(X)5-Cys motif, present in all clustered 
PCDHs and in ?2PCDHs but not in classical cadherins. Due to the ability of forming disulfide bounds 
and the probable contribution to formation of cis-tetramers between PCDHs, it could be considered 
as a novel adhesion interface. 
 
Figure 5 Genomic organization of the mouse clustered Pcdh genes.  
The three clusters of mouse Pcdh genes, Pcdh-? (?), Pcdh-? (?), and Pcdh-? (?), are arranged in chromosome 18 
of the mouse. The Pcdh-? and Pcdh-? gene clusters include variable and constant regions, and C-type variable 
exons: Pcdh-?C1 and -?C2, and Pcdh-?C3, -?C4, and -?C5. The conserved sequence element (CSE) is located 
upstream of each transcription start site and is part of the promoter region except for the Pcdh-?C2 promoter.  
The combination of one of the variable regions with three constant region exons produces by cis-splicing a 
mature mRNA. Pcdh-? and -? constant exons encode large parts of the cytoplasmic tails. The small black boxes 
indicate identified DNase I hypersensitive enhancer sites (HS7 and HS5-1) in the Pcdh-? cluster. The ribbon 
diagram of the represented NMR structure of the EC1 domain of Pcdh-?4 is modified from24. Picture modified 
after25. 
 
????? ?????????????????????????????????????????
The gene expression of clustered PCDHs shows a unique mechanism due to the presence of multiple 
alternative promoters, responsible for high molecular diversity in individual neurons. Their 
expression is monoallelic and shows a combinatorial regulation, with the exception of the C-type 
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isoformsa. This was shown in a single-cell analysis of Purkinje cells using multiple RT-PCR reactions26. 
There are different kinds of monoallelic gene expression patterns: random X chromosome 
inactivation in females, imprinting genes from the maternal or the paternal allele or random 
monoallelic gene expression in autosomes. The regulation of clustered-PCDH expression was found 
to follow this last mechanism16. The genomic organization of PCDH-? and PCDH-? gene clusters 
resembles the organization of the immunoglobulin and T-cell receptor gene clusters, which are 
characterized by generation of a great variability in antibody/TCR production. For clustered PCDHs, 
related but novel mechanisms yield similar results. Different models were proposed to explain the 
genomic regulation of clustered PCDH genes and in 2002 two different groups independently 
showed that their transcription starts from multiple promoters upstream of each variable exon and 
that processing of the mRNA occurs via cis-splicing (see also Figure 6). Trans-splicing is also possible 
but uncommon. This shows that the expression regulation already starts at the transcriptional level 
and that differential promoter activation is the key for the diversity of the expression in neurons. 
The result is a sophisticated mechanism for generating single cell diversity in the brain and for the 
production of an important number of isoforms with different extracellular domain sequences27–29.  
Follow up studies, which included the entire protocadherin ??cluster (Pcdh?? A and Pcdh?? B) and the 
C-type variable exons (C1-C5) of the protocadherin ? cluster, showed something even more
surprising. All the C-type isoforms showed biallelic expression. These results indicate that the Pcdh
family shows differential allelic gene regulation in the same gene cluster, which is a unique
characteristic of the family30.
a As it is investigated by phylogenetic studies, PCDH isoforms show high homology between each other; 
despite this, there are exceptions represented by specific components of the PCDH-? gene cluster (PCDH?c1 
and PCDH?c2) and the PCDH-? gene cluster (PCDH?c3, PCDH?c4 and PCDH?c5). Those 5 PCDHs are the so-
called C-type isoforms, which evolutionary diverge from the other members of the family but are similar to 
each other.  
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Figure 6 Schematic overview of the gene regulation and protein interaction of Pcdh-? and Pcdh-?.  
In the nucleus, monoallelic and biallelic types of gene regulation in the Pcdh-? and Pcdh-? clusters can occur in 
a single neuron. In each maternal or paternal allele, the Pcdh-?1 to ?12, Pcdh-?A1 to ?A12, and Pcdh-?B1 to 
?B8 variable exons exhibit monoallelic and combinatorial expression. By contrast, the C-types of the Pcdh?? 
and Pcdh-? variable exons are expressed biallelically. This model is based on expression data obtained from 
single Purkinje cells. Arrows indicate the strongly expressed variable exons. The differential expression of these 
genes in individual neurons may specify neuronal identity in the brain. Outside the nucleus, the co-expression of 
the Pcdh-? (dark blue) and Pcdh?? (light green) proteins greatly enhances their transportation from the 
endoplasmic reticulum to the cell surface, compared with the expression of Pcdh-? alone. A portion of the Pcdh-
? protein forms a heterocomplex with Pcdh-?. These protein complexes increase the combinatorial diversity on 
the cell surface, and contribute to the differential characteristics specifying the individuality of single neurons. 
The Pcdh-? protein interacts with integrins through its RGD motif. The Pcdh-? and Pcdh-? cytoplasmic domains 
are cleaved by ?-secretase after the extracellular domain is cleaved by metalloproteinase. Their C-terminal 
fragments are transported into the nucleus, and then the Pcdh-? fragment may transactivate the Pcdh-? genes. 
The formation of cis-heteromers between Pcdh-? and Pcdh-? alters susceptibility to this processing by 
proteolysis. ?, Pcdh-?; ?, Pcdh-?; EC, extracellular cadherin domain; TM, transmembrane domain; CP, 
cytoplasmic domain; ER, endoplasmic reticulum. (Figure from25). 
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The expression of C-PCDHs is responsible for the regulation of neuronal development in vertebrates. 
Different mechanisms concur to regulate neural circuit formation through specific cell-cell 
interactions. A self-avoidance mechanism is responsible for the repulsion between sibling dendritic 
branches that arise from a single soma: this process is not shown for every kind of neurons but in 
mammals it has been documented in Purkinje cells and some types of retinal cells31–33 (Figure 7). By 
the self-avoidance mechanism, mutual interaction of dendrites of the same neuron is minimized, 
while the same dendrites can interact with the ones of other neurons of the same kind. This process 
is called self/non-self discrimination. 
C-PCDHs have been shown to play a role in both self-
avoidance and self/non-self discrimination33–37, and 
functional studies have been performed for the PCDH-
? and Pcdh? gene clusters38. 
Lefebvre33 and colleagues showed the roles of C-Pcdh genes 
in self avoidance and self/non-self discrimination processes 
using retinal starburst amacrine cells (SACs) and cerebellar 
Purkinje cells, which express Pcdh-? genes and show self-
avoidance. Self avoidance was lost if Pcdhs were removed 
and it resulted in the formation of self synapses (autapses) in 
SACs due to their ability of forming now dendro-dendritic 
synapses. If only one Pcdh isoform was re-expressed, self-
avoidance was reconstituted but not self/non-self 
mechanism: this indicates that the diversity is the base of 
interaction between proximity neurons33,37. 
Besides cell autonomous self avoidance, there are other 
mechanisms responsible for the C-Pcdh-dependent regulation 
of neuronal development. Different studies carried out in 
other CNS cell lines have demonstrated non autonomous 
roles played by the?Pcdh-? members via heteroneuronal and 
neuron-astrocyte interactions. Using a manipulated set of 
Pcdh-? isoforms in the cerebral cortex, for instance, the 
dendrite arborisation has been shown to be promoted by 
Figure 7 Isoneuronal neurites repel one 
another. (A) The branches of a mouse 
cerebellar Purkinje cell dendritic arbor, 
almost never overlap with one another (B) 
The branches of a retinal ganglion cell in 
culture almost never overlap with one 
another. Modified from32. 
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the increased probability of homophilic matching between a neuron and neighboring neurons. If the 
trans-interaction is instead compromised by mismatching of the isoforms, the arborisation cannot 
develop and the result is similar to the one seen in Pcdh-??KO neurons where self avoidance is 
impaired????
An in vitro study on leukemia cells K562, which do not express endogenous PCDH-?, has revealed the 
existence of strictly homophilic trans interactions for PCDH-?39. Compared to classical cadherins, 
PCDHs show more weak trans-homophilic adhesion activity. In a protein coated bead aggregation 
assay, a mutated neural cadherin (NCAD), where the EC1 domain (responsible for the interaction) 
was replaced with the EC1 domain of CNR/PCDH-?4, loses its adhesive property, meaning that the 
difference in structure of the EC1 domain is the main responsible for the weak trans-homophilic 
adhesion activity of PCDHs24. In contrast, cis homodimers40,41 and cis heterodimers42 of C-PCDHs 
have been observed on the cell surface and it has been proposed that PCDHs acquire the trans-
homophilic adhesion activity after the formation of complexes with other PCDHs. Cis-tetramers have 
been shown to be the unit for homophilic trans interaction by C-PCDHs: the interactions involve 
different isoforms producing promiscuous cis-multimers with no isoform specificity. For the 22 
possible isoforms of PCDH-?s, about 234,256 distinct interacting surfaces can be predicted, which 
offers an enormous diversity of possible interactions on the cell surface 39. PCDH-? have been shown 
to form complexes also with PCDH-? and PCDH-? isoforms43.  
Cells expressing different combinations of the 3 groups of C-PCDHs have been shown to aggregate 
through homophilic trans-interactions between the specific PCDHs expressed, but they fail to 
aggregate if the combination differs even for one isoform in the combination, showing that cell-cell 
adhesion will occur only between cells expressing exactly the same combination of C-PCDHs (Figure 
8)44. 
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Figure 8 Cell–cell adhesion is induced only between cells expressing the same combination of clustered 
protocadherins 
The figure on the left shows that only the same combination of isoforms can lead to cell-cell adhesion. Pcdh-?? 
isoform alone does not induce adhesion, probably because in this context it is not recruited at the membrane. 
On the right, it is shown that Pcdh-?? Pcdh-?, Pcdh-??and the C isoforms interact with a cell with the same 
combination of isoforms: one mismatch is enough to compromise the adhesion. (Modified after 45). 
For C-PCDHs, the EC1 domain is not the responsible region for the specificity of the interaction while 
the specificity can be mediated by EC2/344,46,47. Two independent studies have reported the crystal 
structure of mouse ?-, ?-, and ?-Pcdh fragments which include EC1–347,48: those fragments were 
monomeric in solution and both studies indicated that in contrast to classical cadherins, the trans 
adhesion between cells depends on the EC1–EC4 domains. Cell aggregation experiments in human 
immortalized myelogenous leukemia line (K562) have shown that C-PCDHs interact in antiparallel 
orientation through the formation of zipper-like cis homo- or hetero-dimeric assemblies. 
In addition to their cell-cell adhesion activity, clustered PCDHs play a role in mediating intracellular 
signaling. Their intracellular domain is different from the one of the classical cadherins, and lacks the 
conserved catenin binding sites. The cytoplasmic domains of PCDH-? and PCDH-??interact with two 
tyrosine kinases, proline-rich tyrosine kinase 2 PYK2 and focal adhesion kinase (FAK)49. These 
interactions result in the inhibition of the kinase activities in vitro and in vivo. The activity of PYK2 is 
upregulated in neurons of Pcdh-? KO mice. Studies conducted in mice, zebrafish and chicken have 
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shown that overexpression of PYK2 or ablation of PCDH-? induce apoptosis of neurons49,50 indicating 
that the interaction correlates with the cell survival of a subset of neurons. The interaction with FAK 
is also responsible for positive regulation of dendritic arborisation in cortical neurons46: in neurons 
lacking Pcdh-? the dendrite arborisation is disrupted due to over activity of FAK and PKC. This 
function is regulated by PKC mediated phosphorylation of a C-terminal serine (Ser-922) within the 
Pcdh- ? constant domain51. 
Furthermore, both PCDH-? and PCDH-? proteins bind the receptor tyrosine kinase Ret, which is 
required for the stabilization and phosphorylation of their intracellular domains. Several more 
proteins have been reported to interact with protocadherins, and include phosphatases, kinases, 
adhesion molecules and synaptic proteins. Taken together these findings suggest that PCDHs can 
form big heteromeric complexes with very different functions, which need to be studied in more 
detail in order to be fully elucidated. 
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I.3 ?-Protocadherins
In man and mouse, the ?-Protocadherin subfamily comprises 10 members, which can be subdivided 
into ?0PCDH (one member, PCDH20), ?1PCDHs (four members: PCDH1, PCDH7, PCDH9 and 
PCDH11X/Y), and ?2PCDHs (five members: PCDH8, PCDH10, PCDH17, PCDH18 and PCDH19) (Table 
1). This subdivision is based on overall sequence homology, number of EC repeats (seven versus six), 
and conservation of specific amino acid motifs in cytoplasmic domains. The ?1 and ?2PCDHs are 
expressed as both short and long isoforms, which are generated by alternative splicing and differ 
from each other in the size of their cytoplasmic domain. All the long isoforms show highly conserved 
motifs in their cytoplasmic domains (CM1 and CM2 for ?1 and ?2PCDHs; plus an additional CM3 for 
?1PCDHs only) (Figure 2)4. 
Table 1 Human ?Pcdhs family members  
HGNC ID Approved 
Symbol 
Approved Name Previous 
Symbols 
Synonyms Chromosome 
8655 PCDH1 protocadherin 1 pc42 5q31.3 
13404 PCDH10 protocadherin 10 OL-PCDH, KIAA1400 4q28.3 
8656 PCDH11X protocadherin 11 X-
linked 
PCDH11 PCDH-X, PCDHX, 
PPP1R119 
Xq21.3 
15813 PCDH11Y protocadherin 11 Y-
linked 
PCDH22 PCDHY Yp11.2 
8657 PCDH12 protocadherin 12 VE-cadherin-2 5q31.3 
14267 PCDH17 protocadherin 17 PCDH68, PCH68 13q21.1 
14268 PCDH18 protocadherin 18 KIAA1562, PCDH68L 4q28.3 
14270 PCDH19 protocadherin 19 EFMR KIAA1313, EIEE9 Xq22.1 
14257 PCDH20 protocadherin 20 PCDH13, FLJ22218 13q21 
8659 PCDH7 protocadherin 7 BH-Pcdh, PPP1R120 4p15 
8660 PCDH8 protocadherin 8 PAPC, ARCADLIN 13q21.1 
8661 PCDH9 protocadherin 9 13q21.32 
????? ???????????????????????????????????????????????????
The genomic organization of non-clustered protocadherin genes is peculiar and shows obvious 
differences with the classic cadherin gene structure. The first main difference between the two 
subfamilies of cadherins is the way in which the EC domains are encoded: in protocadherins (both 
clustered and non-clustered) a single large exon is responsible for encoding the extracellular domain, 
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the transmembrane domain and part of the cytoplasmic one, while for classical cadherins there are 
many smaller exons involved. Another difference is the lack of a prodomainb in Pcdhs, while this is 
encoded by classical cadherin genes. ?Pcdhs genes are organized in the same way as the other 
members of the Pcdh gene family but show also additional unique characteristics concerning their 
cytoplasmic domain; this differs not only from classical cadherins but also from C-PCDHs due to the 
presence of conserved motifs (CM1-CM3). CM1 and, when it is present, also CM3 are encoded by 
the same exon, while CM2 is encoded by an exon encoding also the 3’-UTR. Alternative splicing 
occurs often and also intraexonic splicing occurs, which produces a large number of protein isoforms 
(Figure 9). Interestingly, different PCDHs show different degrees of splice variation. PCDH11 X/Y 
(Figure 9D) are expressed in a large number of different isoforms and this is due to the variety of 
transcripts, using various short exons from a larger set included in their gene. The ‘long’ isoform of 
PCDH11X shows a sequence of 11 aa repeated 9 times, and comprising two proline residues per 
repeat: this is the region where PCDH11X and PCDH11Y show the biggest difference52. PCDH11Y is 
encoded by the human genome only (chromosome Y), due to a recent duplication from the X-
chromosome encoded PCDH11X which occurred after the divergence between chimpanzees and 
humans53,54. Only two isoforms are known in human for PCDH10 proteins, called ‘long’ and ‘short’ 
(Figure 9F). If no transcript splicing occurs the short isoform is produced, which shows a short 
cytoplasmic tail in comparison with the long isoform and which lacks the two CMs. The PCDH10 long 
isoform, generated by alternative mRNA splicing, includes both CMs in its elongated cytoplasmic 
domain. In mice, Pcdh10 produces four protein isoforms. PCDH1 (Figure 9A) shows a lot of different 
transcripts in primary human bronchial epithelial cells including a new isoform lacking almost the 
entire extracellular domain: such a large number of different transcripts in the same cell type may be 
an indication of a big variety of functions covered by the different isoforms55. Furthermore, all 
?Pcdhs share the presence of a cysteine at the beginning of the cytoplasmic domain5. In PCDH1 and 
other PCDHs this cysteine is palmitoylated which might be necessary for protein trafficking and 
compartmentalization in polarized neurons56. If the modification does not occur, PCDH1 is not 
localized at the plasma membrane (Karl Vandepoele, not published), but when only this particular 
cysteine residue is mutated, the protein localization is still correct pointing at a redundancy of 
residues important for this specific function.  
  
                                                          
b Prodomain: classical cadherins are activated through cleavage in the late Golgi of a prosequence. This domain 
corresponds to the folded region of the prosequence, and is termed the prodomain. The prodomain shows 
structural resemblance to the cadherin domain, but lacks all the features known to be important for cadherin-
cadherin interactions215. 
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Figure 9 Gene structure and alternative transcripts of the ?-protocadherin family in man and mouse.  
Results are basically identical for human (isoform numbers before slash signs) and mouse (isoform numbers 
after slash signs), although some significant differences exist. If a particular transcript does not exist (or has not 
been identified yet) in one of the two species, this is indicated by a minus sign before or after the slash sign. 
Variant annotations between parentheses refer to the literature, but lack overall consistency. Question marks 
denote presumable transcripts that need to be validated experimentally in one of the two species. All 
transcripts shown are protein coding. For each transcript the protein coding part is indicated by black bars, 
whereas UTRs are indicated by open bars, and splicing events by an angled line. Exons are drawn to scale and 
numbered as indicated. Exon #1 is defined as the exon that contains the standard start codon (indicated by 
ATG); alternatively used exons are indicated by the extension ‘a’; exons that are elongated by read-through in 
the neighboring intron or that become shortened by an intraexonic splice acceptor are indicated by the 
extension ‘.1’. Exons that occur only in either the human or the mouse genome are indicated by ‘h’ and ‘m’, 
respectively. Gray boxes represent exons; the intervening line represents intronic sequence (the latter not at 
scale). Black boxes represent coding sequences in the transcripts, white boxes represent 5’ or 3’ untranslated 
regions. A, alanine-rich region; CM1, CM2 and CM3, conserved motifs; CD, cytoplasmic domain; EC, sequences 
encoding the extracellular cadherin repeats; MPED, Membrane proximal extracellular domain; G, glycine-rich 
region; SR, serine-rich region; TM, sequence encoding the transmembrane domain. (A-D) ?1-protocadherins. 
(A) Protocadherin-1 genes (human PCDH1, mouse Pcdh1) and derived transcripts: 1, truncated transcript; 2, 
long transcript. According to the literature57, the human protein starts with the ATG in exon #1a, which is not 
conserved in mouse or other species. In contrast, the first in-frame ATG in exon #1 is conserved across many 
species including human and shows a better Kozak consensus sequence22. Recently, various novel PCDH1 
transcripts have been identified in primary bronchial epithelium of patients with asthma58. Novel exons were 
identified on the 5’ end of PCDH1, which were connected to the short or long isoform or both. Variations on the 
3’ end of PCDH1 can result in alternative usage of CM2. (B) Protocadherin-7 genes (human PCDH7, mouse 
Pcdh7) and derived transcripts: 1 and 2, two truncated transcripts, only differing at the 3’ end; 3, differs from 
the transcript 4 by a shortened exon 2. (C) Protocadherin-9 genes (human PCDH9, mouse Pcdh9) and derived 
transcripts: 1, short transcript; 2, long transcript; 3, transcript with additional exon #2; 4, transcript with 
variant exon #3.1, lacking CM3 and CM1. (D) Protocadherin-11 genes (human PCDH11X, mouse Pcdh11) and 
derived transcripts: 1 or a, short CP domain; 2 or b, use of alternative exon #3a; 3 or c, full-length transcript; 4 
or d, idem without exon #4; 5, use of alternative human exon #h5a resulting in frameshift; 6, neither exon #4 
nor exon #6; 7, neither exon #3 nor exon #4; 8, no exon #6; 9, use of alternative mouse exon #m6a, resulting in 
premature stop codon and loss of CM2; 10, as transcript 9 but with exon #4 skipped. The human paralog 
PCDH11Y is not depicted here. (E-I) ?2-protocadherins. (E) Protocadherin-8 genes (human PCDH8, mouse 
Pcdh8) and derived transcripts: transcript 1 differs from transcript 2 by a shortened exon #1. (F) Protocadherin-
10 genes (human PCDH10, mouse Pcdh10) and derived transcripts: 1, short transcript; 2-4, long transcripts only 
differing at their 3’ end. (G) Protocadherin-17 genes (human PCDH17, mouse Pcdh17) and derived transcripts: 
1, short transcript; 2, long transcript; 3, transcript with additional exon #4. (H) Protocadherin-18 genes (human 
PCDH18, mouse Pcdh18) and derived transcript: 1, long transcript. (I) Protocadherin-19 genes (human PCDH19, 
mouse Pcdh19) and derived transcripts: 1, transcript skipping exons #2, #3 and #4; 2, transcript with additional 
exons #3 and #4; 3, idem with additional exon #2. (J) ?0-protocadherin. Protocadherin-20 genes (human 
PCDH20, mouse Pcdh20) and derived transcript: 1, transcript with short CP, lacking CM1, CM2 and CM3. 
(Figure from Kahr I., PhD Thesis, adapted from22).  Assembly releases of the human genome (GRC37/hg19) and 
of the mouse genome (GRCm38/mm10), available at UCSC Genome Browser Gateway (http://genome-
euro.ucsc.edu/), further extended with unpublished data obtained in van Roy's laboratory. 
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????? ???????????????????
?-Protocadherins, like other Pcdhs, are mainly expressed in the nervous system but most (if not all) 
of them are also expressed in non-neuronal tissues4. Considering time and space, each member of 
the family shows a specific expression pattern. As already mentioned, most ?Pcdhs are expressed as 
different isoforms but generally, published studies do not discriminate between them. The pattern 
of expression differs considerably in different models for each Pcdh. We might use the expression 
pattern of Pcdh10 as a representative example: PCDH10 is expressed mainly in brain and in the 
nervous system in general, including the olfactory and the limbic system (therefrom their original 
name OL-PCDH)59, but different PCDH10 mRNA expression levels can be found also in most of the 
fetal and adult tissues in humans60,61; in contrast in mouse, Pcdh10 is expressed mainly in brain, 
spinal cord and eye62. The spatiotemporal differences in the expression of the various family 
members have been shown in a representative study in chicken cochleae63: at embryonic day 3 (E3) 
the first set of ?Pcdhs can be identified. From E11 on, various Pcdhs show different localizations on 
the discrete cell types of the cochleae: Pcdh1 is expressed by spindle-shaped cells and acoustic 
ganglion cells; Pcdh7 and Pcdh17 are exclusively expressed in supporting cells, cuboidal cells, hyaline 
cells and acoustic ganglion cells, while Pcdh9 is expressed by acoustic ganglion cells; Pcdh8 is 
expressed in hair cells, spindle-shaped cells and acoustic ganglion cells; Pcdh10 mRNA is expressed in 
spindle-shaped cells and acoustic ganglion cells at later stages. mRNAs of Pcdh1, Pcdh18 and Pcdh19 
are also expressed in blood vessels of the cochlea64. Taken together those data indicate that the 
differential expression of several ?Pcdhs in the embryonic and fetal stages in different species might 
play important functional roles in embryonic development and tissue morphogenesis. In the nervous 
system, the main expression system common for all members of the ?Pcdh family, different studies 
have shown a large range of different distribution patterns of ?Pcdhs in time and space in the brain. 
Pcdh expression changes following the phases of brain development and it is specific for the 
different layers in the cerebral cortex65,66. The adhesion properties and restricted expression 
patterns of ?Pcdhs have led to the speculation that they are involved in developmental processes 
such as brain nucleus formation, axon migration, and synapse formation15. The complexity of 
neuronal identity and neuronal networks in the cerebral cortex may be due to the combinatorial 
occurrence in single neurons of discrete cadherin and protocadherin molecules. Indeed, 
combinatorial expression of molecules belonging to the same cadherin family can contribute to the 
molecular specification of individual cells and their mutual connections. Krishna and colleagues 
demonstrated a combinatorial molecular code in single neurons by checking the cadherin expression 
in the somatosensory cortex of the adult mouse67. ?Pcdhs show the same combinatorial behavior 
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also in the subregions of adult hippocampus and dentate gyrus along the septotemporal axis: the 
expression patterns of Pcdh1, Pcdh9, Pcdh10 and Pcdh20 showed septal preferences, whereas the 
expression patterns of Pcdh8, Pcdh11, Pcdh17 and Pcdh19 showed temporal preferences, pointing 
at their involvement in the formation of hippocampal circuits68. Concerning previous stages, such as 
early post-natal stages, other studies showed region specific patterns of ?Pcdh expression in 
developing rat brain66. NC-Pcdhs were analyzed in rat brain using in situ hybridization. Pcdh7 and 
Pcdh20 mRNAs have a common expression pattern in the somatosensory and visual cortices, Pcdh11 
and Pcdh17 mRNAs are mostly expressed in the motor and auditory cortices, and Pcdh9 mRNA 
shows higher expression in the motor and main somatosensory cortices, confirming their region 
specific expression patterns. This study was performed in the cerebral cortex during the early 
postnatal stage (P3), which is relevant and crucial for the network formation, and suggests a role for 
?Pcdhs in the establishment of selective synaptic connections66. 
????? ??????????????????????????????
?Pcdhs show only a weak adhesion function: Ca2+-dependent homophilic cell-cell adhesion is 
occurring but much weaker than the one achieved by classical cadherins. Pcdh1, Pcdh8, and Pcdh18a 
have been shown to affect cell adhesion using cell sorting assays while Pcdh7, Pcdh10, Pcdh19, and 
Pcdh17 has been shown to mediate adhesion in cell aggregation assays69–74. 
Few examples of homophilic adhesion have been reported for in vitro studies on ?Pcdhs, for 
instance for Pcdh1/AXPC18,70, Pcdh7/NFPC75, Pcdh8/Arcadlin/PAPC71,76, Pcdh1072 and Pcdh1977. The 
preference of homophilic interaction instead of a heterophilic one has been used to mediate cell-
sorting in cell culture and in vivo. The cytoplasmic domain was found to be necessary for Pcdh7 
functionality in the epidermis of Xenopus75, but this was not the case for Pcdh1977 and PAPC78, which 
form oligomers via the conserved cysteine residues in their ectodomain. Pcdh1/AXPC and PAPC70,76 
show an increased adhesive strength when the cytoplasmic tails were removed. These observations 
show that the mechanisms involved in homophilic interactions are different for the various ?Pcdhs 
and have been not fully elucidated yet.  
Heterophilic cis interactions were also reported for ?Pcdhs and there is increasing evidence for an 
association between the ?Pcdhs and classical cadherins. Several studies have shown this association 
for different members of the ?Pcdh family and in different systems. PAPC, for instance, antagonizes 
the adhesion by C-cadherin78 and even if a physical interaction has not been demonstrated, the 
formation of a complex between PAPC, C-cadherin and a leucine-rich repeat protein, Flrt3, has been 
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proposed in Xenopus79. ?2Pcdhs have been shown to associate with N-cadherin to form adhesive cis 
complexes49. Pcdh8/Arcadlin interacts laterally with N-cadherin (N-Cadh) in cultured hippocampal 
neurons of the rat and this association occurs at their transmembrane domains80. Pcdh8 interaction 
induces N-cadh endocytosis through a pathway, which involves the TAO2? kinase and p38 MAPK, 
and causes the downregulation of the adhesive activity of N-Cadh.  
N-cadh forms a cis complex as well with Pcdh19 in the developing zebrafish.81 Pcdh19 is the main 
responsible for this physical interaction, which is not lost in case of a mutation inhibiting N-cadh 
homophilic binding82 (Figure 10A). In a Pcdh19 knock down zebrafish embryo, a malformation of the 
anterior neural tube can be observed, like in N-cadh mutant embryos, suggesting a collaboration of 
the two molecules in brain morphogenesis83. A stronger ability of Pcdh19 to form homodimers has 
been observed when Pcdh19 is in complex with N-Cadh. So far, one could conclude that N-cadh acts 
as a co-factor in cis to facilitate cell-cell adhesion by Pcdh19 in trans. Since another ?2Pcdh, Pcdh17, 
shows the same behavior with respect to interaction with N-Cadh, this suggests a more general 
ability of N-cadh to form cis-complexes with different Pcdhs, whereas Pcdhs are the main mediators 
of adhesion specificity82. The interaction with N-cadh is occurring also for all the members of the 
?1Pcdh subfamily in zebrafish84. A regulation of N-cadh assembly by Pcdh10 has been shown at the 
cell-cell contacts via the recruitment of NAP1 and WAVE1, but direct interaction of N-cadh with 
Pcdh10 has not been shown85. Taken together, those data show that Pcdhs can directly or indirectly 
interact with classical cadherins, influencing in this way their adhesive behavior.  
39 
 
 
Figure 10 Schematic overview of ?-Protocadherins interactions 
See text, I.3.4, for description references and acronyms. (A) Protocadherin 19 (Pcdh19) mediates a new 
mechanism of homophilic cell adhesion with N-cadherin acting as a required cis-cofactor. (B) ?1-protocadherins 
interact with PP1?, probably inactivating it. They might work synergistically with neurotransmitters (NT) to 
regulate synaptic plasticity. (C) Several ?-protocadherins were shown to associate with RYK, which functions as 
a transmembrane receptor for ligands of the Wnt family. Both ?-protocadherins and RYK were shown to be 
involved in the regulation of cell movements during convergent extension in zebrafish and frog, and of axon 
path finding in vivo and in vitro. (D) Paraxial protocadherin (PAPC) interacts with Frizzled-7 to activate 
downstream signaling through RhoA, JNK and PKC, which leads to tissue separation during convergent 
extension movements in Xenopus embryos. Furthermore, PAPC interacts with ANR5 and Sprouty, which, 
respectively, activate or inhibit RhoA signaling, and thereby promote the planar cell polarity (PCP) pathway. 
PAPC expression is regulated by binding of Wnt-5A to Ror2, which in turn activates JNK signaling, leading to 
upregulation of PAPC. P, phosphotyrosine. (E) PCDH1 interacts with SMAD3 with subsequent inhibition of its 
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TGFbeta dependent activation. This results in a suppression of TGFbeta induced gene transcription. (F) 
Protocadherin-7 (Pcdh7) interacts with the histone-regulating protein TAF1/Set; this interaction could be 
causally linked to differentiation of Xenopus embryonic ectoderm. (G) On neural activation, N-cadherin and 
cadherin-11 associate with protocadherin-8 (Pcdh8), which binds to the MAPKKK TAO2?. TAO2? activates p38 
MAPK, which in turn feeds back to TAO2?, in the end triggering endocytosis of the Pcdh8-N-cadherin-TAO2? 
complex. (H) Protocadherin-10 (PCDH10) associates with Nap1, which is a known mediator of WAVE-mediated 
actin assembly. By recruiting Nap1 to cell–cell contact sites, PCDH10 might alter F-actin organization, which in 
turn causes N-cadherin redistribution. As the redistributed N-cadherin molecules can no longer induce contact 
inhibition, the result is uncooperative, accelerated cell movement. It is also shown the classical cadherin-
catenin complex, and the binding of ?-catenin dimers to F-actin. (I) PAPC influences morphogenetic movements 
and cell sorting in Xenopus embryos by down-regulating the adhesive activity of C-cadherin. Moreover, PAPC 
and C-cadherin form a functional complex with FLRT3. Unregulated FLRT3 causes excessive cell dissociation, but 
PAPC binding inhibits the ability of FLRT3 to recruit the small GTPase RND1, and this reduces the magnitude of 
FLRT3-induced cell dissociation. (J) PAPC can inhibit canonical Wnt signaling by interacting with CK2?. This 
interferes with CK2 complex formation, which leads to proteasomal degradation of ?-catenin and subsequent 
inhibition of Wnt target gene transcription.  (Figure modified after 62). 
????? ??????????????????????????????????????????????????????????
In fact, in view of the weak homophilic binding ability of ?Pcdhs, it has been speculated that 
intracellular involvement in signaling pathways might be the main role of the ?Pcdh family members, 
and evidence for this has indeed been reported in different studies. Also in support of this theory is 
the peculiar structure of the cytoplasmic domains (CD) of ?Pcdhs. As already mentioned, the CD of 
?Pcdh is quite different form the one of classical cadherins, and neither the conserved p120 nor the 
conserved ?-catenin binding cytoplasmic domains are present. Comparing the CD of the members of 
the family, it becomes clear that they are different not only from the one of classical cadherins but 
also between each other: their homology ranges from low to moderate2,29.This might allow the 
members of the family to be able to interact with a relevant variety of different intracellular 
interaction partners.  
The ?1 and ?2Pcdhs are expressed as both short and long isoforms, generated by alternative splicing 
and differing from each other by the size of their cytoplasmic domain and the presence or not of 
conserved motifs (CMs). All the long isoforms show CMs (CM1 and CM2 for ?1 and ?2Pcdhs; plus 
CM3 for ?1Pcdhs only) in their cytoplasmic domains22 (Figure 11). This, together with a C-terminal 
PDZ-domain binding site86, is what indicates that ?Pcdhs likely share some cytoplasmic interaction 
partners. A new conserved region has been recently identified in PAPC, the so-called DSR domain: it 
is part of the CM1 domain and is rich in aspartate (D) and serine (S) residues. Regulation occurs via 
phosphorylation of DRS by GSK3?, followed by polyubiquitination by the E3 ubiquitin ligase, ?-TrCP. 
Similar mechanisms of regulation might occur for NC-Pcdhs as well but have not been shown yet87. 
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Figure 11 Multiple amino acid alignment of selected parts of the cytoplasmic domains of the ?-
protocadherins expressed as long isoforms.  
Sequences are human (Hs) or mouse (Mm). CM, conserved motifs (1 to 3). Upstream and downstream 
sequences are not shown to reduce the complexity of the figure. From22. 
 
In recent years different studies have focused on the identification of molecular interaction partners 
of ?Pcdhs (Table 2). Unfortunately, the binding molecules of the CMs remain largely elusive; only 
CM3, common for all ?1Pcdhs, is known to interact with PP1?22,88 (Figure 10B). 
Table 2 Summary of ?Pcdhs known interaction partners 
References and description can be found in the text 
? ???????????? ?????????????????????
??? PCDH1 RYK, PP1?, SMAD3 
??? PCDH7 PP1?, RYK,TAF1/Set 
??? PCDH8 TAO2?, N-cadherin 
??? PAPC Frizzled-7, Sprouty, ANR5, CK2?, C-cadherin, FLRT3 
??? PCDH9 PP1?, RYK 
??? PCDH10 Nap1, RYK, DYNLT1 
??? PCDH11X PP1?, DYNLT1 
??? PCDH11Y PP1?, ?-catenin 
??? PCDH17 N-cadherin 
??? PCDH18 Dab1, RYK 
??? PCDH19 Nap1, RYK, N-cadherin 
??? PCDH20 RYK 
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I.3.4.1 ?1Pcdhs and PP1?
Protein phosphatase 1 ? (PP1?) is one of the major Ser/Thr phosphatases in mammalian cells. It is 
one of the 4 mammalian isoforms of PP1: PP1?, PP1?/?, PP1?1 and PP1?2. PP1 regulates several 
processes such as glycogen metabolism, cell division, cell differentiation, cell death, signal 
transduction and pre-mRNA splicing in mammalian cells89. PP1? is mainly expressed in the nervous 
system, specifically in the brain. Its expression is upregulated in medium sized spiny neurons of the 
striatum where the regulation of DARPP-32 phosphorylation occurs. DARPP-32 stands for Dopamine 
and cAMP Regulated Phosphoprotein, 32 kDa. If phosphorylated, DARPP-32 inhibits the activity of 
PP1?. The latter has been implicated in regulation of long term synaptic plasticity in neurons and 
plays a role in memory formation and learning processes. PP1 isoforms are found in abundant levels 
in the cytosol and in the nucleus. PP1? and PP1? translocate to the nucleus by binding to a co-
transporter that contains a nuclear localization signal (NLS)88,90,91. Recent findings have shown that 
14-3-3? binds to PP1? and causes its retention in the cytosol which suggests that 14-3-3? regulates
nuclear trafficking of PP1? in mammalian cells89. Yoshida and colleagues isolated PP1? in a yeast
two-hybrid screen for intracellular interaction partners of PCDH788 (Figure 10B). This interaction
inhibits the enzymatic activity of PP1? on glycogen phosphorylase and it occurs via the RRVTF
interaction motif or CM3 present in all ?1Pcdhs. As expected, follow-up studies have revealed that
PP1? is a common interaction partner for all ?1-Pcdhs22. Since both PCDH7 and DARPP-32 inhibit the
activity of PP1?, a synergistic collaboration between these two proteins has been proposed88,92. So
far, there is no evidence published for other common interaction partners binding any of the CM
domains of  ?Pcdhs.
I.3.4.2 ?Pcdhs and RYK
?Pcdhs and several ??Pcdhs were isolated in a screening for receptor-like tyrosine kinase (RYK) 
associated proteins (Figure 10C). RYK is defined as an atypical member of the family of growth factor 
receptor protein tyrosine kinases and it is composed of a extracellular Wnt inhibitory factor domain, 
an intracellular atypical domain and a PDZ binding motif93. It has been defined atypical because it 
differs from other family members in a number of conserved residues, localized in the activation and 
nucleotide binding domains. It has been proposed that the recruitment of signaling proteins by RYK 
may occur to mediate the biological activities. Among those activities there is the stimulation of the 
Wnt signaling pathway and a clear involvement in the regulation of cell movement during 
convergent extension of zebrafish and frog94,95 and in regulation of axon pathfinding in multiple 
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species. Notably, ?Pcdhs are required for the same phenomena. Furthermore, there is evidence for 
connection between the ?Pcdh family and the Wnt-triggered RYK signaling pathway. For instance 
PAPC (homologue of Pcdh8 in Xenopus) binds the Frizzled-7 receptor96 (Figure 10D), and it is known 
that RYK binds Frizzled proteins and that PAPC is regulated via Wnt-5a97. Those are all indications of 
a connection between RYK and ?Pcdhs but a direct interaction has not been reported.  
I.3.4.3 Pcdh1 and SMAD3 
Besides the possibility of sharing interaction partners, each ?Pcdh may and does interact in a specific 
way with a different list of proteins, and this can be ascribed to differences in the other sequences of 
the CD besides the CMs. Pcdh1, for instance, interacts with SMAD3 in yeast two-hybrid (Y2H) 
overexpression assays98 (Figure 10E). SMAD3 forms a SMAD3/SMAD4/JUN/FOS complex at the AP-
1/SMAD site to regulate TGF-beta-mediated transcription and it is implicated in a list of functions 
including epithelial to mesenchymal transition (EMT) and epithelial repair. PCDH1 is mainly 
expressed in airway epithelial cells; its expression is strongly increased during mucociliary 
differentiation and this has been related to asthma58,99. Recently, an interaction of Pcdh1 with 
Smad3 has been confirmed via CoIP in 16HBE cell lysates99. Studies involving either overexpression 
of PCDH1 or its expression at the endogenous level have been carried out in HEK293T cells and 
bronchial epithelial cells, respectively, and demonstrated an inhibition of the TGF-? dependent 
activation of SMAD3 due to the interaction with PCDH1. If PCDH1 is knocked down in primary human 
bronchial epithelial cells, fibronectin expression was induced. Interestingly, increased deposition of 
fibronectin (and collagen) into the subepithelial space of the airways is observed in all forms of 
asthma. The Pcdh1-Smad3 interaction is thus able to suppress the activity of SMAD3, suggesting a 
collaboration between two asthma-related genes99. However, the detailed underlying mechanisms 
have not been elucidated yet. 
I.3.4.4 Pcdh7 and TAF1/Set 
Pcdh7 interacts also with TAF1/set besides with PP1? and RYK100(Figure 10F). Pcdh7/NFPC has four 
isoforms (7a, 7b, 7c and 7c1), and PCDH7c and 7c1 have CM1, CM2 and CM3 motifs. However, all 
PCDH7 isoforms interact with TAF1. Disruption of the ectodermal integrity in the Xenopus embryo 
due to the ectopic expression of a dominant-negative form of Pcdh7 lacking the ectodomain can be 
rescued by the expression of TAF175,100. Furthermore, NFPC and TAF1 are responsible for cell-cell 
adhesion in the neural ectoderm: disruptions in either NFPC or TAF1 result in a failure of the neural 
tube to close because of the sudden lack of organization of the cells in the dorsal neural fold. 
44 
Accordingly, the two proteins are necessary for the proper apical localization of F-actin in neural fold 
cells101. Both proteins are also expressed in retinal ganglion cells (RGCs) of Xenopus 102: the inhibition 
of either one of the two interferes with proper RGC development. NFPC is not only expressed in 
RGCs but also within the retina, on RGC axons and by cells within the optical tract and tectum. A 
recent study has shown that NFPC contributes to axon behavior at multiple points in the optic 
pathway, therefore playing an important role in RGC axonogenesis103. 
I.3.4.5 Pcdh8 and TAO2?
Pcdh8, which is named Arcadlin in rats, has been shown to interact with N-cadh at the synaptic 
membrane of rat hippocampal neurons71,80 (Figure 10G). Rat Pcdh8 possesses homophilic binding 
affinity. In Xenopus and zebrafish, arcadlin/PAPC plays an important role in homotypic cell-cell 
adhesion and in gastrulation movements of the paraxial mesoderm76. Homophilic interactions in 
trans between arcadlin extracellular domains trigger a signal transduction cascade connected to p38 
MAPK: the intracellular domain of PCDH8/arcadlin interacts with protein kinase 2? (TAO2?), which in 
turn activates the p38 MAPK pathway and subsequently promotes endocytosis of N-cadherin. N-
cadherin regulates spine dynamics and maintains the shape and density of spines. The PCDH8-TAO2-
p38 MAPK pathway mediated endocytosis of N-cadherin may therefore result in the disruption of 
synaptic adherent junctions71,80. 
I.3.4.6 Pcdhs and NAP1
Several studies have suggested that PCDHs participate in neural circuit assembly although their 
respective specific roles in neuronal development remain largely unknown. In the light of this need 
for more data to understand roles and mechanisms, an intriguing interaction partner of ?-PCDHs is 
Nck-associated protein 1, Nap185 (Figure 10H). Nap1 is a core protein of the WAVE complex, a main 
regulator of actin which plays a central role in many cellular processes including adhesion, migration, 
division and fusion. The different roles played by the WAVE complex in animals goes from 
embryogenesis to cancer invasion and metastasis, including neuronal morphogenesis and 
plasticity104,105. Nap1 modulates actin nucleation, by forming a pentameric complex with WAVE, 
PIR121, Abi1/2, and HSPC300106. It is expressed in the developing cortical plate where it plays an 
important role in cortical laminar-specific neuronal differentiation. This involves a major 
contribution to the neuronal connectivity in the cerebral cortex: if Nap1 is lost the neuronal 
differentiation is disrupted106. PCDH10 has been shown to interact with Nap1 and to associate with 
WAVE1 and Abi in pull-down experiments85. If PCDH10 is overexpressed, Nap1 and WAVE1 are 
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recruited to the cell-cell contacts, which causes a reorganization of F-actin and N-cadh with 
consequent accelerated cell migration. In this way, N-cadh loses the ability of inducing contact 
inhibition so that cells start to behave in uncooperative manners. Though the expression of PCDH10 
does not alter the migration of single cells, groups of cells are negatively influenced. To conclude, 
the PCDH10-Nap1 interaction promotes contact-dependent cell motility, indicating a dependence on 
homophilic interactions between neighboring cells85,107. Chicken Pcdh19 was also shown to interact 
with Nap1 (and interactions of Nap1 with Pcdh1 and Pcdh9 were likewise suggested)77. Despite the 
presence of the CMs in the CD of chicken Pcdh19, the interaction was suggested to occur in a 
domain located at the C-terminus. A sequence alignment of conserved regions of ?Pcdh cytoplasmic 
domains (of mouse OL-Pcdh, mouse Pcdh18, mouse Pcdh17, human Pcdh11, chicken Pcdh9, mouse 
Pcdh8, mouse Pcdh7, and chicken Pcdh1) showed the presence of a very short yet conserved region 
at the C-terminus, which was called CM4 and was proposed to be the interaction site of Nap185. A 
smaller conserved nine-residue sequence, RSFSTFGKE, within the CM4 element, has been recently 
described to be responsible for the Nap1 binding107. In this same study it has been proposed that the 
interaction with Nap1 is indirect and requires the formation of the whole pentameric WAVE 
complex108. Recently, Nap1 has been shown to interact with the intracellular domain of zebrafish 
Pcdh18b and in case one of the two proteins was depleted, very similar effects on axon branching 
and dynamics were observed. As described for the PCDH10-Nap1 interaction, loss of either Pcdh18b 
or Nap1 reduces the density of filopodia and results in reduced axon arborisation, suggesting a 
dependency on interactions between neighboring cells109. To conclude, Nap1 and the WAVE complex 
may be general downstream effectors of ?Pcdhs, and the ?Pcdhs appear to be regulators of the 
WAVE complex and actin dynamics during nervous system development.   
I.3.4.7 Pcdh18 and DAB1 
Pcdh18 also interacts with mouse Disabled homolog 1 (mDab1). Dab1 is a key regulator 
of Reelin signaling and mediates neural circuit formation during brain development: mutations in 
Dab1 cause ataxia, cerebellar hypoplasia and disorganization of the laminar structure of the CNS110–
113. Tyrosine-phosphorylated mDab1 associates with the SH2 domains of Src, Fyn, and Abl110. The 
interaction with Pcdh18 was shown in a yeast two-hybrid screening and occurs at the C-terminal 243 
residues of mPcdh18, in the conserved motif NPTS, unique for Pcdh18114. Fyn, like Dab1, is a 
downstream mediator of the Reelin pathway: mice defective for Reelin, Dab1 or Fyn show very 
similar phenotypes characterized by inverted cortical layers. It has been shown that PCDH-?/CNR 
interacts with Fyn, suggesting that Pcdh18 might be involved in Reelin dependent signaling in view of 
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its direct interaction with Dab1. Furthermore, PAPC interacts with Sprouty (Figure 10D), a protein 
with inhibitory activity on receptor tyrosine kinase signaling proteins. The interaction with PAPC 
inhibits the activity of Sprouty during convergent extension movements in Xenopus115. ANR5 
(ankyrin repeat protein 5), a protein that regulates cell movements during gastrulation, is also an 
interaction partner of PAPC.116 These interaction partners of different NC-Pcdhs suggest an 
important role played by NC-Pcdhs in cell movement and motility.  
I.3.4.8 Pcdhs and tissue morphogenesis
Identification of putative interaction partners is a helpful starting point to understand the 
physiological functions of the ?Pcdh family. As of now it becomes clear from the description of the 
already known interaction partners that ?Pcdhs are involved in tissue morphogenesis and brain 
development. Some examples have already been mentioned in this section but more studies need to 
be conducted with the aim of identifying the functions of ?Pcdhs. The regulation of tissue 
morphogenesis has been studied in different organisms including Xenopus, chicken and mouse, and 
different ?Pcdh members have been involved in different ways in this important regulation. Xenopus 
PAPC, for instance, is one of the best studied ?Pcdhs and has been shown to regulate both canonical 
and non-canonical Wnt signaling. The casein kinase 2 (CK2) complex, which is involved in the 
regulation of Wnt target genes, activation of dishevelled and stabilization of ?-catenin in the 
cytoplasm, has been shown to interact with PAPC117 (Figure 10I and 10L). This interaction 
antagonizes the cytoplasmic stabilization of ?-catenin with subsequent inhibition of Wnt target gene 
transcription117. But PAPC interacts with the Wnt receptor Frizzled-7 as well, interfering in this way 
with the downstream activation of the planar cell polarity (PCP) pathway. Moreover, as already 
mentioned, PAPC interacts with ANR5 and Sprouty, which are involved in the regulation of RhoA 
signaling, promoting the PCP pathway96,115,116,118. Furthermore, the JNK-dependent activation of Wnt-
5A-Ror2 is responsible for the regulation of PAPC118 (further information in Figure 10D and reviewed 
in62). Recent findings have shown that Protein Tyrosine Kinase 7 (PTK7), a tyrosine kinase receptor 
lacking catalytic activity, binds Ror2 to regulate PAPC expression and is required for PAPC activation 
as induced by Wnt5a: the intracellular domain of PTK7 is released after Wnt5a stimulation and 
migrates to the nucleus to activate PAPC transcription119. Surprisingly, Pcdh8-null mice do not show 
any obvious phenotype120,121. Since an overlapping function with Xenopus PAPC has been shown for 
Pcdh10 in zebrafish, a functional redundancy for Pcdh8 and Pcdh10 has been proposed. As already 
mentioned, PAPC can downregulate the adhesion activity of the classical C-cadherin, which induces a 
change in morphogenetic movements79. Recently, a new interaction partner for PCDH10 and 
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PCDH11X has been identified (U. Brunner and I. Kahr, not published): DYNLT1. Dynein light chain or 
Tctex type 1 (DYNLT1) seems to interact with different regions of these two PCDHs. Further studies 
are required to investigate the function of this interaction.  
I.3.4.9 Pcdhs and brain development  
Concerning brain development we can conclude that ?Pcdhs appear to be involved in different 
functions including the maintenance of the complexity of the neural network due to combinatorial 
expression, in particular of Pcdh-?s. Moreover, ?Pcdhs are involved in axonogenesis, dendritogenesis 
and axon guidance as different studies have shown, and they interact with a number of proteins 
involved in neuronal development, hence possibly modifying their activity. Despite these findings, 
underlying molecular mechanisms have still to be elucidated. For example, in a recent study 
Compagnucci and colleagues122, tried to elucidate the function of PCDH19 in human brain 
development: they used induced pluripotent stem cells (iPSCs), able to mimic the closure of the 
neural tube, in order to characterize the location and timing of expression of PCDH19 during cortical 
neuronal differentiation. Generation of the neural tube was resembled by the formation of “neural 
rosettes”, which are composed of Neuronal Stem Cells (NSC) arranged radially around a lumen. The 
study focused in particular on the establishment of apical-basal polarity and the geometry of 
proliferation. PCDH19 localized in the center of the neural rosette, which corresponds to the lumen 
of the neural tube, suggesting a role in the development of the human brain architecture. The same 
study showed PCDH19 localization at the spindle pole of the dividing cells. This may indicate a role of 
PCDH19 in the control of asymmetric versus symmetric cell division during in vitro neurogenesi122. As 
I mentioned above, many more data and studies are needed to elucidate the mechanisms involved 
in Pcdh physiological functions.  
????? ??????????????????????????
?Pcdhs are expressed at high levels in the brain. So, it is not that surprising that many of them are 
involved in neurological disorders, such as autism, schizophrenia, epilepsy and Alzheimer’s disease. A 
role in neurological disorders has been reported for PCDH7123, PCDH10124 , Pcdh8 and Pcdh17125, 
PCDH11X and PCDH11Y126,127 and PCDH18128. The most convincing evidence for involvement in 
neurological disorders comes from studies on PCDH19, which is the most relevant gene in epilepsy 
after SCN1A129. PCDHs have also been shown to be involved in other diseases and symptoms, for 
example, asthma and bronchial hyper-responsiveness (BHR)55. Recent reports also describe a role for 
?Pcdhs in the immune system130–133. Mounting evidence suggests that ?PCDHs can function as either 
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tumor suppressors or proto-oncogenes in various non-neuronal human tumors (reviewed in van Roy, 
2014)11(Table 3). For instance, analysis of pancreatic cancers showed missense mutations of PCDH9, 
-17, and -18134. Strong evidence was reported for frequent epigenetic inactivation of the PCDH10 
gene in various human cancers but not in matched normal tissues61,135,136. Furthermore, loss of 
expression of PCDH1, PCDH9, PCDH10, PCDH17 and PCDH20 has been shown to correlate with poor 
prognosis or resistance to treatments137–142. 
In the next paragraph we will describe the role of ?PCDHs in cancer. Both direct and indirect 
evidence indicates that ?PCDHs might play important roles during tumorigenesis, either as tumor-
suppressor genes or as oncogenes. The roles played by ?Pcdhs in neurological diseases will be 
reviewed following the cancer section.  
Table 3 ?-Protocadherins in cancer: an overview 
(AIG, anchorage-independent growth; APO, decreased apoptosis induction; AUT, decreased autophagy 
induction; CAM, positive in chick chorioallantoic membrane assay for neoangiogenesis; CCA, decreased cell 
cycle arrest; MCF, positive in monolayer colony formation (clonogenicity); MIA, positive in Matrigel invasion 
assay; MPA, positive in monolayer proliferation assay (adherent cells in vitro); MWH, positive in monolayer 
wound healing (cell migration); PCDH, protocadherin; PCDH11X, X-linked protocadherin 11; PCDH11Y, Y-linked 
protocadherin 11; TSG, tumor-suppressor gene; XMC, xenograft metastatic colony formation (in athymic mice); 
XTG, xenograft tumor growth (in athymic mice). *The tumor-specific changes listed are only those reported for 
human tumor samples rather than for tumor cell lines. Data on somatic mutations (mostly substitution 
missense) were obtained from the Sanger Institute Catalogue of Somatic Mutations in Cancer website and from the 
cBioPortal for Cancer Genomics, and the data are given for those PCDHs and tissue types for which the percentage 
of samples with non-synonymous mutations exceeds 7% and more than ten cases were analyzed. Human-
specific paralogue, expressing an Y-encoded cytoplasmic isoform of PCDH11, also known as PCDH-PC). (Table 
from11) 
 
PCDH type  Tumor type*  Reported tumor-specific 
changes*  
Activity  Refs  
PCDH1  Medulloblastoma  Decreased expression  Shorter survival  142 
Pancreatic  Epigenetic silencing  TSG?  143  
PCDH7  Breast  Increased expression in brain 
metastatic tumor cell 
populations  
Metastasis gene?  144 
Breast  Upregulated in bone 
metastatic primary tumors  
MPA, MWH, MIA and 
XMC  
145 
PCDH8  Colorectal, mantle cell 
lymphoma, pancreatic, 
renal cell and 
nasopharyngeal  
Epigenetic silencing  TSG? MCF and MWH  146–149  
Breast  Epigenetic silencing and/ or 
somatic mutations  
AIG and MWH  150 
Prostate  Homozygous deletion‡  TSG?  151 
PCDH9  Glioblastoma multiforme Decreased expression  TSG in glioblastoma 
multiforme? Higher 
152,140,15
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and other gliomas  tumor grade, shorter 
survival, APO, CCA 
and AIG in glioma  
3 
Colorectal, endometrial, 
esophageal and prostate  
Somatic mutations‡ (mostly 
substitution missense)  
TSG?  154,151  
PCDH10  Breast, gastric, colorectal, 
pancreatic, cervical, 
testicular germ cell 
tumors, various lymphoma 
types, multiple myeloma, 
B cell and T cell acute 
lymphoblastic leukemia 
and reactive follicular 
hyperplasia  
Epigenetic silencing  TSG? For multiple 
myeloma: MCF, CCA 
and CAM. For acute 
lymphoblastic 
leukemia: 
chemotherapy 
resistance  
143,  
135,136,14
1,155–158  
Nasopharyngeal, 
esophageal, breast, 
gastric, hepatocellular, 
non-small-cell lung  
Epigenetic silencing  TSG? MCF, AIG, 
MWH and MIA. In 
addition, for gastric: 
shorter survival, 
MPA, APO and XTG  
61,139,159  
Medulloblastoma  Epigenetic silencing and/or 
homozygous deletion  
TSG? MWH  160  
Lung, gastric and 
colorectal  
Somatic mutations‡ (mostly 
substitution missense)  
TSG?  154,151  
PCDH11X  Prostate  Missense mutations  Lethal metastatic 
tumors  
161 
Lung, esophageal, gastric, 
as well as head and neck  
Somatic mutations‡ (mostly 
substitution missense)  
TSG?  154,151  
PCDH11Y|
|  
Prostate  Upregulated  Androgen-
independent growth, 
anti-apoptotic, 
neuroendocrine trans 
differentiation and 
resistance to 
cytotoxic drugs  
162  
PCDH17  Pancreatic and gastric  Epigenetic silencing  TSG?  163 
  
Esophageal squamous cell  Epigenetic silencing and/or 
homozygous deletion  
Poorer 
differentiation status 
of tumors; MPA, CCA, 
MWH and MIA  
138  
Gastric and colorectal  Epigenetic silencing and/or 
homozygous deletion  
TSG? MCF, AIG, APO, 
AUT and XTG  
164 
Colorectal, esophageal, 
gastric, lung, skin 
cutaneous melanoma and 
prostate  
Somatic mutations‡ (mostly 
substitution missense)  
TSG?  154,151 
PCDH18  Skin cutaneous melanoma, 
esophageal and gastric  
Somatic mutations‡ (mostly 
substitution missense)  
TSG?  154,151 
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PCDH19  Gastric and endometrial Somatic mutations‡ (mostly 
substitution missense)  
TSG?  154,151  
PCDH20  Non-small-cell lung  Epigenetic silencing  Shorter survival, MCF 
and AIG  
137
Prostate and skin 
cutaneous melanoma  
Homozygous deletion‡  TSG?  151
I.3.5.1 ?Pcdhs in Cancer
PCDH8 is a strong candidate tumor suppressor gene (TSG) in breast cancer150. In the recent years 
early screening supporting early diagnosis has decreased the incidence of this kind of cancer. Despite 
that progress, breast cancer is still the first cause of death for woman in the U.S.: in 2015, over 
40,000 women died from breast cancer165. PCDH8 has been shown to be inactivated through either 
mutation or epigenetic silencing in a high fraction of breast carcinomas. The lack of PCDH8 
expression associates with loss of heterozygosity and  partial promoter methylation150. The same 
study showed that PCDH8 inhibited the proliferation of the mutant tumor cell line HCC2218 as well 
as the migration of the mammary cell line MCF10A. PCDH8 has been proposed to be a TSG also in 
nasopharyngeal carcinoma (NPC),149 an epithelial malignancy with an unusual geographical and 
ethnic distribution and with a multi-step pathogenesis, which depends on Epstein–Barr virus 
infection, dietary and environmental factors, and accumulation of genetic and epigenetic alterations 
of multiple cancer genes. Promoter methylation is the key mechanism for the inactivation of PCDH8 
expression in NPC. The PCDH8 gene is found to be silenced also in colorectal cancer146, mantle cell 
lymphoma147, and renal cell carcinoma166: mutation and/or promoter methylation have been shown 
and exogenous expression of PCDH8 suppress proliferation in the mutant tumor cell line HCC2218 
and migration of the mammary cell line MCF10A150. 
Mounting evidence points at a role of PCDH10 as a tumor suppressor. Epigenetic silencing by 
PCDH10 promoter methylation has been demonstrated in different kinds of cancer, including breast 
cancer135, lymphomas136, cervical cancer155, testicular cancer156, prostate cancer158, multiple 
myeloma157, hepatocellular carcinoma167 and endometrioid endometrial carcinoma168. Ectopic 
PCDH10 expression in nasopharyngeal and esophageal carcinoma cell lines reduced clonogenicity, 
anchorage-independent growth, migration potential, and in vitro invasion into Matrigel61. Recently, 
it has been shown that PCDH10 is a candidate tumor suppressor gene in medulloblastoma160. 
Medulloblastoma is an aggressive, fast-growing and high-grade tumor: It is relatively rare but is the 
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most common cancer type in children. It is an embryonal tumor, which arises from cells at the 
earliest stage of development in the cerebellum.  
For gastric cancer, PCDH10 promoter methylation was detected at early stages of carcinogenesis and 
was associated with poor prognosis139. Re-expression of PCDH10 in gastric cancer cells inhibited 
tumor growth in nude mice, induced cell apoptosis, and inhibited cell invasion. Inactivation of 
PCDH10 by promoter methylation is a frequent pathogenic event in multiple myeloma (MM): a 
recent study showed that PCDH10 antagonized cell proliferation in multiple myeloma via 
downregulation of Wnt/?-catenin/BCL-9 signaling169. Furthermore, PCDH10 induced apoptosis in 
MM cells which is mediated by activation of caspase-3 and PARP and by downregulation of the anti-
apoptotic proteins Mcl-1, Bcl-2, Bcl-xL, survivin, XIAP and cIAP-1170. The downregulation of these 
proteins may be due to the inhibition of the NF-?B pathway. This suggests that inhibition of the 
constitutively active NF-kB pathway in MM might be the mechanism of the pro-apoptotic function of 
PCDH10170. Moreover, a recent study has shown that PCDH10 is a functional tumor suppressor in 
colorectal tumorigenesis and that it plays a pivotal role in restraining liver metastasis171. Finally, 
silencing of PCDH10 contributes to chemotherapy resistance of leukemia, and the methylation status 
of PCD10 can be used as a diagnostic test for cervical carcinogenesis on the basis of cervical 
scraping172,173. 
PCDH10 plays a role in the apoptosis mechanisms also in gastric cancer cells: restoration of the 
PCDH10 expression in the MKN45 gastric cell line induces cell apoptosis via upregulation of Fas, 
caspase-8, Jun, and CDKN1A139. Also PCDH17 has been shown to be involved in apoptosis regulation: 
expression of PCDH17 induces apoptosis in gastric and colorectal cancer cells164. PCDH17 is a tumor 
suppressor gene as well for esophageal squamous cell carcinoma138, laryngeal squamous cell 
carcinoma174, gastric cancer cell lines163, and colorectal carcinoma164. Recent findings in colorectal 
carcinoma suggested that AMPK (AMP-activated protein kinase) may be involved in PCDH17 
expression regulation: Se-allylselenocysteine (ASC)-induced autophagic cell death is enhanced by 
upregulation of phosphorylated AMPK and demethylation of the PCDH17 promoter, which was 
suppressed by AMPK inhibitor, showing that activation of AMPK signaling plays a role in the PCDH10 
expression level175. 
The activation of the EGFR/MEK/ERK signaling pathway through loss of PCDH17 promotes metastasis 
in hepatocellular carcinoma (HCC): a recent study has shown that PCDH17 expression correlates with 
overall prognosis and metastasis in vivo. Furthermore, PCDH17 has been shown to inhibit metastasis 
via EGFR/MEK/ERK signaling pathway in an experiment using a panel of HCC cell lines176 . 
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So far, there is only weak evidence for the role of PCDH20 and ?1-PCDHs in cancer: the PCDH20 
promoter is frequently silenced in non-small cell lung cancer with poor prognosis, and upregulated 
expression of PCDH1 in medulloblastoma patients predicted survival142. PCDH9 is a candidate TSG in 
glioblastoma and the loss of its expression correlates with poor prognosis. Hence, PCDH9 has been 
proposed as a prognostic biomarker (further examples in Table 3). 
As already mentioned, despite the many studies and lines of evidence about the role of ?PCDHs as 
TSG, some members of the family can behave also as proto-oncogene, although much less has been 
reported on this possibility. So, different studies have reported PCDH7 to have an oncogenic activity. 
Bos and colleagues showed a strong upregulation of PCDH7 expression in brain metastasis of breast 
cancer144 .A strong upregulation has been shown also in case of medulloblastoma177, in androgen-
independent prostate cancer cells178, and in melanoma with poor prognosis179. Furthermore, 
inhibition of PCDH7 suppresses cell proliferation, migration, and invasion in breast cancer cells and 
PCDH7 has been found to be upregulated in bone metastatic breast cancer tissues145. PCDH11X has 
been picked up in a screening to identify protein altering point mutations in lethal prostate 
cancer161, and PCDH11Y negatively influences apoptotic sensitivity of prostate cancer cells and it is 
enriched in advanced castration-resistant prostate cancers162. Gene expression profile of B-cell 
chronic lymphocytic leukemia (CLL) identified PCDH8 as a downregulated gene in patients with poor 
outcome indicating an oncogenic function of PCDH8 in leukemia180. 
I.3.5.2 ?Pcdh in Neurological Disorders  
Different studies have shown that ?Pcdh are expressed in the brain and that they can play important 
roles in brain development and in the regulation of brain functions. Given these characteristics, an 
important role of ?Pcdh in different neurological disorders can be expected.  
I.3.5.2.1 The Autism spectrum disorders (ASDs) and the Rett Syndrome  
Autism spectrum disorders (ASDs) are conditions of coexistence of autism, Asperger syndrome and 
pervasive developmental disorder not otherwise specified (PDD-NOS) with epilepsy, intellectual 
disability or bipolar disorders: this group of childhood diseases is characterized by a prominent 
impairment in social functioning, specifically in social communication, with the presence of 
stereotypic and repetitive behaviors with restricted interests181,182. A twin study conducted in 
California183 has shown that susceptibility to ASD has a moderate genetic heritability component 
together with a substantial environmental component. By association studies, which are sensitive to 
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allelic heterogeneity, a list of 190 genes (including PCDH9 and PCDH10) in association with ASDs was 
proposed108,184. The confirmed list was divided into two parts: first, a group of genes or loci with high 
penetrance but mutated only in a limited number of individuals and second, the group of the so-
called susceptibility genes to ASD. In these categories the genetic variations are different: for the 
first group, genetic variations are more often de novo or rare point mutations, copy number 
variations (CNVs), and cytogenetically detected deletions/duplications; while the genetic variations 
of the second group include SNPs or inherited CNVs observed in the general population and 
associating with low risk for ASD185. The genetic causes of ASD are thus multiple and diverse, 
although ASD-associated genes often play roles in the development and function of synapses. A 
recent study in post mortem ADS patients has clearly shown a reduction in the number of neurons in 
the amygdala, fusiform gyrus, and cerebellum, while the expression of genes involved in neuronal 
synapsis was downregulated in the brain186. Therefore, it has been speculated that ASDs are synaptic 
defect diseases108. 
Different studies indicate that several ?Pcdhs can be involved in cognitive dysfunction. For example, 
as mentioned above PCDH9 has been connected to ASDs in associative studies: recurrent structural 
variations such as copy number variation in PCDH9 introns have been found in autistic patients. This 
association has been further demonstrated by the finding of downregulated PCDH9 transcript levels 
in lymphoblasts of ASD patients187–191. These associations have been shown also in other species, for 
example in dogs192. Pcdh9 KO mice show a reduced thickness of the cortex, which is a symptom 
observed in several psychiatric disorders, including ASD. Although the molecular mechanism of this 
cortical phenotype is not understood, it suggests the role of PCDH19 in ASDs192. Several loci were 
mapped in a study with the aim of identifying inherited causes of ASD performed in families in which 
parents share ancestors, enhancing the role of inherited factors with autism. A large relevant 
homozygous deletion was found in a PCDH gene cluster close to PCDH10 (on 4q28.3 between the 
PCDH10 and the PCDH18 locus), but evidence on a specific role for PCDH10 is so far speculative193. 
Furthermore, PCDH10 is known to be required for cerebellar development and synapse formation of 
cerebellar Purkinje cells and for axon guidance in developing brain194,195. A dysfunction in these 
mechanisms can be related to the symptoms of ASDs184,196. Pcdh10 KO mice show defect in guidance 
of axons extensions in the ventral telencefalon59, the brain part responsible for communication and 
behavior. The dysregulation of those functions is also compatible with ADS phenotype.  
Furthermore, the autism syndrome has been shown to be a coexistent disturbance for patients with 
epilepsy due to PCDH19 mutations (see below)197. Deregulation of PCDH19 in patients with PCDH19 
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related female epilepsy (PCDH19-FE) contributes to the occurrence of ADS causing the coexistence 
of the two phenotypes. Besides this, different missense variants of PCDH19 gene, generally affecting 
the extracellular domain, have been identified in males showing ASD. A single missense variant, 
affecting the C-terminal of PCDH19, has also been identified in a boy with Asperger syndrome198,199. 
Taken together those studies indicate that PCDH19 is involved in ASD by different mechanisms. 
Until the current edition of the Diagnostic and Statistical Manual of Mental Disorders, DSM-V, the 
Rett syndrome was included in the list of autism-related conditions, together with Asperger 
syndrome and childhood disintegrative disorder. Andreas Rett first classified this disorder in 1966200. 
He noticed a recurrent pattern in female patients such as regression after an early normal 
development, inability to use the hands with purpose and compulsive hand movements. The Rett 
condition was recognized after a study which included a series of 35 European girls with similar 
phenotypes201. Despite children with Rett syndrome exhibit behaviors typical of autism patients (for 
example repetitive hand movements, prolonged toe walking, body rocking, and sleeping problems), 
the Rett syndrome is not classified as an autistic syndrome. MeCP2 (methyl-CpG-binding protein 2) is 
a protein present in any kind of cell but highly expressed in brain where it is important for the 
function of several cell types, including neurons. The function of the protein is not completely clear 
but a role in the maintenance of neuronal synapses has been speculated on. Different mutations in 
the MECP2 gene have been shown to cause for example severe neonatal encephalopathy, PPM-X 
syndrome and Rett Syndrome. About 400 different MECP2 mutations have been identified and these 
can cause changes in the structure of the protein or in the amount of protein produced. MEPC2-null 
mice show a neurological phenotype similar to the one of Rett Syndrome patients indicating the role 
of the loss of MeCP2 function in the pathology of the syndrome. Thus, MeCP2 appears to be 
important for neuronal development and maturation, synaptic activity, learning and 
memory123,202,203. Miyake and colleagues123 performed a genome microarray screen to reveal sites 
potentially regulated by MeCP2: within this list they showed that PCDH7 and PCDHB1 promoter 
activities were down-regulated by MeCP2. MeCP2 binds to the upstream regions of the 
protocadherin genes PCDH7 and PCDHB1 in human neuroblastoma SH-SY5Y cells, and PCDHB1 has 
been found to be upregulated in post mortem brains of Rett syndrome patients. This study indicates 
an association of dysregulation of protocadherins with the neuronal and synaptic defects typical of 
Rett patient’s brains123.   
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I.3.5.2.2 Schizophrenia and bipolar disorders 
Schizophrenia (SZ), from Greek skhizein, to split + phr?n, “mind”, is a long-term neurological disease. 
It is characterized by loss of normal thoughts, speech and behavior. It occurs with an incidence of 
approximately 0.5–1% with no gender differences. In 1887 the German psychiatrist Emil Kraepelin 
was the first to characterize the disease and he defined it "dementia praecox", making a clear 
difference with maniac depression disease. In 1911 the disorder was given the name we use 
nowadays, which indicates the fragmented thinking behavior. Different studies have revealed a long 
list of possible causes of schizophrenia. The environment plays an important role: for example, 
exposure to viruses or infection by the parasite Toxoplasma gondii204, or malnutrition in the first 
stages of gestation. The use of addictive substances like mind-altering drugs or cannabis can be a risk 
factor too. Of course, interference with the normal functions of neurotransmitters such as dopamine 
and glutamate can cause schizophrenia as well. Schizophrenia has a strong genetic base205. Twin 
studies indicate a hereditability of around 80% but since the cause is never just one genetic 
variation, like for ASDs the identification of specific molecular genetic profiles for SZ is not 
straightforward206. The PCDH8 gene maps in a region of chromosome 13q207, where a linkage with SZ 
has been shown208. In a screen for polymorphisms in 30 schizophrenic patients, 9 PCDH8 single-
nucleotide variants have been found and proposed as a predisposition factor for SZ in families209. 
PCDH8 has been related to mental retardation in a study carried out on patients with 
retinoblastoma, dysmorphic features and developmental delay, and bearing a 13q14 deletion: this 
deletion affected both PCDH8 and PCDH17125. Increased PCDH17 mRNA expression has been found 
in the Brodmann’s area 46 (BA46) of the brains from patients who have been showing SZ for less 
than 7 years210.  Also PCDH11X/Y genes have been studied to understand their involvement in 
mental disorders. Durand and colleagues identified two PCDH11Y polymorphic amino acid changes 
in autistic patients, but the observation did not show statistically significant relevance when 
compared with controls211. A single splice mutation of PCDH11X has been reported in a single case of 
SZ,198 together with a rare variant of PCDH19. More detailed functional analysis is still required to 
elucidate the mechanisms involved in the correlation between PCDHs and SZ.  
I.3.5.2.3 Epilepsy 
In epilepsy syndromes the normal pattern of neuronal activity is compromised. These syndromes 
influence emotions and behavior and, clinically, patients show seizures (disruption of the electrical 
communication between neurons), muscular spasm and loss of consciousness. Over 65 million 
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people suffer of epilepsy around the World and it can occur in any person and at any age. Different 
features characterize different epileptic syndromes, including the type of seizures, the age of 
symptomatic evidence, the causes and the severity of the seizures, genetic characteristics, and many 
more: the most common way to define the syndromes is by evaluating symptoms or by determining 
the part of the brain where the seizure starts. Epilepsy and mental retardation limited to females 
(EFMR) is an infantile onset epilepsy syndrome with or without intellectual disability (ID) and autism: 
several mutations of PCDH19 have been found in families with EMFR129. It is an X-linked disorder 
with an unusual inheritance pattern since it affects only carrier females with male sparing of the 
phenotype212. To investigate the role of PCDH19  in female patients with epilepsy, a group of 117 
female patients with febrile seizures (FS) was studied: PCDH19 was mutated in 11% of cases showing 
focal epilepsy or Dravet syndrome-like phenotypes, with or without mental retardation and autistic 
features indicating that PCDH19 defects play a major role in infantile-onset epilepsy in females213. 
Most of the mutations occur in the extracellular domain and only frameshift mutations have been 
shown in the intracellular domain of PCDH19. EMFR or PCDH19-FE has been shown to be very 
frequent in the families analyzed, identifying PCDH19 to be the second most relevant gene in 
epilepsy after SCN1A. Over 60 different mutations in the PCDH19 gene have meanwhile been 
identified suggesting that different mechanisms are involved in PCDH19-EF development212,214.  
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Chapter II. HOW TO INVESTIGATE PROTEIN-
PROTEIN INTERACTIONS 
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II.1 An introduction to Systems Biology and Interactomics 
In the common view, biological systems are complex but consisting of simple and similar elements 
that cooperate to yield a complex behavior. However, this is not a realistic view: biological systems 
are actually formed by a large amount of different kinds of elements with different characteristics 
and functions that interact with each other in a selective way. Biological systems have functions that 
rely on combinations and mutual interactions of the different parts involved. Consequently, in living 
systems, for molecules, cells, organisms or even entire species, any prediction of their function is 
impossible to derive from the properties of the individual parts only. This forms the basis for the so-
called System Biology approach.  
Sir Paul Nurse identified four of what he calls ‘the great ideas of biology’: (i) the gene is the basis for 
heredity, (ii) the cell is the fundamental unit of organisms, (iii) biology is based on chemistry, and (iv) 
species evolve by natural selection1. This is how biology has been taught, how studies have been 
designed and carried out and this is the base for therapeutic approaches and for the way of thinking 
in modern science. Different study fields have been developed from these “great ideas” such as 
genetics and molecular biology, cell biology, biochemistry and evolutionary biology, respectively, 
giving four different approaches and points of view. Systems Biology is the “fifth great idea”. Even 
though the Systems Biology discipline is today still developing, its theoretical basis dates back to 
more than a half century ago2. Already at the end of the 18th century, Immanuel Kant wrote about 
Systems Biology without giving it a name: Critique of Judgment, written in 1790, might be defined as 
the first philosophical treatise on Systems Biology. In this book, Kant perfectly described the 
principle of organization and collaboration of systems: “Organisms are organized natural products in 
which every part is reciprocally both end and means”3. 
Despite the fact that the theoretical basis of Systems Biology is relatively old, its application to a real 
field of study needed some time. In 1999, Leland H. Hartwell and colleagues published the paper 
“From molecular to modular cell biology”, in Nature. There, they propose to combine molecular 
analysis / procedure and concepts from informatics: this was the onset of Systems Biology4. Since 
then, the development of new molecular technologies contributed significantly to the development 
of Systems Biology (Figure 12). 
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Figure 12 Systems Biology: Biology drives technology drives computation.  
Figure from https://www.systemsbiology.org/about/what-is-systems-biology/ 
The concept of the cell changed dramatically: the focus is dedicated to the overall biological 
functions, which in a biological organization can be found at different levels, from organelles to 
organisms. In this view the cell acquires an important role as the simplest unit which still exhibits the 
characteristics of life4. A cell consists of hundreds of organized modules (e.g., the proteasome or the 
RNA exosome), composed of both 
macromolecules and small molecules. The 
interaction between those modules is termed 
“molecular sociology”5. The complex web of all 
the macromolecular interactions within and 
between cells constitutes the “interactome” 
network6. But thinking about Systems Biology as 
a single discipline would be a mistake: its power 
lies in its interdisciplinary concept. It brings 
together biologists, chemists, mathematicians, 
physicists, statisticians, computer scientists and 
engineers. Their respective specialties allow 
research to go through the “Omics Cascade”: 
Systems Biology can be considered as the study 
of how the genome, the transcriptome, the 
proteome and the metabolome are regulated to 
determine a defined phenotype (Figure 13).  
Figure 13 Systems Biology: From the Genome to the 
Phenotype 
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Over the years, the concept of “protein function” changed dramatically (Figure 14).  
 
 
Figure 14 Protein function definition 
On the left, the traditional view of protein function. On the right, the post-genomic consideration of protein 
function. Figure taken from7. 
 
 
The traditional view focuses on the action of a single protein molecule: the most representative 
example is the catalysis of a reaction. Within the Systems Biology context, this evolved towards what 
is called “cellular function” or “contextual function”, to underline the role of each protein in a 
network of interacting molecules. Today, what defines the post-genomic era is the need of an 
expanded view on protein functions in a cellular and functional context. The development of 
computational methods to understand functional connections between proteins has been greatly 
facilitated by the advent of fully sequenced genomes7 (Representative examples are shown in Figure 
15). 
Every protein can interact with metabolites, with other proteins and/or with nucleic acids. While the 
interaction with metabolites provides the cells with essential metabolic fluxes, the protein-protein 
interactions (PPIs) and the protein-nucleic acid interactions contribute to organizing, expressing and 
regulating cellular functions. Despite the fact that proteins can act as vital macromolecules at the 
cellular and systemic level, they rarely act alone, and if two proteins interact with each other, they 
usually play a role in the same cellular functions. This is why PPI studies are frequently used as a 
starting point for investigation of unknown proteins according to the principle of ‘guilt by 
association’: showing that a protein with unknown function interacts with one with known function 
gives a hint on the possible role of this unknown protein8. It has been estimated that there are about 
400,000 PPI in the human interactome9. 
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Figure 15 The general mechanism of four representative methods  
A) Phylogenetic profile method: 4 different genomes with a set of proteins (colored squares), in the
phylogenetic profile are represented with 1 if present, 0 if absent. Identical profiles are clustered in boxes on
the right, with profiles differing by one bit connected by lines. Orange and light blue, and blue and purple are
functionally linked because they have the same phylogenetic profile. B) The Rosetta stone concept or the
domain fusion model searches for gene fusion events: protein A and protein B belong to the same organism.
Protein AB is from another organism; the fused domain or Rosetta stone sequence it is homologous to two
separate sequences in another species. For example the fused sequence of TrpC (protein AB) in the Escherichia
coli genome would inform us that the yeast proteins TrG (protein A) and TrpF (protein B) are functionally linked. 
C) The gene neighbor method assume that If two genes (blue and red in the figure) are found to be neighbors in 
several different genomes, a functional linkage may be inferred between the proteins they encode. D) The gene 
cluster (GC) or operon method identifies closely spaced genes, and assigns a probability P of observing a
particular gap distance (or smaller), as judged by the collective set of inter-gene distances10.
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II.2 Protein-Protein Interactions (PPIs) 
 ?????????????????????
PPIs occur by means of hydrophobic binding, van der Waals forces and salt bridges, which occur in 
specific binding domains of each protein. There are different ways to classify PPIs based on their 
structural and functional characteristics11. 
 
Figure 16 The relation between different types of protein–protein interactions (PPIs), their binding energy 
and the localization of their promoters.  
Figure taken from 11. 
 
PPIs can be classified based on their composition, affinity and life-time as homo- or hetero-
oligomeric complexes, non-obligate or obligate complexes and transient or permanent complexes. 
Depending on their persistence, PPIs can be stable (permanent) or transient. In general, stable 
interactions are characteristic of protein complexes, which can include the same or different 
subunits. The hemoglobin complex is a representative example of a stable interaction between alike 
proteins. In contrast, most of the processes in a cell are a lot more dynamic and require transient 
interactions, which can quickly activate or stop a particular process. Those interactions can be either 
fast or slow. Two Src homology domains, SH2 and SH3, are examples of protein domains involved in 
common transient interactions. The binding domains of proteins can be a small cleft, a groove or a 
large surface. The binding interface will influence the strength of the binding. For example, leucine 
zipper domains, which display interaction surfaces, induce stable PPIs while SH2 and SH3 domain 
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interactions induce transient interactions. The difference between obligate and not obligate 
interactions depends on binding affinities. In an obligate interaction the components of the complex 
cannot exist independently due to their intrinsic instability whereas the constituents of a non-
obligate interaction are stable on their own. An obligate homodimer is the DNA-binding P22 Arc 
repressor, while an obligate heterodimer is the human cathepsin DA. An example of a non-obligate 
homodimer is Sperm lysin, whereas the RhoA - RhoGAP signaling complex represents a non-obligate 
heterodimer. Of note, this is not a very strict classification. Every PPI may combine characteristics of 
these specific classifications while many PPIs do not strictly belong to a specific type. More 
specifically, physiological conditions and environments play a big role in influencing the 
characteristics of the interactions11,12 (Figure 17). 
 
Figure 17 Examples of different types of protein–protein interactions  
(A) Obligate homodimer, P22 Arc repressor; (B) Obligate heterodimer, human cathepsin D that consists of a 
non-homologous light (red) and heavy (green) chain; (C) Non-obligate homodimer, sperm lysine; (D) Non-
obligate heterodimer, RhoA (green) and RhoGAP (red) signaling complex; (E) Non-obligate permanent 
heterodimer, thrombin (red) and rodniin inhibitor (green); (F) Non-obligate transient heterotrimer, bovine G 
protein, i.e., the interaction between Ga (green) and Gb (red, orange) is transient. The proteins in an obligate 
interaction are not found as stable structures on their own in vivo.  Picture from 11. 
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 ?????????????????? ??????????????????????????
There are two strategies adopted by eukaryotes to expand the coding capacity of the genome: the 
first includes alternative mRNA splicing and alternative promoter usage at the transcriptional level, 
and the second comprises various posttranslational modifications. PTMs allow biochemical 
mechanisms important for transient cell signaling processes. They occur after protein translation 
events to obtain in a regulated way a mature active or inactive product. Via PTMs, amino acid 
residues are covalently modified. The site of the PTMs is the amino acid side chain or the C- or N- 
terminus of the modified protein. For instance, a clear correlation has been shown between cancer 
generation or progression and a high rate of mutations of protein PTM effectors (such as kinases, 
phosphatases, or ubiquitin E3 ligases)13–16. There are many different types of PTMs. One category of 
PTMs is covalent cleavage of the peptide, which is mainly achieved by proteases and occurs through 
a break of the peptide backbones. It is an irreversible and ubiquitous process that can result in 
activation/inactivation of the protein and regulation of biological processes17. A simple example of 
this type of PTM is the cleavage of the initiation methionine, which produces an active form of the 
protein18. A majority of PTMs is based on enzyme-mediated mechanisms adding electrophilic groups 
to nucleophilic side chain residues. The major PTMs of this type are phosphorylation, ubiquitination, 
methylation and acetylation. Phosphorylation is catalysed by kinases, which transfer a phosphate 
group from ATP to the side chain of serine (S), threonine (T) or tyrosine (Y) of the protein 
substrate19–21. These modifications are reversible by virtue of phosphatases22. Ubiquitination occurs 
when ubiquitin molecules are added to substrate proteins. The regulation of this modification is 
responsible for the dynamic state of synthesis and degradation of target proteins. Ubiquitin-protein 
ligases catalyse the process while deubiquitinating enzymes (DUBs) oppose the role of the ligases23–
26. Methylation is another main PTM: it is a reversible process catalyzed by methyltransferases, 
which use lysine and arginine residues as the primary acceptors of methyl groups27,28. Acetylation is 
the result of attaching acetyl groups to the lysine side chains of proteins. A collaboration between 
acetylation events and other PTMs has been shown to play a role in the dynamic control of different 
signaling pathways29–31. PTMs are much more predominant in eukaryotes than prokaryotes, 
regarding both PTM type and frequency, even if recently many studies have shown important 
regulatory roles of protein modification in bacteria32. As a result of PTMs, different protein isoforms 
are generated, which may vary in properties and also in interacting partners. This is the reason why 
it is important to consider the proper system when PPIs are investigated. Allowing the protein under 
investigation to undergo the expected in vivo PTMs is expected to facilitate the identification of 
physiologically relevant interaction partners.  
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Taking advantage from the different events occurring during the PPI process, many methods have 
been developed to study the way that proteins interact with each other. Each method is 
characterized by different levels of specificity and sensitivity and most of them are used at the same 
time to obtain a more complete or specific analysis. Genetic, biochemical, computational and 
biophysical technologies have been developed to study PPIs (a summary can be found in Table 4). 
In this chapter, genetic and biochemical methods are presented and a quick overview of 
computational methods is given. The biophysical technologies (not presented here) have the 
advantage of giving information about the kinetics of the interactions. They use a range of 
biophysical characteristics, such as the changes in emission of heat or in speed of rotation that 
proteins undergo during their associations. Other biophysical specificities have been used to develop 
more techniques including dual polarization interferometry, surface plasmon resonance, static light 
scattering and circular dichroism methods33. 
Next to the in vivo and the in vitro methods to detect PPIs, which are overviewed in the following 
paragraphs, in silico methods have been developed to support experimental findings (complement 
the interactions detected by ‘wet’ experimental work). A list of those methods (together with the in 
vivo and in vivo ones) with a summary of their respective characteristics can be found in Table 412 . 
Table 4 Summary of PPI detection methods (modified after Srinivasa rao et al., 201412). 
[(#), techniques used in this dissertation; (*), techniques described in this dissertation] 
Approach Technique Summary 
In??vitro Tandem affinity purification-
mass spectroscopy (TAP-MS) 
(*) 
TAP-MS is based on the double tagging of the protein of interest, followed by a two-step 
purification process and mass spectroscopic analysis 
Affinity chromatography (*) Affinity chromatography is highly sensitive, can even detect weakest interactions in 
proteins, and also tests all the sample proteins equally for interaction. 
Coimmunoprecipitation (#) 
(*) 
Coimmunoprecipitation confirms interactions using a whole cell extract where proteins are 
present in their native form in a complex mixture of cellular components 
Protein microarrays (*) Microarray-based analysis allows the simultaneous analysis of thousands of parameters 
within a single experiment 
Phage display  The phage-display approach is based on the incorporation of the protein and genetic 
components into a single phage particle 
X-ray crystallography X-ray crystallography enables visualization of protein structures at the atomic level and
enhances the understanding of protein interaction and function 
NMR spectroscopy NMR spectroscopy can even detect weak protein-protein interactions 
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In??vivo Yeast 2 hybrid (Y2H) (#)(*) Yeast two-hybrid is typically carried out by screening a protein of interest against a random 
library of potential protein partners 
Synthetic lethality Synthetic lethality is based on functional interactions rather than physical interaction 
 MAPPIT (#)(*) A cytokine receptor-based two-hybrid system that operates in mammalian cells. Occurring 
at the plasma membrane and is based on JAK-STAT signal transduction pathway. 
 KISS(*) KInase Substrate Sensor method extending the MAPPIT technology to a wider range of PPIs 
including membrane associated PPIs. 
 Protein-fragment 
complementation (*) 
Protein-fragment complementation assays (PCAs) can be used to detect PPI between 
proteins of any molecular weight and expressed at their endogenous levels 
 FRET/BRET (*) Based on RET are used as the common tools in the study of biochemical reaction kinetics. 
In??silico Orthologue-based sequence 
approach 
Orthologue-based sequence approach based on the homologous nature of the query 
protein in the annotated protein databases using pairwise local sequence algorithm 
Domain-pairs-based 
sequence approach 
Domain-pairs-based approach predicts protein interactions based on domain-domain 
interactions 
Structure-based approaches Structure-based approaches predict a PPI based on structural similarities (primary, 
secondary, or tertiary) 
Gene neighborhood If the gene neighborhood is conserved across multiple genomes, then there is a potential 
possibility of the functional linkage among the proteins encoded by the related genes 
Gene fusion Gene fusion, which is often referred to as Rosetta stone method, is based on the concept 
that some of the single-domain containing proteins in one organism can fuse to form a 
multi-domain protein in other organisms 
In??silico 2 hybrid (I2H) The I2H method is based on the assumption that interacting proteins should undergo 
coevolution in order to keep the protein function reliable 
Phylogenetic tree The phylogenetic tree method predicts the protein-protein interaction based on the 
evolution history of the protein 
Phylogenetic profile The phylogenetic profile predicts the interaction between two proteins if they share the 
same phylogenetic profile 
Gene expression Gene expression may predict interactions based on the idea that proteins from the genes 
belonging to the common expression-profiling clusters are more likely to interact with each 
other than proteins from the genes belonging to different clusters 
 
II.2.3.1 Genetic methods 
II.2.3.1.1 Yeast Two-hybrid  (Y2H) 
General 
Until 1989, PPIs have been studied solely by using biochemical techniques such as co-fractionation 
by chromatography, crosslinking, co-immunoprecipitation, which all require in vitro handling of 
protein extracts. The first genetic screen in yeast cells was described by Stanley Fields and Ok-kyu 
Song in 1989, and revolutionized protein interaction analysis34. This so-called Yeast Two-Hybrid (Y2H) 
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approach became one of the most widely used methods to investigate PPIs until today. Many 
related methods have been developed since then to answer different questions. In this chapter the 
Y2H approach and variant Y2H methodologies will be described. 
The Y2H method 
Only few years before the seminal publication by Fields and Song34, the Ptashne laboratory had 
discovered the modular structure of GAL4, a transcriptional activator in yeast35. The yeast GAL4 
transcription factor consists of separable domains responsible for DNA binding and transcriptional 
activation. These researchers showed that Gal4 binds the upstream activation element of target 
genes and thus activates transcription in the presence of galactose. They demonstrated that the N-
terminal fragment alone can still bind to DNA, but cannot activate transcription in the presence of 
galactose. This means that GAL4 cannot activate transcription unless it is associated with an 
activation domain. Their findings demonstrated the role of the C-terminal fragment of GAL4 as an 
activation domain. The Y2H method takes then advantage of the fact that both fragments are in 
proximity, even when not covalently linked, and reconstitute a fully functional protein.  
The Y2H method is thus based on the fact that most eukaryotic transcription factors show a modular 
structure composed of a DNA binding domain (DBD) linked to an activation domain (AD). When both 
domains are in proximity then a functional transcription factor can be obtained36. 
Technically, a cDNA sequence encoding a bait protein of interest is genetically fused to the DBD of a 
transcriptional activator and a cDNA sequence encoding a prey protein (fragment) is fused to the AD 
of the transcription factor. The interaction between the two-hybrid  proteins reconstitutes the 
transcriptional activity. In this way, the DBD binds a specific region of the reporter gene promoter 
while the AD interacts with the RNA polymerase II, resulting in the activation of a reporter gene or 
selected genes. A measurable output is generated, which can be a reporter signal or growth under 
selection pressure (Figure 18).  
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Figure 18 Y2H, the concept 
In Yeast, haploid cells mate with other haploid cells of a different mating type (an “a” cell can only mate with a 
“?” cell but not with another “a” cell, and vice versa). After secreting pheromones and growing projections, the 
mating occurs and produces a stable diploid cell. The interaction of the bait (X) with the prey (Y) in the diploid 
cell leads to the reconstitution of a functional transcription factor by complementing its DBD and the AD. The 
AD interacts with RNA pol II driving transcription of the reporter gene. 
 
In the original paper, Fields and Song used the yeast GAL4 transcriptional activator to confirm the 
known interaction between SNF1 and SNF4. This interaction led to the transcription of a GAL1-
lacZ fusion gene. A yeast strain expressing both hybrid genes induced the expression of the reporter 
gene encoding the enzyme beta-galactosidase, which labels the yeast cell blue when using a 
colorimetric substrate34. 
Pros and cons of the Y2H approach 
Thanks to several advantages, the Y2H approach is the most widely used technique to investigate 
PPIs. The system is highly sensitive hence weak or transient interactions can be detected37. 
Moreover, the technique is cheap, fast and simple requiring limited technical resources. It can be 
used to investigate specific PPIs but also for high-throughput screening procedures38,39. Furthermore, 
the method uses living cells and provides an eukaryotic environment. In contrast with the classic 
biochemical approaches, no production and purification of proteins is required.  
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Despite the high number of benefits, the technique is not perfect and shows limitations. A major 
problem of the method is the high percentage of false positives. False positives are physical 
interactions detected, which cannot be reproduced in a different system and might be generated 
due to technical (by an event different from PPI) or biological (PPI not occurring in vivo) reasons. Y2H 
experiments work through overexpression of prey and bait plasmids, which can result in nonspecific 
interactions. Moreover, the overexpression occurs in a compartment (nucleus), which does not 
necessarily correspond to the natural cellular context of the hybrid proteins and the use of fusion 
proteins implies that their conformations may differ from the native ones, compromising their 
binding abilities. Self-activation of the reporter gene individually by the bait and/or the prey proteins 
will result in a false positive signal too. Another problem of the Y2H system is the generation of false 
negatives, defined as PPIs which cannot be detected due to limitations of the method. For example, 
interactions including membrane proteins are mostly undetectable in Y2H. Furthermore, interactions 
of proteins of higher eukaryotes may not be detected due to the absence of posttranslational 
modifications, which may be hard to reproduce correctly in the lower eukaryote yeast. Between two 
independent large-scale Y2H screens, less than 30% of the identified interactions overlap39. This is 
caused by a low assay sensitivity, which implies a large number of not identified true interactions, 
but also by the low coverage which depends from the used collection and low sample sensitivity, 
defined as the number of detected interactions in a single trial. Already in the 1989, Fields and Song 
were aware of the following limitations of their method: “The system requires that the interaction 
can occur within the yeast nucleus, that the Gal4-activating region is accessible to the transcription 
machinery and that the Gal4 (1-147)-protein X hybrid is itself not a potent activator”. Due to these 
severe limitations the sensitivity of the Y2H is estimated to ~25%, thus there is a growing interest for 
the development of alternative Y2H variants40. 
II.2.3.1.2 Variant Y2H methodologies 
One of the most obvious limitations of the Y2H methods is the impossibility of studying proteins that 
can directly activate the transcription, independently of their fusion context as a prey protein. To 
solve this problem two different methods have been developed. 
First, the repressed trans-activator (RTA) system was introduced41 (Figure 19A). Here, while the bait 
fusion protein is able to activate transcription, the prey proteins are fused to the N-repression 
domain (RD) of a transcription repressor (e.g. Tup1). Interaction between the activator bait and a RD 
prey fusion causes repression instead of activation of the reporter gene. This strategy has been used 
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to identify novel protein interactions with a variety of transcriptional activators, including herpes 
simplex virus 1 (HSV-1) regulatory protein VP1641 , c-myc 42, and the androgen receptor43. 
Another variation on the original model is the RNA polymerase III-based two-hybrid system, which 
was developed to detect interactions that cannot be studied by the original RNA polymerase II two-
hybrid system (Figure 19A). Here the prey protein is combined with a different fusion partner, 
namely a subunit of the multimeric protein complex TFIIIC, which is one of the two transcription 
factors involved in RNA polymerase-III mediated transcription. This makes the method RNA 
polymerase-II independent, and avoids false positivity due to trans activation by the bait fusion 
protein. 
The original Y2H method and the two variants presented above are based on the translocation of the 
hybrid proteins into the nucleus, which makes the method unsuitable for a high percentage of 
protein interactions. This is the reason why different approaches have been developed where the 
interacting cytoplasmic proteins or protein domains are in their natural cellular compartment. 
One method to analyze cytosolic proteins, later extended to membrane-bound proteins, is the 
ubiquitin-based split protein sensor44 (Figure 19D). Ubiquitin (Ub) is a 76 amino acid protein 
important for the natural turnover of cellular proteins. Proteins, to which ubiquitins are covalently 
bound, are labelled to undergo proteasomal degradation. The split ubiquitin method is based on the 
separation of ubiquitin into two fragments, the C-terminal half (Cub) and the N-terminal half (Nub) 
including a mutation (I13G or I13A) to avoid spontaneous dimerization. If interaction between the 
fragments occurs, it results in a reconstituted split-Ub. The cleavage by an ubiquitin-specific protease 
releases a transcription factor and activates the reporter gene expression. 
The SOS- and RAS-recruitment systems are two other variants developed to study cytosolic and 
membrane proteins (Figure 19B). They don’t need a transcriptional read out since they use the Ras 
signaling pathway, which is homologous between yeast and mammals45. Ras is a G protein, also 
called small GTPase, which means that it is a guanosine-nucleotide-binding protein that functions as 
a binary signaling switch with "on" (GTP-bound) and "off" (GDP-bound) states. The switch happens 
at the plasma membrane and is mediated by GEF proteins, Sdc25p in yeast and SOS in mammals. 
The system takes advantage of the capacity of hSOS to substitute the yeast Ras GEF (guanine 
exchange factor), Cdc25 in a cell with mutant cdc25 gene. 
In the SOS recruitment system the bait is fused to mammalian SOS; if the bait interacts with a prey in 
the proximity of the plasma membrane, SOS activates the GDP to GTP exchange in Ras, activating in 
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this way the signaling pathway. In the Ras recruitment system (RRS), the bait protein is fused to a 
constitutively active mammalian Ras. In this case, only the correct localization is needed to activate 
the downstream signaling. The interaction with a membrane prey will mediate this translocation. 
The activation of the signal cascade causes cell survival and growth.  
For the analysis of membrane-localized PPIs, a variation of the RRS has been developed, which has 
been called reverse RRS (rRRS) Y2H. The bait is here an intrinsic membrane protein or a membrane-
anchored protein and the prey is the Ras fusion protein. In 2000, Ehrhard and colleagues, developed 
a similar membrane-associated two-hybrid  assay based on the recruitment of a chimeric G protein 
subunit to the membrane due to the interaction with a Ste2 hybrid protein that leads to the 
signaling cascade activation46. 
In the past decades, the Y2H system has been adapted to cover an increasingly wide range of 
applications, including the targeting of PPIs for therapeutic actions. Y2H variants have been 
developed to investigate interaction of proteins and small molecules in the best possible 
physiological setting47. First, the so-called reverse Y2H can detect mutations or molecules that 
dissociate PPIs. To this end, Vidal et al., used the gene URA3 as a reporter48. Expression of URA3 is 
toxic for cells growing in a medium containing 5-fluoroortic acid, therefore the interaction of the 
proteins of interest will lead to cell death. The inhibition of the association would thus lead to cell 
growth. Another variation is the yeast three hybrid that allows the screening for proteins that 
directly interact with a specific molecule in vivo49. In this method, the third molecule is a synthetic 
heterodimer of two different small organic ligands. 
For further details on different Y2H system we refer to Table 5 and Figure 1940,47. 
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Table 5 Overview of different Y2H systems 
Y2H Method Possible bait  Response Principle Reference 
Classic Y2H System Non-trans activating 
proteins capable of 
entering the nucleus 
Transcriptional 
Activation 
Artificial recruitment of bait  
and prey proteins to the  
nucleus 
34 
SOS recruitment 
system 
Trans activating, 
cytosolic proteins 
Ras signaling Detection of PPIs at the 
membrane on the basis of 
the defective cdc25 allele in 
yeast. A PPI translocates a 
Ras fusion protein to the 
membrane and allows 
growth 
50–52 
Split Ubiquitin 
system (MYTH) 
Nuclear, membrane 
and cytosolic proteins 
Uracil 
autotrophy and 
5-FoA resistance 
The reunion of two 
ubiquitin fragments in the 
cytosol due to a PPI 
establishes the cleavage 
activity which releases a 
transcription factor 
allowing activation of the 
reporter gene.  
53,54 
RAS recruitment 
system  
Trans activating, 
cytosolic proteins 
Ras Signaling See “SOS recruitment 
system” 
45,50,51 
Dual bait system Two non-trans 
activating proteins 
capable of entering the 
nucleus 
Transcriptional 
Activation 
Y2H with two baits. 
Interaction occurs In the 
nucleus.  
55 
G-protein fusion 
system 
Membrane protein Inhibition of 
protein G 
signaling 
To monitor PPIs between 
integral membrane 
proteins. 
56 
RNA polymerase III 
based two-hybrid   
Trans activating 
proteins in the RNA 
polymerase II pathway 
Transcriptional 
Activation 
Activation of RNA-polIII 
transcription by 
recruitment of 
transcriptional activator 
57 
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Repressed trans 
activator system 
Trans activating 
proteins capable of 
entering nucleus 
Inhibition of 
transcriptional 
activation 
Interaction between 
transcriptional activator in 
the nucleus. 
41,43 
Reverse Ras 
recruitment 
system 
Membrane proteins Ras signaling The prey is a Ras fused 
protein and the bait a 
membrane protein. 
Principle of the RRS 
58 
CINEX-P System Extracellular proteins Downstream 
signaling and 
transcriptional 
activation 
System to show PPIs in the 
ER  based on the Ire1p, a 
type 1 ER membrane 
protein and the activation 
of the unfolded protein 
response 
59 
Split-Trp System Cytosolic, membrane 
proteins 
Trp1p activity The split-Trp protein 
sensors allow for the 
detection of PPIs by 
enabling trp1 cells to grow 
on medium lacking 
tryptophan 
60 
Cytosolic split-
ubiquitin system 
Trans activating, 
cytosolic proteins 
Transcriptional 
activation 
Used for membrane 
anchored cytosolic baits 
and occurs close to the ER 
membrane   
61 
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Figure 19 The Yeast two-hybrid systems, their subcellular location within a yeast cell, and their operating 
mode (represented at the moment of bait-prey interaction). 
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Protein X: bait, dark blue puzzle piece; Protein Y: prey, light blue puzzle piece. 
When X and Y interact three events can occur: reconstitution of a split-protein, like in A, D and E; membrane 
recruitment, such as in B and C, or protein dimerization, F.  
(A) Nuclear Y2H systems occur in the nucleus. Y2H and RTA Y2H require RNA pol II activity while PolIII Y2H
involves RNA pol III. (B) Ras signaling based Y2H: SRS, RRS and rRRS Y2H are based on the recruitment of the
proteins to the membrane. The interaction of X and Y activate the MAPK downstream pathway. (C) G-protein
signaling-based Y2H: able to investigate interaction between integral membrane bait and a soluble prey fused
to the ?-subunit of a heterotrimeric G-protein. The interaction of X and Y lead to the recruitment of  G-protein
?-subunits and the subsequent inactivation of the G protein signaling pathway, involved in pheromone
response and used as a read out. (D) Split-ubiquitin based Y2H systems: the subcellular localization depends
from the nature of X and Y and on the reporter. The interaction leads to complementation of ubiquitin followed 
by proteolytic release of the dha reporter detected via western blot, or of a transcription factor or of a
destabilized version of the URA3 enzyme. RUra3p undergo rapid degradation after being released. In absence if 
the enzyme cells grow in medium with 5-FOA and this is used as read out. The MbY2H (membrane trans
activator split-ubiquitin) system is used for interaction between membrane proteins of the endoplasmic
reticulum. The CytoY2H is an adaptation of MbY2H to investigate cytosolic proteins which are anchored to the
ER membrane. (E) Split-protein sensor Y2H. The Split-Trp Y2H is based on the reconstitution of the activity of an 
enzyme responsible for the synthesis of tryptophan. (F) ER Y2H system. The SCINEX-P (screening for interactions 
between extracellular proteins) system is based on signaling of the yeast unfolded protein response (UPR) using
the properties of Ire1p, a type I transmembrane (TM) protein that resides in the yeast E. The activation of Ire1p
leads to translation of HAC1. In the system, X is fused to an Ire1 variant (Ire1p) able to splice Hac1 mRNA for
translation only when the interaction with Y occurs. The prey is fused to a variant of ire (?Irep) able to
phosphorylate only the associated Ire1 partner. The phosphorylation activates Ire1p and the transcription of
the reporter gene. (Figure from40).
II.2.3.1.3 Genetic Protein-Protein Interaction Methods in Prokaryotes: a quick overview 
Despite the limitation given by the lack of PTMs, prokaryotes are still considered a valid alternative 
to yeast for two-hybrid methods. Working with Escherichia coli allows very fast experiments given 
the fast growth of the bacteria and the high transformation efficiency. The sensitivity of a prokaryote 
system is higher if we consider the lack of endogenous proteins, which could compete with bait and 
pray for binding. Additionally the toxicity levels in yeast can differ from prokaryotic cells. Different 
systems have been developed in E. coli for PPIs studies33. 
The Repressor-based two-hybrid  system was the first bacterial two-hybrid  approach to be 
developed62. It uses the LexA repressor and is able to detect interactions via a technically easy and 
quantitative assay. The repressor is a homodimeric DNA binding protein where the N-terminal 
domain represents the DNA binding domain (DBD) and the C-terminal domain is responsible for the 
dimerization necessary for stable DNA binding. The proteins of interest X and Y can be fused each 
with a different variant of the LexA repressor to avoid prey interactions. If they interact, the 
heterodimerization induces an efficient repression of the reporter gene lacZ. Quantitative ?-
galactosidase assays are performed to measure the effect of the two-hybrid proteins on reporter 
gene expression. An adaptation of the technique was developed by the use of the bacteriophage ? cI 
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repressor as DBD and the subunit of RNA polymerase as AD63. Joung and colleagues64 developed 
another variant where a motif of murine Zif268 is used as DBD and the AD is an operon of HIS3. The 
output is given by the activity of the spectinomycin resistance gene aadA. Other variants of the 
original system are listed in Table 6, shown in Figure 20 and reviewed by Stynen et al. 33.  
Table 6 List and description of Y2H variants 
Method Variants Description And References   Figure 
20  
Repressor-based 
two-hybrid system 
Interaction between two proteins of interest, X and Y, can be 
monitored by fusion of each with a variant of the LexA repressor (408 
or wild type). Heterodimerization given by the interaction activate the 
repression of the reporter lacZ. 
62 (A) 
PhaR two-hybrid 
system 
The bait X is fused to the DNA-binding domain (DBD) of the repressor 
PhaR and the prey Y is fused to PHB granule-associated protein PhaP: 
the interaction permit the recruitment of PhaR to PHB granuls which 
results in lacZ expression. 
65 (B) 
GFP recruitment 
system 
The bait X localizes at the cell division sites thanks to the activity of 
fusion protein B. subtilis DivIVA.  The prey protein is fused to GFP. In 
case of interaction, a fluorescence will be localized the division sites. 
(GFP recruitment systems are also available for the pathogenic fungus 
Candida albicans, for C. elegans, and for mammalian cells.) 
66 (C) 
ToxR two-hybrid 
system 
The V. cholerae ToxR transcriptional activator requires dimerization of 
its periplasmic domain for full reporter transcriptional activation. In the 
ToxR two-hybrid system, the periplasmic domain is replaced by two 
proteins of interest, X and Y. An interaction between these two 
proteins results in efficient ctx promoter binding of the truncated ToxR 
protein (ToxR=) and subsequent gene expression of lacZ or the 
chloramphenicol acetyltransferase gene (cat) 
67 (D) 
Tat two-hybrid 
system 
The Tat signal sequence (ss) peptide tethers bait protein X to the 
periplasm. A chimeric fusion of prey Y with the maltose-binding protein 
without a signal sequence (ssMBP) localizes to the periplasm only upon 
interaction of X with Y. This translocation is required for growth on 
medium with maltose as the sole carbon source. Alternatively, the prey 
protein Y is fused to a localization-deficient DsbA enzyme (ssDsbA), 
which catalyzes the formation of active alkaline phosphatase (AP). 
Active AP converts p-nitrophenyl phosphate (pNPP) to yellow p-
nitrophenol (pNP) 
68 (E) 
Bacterial two-
hybrid system for 
DNA-protein 
interactions 
To increase sensitivity in the search for zinc finger-DNA associations, 
the binding of a zinc finger motif X to its target DNA sequence, Y (zinc 
finger binding motif Zfbm Y), is facilitated by inclusion of two fixed zinc 
fingers from Zif268 and the target DNA sequence Zif268 bm. The zinc 
finger fusion further consists of the S. cerevisiae Gal11 interaction 
domain (Gal11 ID), which binds the S. cerevisiae Gal4 dimerization 
domain (Gal4 ID). The latter domain is fused to the N-terminal domain 
of the RNA polymerase subunit for indirect activation of an operon 
comprising the S. cerevisiae auxotrophic marker HIS3 and aadA, which 
64 (F) 
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confers resistance to spectinomycin. 
Bacterial reverse 
two-hybrid system 
Interaction between chimeric proteins of bait X with the bacteriophage 
cI repressor (which binds the cI OR2 operator) and prey Y with the N-
terminal domain of the RNA polymerase subunit results in activation of 
a gene encoding the C-terminal domain of the bacteriophage 186 cI 
repressor (186 cI CTD). This truncated protein sequesters and 
inactivates full-length 186 cI, which normally downregulates cytotoxic 
186 prophage genes. Resulting cell death can be circumvented by 
mutations that block the bait-prey interaction. 
69 (G) 
Intein-mediated 
split-GFP assay 
Bait protein X is in fusion with the N-terminal fragments of the intein 
VDE and GFP, while prey protein Y constructs include their respective 
C-terminal counterparts. Interaction between X and Y reconstitutes 
VDE, which splices out and covalently reattaches the GFP fragments to 
create an isolated GFP monomer, detected by fluorescence.  
70 (H) 
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Figure 20 Specific bacterial genetic PPI detection methods. 
 (A) Repressor-based two-hybrid system (B) PhaR two-hybrid system. (C) GFP recruitment system. (D) ToxR two-
hybrid system. (E) Tat two-hybrid system. (F) Bacterial two-hybrid system for DNA-protein interactions. (G) 
Bacterial reverse two-hybrid system. (H) Intein-mediated split-GFP assay. For references and details see text, 
table and Stynen et al., 201233. (Figure and description adapted from33) 
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II.2.3.1.4 Two-hybrid  systems in mammalian cells 
As described above, the Y2H system shows several limitations despite its high number of benefits. 
The mammalian two-hybrid  systems have been developed to study human or mouse protein 
interactions in a more natural environment. These systems may better mimic the in vivo situation, in 
terms of the natural folding, the posttranslational modifications and the cellular localization of the 
proteins being investigated. 
M2H system 
The mammalian two-hybrid  system (M2H system) is a conceptual replica of the Y2H: it is a genetic, 
in vivo assay based on the reconstitution of the function of a transcriptional activator. The GAL4 DBD 
is fused with protein X and the AD of the Herpes simplex VP16 protein is coupled to protein Y. The 
interaction of protein X with protein Y activates the transcription of the reporter gene. As reporter 
genes are mostly used those encoding luciferase, beta-galactosidase or chloramphenicol 
acetyltransferase (CAT)71. The M2H system can be used to verify PPIs detected via Y2H screenings 
and it was first used to study leucine zipper interactions: in 1991 Dang et al. observed, via M2H, the 
oligo dimerization in Chinese Hamster Ovary cells between leucine zipper regions from c-Jun and c-
Fos72. 
Based on the same principle of the Ras recruitment system in yeast, an adaptation of the system was 
also developed in mammalian cells, the so-called mammalian RRS: it can be used as a validation 
method of the yeast RRS system basically for every cytoplasmic protein (except for the ones 
interfering with the MAPK pathway)73. This method was used to confirm the interaction between 
Grb2 and Sos in HEK293 cell line and p11 and p85 of the phosphatidylinositol 3-kinase (PI3K)73. 
Protein fragment complementation assays (PCA) 
Protein fragment complementation assays (PCAs) are another set of techniques that allow the 
detection of PPIs in cells in vivo 74. PCAs are based on the principle that proteins should exist in close 
proximity so that complementation and folding can occur (different PCA strategies can be found in 
Table 7). From the ubiquitin-based split protein sensor, which is based on the complementation of 
two inactive subunits to form a functional protein in yeast (see paragraph II.2.3.1.2 of this 
dissertation), different analogous techniques have been developed. The main differences are in the 
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type of protein fragments. Briefly, a functional protein is reconstituted by the interaction between 
bait and prey tagged with non-functional halves of this protein (Figure 21).  
 
 Figure 21 Schematic representation of the BiFC analysis.  
The N-terminal and C-terminal fragments (YN and YC) of 
YFP are fused to two proteins of interest (A and B). If A 
and B interact, the formation of a fluorescent complex 
occurs. Modified from 75,76. 
 
 
 
One of the most important advantages of the technique is that the interaction generates a 
functional protein that can activate the reporter gene or even act as a reporter itself, providing the 
read out of the assay directly where the interaction occurs77,78. Many reporter proteins can be used 
and different PCA strategies have been developed using the complementation of diverse proteins as 
a read out. An overview of different PCA strategies is shown in table 6. When the strategy is applied 
in the context of fluorescent proteins, the technique is named bimolecular fluorescence 
complementation assay or BiFC. Originally, the Fluorescence complementation (FC) was shown in 
vitro using GFP fragments in Escherichia coli79. This was the basis for Kerppola and colleagues to 
develop the FC method in mammalian cells, using a yellow fluorescent protein (YFP): it was first used 
for the visualization of the interactions between the basic leucine zipper (bZIP) and NF-?B family of 
proteins in mammalian cells. The unique characteristic of the method is that allows direct 
visualization of PPIs in living cells: the signal is directly visualized by fluorescent microscopy or 
analyzed by flow cytometry76,80,81. 
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Table 7 PCA strategies, modified from82 
Strategy Readout System Advantages Disadvantage Ref. 
Split Ubiquitin 
System 
Coupled 
reporter 
Flexibility in reporter system. 
Signal amplification. 
No exogenous substrate for 
detection of 
complementation. 
Require endogenous 
activity. 
Irreversible cleavage of 
reporter. 
83
Split ?-
galactosidase 
assay 
Absorbance 
Fluorescence 
Signal amplification. Irreversible 
complementation. 
Exogenous substrate 
required for detection of 
complementation. 
84
Dihydrofolate 
reductase 
complementation 
Fluorescence 
Cell survival 
Signal amplification. Irreversible 
complementation. 
Exogenous substrate 
required for detection of 
complementation. 
85
?-lactamase 
protein fragment 
complementation 
Absorbance 
Fluorescence 
Signal amplification. 
Fast complementation. 
Irreversible 
complementation. 
Exogenous substrate 
required for detection of 
complementation. 
86
Bimolecular 
fluorescence 
complementation  
(YFP fragments) 
fluorescence High spatial resolution. 
No exogenous substrate for 
detection of 
complementation. 
Slow fragment 
complementation. 
Irreversible 
complementation. 
No signal amplification. 
87,88
Luciferase 
complementation 
Bioluminescence Fast complementation. 
Study of protein interaction 
dynamics via reversible 
complementation. 
Signal amplification. 
Exogenous substrate 
required for detection of 
complementation. 
89
Split TEV assay Coupled 
reporter 
Flexibility in reporter system. 
Signal amplification. 
No exogenous substrate 
required for detection of 
complementation. 
Irreversible cleavage of 
reporter.  
89
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The mammalian-membrane two-hybrid assay (MaMTH)  
MaMTH is based on the ubiquitin-based 
split protein sensor technique and it was 
developed for the study of interactions 
between membrane proteins in human 
cells in a stimulus-dependent manner. 
Ubiquitin is divided in two fragments, Nub 
and Cub. The prey protein is fused to the 
Nub fragment and the bait forms a fusion 
protein with the Cub fragment linked to a 
transcription factor (TF), which is cleaved 
from specific DUBs if interaction with the 
bait occurs. The TF migrates to the nucleus 
and activates the reporter gene90 (Figure 
22). As cell line, Hek293T cells stably 
expressing reporter constructs are used. 
The system was first successfully applied to 
show the known interactions between the 
ErbB4 and EGF receptors.  
 
Resonance energy transfer system 
The resonance energy transfer (RET) principle91 is based on Stryet’s studies. He observed that 
electron excitation energy could be transferred over distances of the order of 30 Å. This process is 
the cause of light-induced damage, which occurs during the so-called photodynamic action92. 
Based on RET, two techniques have been developed in order to study PPIs in living cells: Förster 
resonance energy transfer (FRET) and bioluminescence resonance energy transfer (BRET). The FRET 
is based on a radiation-free energy transfer between neighboring molecules. With conventional 
fluorescent microscopy it is possible to analyze the localization of labelled molecules in a spatial 
resolution limit of approximately 200 nanometers (0.2 micrometers). In order to study the 
occurrence of PPIs and the relative proximity between these proteins, new and not diffraction 
Figure 22 The MaMTH system.  
In MaMTH bait and prey fusion proteins are cotransfected 
into HEK293T cells. In case of interaction, a TF is released
that activates the reporter genes responsible for the 
transcription of luciferase or GFP.  
Modified from 90. 
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limited approaches were required: the FRET technique, when applied to optical microscopy, is able 
to determine intermolecular distances of a few nanometers. 
Figure 23 Schematic diagrams showing the three conditions necessary for efficient FRET. 
Picture taken from 93 
The core of the technique is the fact that the energy transfer can occur between any two 
chromophores, assuming that the emission spectrum of the donor overlaps with the excitation 
spectrum of the acceptor (Figure 23 a). Importantly, Förster and others have shown that the energy 
transfer efficiency is highly dependent on the distance between the donor and acceptor and their 
relative orientation (Figure 23 b and c)92,94 . 
Different fluorescent proteins can be coupled 
to the investigated proteins, characterized by 
distinct emission and excitation spectra, 
including cyan fluorescent protein (CFP), GFP, 
YFP and Dansyl-Fluorescein (FITC)95. 
The FRET technique opened possibilities for 
different applications. The intermolecular 
FRET (Figure 24) can occur between one 
Figure 24 Intermolecular FRET 
Description in the text. Figure modified from 96 
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molecule (protein A) fused to the donor (CFP) and another molecule (protein B) fused to the 
acceptor (YFP). When the two conjugated proteins bind to each other, FRET occurs; when they 
dissociate, FRET diminishes.  
The detection method of FRET is also a discriminant to obtain more accurate results: commonly the 
detection methods are based on intensity or fluorescence lifetime. Fluorescence lifetime imaging 
microscopy is considered the most accurate detection method95. For long time, the cyan and the 
yellow pairs of fluorescent protein have been the most common, but lately they have been replaced 
by green-red variants to permit a longer wavelength excitation and to reduce auto fluorescence and 
photo toxicity96. Despite the many advantages of using fluorescent proteins, it is important to 
mention the complications by auto-fluorescence, photo-bleaching or photochemical destruction of 
the fluorophores. To avoid this downside of the FRET technology, bioluminescence resonance energy 
transfer (BRET) has been developed. Instead of using a fluorescent protein as a donor, BRET utilizes a 
bioluminescent luciferase (typically from Renilla reniformis). The donor and the investigated protein 
are fused while a GFP mutant is fused to the putative interaction partner. Luciferase, in the presence 
of its substrate (coelenterazine), emits bioluminescence leading to the excitation of the acceptor and 
consequently the emission of fluorescence. The transfer is possible if the distance between the 
luciferase and the fluorescent protein is less than 100 Å. The first example of BRET was the 
demonstration of the homodimerization of the clock protein KaiB from cyanobacteria97. 
MAPPIT  
(Forward) MAPPIT is a cytokine receptor-
based two-hybrid system that operates in 
mammalian cells98. The technique is based 
on type-I cytokine signal transduction. Type-
I cytokine receptors such as erythropoietin 
receptor (EpoR), growth hormone receptor 
(GHR), leptin receptor (LR) and granulocyte 
colony stimulating factor receptor (G-CSFR) 
show a highly conserved structure in their 
extracellular domain, which is responsible 
for the binding of the ligand and they mostly 
Figure 25  MAPPIT. The concept  
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transduce the signal intracellularly via the JAK-STAT pathway. Such receptors do not show any 
intrinsic kinase activity and phosphorylation occurs in association with JAKs (Janus kinases). Upon 
binding of the ligand to the receptor, a reorganization of the receptor subunits occurs which leads to 
the cross-phosphorylation of tyrosine residues on the receptor-associated JAK kinases. These events 
enable the recruitment and activation of STAT transcription proteins. Phosphorylated STATs migrate 
as dimers in the nucleus and activate specific gene transcription (Figure 25 and Figure 26a). It has 
been shown in different receptor systems that the mutation of certain tyrosine residues in the 
cytosolic domain of the receptor leads to the complete loss of STAT activation. The MAPPIT 
technology applies this finding to create a non-functional mutated receptor able to restore its 
function in case of interaction between the bait and the prey. 
The first hybrid protein used in MAPPIT is a receptor chain that consists of the extracellular domain 
of the human erythropoietin receptor (Epo) receptor and the transmembrane and intracellular 
domain of a mutated murine leptin receptor (LR) that still allows JAK activation but is deficient on 
STAT3 recruitment sites: tyrosine (Y) Y985, Y1077 and Y1138 are replaced by phenylalanine (F) 
residues. The mutation of the three conserved Y residues in its cytoplasmic domain to F knocks out 
STAT3 activation and also disables feedback mechanisms. The bait is C-terminally fused to such 
mutated receptor. The second hybrid used is the prey protein linked to a receptor fragment 
containing functional STAT3 recruitment sites, such as the C-terminal part of gp130, a signaling 
subunit of receptor complexes for ligands of the interleukin-6 family. After co-expression, bait and 
prey interactions are observed as functional complementation of the signaling pathway: upon 
stimulation with the ligand and bait-prey interaction, STAT3 molecules are able to migrate to the 
nucleus and induce transcription, as detected by using reporter or selection target genes. In the 
original model, the read-out was either a STAT3 phosphorylation test or a STAT3-based reporter 
assay leading to the expression of luciferase or an IL5R?-derived membrane-tag. In the Binary 
MAPPIT models, the luciferase-based reporter assay is usually the read out of choice. For the 
detection, the reporter construct used consists of the luciferase gene under the control of the rat 
pancreatitis-associated protein 1 (rPAP1) promoter, which is a strong STAT3 responsive promoter99. 
The approach was evaluated using well-known interactions namely those between SV40 large T 
antigen (SVT) and p53, and between a member of the SOCS family and its binding motif 
(phosphorylated Tyr 402) in the Epo receptor, demonstrating how the technique can detect both 
modification–independent and tyrosine-phosphorylation dependent interactions98. Like every 
technique, MAPPIT technology has some limitations when it comes to general applications. 
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However, the derivation of related technologies from the standard protocol with different modes of 
action has enabled the analysis of a broad set of PPIs. 
The MAPPIT system has been adapted to different needs. For example, to study protein interactions 
with the LR in its normal oligomeric configuration, different residues of Y can be mutated into F. In 
this case, LR itself is the bait protein and if the Y1138F mutation is present, STAT3 is not 
recruited.  Upon stimulation, the other two tyrosine residues can be phosphorylated by JAK2. The 
interaction with the prey activates STAT3 and induces the reporter. The cytosolic domain of the 
receptor itself can be replaced by a flexible linker composed of Gly-Gly-Ser (GGS) repeats preventing 
any background activation resulting from prey association with the LR-F3. This replacement is 
possible since only the membrane proximal region of the LR is responsible for the binding with 
JAK2100. Another variant is the adaptation of MAPPIT to cells which do not express high levels of 
STAT3. Hematopoietic cells are a representative example where STAT3 is expressed at very low 
levels while STAT5 is highly expressed. In this case, instead of being coupled with gp130, the prey 
plasmid includes a fragment of the ?c (beta common) receptor which bears STAT5 recruitment 
sites101.  
As mentioned above, the MAPPIT technology can detect tyrosine phosphorylation-dependent 
interactions. To enable the detection of other modification-dependent interactions, Heteromeric 
MAPPIT has been introduced102 (Figure 26b). Here, the chimeric receptor bait contains, instead of 
the EpoR extracellular domain, the extracellular domains of each of the subunits of the heteromeric 
granulocyte/macrophage colony stimulating factor receptor (GM-CSFR): the ? chain with the ligand 
binding site and a ?c chain responsible for signal transduction. While one ectodomain is coupled to 
the bait protein, the other one is fused to a modifying enzyme: after expression, the bait is 
enzymatically modified and allows the modification-dependent interaction with the prey. Ligand 
stimulation remains responsible for the STAT3 activation, detectable in the MAPPIT tests. This 
method was first used by Lemmens et al. to detect serine phosphorylation-dependent interactions in 
TGF-?R (transforming growth factor-? receptor) family signalling102.  
Another variation of the MAPPIT system is the so-called Reverse MAPPIT (Figure 26c). In this case, a 
positive read out is generated upon interference with a PPI, i.e. the dissociation of a protein moiety 
able to inhibit the active form of the cytokine receptor complex. Here, the leptin receptor is 
functional but the prey is bound to a phosphatase which inhibits JAK/STAT signaling. Competing 
proteins or small organic proteins can destroy the interaction between the inhibitory prey and the 
bait, leading to the reactivation of the signaling pathway.  
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Figure 26 Overview of the different MAPPIT approaches. 
(a) MAPPIT: the bait X is anchored to a mutated cytokine receptor containing a mutated STAT recruitment site
unable to mediate cytokine signalling. The prey Y is fused to a fragment of gp130 showing functional STAT
docking sites (black dots). If X and Y interact, the signaling is reconstituted and STAT3 undergoes tyrosine
phosphorylation. Phosphorylated STAT3 migrates to the nucleus, binds to the rPAP-1 promoter and activate the 
transcription of the reporter gene. (b) Heteromeric MAPPIT: the system uses the extracellular domain of GM-
CSFR composed of two chains. The bait is fused to one chain while the other chain is coupled with a modifying
enzyme (E) able to modify the bait. After such modification, the prey can recognize the bait, interacts and
activate the JAK/STAT signaling cascade.
 (c) Reverse MAPPIT: in this case the receptor is functional but the prey Y is linked to a domain (‘‘I’’) which
inhibits the JAK/STAT signaling cascade. Using a competitor or a small molecule the interaction between bait
and prey can be disturbed and the signaling reactivated. (d) MASPIT: it is a three hybrid approach where the
chimeric receptor is coupled with DHFR (“D”). Methotrexate (MTX) fusion compound contains a small molecule
of interest coupled with MTX. MTX binds to DHFR presenting the small protein as bait. The interaction with a
prey protein Y results in the transcription of the reporter gene103.
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Besides all these variations, there is also a three-hybrid system, named MASPIT104 (Figure 26D), 
which allows organic molecules to be displayed as bait through the use of chemical dimerizers. The 
chimeric receptor is fused to DHFR (dihydrofolate reductase) : it traps a methotrexate (MTX) fusion 
compound (MFC) in which a small molecule is connected to MTX via a polyethylene glycol (PEG) 
repeat linker. This fusion compound thus includes the organic molecule able to act as bait. If the 
binding of a protein prey to the fusion compound occurs, then the signaling cascade of STAT3 can be 
initiated. MASPIT also allows screening for novel protein targets of a certain organic molecule. For 
the analysis, both the FACS-based cDNA library screening or the array-based procedure can be used 
(see below). 
The applications of the MAPPIT technology cover a wide range of possibilities.  
Among the applications of MAPPIT, the technology has been performed for pathway walking 
analysis. Ulrichts et al.105 performed binary MAPPIT experiments to investigate the Toll Like Receptor 
(TLR) pathway: TLRs are a family of proteins which play a role in the innate immunity. The signaling 
pathway is activated by the interaction of the receptor complex with one or more adaptor proteins 
which are recruited via homotypic TIR– TIR (Toll/IL-1 receptor domain) domain interactions. MyD88 
(Myeloid Differentiation primary response protein 88), Mal/TIRAP (MyD88-adaptor-like protein/TIR 
domain containing adaptor-like protein), Trif/Ticam-1 (TIRdomain containing adaptor inducing 
interferon-b/TIR containing adaptor molecule), Tram/Ticam-2 (Trif-related adaptor molecule/TIR 
containing adaptor molecule-2) and Sarm (sterile alpha and HEAT-Armadillo motifs containing 
protein) are examples of TIR-containing adaptor proteins. In this study, MAPPIT technology was used 
to investigate TLR adaptor recruitment: all known TLR adaptors were screened as baits or preys 
along with the intracellular part of TLR4 as bait to detect interactions downstream (the 
homodimerization of the receptor with IRAK4106). 
The MAPPIT technology can also be applied for drug screening. As a proof-of-concept study, Reverse 
MAPPIT has been used to detect the disruption of the interaction between MDM2 and p53 by 
Nutlins 107. The E3 ubiquitin-protein ligase MDM2 interacts with p53 leading to ubiquitination and 
protein degradation in the proteasome of p53, abolishing the apoptotic functions of p53 and the 
cell-cycle arrest108. This interaction became subject of therapeutic studies since its inhibition in 
cancer cell lines leads to induction of CDKN1A expression, cell cycle arrest and apoptosis.  Nutlins are 
cis-imidazoline analogues able to inhibit the interaction between p53 and MDM2 as they bind a 
hydrophobic region of MDM2 responsible for the p53 interaction109. Technically, the receptor is 
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capable of STAT activation while the prey includes a module which interferes with the JAK-STAT 
signaling: interaction of the inhibitory prey and the bait results in inhibition of reporter induction. 
Competing proteins and small molecules can be used to disrupt the interaction: this will restore the 
signaling, thus leading to a positive readout. Different interactions have been monitored with this 
technique including EpoR and SOCS interaction or FKBP12 and ALK-4107. 
Drug profiling is another field where MAPPIT technology can be successfully applied. MASPIT 
(MAmmalian Small molecule Protein Interaction Trap), for instance, was used to evaluate the ABL 
kinase inhibitor PD173955110. In this study, a cDNA library screen was performed using PD173955 as 
bait and several additional tyrosine kinases were identified. Finally, MAPPIT technology can be 
applied in large-scale interactome mapping. 
To summarize, a key advantage of the MAPPIT technology is its ability to study the molecular 
interactions in the optimal physiological context for human (or mouse) protein interactions since it is 
performed in mammalian cells. The commonly used cell type is Hek293T, but different cell types, 
including epithelial, hematopoietic and neuronal cells can also be used. Dynamic, weak and transient 
interactions can be detected by the system and the procedure is fast, makes use of simple read-outs 
(making it suitable for large-scale analyses) and can be largely automated (for Array-MAPPIT), which 
gives a convenient cost-benefit.  
Recently, a new in situ technology was developed on the basis of the MAPPIT system concept. A 
limitation in the original MAPPIT is the fact that the bait is linked to the plasma membrane: this 
means that some interactions cannot occur in their native localization and full-size transmembrane 
proteins cannot be used as baits. Furthermore, MAPPIT applications revealed an intrinsic artefact: 
TYK2-containing prey fusion proteins were identified as constitutive positive signals from multiple 
screening campaigns. To overcome those limitations a variation of the MAPPIT technology called 
KISS or KInase Substrate Sensor has been developed (Figure 27). 
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The fact that preys containing TYK2 fused to gp130 show a cytokine-independent MAPPIT reporter 
activity, means that TYK2 can phosphorylate both the STAT3 binding sites in the gp130 fragment and 
STAT3 itself. TYK2 has this inherent ability provided it is fused with gp130 in cis. By designing the 
assay in such a way that bait-fused TYK2 and prey-linked gp130 are provided in trans, the luciferase 
reporter signal depends on bait-prey interaction. So in this new method, the prey is the same as this 
in the original MAPPIT assay, but the bait is coupled with a constitutively active tyrosine kinase: if 
bait and prey interact, STAT3 phosphorylation occurs followed by the activation of the luciferase 
reporter111. 
Different studies have been performed to show the broad range of interactions detectable by KISS, 
involving proteins with different topological characteristics and occurring in different subcellular 
compartments. For example, cytoplasmic interactions between p51 and p66 subunits of HIV-1 RT 
were detected with KISS. PPIs involving G protein–coupled receptors (GPCRs) were demonstrated 
using the interaction of somatostatin receptor 2 (SSTR2) or angiotensin receptor 1 (AGTR1) with beta 
arrestin 2 (ARRB2) implying correct localization at the membrane of GPCR-TYK2. Interactions 
between integral transmembrane proteins can be detected as well with KISS: the technique was 
successfully used to show the ER stress-induced oligomerization of the transmembrane ER stress 
sensor ERN1112. 
 
Figure 27 KISS.   
In the KISS method the bait is coupled to a 
constitutively active tyrosine kinase able to 
activate STAT protein upon interaction of X 
and Y. The activation of STAT3 leads to 
reporter gene expression. Picture from 111. 
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II.2.3.2 Biochemical methods
II.2.3.2.1 Coimmunoprecipitation (CoIP)
The term immunoprecipitation (IP) refers to a technique used for antigen detection and purification 
using a specific antibody. Detection can then be done either by western blot analysis or by mass 
spectrometry. CoIP follows the same basic idea and is used also to purify molecules bound to the 
antigen: in this way, intact protein complexes can be immunoprecipitated (Figure 28).  
CoIP is a commonly used biochemical technique for the analysis of PPIs, including interactions of 
subunits in a protein complex. The analysis is most often performed on a whole-cell extract and the 
use of eukaryotic cells allows posttranscriptional modifications, which may be important for 
formation or maintenance of the PPI. To immuno-purify the target protein together with all its 
interacting partners, an antibody (monoclonal or polyclonal) directed against the antigen of interest 
is added to the cell lysate and will form an immune complex with the target. This complex can then 
be purified after being captured by an immobilizing support such as protein-G or protein-A 
Sepharose: those proteins can bind the IgG from a variety of mammalian species through their Fc 
Figure 28 Summary of a standard coimmunoprecipitation assay. 
Picture from https://www.thermofisher.com 
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region113. The eluate is analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and this is often followed by a western blot analysis to confirm the identity of the antigen. 
Obviously the collection of available antibodies doesn’t cover the complete list of antigens that can 
be considered as protein of interest. To circumvent this limitation, a target protein is often fused to a 
protein tag like glutathione S-transferase (GST), or to an epitope tag such as HA, HIS, V5. When using 
a GST-tagged protein the assay is called a GST pull-down assay. This assay is used when bait-protein 
specific antibodies are not available or when it is difficult or impossible to find a cell line able to 
express the bait protein. An affinity system is then used instead of an antibody: i.e. a glutathione 
resin able to bind the GST fused proteins. It is important to underline that this is a heterologous 
system, which means that it might show some downsides such as: the protein may be problematic to 
express, the protein cannot be purified because it is not soluble, and the protein might be non-
functional when expressed. On the other hand, using a tag gives the advantage that it can be easily 
fused to different proteins so that the same antibody can be used economically.  
The fact that the concept of a CoIP experiment is straightforward does not mean that all CoIP 
experiments need to follow a single protocol. More specifically, relevant aspects need to be 
considered including the nature of the interaction, the nonspecific binding to parts of the IP assay 
and the antibody-dependent background. A critical step of the CoIP assay is the stability of the 
interactions during the washing steps since mechanical and chemical stresses are applied on the 
complexes during their enrichment. In the case of labile complexes, the composition of the lysis 
buffer needs to be optimized. To avoid disruption of the interactions, sonication and vortexing are 
non-advised. A solution for unstable complexes is to perform a crosslinking step: with this approach 
proteins belonging to the same complex are covalently cross-linked and the bait protein can be 
precipitated without the risk of losing interaction partners during the CoIP. A common problem of 
the CoIP assay is the interference of the antibody bands during the gel analysis: the light chain and 
the heavy chain of the antibody are co-eluted with the targets and show a 25- and a 50-kDa band in 
reducing SDS polyacrylamide gels, which could overlap with the protein bands under study. To avoid 
the presence of the antibody chains in the eluate, the antibody can be immobilized to the support, 
allowing a more specific elution of the target and its binding partners114,115. 
To validate the results of CoIP experiments different controls are needed. Use of a monoclonal 
antibody will avoid the risk of non-specific pulldown by a heterogeneous mixture of antibodies, but if 
a polyclonal antibody is unavoidably the choice, it can be used first in a comparable lysate that does 
not contain the target protein, in order to remove reactive but non-specific antibodies. It is also 
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important to prove that the co-precipitation requires the antigen of interest; for this purpose a 
control sample without lysate can be used in parallel. A pulldown with an irrelevant antibody of the 
same species and isotype as the specific antibody, is a good negative control to test the system. 
In the classic CoIP protocol, Sepharose beads are used as solid support: the main characteristic of 
this resin is the high porosity, perfect for the original aim of purifying milligrams of proteins in 
columns, but much less for small-scale techniques such as CoIP. To avoid antibody background and 
loss of proteins during the washing, magnetic beads have been developed. Those beads are small 
and nonporous to avert the occurrence of hidden faces where the antibody could bind aspecifically; 
so less washing steps will be required. The properties of the magnetic beads make the experiments 
more productive and reproducible. The disadvantage of these magnetic beads is the cost, which is 
considerably higher when compared to the sepharose beads. 
II.2.3.2.2 Luciferase based CoIP methods 
LUMIER is a luminescence-based mammalian assay that combines a genetic and a biochemical 
method.  Co-affinity purification is used to enrich a protein from the extract and consequently its 
interactors. This principle was used and optimized to obtain an assay based on a luciferase read out.  
A protein is fused to a FLAG-tag and the other 
contains the Renilla luciferase enzyme. An anti-flag 
antibody is used to precipitate the protein complex 
of interest and a luciferase read-out is used to show 
the presence of an interaction (Figure 29). Barrios-
Rodiles and colleagues developed the technique to 
systematically map PPI networks in mammalian cells 
and they applied it to the transforming growth 
factor–? (TGF?) pathway116. A disadvantage of the 
method is that FLAG-tagged proteins cannot be 
quantified. Recently a new version of the technique, 
called LUMIER with bait control (LUMIER with 
BACON) was developed. The FLAG-tagged proteins 
are systematically quantified by ELISA117,118. 
 
Figure 29 LUMIER is luminescence-based strategy
for the detection of mammalian protein-protein
interactions 
Luciferase-tagged bait is coexpressed with a Flag-
tagged prey. Detection is detected as light 
emission. Picture from 116 
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Another dual luciferase reporter pulldown assay used for PPIs is DULIP, for dual luminescence-based 
co-immunoprecipitation assay. This method allows quantification of both bait and prey hybrid 
proteins using two different luciferase tags. The bait protein includes a protein A tag for co-
precipitation of the complex in the microtiter plates. Quantitative interaction maps can be calculated 
through normalization of the interaction ratios for all the tested proteins. In 2015, Trepte and 
colleagues used this technique to investigate the effect of point mutations in the interaction 
strength of synaptic proteins119,120. 
II.2.3.2.3 Affinity Chromatography  
Affinity chromatography separates proteins on the basis of the reversible formation of protein-
ligand complexes. This technique shows high resolution and high selectivity and usually results in 90-
99% purity. A target protein is immobilized on a solid support in a column and the cell lysate is 
added: only specifically binding proteins will be retained and in principle all the remaining proteins 
can be simply washed away. The bound proteins can be eluted by high salt concentration solutions, 
chaotropic solvents or SDS 115,121. It is convenient to label the extract in vivo with tags. This step will 
favor detection with high sensitivity and the non-labelled binding proteins can be excluded. This 
technique was used for the first time in 1976 to detect phage and host proteins that interacted with 
different forms of E. coli RNA polymerase122. The purification power of the experiment can be 
enhanced by the use of a second affinity tag. In case of affinity chromatography high-throughput 
screening, a particularly interesting multi-tag is the tandem affinity purification (TAP) tag123. The 
TAP- tag is a composite tag, which includes two different epitope domains and a protease cleavage 
site: it is composed of a calmodulin binding peptide (CBP) followed by the Tobacco etch virus (TEV) 
protease cleavage site and two IgG binding units of protein-A of Staphylococcus aureus. The strategy 
is based on a dual-purification process: a TAP-tagged protein is expressed in-cell and forms 
complexes with the endogenous proteins; the purification occurs via a two-step affinity procedure. 
During the first one, the TAP-tag fused proteins are purified from the lysate by selection on an IgG 
matrix, retaining all the protein-A-tagged proteins. The TEV protease can then cut the bound tag. In 
the second step the protein complex is immobilized to calmodulin-coated beads via the CBP of the 
TAP-tag. The result of the process is a highly purified extract of proteins with very low background. 
Moreover, the non-denaturating conditions of the assay enhance the possibility to obtain intact 
protein complexes121,123–125. Next, the purified protein sample undergoes separation by an one-
dimensional SDS/PAGE and analyzed in MS (Figure 30)126,127. Mass-spectrometric analysis allows 
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determining the molecular masses through the measurement of the mass to change (m/z) ratio of 
charged molecules (ions) in gas phase.  
Figure 30 Schematic representation of the 
TAP–MS methodology.  
A construct with double tag is used, including a 
calmodulin-binding peptide, TEV protease 
cleavage site, and two IgG-binding units of 
protein A. The protein A is used as tag to 
recover the fusion protein from the extract, a 
protease cleavage allowed the release of bound 
IgG material. Extra purification step is 
performed to remove contaminants using the 
affinity of calmodulin-binding peptide for 
calmodulin beads. Ethylene glycol tetra-acetic 
acid EGTA released with the proteins offer high-
purity of the recombinant proteins. (Figure from 
128) 
Tags 
Proteins produced in a different host could undergo a degradation process. On the other hand, cells 
that undergo a transfection/transduction process are forced to overproduce a large amount of 
protein, which can activate the proteasomal pathway. Introducing a tag has positive and negative 
sides. Affinity tags, besides preventing proteolysis and increasing solubility, may improve protein 
yield and facilitate protein refolding. They have also been used to increase the sensitivity of binding 
assays for tagged single-chain fragments of antibody variable regions (ScFv)129. On the other hand, it 
has been shown that affinity tags can interfere with the quality of the protein produced, for 
example, by changing the biological activity, by inhibition of enzyme activity, by alteration of the 
protein conformation or by causing toxicity128.  Specific cloning vectors are used to create fusion 
proteins considering the right reading frame. Glutathione S-transferase (GST), for instance can be 
used as tag in an one-step purification experiment with glutathione (able to protect proteins from 
proteolysis). Other tags have been used to enhance stability and solubility of the proteins, e.g. 
maltose-binding protein (MBP), thioredoxin A (TrxA), small ubiquitin related modifier (SUMO), 
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ketosteroid isomerase (KSI), and Trp?LE. The use of a tag becomes crucial in case of uncharacterized 
proteins or in the absence of a good antibody for the protein of interest, as is often observed in 
systematic, large-scale interactome studies. Flag, HA and c-myc are the most commonly used tags 
for western blot analysis, IP, CoIP, immunofluorescence (IF), and flow-cytometry. The earliest affinity 
tag developed was an epitope of the human c-myc proto – oncogene product (EQKLISEEDL), 
interacting with a specific c-myc 9E10 antibody130: it has been used to purify c-myc fusion proteins 
for structural studies131. The HA-tag is a nine amino acid sequence (YPYDVPDYA) derived from the 
human influenza virus hemagglutinin protein. Despite the fact that the epitope might be spatially 
located, its introduction can interfere with folding, trafficking or normal functions of the protein. The 
FLAG epitope is a short, hydrophilic octapeptide (DYKDDDDK), including an enterokinase-cleavage 
site, that can be used for antibody-based purification and it was the only epitope tag to be 
patented132. An added advantage of this tag is its high hydrophilicity with a maximum score on the 
hydrophilicity scale according to Hopp and Woods. 
II.2.3.2.4 Proximity-ligation assay (PLA) 
PCR-based technologies, used for the detection of nucleic acids, and antibody-based methods 
applied for protein studies have been two key technologies for the advances that life science 
research has made over the years. Original combined applications of both techniques lead to the 
development of immuno-PCR (iPCR) and, proximity ligation (PLA) and extension (PEA) assays, which 
use the specificity of detection given by an antibody, with the capacity of amplification given by PCR 
or RCA (see below).  
The PLA assay (Figure 31) uses DNA oligomers and DNA modifying processes such as ligation and 
cleavage. In the original PLA method, the protein of interest is tagged with a pair of proximity 
probes. A proximity probe pair is composed of two oligonucleotide-labelled antibodies able to bind 
in close proximity (30-40 nm apart) to different epitopes of a protein or two proteins in a complex. 
This system can follow a direct or an indirect protocol: in the first case, detection is performed by 
direct primary antibody while in the second, secondary conjugates. After binding to a target 
molecule or interacting molecules, the proximity antibody-conjugated oligonucleotides can hybridize 
to two additionally introduced connector oligonucleotides to form a ligation product. Amplification 
and detection can then be done in two ways: via a qPCR detection which occurs simultaneously to 
the amplification and which requires linear amplification products, or using rolling circle 
amplification (RCA) if the ligation creates a circular single stranded DNA molecule.  
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Figure 31  Proximity ligation assay.  
Two probes stay in close proximity by binding to a 
protein or two proteins present in one complex: upon 
introduction of linear connector oligonucleotides, they 
can be joined and circularized. The rolling circle 
amplification can start and one of the probes is used 
ad primer. The products are hybridized with labeled 
detection oligonucleotides 
Picture from Human protein atlas133. 
 
RCA is an isothermal enzymatic reaction which is based on particular DNA polymerases such as Bst 
and Vent exo-DNA polymerase for DNA, and T7 RNA polymerase for RNA, to obtain a long repetitive 
single-stranded amplicon showing up to 1000 of reverse complementary elements of the circular 
template. The product of the reaction is detected and visualized via hybridization of complementary 
fluorescence-labelled oligonucleotides134–136. The method has been used to show the known 
interaction between endogenous c-Myc and Max: the interaction was visualized at a single molecule 
level134. PLA experiments can be carried out with samples and reagents in a single tube as a 
homogenous assay thus avoiding variability due to successive washing steps. It is also possible to 
conduct the experiments in a solid phase if proteins are immobilized in a solid support such as 
affinity beads and it is mainly used for direct detection of proteins in biofluids. The in situ PLA is the 
method to study PPIs described from Soderberg et al. for the first time in 2006 134 and in this case 
the assay is performed in fixed cultured cells or tissue sections. Due to the fixation, transient 
interactions can be detected but real time analysis of the interactions in living cells is not possible.  
PLA has been used as basis to develop a high-throughput biomarker screening technology. 
Numerous PLA probes can be bound to different combinations of oligonucleotides resulting in a 
sequence that can be used as primer for qPCR amplification. This multiplex PLA has been extended 
following the principle of homogenous multiplex proximity ligation assay up to four 24-plex panels 
which contains 74 biomarkers. The sensitivity of the test is very high and after optimization of the 
technique, including pre-amplification strategies, very low sample quantities are required. The assay 
has been validated in plasma samples of 74 patients with colorectal cancer and in a sample set of 74 
healthy individuals137. 
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II.2.3.2.5 Other biochemical methods 
A few more biochemical methods can be applied to identify or characterize PPIs. Here, the two most 
commonly used biochemical methods will be briefly described: protein microarrays and cross-linking 
approaches. 
Protein microarrays or Protein chips can be performed for a large variety of applications. Initially, 
this approach was applied for screening of protein biochemical activities138, however further 
applications of the approach include the identification of PPIs, protein-phospholipid interactions, the 
small molecule target identification, and the search for substrates of protein kinases. Furthermore, 
protein microarrays can be used in the clinic for diagnostic applications and for monitoring of 
disease stages139. The classic approach is the so-called analytical protein microarrays, which are 
mostly used to analyze a mixture of proteins for binding affinities, specificities and expression levels 
of its components. A glass microscope slide is used as the solid surface and a library of antibodies is 
arrayed on the slide. The array is then probed with a heterogeneous protein solution140. There are 
two types of protein microarrays related to the analytical one: the functional and the reverse-phase 
protein array. In the first case, the array includes full-length functional proteins or domains, and it is 
used to study the activities of an entire proteome. This approach has been used to study various 
interactions such as protein-protein, protein-DNA, protein-RNA, protein-phospholipid, and protein-
small molecule interactions138,139. In the reverse-phase protein array, the lysate is on the slide and 
specific antibodies are added on it. The antibodies are typically detected with chemiluminescent, 
fluorescent, or colorimetric assays. This variation enables the determination of disease-related 
altered protein mixtures. For example, reverse-phase protein microarrays can detect post-
transcriptional modifications, which may occur in pathological conditions141. 
As already mentioned, an advantage of the protein array technology is that it can be used with many 
types of molecules as probe enabling the study of protein-DNA or protein-small molecule 
interactions, beside PPIs. The downside of the protein chip is that it is an in vitro approach and that it 
shows some technical limitations such as, for example, the difficulty to purify the numerous proteins 
under native conditions and to spot them accurately on a surface.  
Cross-linking techniques have been used to allow the study of transient and low affinity interactions. 
Proteins able to approach each other in a close range can be covalently cross-linked in living cells 
allowing the study of their interactions. There are different kinds of chemical cross-linking agents 
that can be used for this purpose; the most commonly used are the imidoester cross-linker dimethyl 
suberimidate, the N-Hydroxysuccinimide-ester cross-linker BS3 and formaldehyde. Formaldehyde is 
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most frequently used and is a reactive dipolar compound that cross-links proteins via the amino- and 
imino-groups of their lysine, arginine and histidine residues. It is a fast and perfectly reversible 
reaction, which allows an affinity purification or immunoprecipitation step before MS identification 
142–144. In 2005, Suchanek and colleagues introduced a new cross-linking strategy based on photo 
reactive amino acid analogs: two photoactivatable amino acids, such as photo-methionine and 
photo-leucine, are incorporated into the proteins and activated upon UV light exposure, which 
induces covalent cross-links. Detection of protein complexes is done via western blot145. 
II.2.3.2.6 BioID  
Most of the biochemical methods to detect PPIs, such as CoIP and TAP-Tag, include steps (such as 
detergent-mediated cell lysis and subsequent washing steps) which can compromise the stability of 
weak interactions or cause the loss of the transient ones. Some strategies have been developed over 
the years to overcome this problem, for example the use of the cross linking with a down-side of 
creating large insoluble complexes. Recently, different studies focused on the possibility of enzyme-
catalyzed proximity labelling to be used for PPI detection. Some enzymes can be used as a label for 
the protein of interest and their short life allows an activity limited to proximity. Different enzymes 
have been used for this aim146. BioID (proximity-dependent biotin identification) was originally 
developed by Roux and colleagues to study the surrounding neighbors of a protein of interest based 
on a promiscuous prokaryotic biotin protein ligase147,148. The E. coli enzyme BirA (BirA R118G) is a 35-
kD DNA binding biotin protein ligase able to regulate the biotinylation of a subunit of acetyl-CoA 
carboxylase. BirA shows an extreme specificity in biotinylating its substrate peptide requiring a 
specific recognition sequence; it combines ATP and biotin to produce biotinoyl-5’-AMP, a highly 
reactive intermediate with very short life. The method uses a modified enzyme, BirA* which can 
biotinylate any protein with an exposed lysine residues, found in proximity of the enzyme (about 10 
nm) missing the specificity of BirA. The mutated enzyme is first fused to the protein of interest and 
then introduced in the cells. In presence of medium with biotin, the BirA* will biotinylate proximal 
proteins which can be purified by streptavidin binding and identified via MS149. However, this 
method does not guarantee the identification of the physical interactions between the protein of 
interest and the candidates, but rather the proximity to the bait (Figure 32). 
Initially, BioID was applied to investigate the neighbor proteins of Lamin A, an intermediate filament 
protein, which play a role in the cytoskeletal of the nuclear lamina. The fusion protein was 
introduced in Hek293 cells. 100 proteins (including well known lamina-binding proteins and new 
interaction partner) were biotinylated after sub-ministration of biotin147. Recently a new improved 
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smaller biotin ligase has been proposed and used to improve the ability of labelling proximate 
proteins150. 
 
 
Figure 32 BioID: the principle 
The protein of interest is tagged with a modified promiscuous biotin ligase BirA (BirA*) and introduced in the 
cells. An incubation of about 24 hours with medium supplemented with biotin allows the biotinylation of the 
proximity interactors. The radius of action is about 10 nm. Picture from 149 
 
. 
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II.3 Interactome Mapping
Recently, the exploration of the so-called “protein interactome” became possible thanks to the 
development of new and innovative technologies based on the analysis of PPIs at a high-throughput 
level. An interactome is defined as the complete set of interactions within an organism. In the early 
days two experimental approaches have been mainly used to start mapping the complete sets of 
PPIs: the yeast two-hybrid screening method and the detection of protein complexes by affinity 
purification and mass spectrometry. Next to these classic ones, new techniques have been 
developed including PCA-based methods and more recently also high-throughput applications of 
MAPPIT. These main methods will be presented in the following paragraphs.  
 ??????????????????????????????????????
High-throughput two-hybrid screening utilizes yeast mating. Two haploid strains are involved: one in 
which a query or bait protein is fused to a DNA binding domain (BD) able to bind to an engineered 
site upstream a reporter gene, and another one in which the interaction or prey protein is fused to a 
transcription activator domain (AD). The measurement of reporter activity in the diploid organisms, 
resulting from mating between the two strains, is the read out of the assay: if the two proteins 
interact mutually, the AD activates the reporter leading to the transcription of the reporter gene 
which will be used for the selection. 
The concept formed the basis of developing the Y2H system into a high-throughput screening tool 
during the early 1990s. In 1996, the lab of Fields published a paper about the use of the Y2H system 
on a genome-wide scale to identify interactions between the proteins of the E. coli bacteriophage 
T7151. However, at that time, the two-hybrid methodology was not suitable for a large-scale project 
like the human interactome without specific methodological improvements towards completeness 
and selectivity of the screens. Large scale interactomic studies have since then been pursued for 
Saccharomyces cerevisiae and for Arabidopsis thaliana with the aim of applying the strategy 
developed also to other genomes and the eventual elucidation of the human protein interactions 
map152,153. Subsequently, more extensive interactome mapping projects have been carried out for 
eukaryotes like worm and fly38,39,154,155. The very first original large-scale analyses aiming at whole 
proteome coverage were performed in yeast38,39. Uetz’ studies led to the identification of 957 
interactions among 1004 S. cerevisiae proteins while Ito’s screening identified 4549 interactions 
among 3278 yeast proteins. It is important here to notice that there was a limited overlap between 
the data from the two experiments. Successive studies showed how Y2H screens generally generate 
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high quality binary data, indicating that the observed low level of overlap between various sets of 
results is not due to the low quality of positive hits but due to assay sensitivity and screening 
completeness thus precision needs to be considered156 (more details in paragraph II.3.6 of this 
dissertation). With time, it became clear that the identification of the complete collection of all 
physical interactions that take place within a cell will require the creation of genome-scale resource 
collections of open reading frames, the so called ORFeome. An ORF is the entire coding sequence 
between the initiation and termination codons, excluding the untranslated 5’UTR and 3’UTR of 
mRNAs157. Ideally, any cloned ORF should include the different isoforms, and gene’s variants. 
Technically, the exhaustiveness of an ORFeome resource mainly depends on the quality of the 
genome annotations. Importantly, the ORF collection can be easily transferred in the plasmid vectors 
required to apply the different techniques. The first human ORFeome version 1.1 dates to 2004158. In 
this work, researchers cloned all unique human ORFs that were at that time available as full-length 
cDNAs in the Mammalian Gene Collection159. The human ORFeome v1.1 collection158 has been used 
to perform the second large scale Y2H study for humans: 7200 different protein-coding genes were 
investigated and 2754 interactions were detected. Co-affinity confirmation tests yielded positive 
results for 78% of the candidate PPI.  
As already discussed, yeast remains a very good model to study human biology: despite the fact that 
the last common ancestor dates back a billion years ago, humans and yeast still share a substantial 
part of their genetic heritage. The yeast genome includes about 6000 protein coding genes, less than 
a third of the human amount, but 2300 of those are human orthologs. Most of the common genes 
show important roles for the cells in both organisms and mutations or perturbations of them is the 
cause of a range of human disorders including many Mendelian diseases and cancer. This strong 
similarity is one of the main reasons of the success of the different Y2H techniques and of their 
development into high-throughput assays. The latest improvement of the technique involves the 
development of the so-called “humanized Y2H”160. There are five different degrees of yeast 
humanization, shown in Figure 33 which goes from the use of non-humanized yeast to address 
questions about human biology to the humanization of the whole yeast genome or humanization of 
full pathways and complexes. 
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Figure 33 Five degrees of yeast humanization.  
Yeast has proven useful for the direct study of human biology in a variety of forms, illustrated here to 
distinguish those cases in which yeast cells were simply studied for human-specific processes and drugs (degree 
0), to the heterologous expression of human genes in yeast (degree 1), all the way to the directed replacement 
of specific amino acids, genes, and pathways (degrees 2–4, respectively). 
Degree 0: Studying non-humanized yeast to address human biology; Degree 1: Expressing human proteins in 
yeast regardless of orthology; Degree 2: Humanizing specific positions within native yeast genes; Degree 3: 
Humanizing entire yeast genes; Degree 4: Humanization of full pathways and complexes 161. 
 
The first experiment of humanization dates back to 1985 when Kataoka and colleagues 
demonstrated the functional homology of mammalian and yeast RAS genes expressing human or 
chimeric Ras in ?Ras mutant yeast162. Since then, over 400 yeast genes have been humanized: the 
ultimate goal of this system’s evolution is the application for therapeutic purposes. Making 
personalized strains or express any possible allele or combination of genes could be the start to 
identify critical mutations responsible for a disease of a specific patient and screening of such yeast 
strains could be performed for therapeutic resistance or response for the specific case161. 
 ?????????????????????????? ???????????????????????
Affinity purification (AP) followed by mass spectrometry (MS) analysis is the second most widely 
used approach for high-throughput mapping of PPIs. AP is used to isolate those complexes that 
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comprise a protein of interest. After AP of the tagged-target protein, under conditions that preserve 
the protein complexes, MS is applied for identification of the proteins.  
The first time that a large scale analysis of PPIs by AP combined with MS was reported was in 2002 
when two studies on S. cerevisiae were published163,164. In the first study, Gavin et al. combined TAP 
with MS and could purify 589 specifically interacting proteins; the reproducibility of the purifications 
was found to be as high as 70%. In the second study, Ho et al. purified 725 FLAG-tagged proteins and 
analyzed the complexes through tandem MS. They obtained data for up to 25% of the yeast 
proteome. Results were confirmed by immunoprecipitation experiments in 74% of the interactions. 
More extensive studies on the yeast interactome have meanwhile been performed: these data cover 
47% of the yeast proteome but the data are overlapping only for 18% 165,166. 
In 2007, the AP approach was applied on the human interactome167: 338 protein baits were selected 
on the basis of known or suspected disease implications and functional associations. A dataset of 
6,463 interactions among 2,235 distinct proteins was generated. Since then, different studies were 
performed to produce a more complete human interactome map. Recently, a new platform has 
been developed by the Harper and Gygi labs. In the study carried out by Huttlin and colleagues, the 
AP-MS approach was used to define the BioPlex network: 2,594 baits were investigated offering 
23,744 interactions among 7,668 proteins, more than the 10% of the total human amount168 (Figure 
34). The most recent update defines an interaction network of 33.000 interactions involving 8.000 
proteins and using 3.200 baits. They also developed a new version of the CompPASS method, called 
CompPASS-Plus, to analyze the data.  
 
Figure 34 High-Throughput Interaction Mapping via AP-MS 
Starting from 13,000 ORFs from the Human ORFeome collection v 8.1 169, FLAG-HA-tagged baits were prepared 
to constitute a lentiviral library. Hek293T cells were infected under puromycin selection and the expressed baits 
were immuno-purified and, analyzed via MS. Modified from168.  
120 
 ????????????????????????
One of the limitations of all the affinity based approaches and of the classical mass spectrometry–
based strategies is the requirement of cell lysis as an inevitable step. The isolation of complexes from 
the lysate means that all the compartments of the cell are mixed and some complexes are identified 
even though they are not likely to happen in vivo because of different localization of the proteins. 
Additionally, the use of tags can increase the number of non-specific complexes170. 
Different strategies have been applied to overcome the risk of false positives caused by background 
contaminants due to aspecific protein interactions with the solid-phase support, affinity reagent or 
epitope tags. These include the use of more stringent washing protocols which may lead to the loss 
of weak interactors, the introduction of the TAP-tag, the creation of a CRAPome (currently available 
also for Homo sapiens and Saccharomyces cerevisiae at http://www.crapome.org/) which is a 
contaminant repository for affinity purification which allows the identification of false positives by 
comparing the occurrence of such interactions in unrelated AP-MS negative control experiments171. 
To avoid losing interactions, cross linking strategies with simple reagents as formaldehyde or with 
more advanced isotope-labelled cross-linkers have been applied163,172; despite all these optimization 
strategies, the conditions are still not optimal. In this context and considering the fact that only a 
small percentage of expected PPIs has been identified with the existing methods173, a new technique 
has been developed, the Virotrap 174. 
Virotrap is a co-purification strategy able to trap protein complexes under native conditions in virus-
like particles (VLPs) that bud from human cells. Due to the evolutionary stress, viruses developed a 
condensed organization of all information into a small genome. In case of HIV-1, a single protein, the 
p55-GAG, is sufficient for the production of the virus-like particles175. To eliminate the cell lysis step, 
secreted VLPs are used as traps for protein complexes and as a protective envelop for further 
purification. The empty VLPs produced in the absence of a virus, contain about 5000 uncleaved Gag 
proteins each176. The bait proteins in a Virotrap experiment are fused to the C-terminus of the Gag 
protein, which means that the VLP inner membrane is coated by bait fusion proteins and the 
interacting proteins are trapped inside the VLP after the budding events. Virotrap was first used to 
demonstrate the known interaction of HRAS and RAF1. The enrichment was performed by 
ultracentrifugation and then optimized to avoid this step using the co-expression of a tagged version 
of the vesicular stomatitis virus glycoprotein (VSV-G) that is expressed at the same time as the fusion 
baits and preys. The HRAS–RAF1 interaction was confirmed using this single-step protocol (Figure 
35). 
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Figure 35 Virotrap principle 
Expression of a GAG-bait fusion protein (1) will pick up interactors during trafficking to the membrane. There, 
multimerization occurs (2) and subsequent budding of VLPs from cells (3) after sufficient Gag-bait fusion 
proteins are assembled and have reached the membrane. Interaction partners of the bait protein are trapped 
within these VLPs which are released in the supernatant and purified via a tagged VSV-g protein. Interaction 
partners are identified after purification by western blotting or MS analysis (4). ( Modified from 174 ) 
 
To compare Virotrap with other technologies, binary analysis of the human positive reference set 
(hsPRS-v1, 92 PPI pairs) and the corresponding random reference set (hsRRS-v1, 92 randomly 
selected pairs) described by Braun et al. 177 has been performed showing that Virotrap complements 
other methods and can detect different sets of PPIs when compared to MAPPIT, for example. Every 
analyzed method is able to detect ~20-35% of known protein interactions. The results only partially 
overlap suggesting the complementarity of Virotrap with the other methods174 (Figure 36). 
 
Figure 36 Binary Virotrap assays for the Positive Reference Set (PRS) 1 and comparison against other binary 
protein-protein interaction assays. 
For the purpose HEK293T cells were transfected with PRS and RRS (184 interactor pairs). Single step purification 
and WB analysis of the eluted particles and lysates of the producer cells were performed. E-tag antibody was 
used in VLP samples. The blocks show that Virotrap results in 30% positive interactions (at the expense of 5% 
false positive signals in the RRS set, not shown) (Modified from 174 ). 
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The analyses of the data generated by Virotrap required new analysis tools. SFINX 
( http://sfinx.ugent.be/), the Straightforward Filtering INdeX for data analysis has recently been 
developed and can also be used also for AP-MS datasets178. SFINX combines the positive feature of 
different classical methods and offers the identification of true positives in a fast, user-friendly, and 
highly accurate way. Classical methods such as PP-NSAF, the CompPASS scores, and SAINT, use the 
spectral count data defined as the total number of peptide-to-spectrum matches assigned to the 
protein of interest. One of the innovative characteristics of SFINX is the use of peptide counts 
instead of spectral counts where the peptide count is the number of distinct peptide sequences 
found for the protein of interest. The protein gets detected as a true interactor if it is sufficiently 
exceptional for the bait projects and sufficiently reproducible178. 
 ???????????????????????????????????????????????????
PCAs are a family of assays which allow the quantitative probing of molecular interactions in living 
cells in multicellular organisms, or in vitro. The technique has been described in II.2.3.1.4. The assay 
is based on the PCA principle, where two proteins of interest are fused with complementary 
fragments of a reporter protein, which is reconstituted in case of PPI. DHFR (dihydrofolate 
reductase) is an enzyme involved in the biosynthesis process of purines, thymidylate and certain 
amino acids. Methotrexate (MXT) binds and inhibits DHFR179. Two detection methods have been 
successfully developed: a survival detection assay, using the ability of cells expressing 
complementary fragments of DHFR to survive in a selective medium and a fluorescent assay based 
on the detection of fluorescein-conjugated MXT binding to a reconstituted DHFR. Tarassov et al.180 
used a DHFR-based complementation assay in a genome-wide in vivo assay. In this first screen 1124 
yeast proteins were analyzed and 2770 interactions were identified180 confirming between 16 and 
41% of PPIs identified in previous large scale studies.  
 ?????????????
MAPPIT is based on the JAK-STAT signal transduction pathway triggered by the interaction between 
cytokine receptor-derived hybrid proteins99. The interaction of bait and prey chimeras leads to the 
recruitment and successive activation and nuclear translocation of STAT3 dimers. The result is the 
transcription of a reporter gene in case of the analytical tests or of a selectable marker gene for 
screening experiments, as these genes are under the control of a STAT3 responsive rPAP1 promoter. 
Given the simplicity of the assay two high-throughput approaches were developed: screening of 
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complex prey cDNA libraries using a FACS-based approach, and an array-based assay using the 
human ORFeome181. 
II.3.5.1 FACS-based approach 
For the first approach, a stably-transfected Hek293 cell line expressing a STAT3-responsive rat 
pancreatitis-associated protein I (rPAP)-puroR selection cassette and a Flp recombination target (FLP) 
integration cassette in a transcriptionally active locus was generated. In addition, the cells express a 
murine ecotropic retroviral receptor to enable the retroviral delivery of a prey cDNA library. In this 
cell line, cell clones expressing the chimeric receptor coupled with the bait can be generated using 
the FLP integration cassette, via a FLP recombinase assisted integration. This is then followed by an 
infection with a retroviral prey cDNA library. Upon stimulation with the ligand of the receptor and 
under the control of the puromycin selection, colony formation is occurring only if bait and prey 
interact (Figure 37).  
 
Figure 37 Schematic representation of a MAPPIT cDNA library screening procedure. 
A bait-expressing cell pool undergoes a retroviral delivery of the prey cDNA library. After stimulation with the 
ligand, cells containing bait-prey complex are enriched in a MACS step with magnetobeads attached to the 
hIL5Ra membrane tag. After a second stimulation, single positive cells are sorted and clones are validated in a 
dot-blot assay. RT-PCR and sequencing are used to determine the identity of the interacting preys.  Figure 
from182. 
 
In 2004, Lievens et al. optimized the method to avoid the use of puromycin selection, which 
appeared to limit the screening sensitivity of the technique182: in this new method a membrane 
surface tag is used as a marker, under the control of the STAT3-dependent rPAP1 promoter, enabling 
selection by flow cytometry. Indeed, instead of using the puromycin cassette, an rPAP1-hIL-5R??cyt 
construct was stably integrated in the cell line. hIL-5R??cyt is a fragment of the human interleukin 5 
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receptor, ? subunit, missing the cytoplasmic part181 to avoid internalization, for which a high-affinity 
monoclonal antibody is available. 
 
Figure 38 Flow chart of the FACS-based MAPPIT cDNA screen. 
See text for details. 
 
Briefly, the bait construct is cloned in a vector for expression of the bait-receptor chimera and 
transfected into the host cells. After selection of positive clones expressing the bait-chimera, the cell 
line is infected with a prey cDNA library and stimulated with receptor ligand. A magnetic cell sorting 
(MACS) enrichment for positive cells is performed before the fluorescence-activated cell sorting 
(FACS) analysis. Usually a cell sample that has been infected with a mock retroviral library is 
processed in parallel to be used as a background control. The isolated clones are validated using a 
dot blot assay, a technique for detecting, analyzing, and identifying proteins, similar to the western 
blot, where mixtures including the proteins of interest are directly spotted on a membrane without 
prior electrophoretic separation. The identities of the preys are then determined through RT-PCR 
and sequencing (Figure 38). Due to the large complexity of the library involved, the isolation of 
positive cells and the identification of preys are difficult and lengthy. To make the process faster and 
easier, an alternative was developed: the so-called Array MAPPIT, a fast, automated and cost-
effective approach.  
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II.3.5.2 Array MAPPIT 
This method is based on the availability of a large collection of full length human ORFs183, which 
were transferred in the MAPPIT prey vector to create the library collection. This method requires a 
protocol based on a reverse transfection: prey and luciferase reporter plasmids are mixed with 
gelatin and a transfection agent and spotted in microtiter plates or on microscope slides, and dried 
(Figure 39). When needed, (the plates can be stored for a several weeks) the plates are overlaid with 
bait-expressing cells leading to plasmid uptake and expression of the preys. The stimulation with the 
receptor ligand activates the bait-receptor chimera, which leads to a correlated and measurable 
luciferase signal. Unstimulated samples are used as control for the background. The prey identity is 
simply identified through the position on the plate. The procedure, mostly automated, takes 5 days. 
The first Array MAPPIT screening was performed in 2009181 to identify interaction partners of SKP1 
and Elongin C. The microtiter plate included 1,879 full length ORF preys selected as they were 
classified in the ‘signal transduction’ section in Gene Ontology184. The test was performed twice to 
evaluate the reproducibility and led to the identification of 5 interaction partners of SKP1, of which 
three known and two unknown, and 5 partners for Elongin C, 4 of which were previously identified. 
These results were obtained with a very stringent threshold: lowering it implies that the number of 
detected interactions is increased but also the number of false positives181. 
 
Figure 39 Array MAPPIT. 
 (See text for details) 
126 
II.3.5.3 A MAPPIT/MASPIT cell microarray screening platform
MAPPIT and MASPIT assays, as already presented before in this chapter, operate in mammalian cells 
and are based on reconstitution of a signaling deficient cytokine receptor. The efficiency of the 
system has been shown to be similar or better than other well established interaction assays. 
Recently, a highly miniaturized screening platform185 for the identification of novel protein 
interactors of both proteins and small molecules based on MAPPIT/MASPIT platform was developed: 
the combination of the techniques with a cell microarray format offer an assay suitable for industry 
application. The screening offer the human ORFeome v8.1 and ORFeome Collaboration prey 
collections, which show about 15K plasmids and use reverse transfected cell microarrays. The prey 
collection and the reporter plasmid are printed on a polystyrene plate (Figure 40). The system has 
been validated in a study for RNF41 interaction partners. A mutated RNF41, unable to auto-
phosphorylate, was used as bait. The results were ranked according to the normalized fluorescence 
signal intensity. A number of known interaction partners were identified and a list of novel candidate 
was proposed: two of them are currently investigated for functional implications.  
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Figure 40 Microarray production  
(Left panel): The ORFeome plasmid collection, which is available in Gateway entry vectors, is transferred to prey 
destination vectors through recombinatorial cloning. The resulting prey plasmids are individually mixed with a 
fluorescence reporter plasmid, transfection reagent and a number of additional agents. These reverse 
transfection mixes are then printed on polystyrene plates, dried and stored until needed for screening. 
Microarray screening (right panel): Cells are transfected in bulk with the desired bait fusion plasmid (MAPPIT) 
or the DHFR anchor plasmid (MASPIT) and added to the microarray plates, and the cognate cytokine is added 
to the appropriate wells, depending on the stimulation schedule. One day later, cells are treated with the 
appropriate stimuli: depending on the assay (MAPPIT or MASPIT) and the experimental setup (screen in 
standard conditions or comparing two physiological states), wells are either left untreated or treated with 
cytokine, fusion compound or additional stimuli. Next, cells are grown for another 2 days until the plates are 
scanned using a fluorescence imager. ( Figure and description from 185) 
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II.3.5.4 Interactomics and MAPPIT 
The MAPPIT technology has been applied in a large-scale interactome mapping program led by the 
Centre for Cancer Systems Biology (CCSB) located at the Dana Farber Cancer Institute in Boston (US). 
This “Human Interactome Project” has as main goal the generation of the first reference map of the 
human interactome network. Their strategy involves mapping PPIs via Y2H assays and confirming the 
interactions found using alternative binary assays like MAPPIT.  
Two proteome-scale studies have been reported on so far. The first one (HI-I-05) was performed by 
Rual et al. in 2004158: this study covering ~7.000 genes lead to the identification of 2.700 binary 
interactions, using a stringent, high-throughput yeast two-hybrid system. The second study (HI-II-
14)186 identified ~14.000 binary interactions starting from combinations of proteins encoded by 
13.000 genes.  
The MAPPIT system was applied as a validation assay to confirm the interactions of the HI-II-14 
study186. In the same study two other methods have been used to confirm the results: the in vitro 
nucleic acid programmable protein array (wNAPPA)177 assay, and a protein-fragment 
complementation assay (PCA)187. In all cases, the amount of interactions detected is dependent on 
the chosen threshold as shown in Figure 41. The percentage of interactions detected for each 
different threshold is similar to the one obtained from a tested positive reference set formed by 
known interactions, described in literature and databases, and clearly above a random reference set 
(randomly chosen protein pairs) that were tested. Overall, MAPPIT performance was found to be 
superior. 
Similarly, the MAPPIT technology was also used to validate results for smaller systematic 
interactome mapping experiments: in 2008 for yeast156, and in 2009 for C. elegans188.  
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Yu and colleagues156 described a high quality binary protein interaction map of the yeast 
interactome network: their final dataset (“CCSB-YI1”) included 1809 interactions among 1278 
proteins.PCA and MAPPIT technology were successfully used to analyze the quality level of the 
dataset: 94 randomly chosen interaction were retested for confirmation. The following graph shows 
the results in percentage of positive interactions detected: 
 
 
 
 
Figure 41 MAPPIT, PCA and wNAPPA to detect PPIs.  
The graph on the left shows fraction of HI-II-14, PRS 
(Positive Reference Set), and RRS (Random reference 
Set) pairs (right) recovered by MAPPIT, PCA, and 
wNAPPA at increasing assay stringency. Figure from186 
 
Figure 42 Fraction of protein pairs in PRS, 
RRS and in the dataset CCSB-YI1 that are
positive by PCA, MAPPIT and Y2H.  
Picture adapted from 156. 
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The same type of study has was carried out by 
Simonis and colleague in 2009188 to investigate 
the C. elegans interaction network. The study 
allowed to test a matrix of ~10.000 * ~10.000 
proteins and produced a new dataset called 
WI2007, which includes 1816 PPIs between 1496 
proteins. To characterize the new dataset, a novel 
framework developed by Venkatesan et al. was 
applied189. Samples from the dataset (WI-2007) 
have been used and compared with a PRS (cePRS-
v1) and a RRS (ceRRS-v1) dataset in MAPPIT 
experiment. Results are shown in Figure 43. 
. 
 ?????????????????????????
The methods explained above obviously produce large amounts of data. Different techniques offer 
different levels of false positives and false negatives and a specific coverage of the proteome. That is 
why defining the quality of the data becomes really important. As mentioned earlier, in 2009, 
Venkatesan and colleagues proposed a method to systematically evaluate the quality of individual 
binary PPIs reported in interaction mapping experiments189. The interaction mapping framework 
developed by these researchers tries to consider every source of false negatives and false positives 
and includes four parameters to define the quality: screening completeness, assay sensitivity, 
sampling sensitivity and precision (Figure 44). A subset of data is retested in orthogonal assays 
considering the rate of false positives and false negatives of each method. For this aim two subsets 
are used: a positive one (PRS) and a random reference set (RRS) consisting of well documented pairs 
of interacting human proteins and randomly chosen protein pairs, respectively. As already 
mentioned, an interaction tool kit was introduced by Braun and colleagues177 consisting of four 
complementary high-throughput protein interaction assays: PCA, LUMIER, NAPPA and MAPPIT. After 
a screening, all the positive interactions are retested in the four assays. In this way data resulting 
from an Y2H based proteome-wide screen are retested extensively.  
Figure 43 Characterization of WI-2007 database 
The proportions of cePRS-Y2H-v1, a random sample of WI-2007 and ceRRS-v1 observed in MAPPIT; the fraction 
of positive found for WI-2007 is comparable with the positive dataset and significantly higher than the random 
dataset fraction. Picture adapted from 188. 
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Figure 44 Conceptual framework for interactome mapping. 
Screening completeness (fraction of all pairwise protein combinations tested), assay sensitivity (fraction of all 
biophysical interactions identifiable by a given assay), sampling sensitivity (fraction of all identifiable 
interactions that are detected in a single trial) and precision (fraction of pairs reported by a given assay that 
are true positives) are first independently studied and then combined. PRS: positive reference set; RRS: random 
reference set. Solid black lines are true biophysical interactions, dashed lines are true biophysical interactions 
missing in that network, solid colored lines are biophysical artefactual pairs .Figure from 189. 
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 ???????????????????
Many databases for PPIs have been recently created to be able to merge and unify the enormous 
amount of data and information coming from high throughput experiments and computational 
analysis. The databases can be directed towards specific subsets of interactions e.g., kinase–
substrate interactions, or based on a specific organism or disease. 
Szklarczyk and Jensen classified the existing databases in 3 categories 190. The first is for pathway 
databases where the consensus knowledges are collected by experts, like Reactome191 and KEGG192. 
Reactome193 is a free source database, curated by PhDs, that assures a high specificity: information is 
detailed and precise for each interaction, including stoichiometry of the reaction, type of interaction, 
substrates and localization, and roles played in different diseases. Recently, collaboration with 
WikiPathways (a community-based platform) started: data of Reactome pathways are converted to 
the GPML format used in WikiPathways enlarging the coverage of the database showing the 
importance of the collaboration between the different resources194. Kyoto Encyclopedia of Genes 
and Genomes or KEGG195, is one of the most widely used pathway databases because it includes the 
largest number of different species (about 1.500 genomes). It allows linkage with diseases and drugs 
where a disease is the perturbed status of the molecular system and drugs are perturbants of the 
molecular system. All the information is offered in pathway maps or in molecule lists 192. Also the 
Gene Ontology (GO) Consortium operated towards the same aim of developing tools to unify the 
different information. They created  vocabularies (ontologies) which can be applied to all 
eukaryotes: biological process, molecular function and cellular component184. Also the Sequence 
Ontology was included to permit the classification and standard representation of sequence 
features196. The second type of databases includes those collecting primary experimental data, for 
example BioGRID. BioGRID (The Biological General Repository for Interaction Datasets) is one of the 
largest databases experimentally verified containing 749.912 interactions as drawn from 43.149 
publications that represent 30 model organisms197. Beside PPIs, chemical and genetic ones, the tool 
includes data on the influence of protein post-translational modifications, such as phosphorylation 
and ubiquitination. MINT (The Molecular INTeraction database) is another excellent example of this 
kind of databases: only physical interactions are included while genetic or computationally identified 
interactions are not198,199. Finally, the last type of databases includes computationally predicted 
interactors, but performs no manual curation. STRING (Search Tool for the Retrieval of Interacting 
Genes/Proteins) for example is a free source which combines experimental data, computational 
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prediction methods and public text collections. The new version 10.0 of STRING includes more than 
2000 organisms. Physical and functional interactions on a global scale are included in the collection. 
A powerful feature of PPI databases is the graphic visualization of the interactions and the pathways 
instead of offering a list of partners.  There are different visualization methods: an example for the 
JAK1 interaction is shown in Figure 45.   
 
Figure 45 Different databases offer different visualization. 
(a) BioGRID HTML table. Physical interactions are shown in yellow as “experimental evidence”. (b) JAK1 
interactions shown in the IntAct “graph viewer” with small molecules being depicted as triangles. The image 
shows only the interaction with JAK1and not between other molecules (nodes). (c) JAK1 STRING network. Each 
different colored line that connects proteins indicates a separate evidence channel for the particular 
interaction, such as text mining (green), experiments (magenta), and databases (blue). (d) InnateDB’s 
Cytoscape with Cerebral plug-in view uses “cellular component” GO annotation to visualize protein considering 
their localization. The horizontal lines indicate different cellular compartments. (Figure from 190).
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The word “Cancer” (gr. ?????????, from ????????, crab) was proposed by Hippocrates (460-370 BC) 
to define uncontrolled growth and proliferation events: he introduced the terms 
carcinos and carcinoma to describe ulcer/non-ulcer-forming tumors. The evidence of cancer 
existence in humans and other animals is dated back to the beginning of recorded history, the first 
record being the Edwin Smith Papyrus, from a 3000 BC Egyptian text book. Remarkably, here the 
author stated in that “There is no treatment” for this disease. Despite an increased basic 
understanding of cancer, in 2016, cancer remains in many cases an untreatable disease and a leading 
cause of death worldwide (8.2 million deaths in 2012)1. Lung cancer and prostate cancer are the 
most common cancer types in men in developed countries, while breast cancer is the most common 
and deadliest type of cancer for women. An increase of about 70% of cancer occurrence in the next 
20 years has been estimated, mostly due to growth and increase of the average life expectancy of 
the world’s population, particularly in developing countries. 
 
Figure 46 Estimated Incidence, Mortality and Prevalence Worldwide in 2012, All Cancers (excluding non-
melanoma skin cancer) 
GLOBOCAN is a project which provides information about incidence, mortality and prevalence of different types 
of cancer, sub-divided in world regions and gender. In 2012, 14.1 million new cancer cases and 8.2 million 
cancer deaths have been reported. Cancer incidence in the male population is highly variable between different 
countries while the incidence in the female population is more stable region-wise. Mortality rates are 15% 
higher in developed world regions for male and 8% for female.  (Figure taken from http://www.iarc.fr 2) 
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Cancer is the results of a combination of genetic and epigenetic alterations and external risk factors. 
Genetic3 (mutations or chromosome translocation) and epigenetic4 ( such as histone modifications, 
and dysregulation of DNA binding proteins) alterations might lead to increased activity of proto-
oncogenes and loss of activity of tumor suppressor genes contributing to tumor formation and 
progression. 
Accumulating evidence suggests that non-clustered protocadherins (Pcdhs) can function as tumor 
suppressors or proto-oncogenes in various non-neuronal human tumours.5,6The Pcdh family 
represents the largest sub-group of the cadherin superfamily 7. They are mainly but not exclusively 
expressed in the nervous system. Pcdhs differ in various aspects from classic cadherins and can be 
subdivided in clustered Pcdhs (C-Pcdhs), and non-clustered Pcdhs (NC-Pcdhs) or ?-protocadherins 
(?Pcdhs)7,8, based on overall sequence homology, number of EC repeats (seven versus six), and 
conservation of specific amino acid motifs in cytoplasmic domains. The subfamily of ?Pcdhs is well 
conserved among vertebrates and comprises 10 members in humans. ?Pcdhs can be expressed as 
short or long isoforms, generated by alternative splicing and differing from each other by the size of 
their cytoplasmic domain. All the long isoforms show highly conserved motifs (CM1 and CM2 for ?1- 
and ?2Pcdhs; plus CM3 for ?1Pcdhs only) in their cytoplasmic domains 8. 
Evidence from the last few years indicates an important role for ?Pcdhs in human cancer. For 
instance, missense mutations were found in PCDH9, -17 and -18 in a large-scale analysis of 
pancreatic cancer9. Pcdh8 is a strong candidate tumor suppressor in breast cancer10, and also 
PCDH10 and PCDH20 were proposed as tumor suppressors11–14. For PCDH10, literature shows strong 
evidence for frequent epigenetic inactivation in various human cancers, including nasopharyngeal, 
gastric and cervical cancer. Pcdhs can also show oncogenic activity, for example PCDH11Y is a 
candidate proto-oncogene in prostate cancer15. More specifically, progression to the hormone-
independent status is correlated with expression of a cytoplasmic variant of PCDH11Y, which is the 
isoform encoded by the male chromosome Y.  
Research on the Pcdh family is still in its infancy. In particular, the molecular interaction partners of 
short or long cytoplasmic domains of ?Pcdhs are still largely unknown. In general, a preliminary step 
in understanding protein structure and function is to determine which proteins interact with each 
other, thereby pointing out relevant biological pathways. The identification of interaction partners 
might reveal in which signaling pathways Pcdhs are involved and how their functions can be restored 
or inhibited in function of therapeutic needs. An interesting molecular interaction partner for the 
151 
 
CM3 domain is, for example, protein phosphatase-1-? (PP1?).8 Specific interaction partners for CM1 
or CM2 have not been identified to date.  
The aim of the PhD project described in this dissertation has been to investigate the putative tumor 
suppressor or oncogenic role of ?Pcdhs by identification and functional analysis of novel intracellular 
interaction partners and to elucidate their role in different signaling pathways. The focus on the 
conserved motifs CM1 and CM2 is due to their high evolutionary conservation across species7, which 
points at an important role in intracellular signaling. Of course, we cannot exclude a priori that this 
conservation is due to structural needs, i.e. intramolecular interactions rather than intermolecular 
interactions. Unfortunately, the structure of Pcdh cytoplasmic domains is not yet resolved. 
In our studies we focused on PCDH10 as representative of ?2Pcdhs and on PCDH11X as 
representative for the ?? subgroup. Other members of the family have been included in various 
experiments. In the first part of the project we investigated novel molecular interactions of Pcdh 
cytoplasmic domains using Mammalian Protein-Protein Interaction Trap (MAPPIT) technology. Array 
MAPPIT was selected as a robust screening assay. Putative interaction partners were confirmed with 
orthogonal assays and analyzed to obtain a priority list. The aim of the second part of the project 
was the functional characterization of the molecular interactions discovered, hardly predictable as it 
depends on the nature of these molecular partners (e.g. novel versus well-known proteins, barely 
studied versus well-characterized proteins, structural versus regulatory/signaling proteins). The 
functional implications of these molecular interactions will be studied using contemporary molecular 
technologies. 
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Chapter III. IDENTIFICATION OF NOVEL 
INTRACELLULAR INTERACTION PARTNERS 
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III.1 Introduction 
E-cadherin is a transmembrane cell-cell adhesion molecule whose cytoplasmic domain is coupled 
to the actin cytoskeleton via catenins. We have demonstrated that the E-cadherin/catenin 
complex plays an instrumental role in tumor suppression1. On the other hand, nuclear beta-
catenin can act as a potent oncogene. The ?-protocadherin family comprises 10 members, all with 
an extracellular domain related to E-cadherin but for the rest differing strongly from E-cadherin2,3. 
For instance, their cytoplasmic domains (CDs) occur in at least two forms, which are not 
interacting with classic catenins. The longer CD type contains two to three conserved motifs 
(CMs), which most likely serve as interaction domains for signaling proteins. Protocadherins are 
probably rather communicative than adhesive proteins and functional differences may exist 
between long and short isoforms. Hence, it is of utmost importance to identify and characterize 
the still enigmatic cytoplasmic molecular partners of ?-protocadherins (?Pcdhs). 
?Pcdhs are expressed at high levels in the brain. So it is not that surprising that many of them are 
involved in neurological disorders, such as autism, schizophrenia, epilepsy and Alzheimer’s 
disease. A role in neurological disorders has indeed been reported for PCDH74, PCDH105, Pcdh8 
and Pcdh176, PCDH11X and PCDH11Y7–9 and PCDH1810, but the most convincing evidence comes 
from studies on Pcdh19, which is the most relevant gene in epilepsy after SCN1A11. PCDHs have 
also been shown to be involved in other diseases and symptoms, for example, asthma and 
bronchial hyper responsiveness (BHR)12. Recent reports also describe a role for ?Pcdhs in the 
immune system13–16.  
Indeed, both direct and indirect lines of evidence indicate that non-clustered (NC) Pcdh genes 
play important roles during tumorigenesis, either as tumor-suppressor genes or as oncogenes. 
For instance, missense mutations were found in Pcdh9, -17 and -18 genes in a large-scale analysis 
of pancreatic cancer17. PCDH8 is a strong candidate tumor suppressor in breast cancer18 and also 
PCDH10 and PCDH20 were proposed as tumor suppressors19–22. For PCDH10 the literature shows 
strong evidence for frequent epigenetic inactivation in various human cancers, including 
nasopharyngeal, gastric and cervical cancer (reviewed by van Roy, 2014, Nat. Rev. Cancer)23. On 
the other hand, there is accumulating evidence for a role of PCDH11 as proto-oncogene in 
prostate cancer24. More specifically, progression to the hormone-independent status of prostate 
cancer is correlated with expression of a cytoplasmic variant of PCDH11Y, which is an isoform 
encoded by the male chromosome Y. (More examples and details in Chapter I). 
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Research on the protocadherin families is still in its infancy. In particular, it is still enigmatic what 
the molecular interaction partners are of the short or long cytoplasmic domains of ?Pcdhs. Their 
identification might reveal in which signaling pathways Pcdhs are involved and how their 
functions can be restored or inhibited for therapeutic needs. ?Pcdhs are expressed as long and 
short isoforms. For long isoforms, the cytoplasmic domains are characterized by the presence of 
conserved amino acid motifs CM1 to CM3. As these CMs are highly conserved within the ?Pcdh 
family, and despite the obvious differences between the members of this family, it is possible and 
even most likely, that ?Pcdhs share some core interaction partners. 
An interesting molecular interaction partner for CM3 is protein phosphatase-1-? (PP1?)25. 
However, specific interaction partners for CM1 or CM2 have not been reported to date. 
Nonetheless, several ?Pcdhs have been shown to interact with intracellular partners and have 
therefore been implicated in signaling pathways. One of those interactions is the binding of 
PCDH10 to NAP1 (Nck-associated protein 1), which recruits WAVE1 (SCAR1) to cell-cell contacts, 
resulting in a non-standard assembly of PCDH10 with F-actin and N-cadherin at this location26. In 
the presence of PCDH10 the complex NAP1-WAVE1 becomes redistributed at cell-cell contacts 
instead of at the lamellipodia where it is usually localized to participate in the cell migration 
process. In this way the cell-cell contacts become locally unstable. On the basis of this remarkable 
interaction, a role for PCDH10 has been proposed in upregulation of the cell motile machine at 
cell-cell contact sites, by modulating the cadherin-dependent inhibition of cell movement. (For 
other interaction partners, check Chapter I). 
Because ?Pcdhs are most likely involved in signaling pathways, we were in particular looking for 
interaction partners that could mediate such signaling. Moreover, the CMs became our major 
focus, because we speculated that their high evolutionary conservation across species points to 
an important role in intracellular signaling. Of course, we could not exclude beforehand that this 
conservation is due to structural needs, i.e. intramolecular interactions rather than 
intermolecular interactions, since so far structures of Pcdh cytoplasmic domain remain to be 
resolved. 
Different approaches have been followed to identify novel (common or exclusive) interaction 
partners of ?Pcdhs and the robust array-MAPPIT technology was chosen to perform the 
important initial screening experiments.  
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The Mammalian Protein-Protein Interaction Trap (MAPPIT) is a two hybrid system for the 
detection of PPIs in intact mammalian cells. The method is described in detail in Eyckerman et 
al.27 and in Chapter II of this dissertation. Briefly, the technique is based on a modified JAK-STAT 
signaling pathway. The first hybrid is a modified cytokine receptor fused with the protein of 
interest and missing STAT3 recruitment sites (the bait). MAPPIT prey constructs are composed of 
a candidate interaction partner or of an ORF C-terminally fused to a part of the gp130 chain 
carrying the STAT3 recruitment site. Functional complementation of the STAT3 signaling 
pathways can only result in case of a molecular interaction between bait and prey and is 
measured via a luciferase reporter containing the rat pancreatitis-associated protein I (rPAP) 
promoter responsive to STAT3 28. A collection of 10,000 ORFs was screened for interactions with 
cytoplasmic domains of different PCDHs. Binary MAPPIT assays were performed to confirm the 
interactions and to select common candidate interactors. A shortlist of selected candidate 
interaction candidates has then been challenged in co-immunoprecipitation experiments.   
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III.2 Materials and Methods 
 Plasmids III.2.1
LR-bait constructs were generated as previously described and named pCLG27. This constructs 
contains the bait of interest C-terminally fused to the long receptor isoform of the murine leptin 
receptor (LR), truncated after the JAK binding site and fused to a 20xGGS hinge. The pCLG vector 
is derived from pcDNA5/FRT plasmid (Flp-In system; Life technologies): it includes an FRT site 
related to the hygromycin resistance gene for Flp recombinase dependent integration to the host 
cell line, in this case TRex44.29 The MAPPIT pCLG-hPCDHs bait vectors were generated by cloning 
the full cytoplasmic tail of the respective PCDHs or fragments in the pCLG vector backbone into 
the BamHI-XhoI or BamHI-NotI sites, as described in 30. MAPPIT preys were either cloned into the 
EcoRI-XhoI or EcoRI-XbaI site of the pMG2 plasmid or were obtained by Gateway 
recombinationatorial transfer of the full size ORF cDNA of the candidates from an entry clone 
selected from the ORFeome collection version 5.131 into a pMG1 destination vector as reported 
before32. The generation of the STAT3-responsive luciferase reporter plasmid (pXP2d2-rPAP-luci) 
has been described before33. The reporter contains a STAT3-dependent promoter fragment 
derived from the rat Pancreatitis Associated Protein 1 (Pap) gene fused to luciferase. 
 Transient MAPPIT experiment III.2.2
Hek293T cells were cultured in Dulbecco’s modified Eagle’s medium DMEM+10% fetal bovine 
serum, grown in a humidified atmosphere at 37°C and 5% CO2, seeded in 96 microtiter well plates 
and transfected by calcium phosphate precipitation as previously described33. (Transfection 
reagents: 2.5 M CaCl2. Prepared in distilled water, filter-sterilized by passage through a 0.45 ?M 
nitrocellulose membrane and stored at 20°C. Hepes-Buffered Saline (HeBS): 280 mM NaCl, 1.5 
mMNa2HPO4, 50 mM HEPES. Adjusted to pH to 7.05 with NaOH. Filter-sterilized by passage 
through a 0.45 ?M nitrocellulose membrane and stored at 20°C. Briefly, for a transient MAPPIT 
experiment, cells were transfected after 24h from seeding in the 96 well plates with bait (25ng 
per well), prey (25ng per well) and reporter (5ng per well) plasmids. Samples were prepared in 
triplicates. 24h after transfections, triplicate wells were stimulated either with vehicle (media) or 
leptin (100ng/ml). Luciferase activity was measured using the Luciferase Assay System kit 
(Promega) on an Envision plate reader (Perkin Elmer) 24H after stimulation: cells were lysed for 
10 minutes in 50??l luciferase lysis buffer (25 mM Tris-phosphate, pH 7.8, 2 mM DTT, 2 mM 2,2 
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diaminocyclohexane-N,N,N0,N0-tetra-acetate (DCTA), 10 % glycerol, 1 % Triton X-100. Store at 
20°C) and 35?l of Luciferase substrate buffer (40 mM tricine, 2.14 mM (MgCO3)4 Mg(OH)2 5H2O, 
5.34 mM MgSO4 , 66.6 mM DTT, 0.2 mM EDTA, Coenzyme A, 734 ?M Adenosine 50 triphosphate, 
940 ?M D-luciferin. Stored at 20°C). The reagent is light sensitive and 35 ?l of luciferase substrate 
buffer were added just before measuring. Luciferase fold change was determined by calculating 
the ratio of leptin stimulated to unstimulated wells.  
 Array MAPPIT III.2.3
Array MAPPIT screens were performed for PCDH10, PCDH11X and PCDH9 to identify novel 
common or exclusive interaction partners. The screens were performed using a subset of about 
10.000 ORF preys selected from the human ORFeome collection version 5.131 as previously 
described34. Briefly, Hek293T cells were transfected in buck with the pCLG-PCDH9, -10 or -11X 
bait encoding plasmid; cells were plated 24h after transfection in array screening plates already 
printed with the prey and reporter reverse transfection mixtures. 24 hours later, each condition 
(prepared in duplicates) was stimulated with leptin (100ng/ml) and 24 hours later luciferase 
activity was detected and measured. The ratio between the average values of the two leptin 
stimulated samples were calculated and given as the MAPPIT signal. The signal intensity ranking 
list of preys was created for each screen. Preys were ranked also according to within experiment 
variation applying a one-sided balanced test35. 
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III.3 RESULTS: MAPPIT technology
 ????????????? ?????????????????? ???????????????????????????????????
The first MAPPIT screens, with the cytosolic domain of the ?-Protocadherin family, date back 
several years, when Dr. Uta Brunner from our group, performed a MAPPIT cDNA library screening 
for PCDH 11X/Y interaction partners. PCDH11 belongs to the ?1PCDH subfamily and it has been 
linked to tumor development. MAPPIT was picked as a promising approach not only because it 
allows the detection of protein interactions in mammalian cells but also because the interactions 
occur in proximity of the plasma membrane, the natural environment for PCDHs. In previous 
studies, Protein Phosphatase 1? (PP1?) has been identified, via a pull-down assay, as an 
interactor with the CM3 domain of ?1PCDHs including PCDH1125. PP1? plays a crucial role in the 
pRB tumor suppressor pathway, is essential for cell division, and participates in the regulation of 
glycogen metabolism, muscle contractility and protein synthesis but the role of its interaction 
with ?1PCDHs is still not clear36. 
Initial tests with the cytoplasmic tail of PCDH11X as bait and the known interactor PP1? as prey 
resulted in a clear-cut interaction, showing that MAPPIT can be used for this particular aim. In the 
same test, PCDH11X/Y and PCDH9 interacted with PP1???The interaction screening was 
performed in a cell line derived from the Hek293 FlpIn T-Rex cell line (Invitrogen), the TRex44 
MAPPIT screening cell line: this cell line allows the generation of a pool of isogenic cells 
expressing the chimeric bait receptor and the mouse virus receptor (mEcoR) to permit viral 
delivery of the prey cDNA library made as described in Lievens et al.29. These cells contain a 
reporter cassette encoding a STAT3-responsive rPAP1 promoter-driven hIL5R?-derived 
membrane tag 29,37. Retroviral transduction of the prey cDNA library into the bait-expressing cell 
pool is the first step of the screening protocol. The stimulation with ligand allows the selection of 
cells in which bait-prey interactions occur. Positive cells are enriched using magneto-beads thanks 
to the hIL5R? membrane tag. By an additional cell sorting step the number of false positives can 
be reduced at this stage of the protocol. After a second stimulation with the ligand, single positive 
cells are spotted into multi-well plates. A dot blot assay is used for validation, and finally RT-PCR 
and sequencing is applied to reveal the identity of the preys. 
This screening for PCDH11 interactors yielded a list of putative candidates, but none of them 
could be confirmed in a one-to-one, or binary MAPPIT re-test.  
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Several putative interactions partners (DYNLT1, FHL2, PDLIM7, FASCIN1, and Zyxin), suggested by 
the literature or by previous experiments, were subsequently cloned or obtained from the ORF 
prey collection to perform an analytical test using the full-length cytoplasmic tail of PCDH11X. 
This confirmed the interactions with the candidates, as expected. A clear interaction was 
identified between PCDH11X and DYNLT1. Interactions were mapped using different constructs 
for PCDH11X including all, some or any conserved motifs25 (Uta Brunner, data not published). 
A MAPPIT cDNA library screen was also performed for the identification of interactors of the 
PCDH10 cytoplasmic domain (Irene Kahr, data not published). At the time of the experiment no 
interactor of PCDH10 was known, so the interaction between PCDH11 or PCDH9 and PP1? was 
used as positive control and the bait was tested for interaction–independent activation via 
transfection with and without an irrelevant prey, in this case SV40 large-T antigen (SVT). The 
screen was performed in the same cell line and with the same protocol as in the case of the 
previous test on PCDH11. 
Also in this case, as for the abovementioned PCDH11 cDNA library screening, the results were 
disappointing: sequencing of PCR products and consecutive BLAST searches showed only 14 
readable sequences, and none of these were in frame with gp130. The MAPPIT cDNA screen was 
therefore not repeated: auto activation for the PCDH10 bait can lead to spontaneously 
hIL5R??cyt surface tag expression at a level prohibiting selection of true PPIs. Despite this failure 
of the MAPPIT cDNA library screen, Y2H screens were performed but also these failed in 
identifying putative interaction partners of PCDH10. Nonetheless, a binary MAPPIT experiment 
was performed using the PCDH10 cytoplasmic domain as bait: putative interaction partners of 
PCDH11 identified in our laboratory by Uta Brunner via MAPPIT or Y2H cDNA library screens (data 
not published) were retested in such one-to-one experiment. The results for PCDH10 
demonstrated a clear interaction with one of the putative interaction partners of PCDH11, 
DYNLT1, also known as Tctex-1 (PhD project of Irene Kahr, data not published). DYNLT1 was then 
used as positive control in all the following MAPPIT experiments.  
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 ?????? ?????????????
Instead of repeating the experiment using the FACS based MAPPIT screening methods, we 
applied the newly developed Array MAPPIT37 technology (for further details we refer to Chapter 
II) to screen for novel interaction partners. As baits we used the cytoplasmic domain of human 
PCDH9, PCDH10 and PCDH11X, as preys the library built on the ORFeome v5.1. The screens were 
performed in Hek293T cells and in an automated 384-well plate format. By comparing the results 
of the screening of different PCDHs and evaluating the relevance of the putative interaction 
partners for our research, we could establish a priority list of interaction candidates (Figure 47). 
 
Figure 47 Summary of the MAPPIT procedure presented in this chapter and used to obtain the short 
priority list of common/exclusive candidate interaction partners of different members of the ?PCDH 
family 
 
The test is based on the activation of a luciferase reporter gene and the duration of the analysis 
process is dramatically reduced (5 days from transfection to measurement) since the preys can be 
identified simply by their position on the array. The method takes advantage of the availability of 
a large collection of the full-length human ORFs which can be transferred easily in the prey vector 
by recombinational cloning38. 
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The general protocol of the array is based on a reverse transfection. First, microtiter plates 
containing plasmid preys covering the complete prey collection need to be generated. Then the 
screening proceeds with the covering of the plates by the bait-expressing cell pool, the 
stimulation with the appropriate ligand and the measurement of the luciferase activity. This 
approach is really fast and mostly automated39. For the experiments with PCDHs we did not use a 
stably transfected cell line but we proceeded with transiently transfected cells using the calcium 
phosphate protocol. Currently, a collection of 15,000 preys, corresponding to the ORFeome v8.1 
collection (Centre for Cancer Systems Biology, CCSB, Boston), is available for screening. At the 
time of the experiment the collection included 10,000 preys. The absolute counts (triplicate for 
each condition, stimulated and non-stimulated) are analyzed and used to calculate the fold 
induction for each prey: this will be compared with the fold induction value of the empty prey 
which is used as threshold. The results come ranked based on fold induction and are represented 
on a plot. For each Array MAPPIT screen, a list with the top 96 hits is retested in a binary MAPPIT 
set up to check for specificity.  
II.3.2.1 Array MAPPIT analysis for the PCDH11X cytoplasmic domain 
 
Figure 48 Array MAPPIT screen for PCDH11X 
A) Every condition was screened in duplicates. The volcano plot represents the logarithmic (log) scale (x axis) 
of the ratio (fold change) of the leptin stimulated condition to the unstimulated condition and the p-value 
calculated using one sided balanced test. At the top right the most prominent candidates are gathered 
combining the high MAPPIT signal with high statistical significance. B) The top ranked 48 candidates. 
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The Array MAPPIT experiment for the PCDH11X cytoplasmic domain was performed and results 
are shown in Figure 48. 
At first glance, we noticed that PP1??appears, as expected, among the top hits (PPP1CA or 
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit, position 15 in the ranking list), 
confirming the validity of the test. Interestingly, also the catalytic subunits of PP1? (i.e. PPP1CB) 
and PP1? (i.e. PPP1CC) are among this top list (position 13 and 20, respectively), indicating that 
?1PCDHs might interact directly or indirectly with each of the PP1 isoforms. 
The second protein on the list (PDLIM7, or Enigma) was already detected in the short list of 
candidates specifically tested in a one-to-one experiment. It is a member of a family of proteins 
that contain N-terminal PDZ domains and C-terminal LIM domains and probably functions as an 
adapter. It is known to associate with actin laments of skeletal muscle. However, it also localizes 
via its PDZ domain to the actin microfilament network of non-muscle cells40, indicating that its 
function extends to other tissues. Microscopic analysis showed co-localization of PDLIM7 with 
PCDH11X (Uta Brunner, unpublished data). 
Next we proceeded to the specificity test, performing binary assays on the top 96 candidates 
(Figure 49). In the retest as a negative control we used an empty vector containing gp130 only 
and as positive control known JAK2 binding proteins such as REM2 GTPase and EF-hand domain-
containing family member A1 (EFHA1). As internal control we also used two irrelevant baits: the 
DHFR from E. coli and bromodoman 4 C-terminal domain (Brd4-CTD). This control can exclude 
false positives due to the binding of the preys to the JAK2 molecules linked to the leptin receptor 
and can ensure that the interactors are specific for the selected PCDH. 
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Figure 49 Re-test for candidate interactors 
of the PCDH11X cytoplasmic domain in a 
one-to-one MAPPIT assay 
We used the full length cytoplasmic tail of 
PCDH11X; the test confirmed known and 
putative interaction partners, 
demonstrating the validity of the Array 
MAPPIT test. White: non-relevant eDHFR 
bait, Blue: original PCDH11X bait. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
168 
 
The experiment was performed twice with comparable results allowing the selection of a short 
list of candidates. On the basis of literature indications, also a few candidates, which turned 
positive in only one of the two tests, were retained. 29 interaction partners were confirmed for 
PCDH11X and these are listed in Table 8. As mentioned above, ?PCDHs share several domains 
(CMs) in the cytoplasmic tail. To identify common interaction partners we decided to perform a 
cross test using the cytosolic domain of PCDH9, PCDH10 and PCDH11X as baits (details and 
explanation in the next paragraph). The cross test re confirmed 25 of the 29 partners. The 
complete list was subjected to an Ingenuity Pathway analysis in order to identify common 
associated pathways (Figure 50). 
 
 
Figure 50 Analysis of interactions between confirmed candidates of PCDH11X with Ingenuity Pathway 
System.  
As expected the system put in relationship PPP1CA, PPP1CB and PPP1CC, but also HSPA8, heat shock 70kDa 
protein 8, with CUL5.  
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Table 8 List of positive candidates for PCDH11X after MAPPIT experiments. Table obtained via IPA.  
 
 Symbol Entrez Gene Name Location 
1 ACOT8 acyl-CoA thioesterase 8 Cytoplasm 
2 CUL5 Cullin 5 Nucleus 
3 DMRTC1 DMRT-like family C1B Other 
4 DTX3L deltex 3 like, E3 ubiquitin ligase Cytoplasm 
5 EPB42 erythrocyte membrane protein band 4.2 Plasma Membrane 
6 FHL3 four and a half LIM domains 3 Plasma Membrane 
7 GGN Gametogenetin Nucleus 
8 GNA14 guanine nucleotide binding protein (G protein), alpha 14 Plasma Membrane 
9 GTPBP4 GTP binding protein 4 Nucleus 
10 HORMAD2 HORMA domain containing 2 Nucleus 
11 HSPA8 heat shock 70kDa protein 8 Cytoplasm 
12 KRT222 keratin 222, type II Other 
13 MXD3 MAX dimerization protein 3 Nucleus 
14 NFIA nuclear factor I/A Nucleus 
15 NKD2 naked cuticle homolog 2 (Drosophila) Nucleus 
16 PDLIM7 PDZ and LIM domain 7 (enigma) Cytoplasm 
17 PPP1CA protein phosphatase 1, catalytic subunit, alpha isozyme Cytoplasm 
18 PPP1CB protein phosphatase 1, catalytic subunit, beta isozyme Cytoplasm 
19 PPP1CC protein phosphatase 1, catalytic subunit, gamma isozyme Nucleus 
20 RAB34 RAB34, member RAS oncogene family Cytoplasm 
21 RFTN2 raftlin family member 2 Other 
22 SKIL SKI-like proto-oncogene Nucleus 
23 SULT1A3/SULT1A4 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 Cytoplasm 
24 SYTL2 synaptotagmin-like 2 Cytoplasm 
25 TRIM23 Tripartite motif containing 23 Nucleus 
26 TTLL1 tubulin tyrosine ligase-like family member 1 Extracellular Space 
27 UBTD2 ubiquitin domain containing 2 Other 
28 USP12 ubiquitin specific peptidase 12 Cytoplasm 
29 USP46 ubiquitin specific peptidase 46 Other 
 
170 
II.3.2.2 Array MAPPIT analysis for the PCDH10 cytoplasmic domain
Of the ?2PCDHs, we decided to screen PCDH10 as bait using the 10,000 ORF prey library. The 
human PCDH10 gene is frequently silenced in several carcinomas, and its ectopic expression 
strongly suppresses tumor cell growth, migration and invasion20,41–45. Despite its obvious 
relevance to cancer, not much is known about PCDH10. Our Array MAPPIT screen produced a list 
of putative interaction partners. As expected for a ?2PCDH lacking the consensus PP1?-
interaction motif CM3, PPP1CA is not included in this list. The results are shown in the volcano 
plot of Figure 51 and the list of the top 96 candidates can be found in Table 11. 
We performed a re-test experiment for the top 96 candidates, to validate the results obtained 
from the Array MAPPIT. The analysis of this re-test was not as straightforward as might be 
expected for MAPPIT experiments under optimal conditions. This was due to a high background 
for the PCDH10 bait vector in our experiments. We obtained a final list of 25 candidate 
interactors. An experiment of “cross test” followed (see below). Of the 25 retained candidate 
interactors of the PCDH10 cytoplasmic domain, 12 turned out to be positive again in the cross 
test when PCDH10 was considered as bait (Table 9). 
Figure 51 Array MAPPIT screen for PCDH10 
Every condition was screened in duplicates. The volcano plot represents the logarithmic (log) scale (x 
axis) of the ratio (fold change) of the leptin-stimulated condition to the unstimulated condition and the p-
value calculated using one sided balanced test. At the top right the most prominent candidates are 
gathered combining the high MAPPIT signal with high statistical significance. 
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Table 9 List of positive candidates for PCDH10 after MAPPIT experiments. Table obtained via IPA. 
 
 Symbol Entrez Gene Name Location 
1 DMRTC1 DMRT-like family C1 Other 
2 HEY1 hes-related family bHLH transcription factor with YRPW motif 1 Nucleus 
3 HOXB7 homeobox B7 Nucleus 
4 MXD3 MAX Dimerization Protein 3 Nucleus 
5 MXI1 MAX interactor 1, dimerization protein Nucleus 
6 PDE1B phosphodiesterase 1B, calmodulin-dependent Cytoplasm 
7 RGS20 regulator of G-protein signalling 20 Cytoplasm 
8 RNF115 Ring Finger Protein 115 Cytoplasm 
9 RRAGC Ras-related GTP binding C Cytoplasm 
10 STAU1 staufen double-stranded RNA binding protein 1 Cytoplasm 
11 TRIM23 tripartite motif containing 23 Nucleus 
12 VGLL4 vestigial-like family member 4 Nucleus 
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II.3.2.3 Array MAPPIT analysis for the PCDH9 cytoplasmic domain 
 
 
Figure 52 Array MAPPIT for PCDH9 
Every condition was screened in duplicates. The volcano plot represents the logarithmic (log) scale (x axis) of 
the ratio (fold change) of the leptin stimulated condition to the unstimulated condition and the p-value 
calculated using one sided balanced test. At the top right of the volcano plot the most prominent candidates 
are gathered combining the high MAPPIT signal with high statistical significance. On the left of the figure, 
the top ranked 48 candidates 
 
 
The Array MAPPIT screen using the PCDH9 cytoplasmic domain was also carried out using the 
same protocol as explained above. Results are shown in Figure 52. The list of the top 96 
candidates has been validated via a re-test experiment. 
The background signal for PCDH9 was significantly lower compared to this for other ?Pcdhs, and 
this allowed an easier selection. We obtained a list of 34 candidates (Table 10). 19 of them were 
confirmed in the subsequent cross-test.  
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Table 10 List of positive candidates for PCDH9 after MAPPIT experiments. Table obtained via IPA. 
 Gene Description Location 
1 AGBL3 ATP/GTP Binding Protein-Like 3 Cytoplasm 
2 DPYSL5 dihydropyrimidinase-like 5 Cytoplasm 
3 COTL1 coactosin-like F-actin binding protein 1 Cytoplasm 
4 FARP2 FERM, RhoGEF and pleckstrin domain protein 2 Cytoplasm 
5 PPP1CB protein phosphatase 1, catalytic subunit, beta isozyme Cytoplasm 
6 PPP1CA protein phosphatase 1, catalytic subunit, alpha isozyme Cytoplasm 
7 CAMKK1 calcium/calmodulin-dependent protein kinase 1, alpha Cytoplasm 
8 PPP1CC protein phosphatase 1, catalytic subunit, gamma isozyme Nucleus 
9 DMRTC1 DMRT-like family C1 Other 
10 TGFBR2 transforming growth factor, beta receptor II (70/80kDa) Plasma Membrane 
11 MXI1 MAX interactor 1, dimerization protein Nucleus 
12 USP33 ubiquitin specific peptidase 33 Cytoplasm 
13 PPFIBP2 PTPRF interacting protein, binding protein 2 (liprin beta 2) Nucleus 
14 COPS3 COP9 signalosome subunit 3 Cytoplasm 
15 GOLGA8DP golgin A8 family, member D, pseudogene Other 
16 HSF2 heat shock transcription factor 2 Nucleus 
17 SCEL Sciellin Cytoplasm 
18 MEF2A myocyte enhancer factor 2A Nucleus 
19 MAX MYC associated factor X Nucleus 
20 C1orf106 chromosome 1 open reading frame 106 Other 
21 HDAC11 histone deacetylase 11 Nucleus 
22 FMN1 formin 1 Nucleus 
23 CWC25 CWC25 spliceosome-associated protein homolog (S. cerevisiae) Other 
24 AGBL3 ATP/GTP binding protein-like 3 Other 
25 B4GALT2 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 2 Cytoplasm 
26 TRIM23 Tripartite motif containing 23 Nucleus 
27 TRIT1 tRNA isopentenyltransferase 1 Cytoplasm 
28 SETD2 SET domain containing 2 Cytoplasm 
29 ZNF341 zinc finger protein 341 Nucleus 
174 
30 KLF17 Kruppel-like factor 17 Nucleus 
31 SH3D19 SH3 domain containing 19 Plasma Membrane 
32 DCAF12L1 DDB1 and CUL4 associated factor 12-like 1 Extracellular Space 
33 PAX8 paired box 8 Nucleus 
34 KLF4 Kruppel-like factor 4 (gut) Nucleus 
 ?????????????????????????????????????
Cross-tests were used to identify common interaction partners among different members of the 
?PCDH family. Each confirmed prey of each PCDH bait was re-tested in a binary test with the two 
other PCDH baits.  
In the first cross-test PCDH9, PCDH10 and PCDH11X baits were screened for interactions with the 
confirmed candidates of PCDH11X. Few shared candidates were identified in the test: for example 
the PCDH10 bait gave a positive signal for PDLIM7 and NFIA, while PCDH9 was shown to be a 
candidate interactor for CUL5 and SKIL. Cross-tests have been performed with the same protocol 
for the confirmed candidates of PCDH10 and PCDH9. Positive interactions were added to the list 
of candidates for each bait. Results for each prey can be found in Table 11. 
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Table 11 Overall summary of our MAPPIT analyses. 
A list of 96 top candidate interactors was obtained after every Array MAPPIT experiment. The first column 
shows the complete list of (96x3=) 288 preys. “Rank R (1)” values refer to the Array results for each 
experiment. The list of preys is alphabetically ordered so different colors are present to indicate the original 
array ( orange, Array MAPPIT for the PCDH11X bait; blue, Array MAPPIT for the PCDH10 bait; yellow, Array 
Mappit for the PCDH9 bait). In the “Retest” column confirmed interactions are indicated with (+). In the last 
three columns, results are shown of three cross test experiments performed on interactions confirmed for 
each bait. (+)= interaction; (-) = no interaction; (?)=result missing/not trustable. In green are indicated the 
proteins included in the definitive selection. The final priority list was based on this combinatorial selection. 
 
Prey name Rank R(1) PCDH Retest Cross test 
PCDH9 
Cross test 
PCDH10 
Cross test 
PCDH11X 
ACADM 73 PCDH11X     
ACAP1 50 PCDH11X     
ACOT8 12 PCDH11X (+) (-) (-) (+) 
ADC 15 PCDH9     
ADH4 11 PCDH10     
AFAP1L2 96 PCDH11X     
AGBL3 64 PCDH9 (+) (+) (-) (+) 
AGK 75 PCDH9     
ALDH1L2 88 PCDH11X     
ALG11 92 PCDH10     
ANKRD19 31 PCDH9     
ANKRD36 19 PCDH9     
APOL4 19 PCDH10     
ARHGAP28 61 PCDH9     
ARHGDIG 21 PCDH10     
ARHGEF1 44 PCDH11X     
ARL13B 25 PCDH9     
ARL17A 44 PCDH10     
ARNTL 94 PCDH10     
ARR3 48 PCDH9     
ATG3 7 PCDH10     
ATP5J2 73 PCDH9     
B4GALT2 66 PCDH9 (+) (+) (-) (+) 
BAIAP2 37 PCDH10     
BAIAP3 88 PCDH9     
BARX1 29 PCDH11X     
BBOX1 19 PCDH11X     
BIN3 52 PCDH11X     
BLZF1 27 PCDH11X     
BRMS1 16 PCDH10     
C10orf104 68 PCDH10     
C10orf32 74 PCDH9     
C16orf87 85 PCDH11X     
C17orf101 75 PCDH10     
C18orf32 67 PCDH10     
C1orf106 50 PCDH9 (+) (?) (+) (+) 
C20orf196 95 PCDH11X     
C2CD2 91 PCDH11X     
C2orf15 42 PCDH9     
C3orf26 62 PCDH11X     
C5orf32 72 PCDH10     
C8orf31 49 PCDH9     
C9orf131 89 PCDH10     
C9orf173 21 PCDH9     
CAMKK1 16 PCDH9 (+) (-) (-) (-) 
CAPN7 57 PCDH10     
CARD10 46 PCDH9     
CCDC21 35 PCDH10     
CCDC94 30 PCDH10     
CCM2 45 PCDH9     
CDC45L 18 PCDH10     
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CDKN1B 47 PCDH10     
CHRNA1 69 PCDH9     
CIAPIN1 42 PCDH11X     
CLIP3 36 PCDH10     
CNN1 57 PCDH9 (+) (-) (+) (-) 
COMMD8 24 PCDH11X     
COPS3 21 PCDH9 (+) (?) (-) (+) 
COQ10B 80 PCDH11X     
CORO1B 43 PCDH11X     
COTL1 4 PCDH9 (+) (+) (-) (+) 
CREB1 59 PCDH11X     
CREB5 26 PCDH10     
CSNK1G2 38 PCDH9     
CSRP2BP 23 PCDH10     
CUL5 9 PCDH11X (+) (+) (-) (+) 
CWC25 56 PCDH9 (+) (+) (+) (+) 
CXorf1 55 PCDH9     
DCAF12L1 87 PCDH9 (+) (?) (+) (+) 
DCUN1D1 95 PCDH10     
DGCR14 32 PCDH11X     
DMD 46 PCDH11X     
DMRTC1 78 PCDH11X (+) (+) (-) (+) 
DMRTC1 20 PCDH9 (+) (?) (+) (?) 
DMRTC1 1 PCDH10 (+) (+) (+) (+) 
DMRTC2 24 PCDH10 (+) (-) (-) (-) 
DNMBP 34 PCDH9     
DPYSL3 90 PCDH10     
DPYSL5 2 PCDH9 (+) (+) (-) (-) 
DSN1 85 PCDH9     
DTX3L 40 PCDH11X (+) (-) (-) (+) 
DYX1C1 89 PCDH11X     
EFTUD1 37 PCDH11X     
EIF2S2 66 PCDH10     
EIF3I 73 PCDH10     
EME1 96 PCDH10     
EPB42 49 PCDH11X (+) (-) (-) (+) 
ERCC8 29 PCDH9     
ERF 3 PCDH10     
ESYT1 54 PCDH11X     
ETS1 36 PCDH11X     
FAF2 46 PCDH10     
FAM195A 70 PCDH11X     
FARP2 5 PCDH9 (+) (-) (-) (-) 
FCGR3A 92 PCDH9     
FGD2 81 PCDH9     
FHL3 8 PCDH11X (+) (-) (-) (+) 
FLJ32063 66 PCDH11X     
FLJ37201 16 PCDH11X     
FMN1 52 PCDH9 (+) (+) (+) (+) 
FOXO3 44 PCDH9     
FOXP4 77 PCDH10     
FSD1 69 PCDH11X     
GCKR 74 PCDH11X     
GGN 7 PCDH11X (+) (+) (-) (+) 
GKAP1 93 PCDH9 (+)    
GNA14 17 PCDH11X (+) (-) (-) (-) 
GNAQ 40 PCDH9     
GOLGA8D 26 PCDH9 (+) (+) (+) (+) 
GOLGA8E 29 PCDH10 (+) (+) (?) (+) 
GOLGA8F 33 PCDH9     
GTPBP4 47 PCDH11X (+) (-) (-) (+) 
GTPBP5 47 PCDH9     
GTPBP8 58 PCDH10     
GUCY1B3 26 PCDH11X     
HDAC11 51 PCDH9 (+) (?) (+) (+) 
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HEY1 59 PCDH10 (+) (+) (+) (-) 
HIF1A 9 PCDH9     
HIST1H4A 32 PCDH9     
HORMAD2 22 PCDH11X (+) (-) (-) (+) 
HOXB7 12 PCDH10 (+) (?) (+) (+) 
HPRT1 91 PCDH9     
HSF2 27 PCDH9 (+) (?) (?) (?) 
HSPA8 51 PCDH11X (+) (-) (-) (+) 
IGF1R 71 PCDH11X     
ING2 55 PCDH10     
KATNA1 61 PCDH11X     
KCNIP4 60 PCDH11X     
KCNIP4 13 PCDH10     
KLF17 80 PCDH9 (+) (+) (+) (+) 
KLF4 94 PCDH9 (+) (+) (+) (?) 
KLF6 51 PCDH10     
KLHL18 45 PCDH11X     
KRT222 75 PCDH11X (+) (-) (-) (?) 
LIG1 60 PCDH10     
LMX1B 39 PCDH11X     
LOC283693 50 PCDH10     
LPXN 28 PCDH11X     
LSM3 33 PCDH11X     
LUC7L3 78 PCDH10     
MAGEF1 24 PCDH9     
MAP2K3 30 PCDH9     
MAP2K3 32 PCDH10     
MAX 23 PCDH9     
MAX 41 PCDH9 (+) (+) (+) (+) 
MAX 6 PCDH10 (+) (+) (-) (+) 
MBIP 23 PCDH11X     
MEF2A 39 PCDH9 (+) (+) (+) (+) 
MEF2A 40 PCDH10     
MIER1 86 PCDH10     
MIPEP 67 PCDH11X     
MKKS 62 PCDH10     
MRAS 38 PCDH11X     
MTRF1L 94 PCDH11X     
MXD3 
(MAD3) 
68 PCDH11X (+) (+) (-) (+) 
MXD3 
(MAD3) 
1 PCDH10 (+) (+) (+) (+) 
MXD4 5 PCDH10     
MXI1 17 PCDH9 (+) (?) (-) (+) 
MXI1 22 PCDH10 (+) (-) (-) (+) 
NAA20 34 PCDH11X     
NCRNA0017
1 
18 PCDH9     
NCRNA0018
8 
83 PCDH11X     
NFIA 35 PCDH11X (+) (-) (-) (+) 
NHLRC2 77 PCDH11X     
NKD2 72 PCDH11X (+) (-) (-) (+) 
NLRP12 27 PCDH10     
NOL7 56 PCDH11X     
NT5C1B 6 PCDH11X     
OLIG3 18 PCDH11X     
PANK1 63 PCDH10     
PAX8 90 PCDH9 (+) (+) (-) (+) 
PBX2 58 PCDH9     
PDE1B 81 PCDH10 (+) (+) (+) (-) 
PDHA2 71 PCDH9     
PDIK1L 61 PCDH10     
PDLIM7 2 PCDH11X (+) (-) (-) (+) 
PHF16 14 PCDH11X     
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PIK3R5 36 PCDH9 
PITPNB 15 PCDH10 
PIWIL1 14 PCDH10 (+)(?) 
PLA2G4C 53 PCDH11X 
PLCXD1 93 PCDH10 
POLR2K 25 PCDH11X 
PPFIBP2 11 PCDH9 (+) (+) (+) (-) 
PPP1CA 15 PCDH11X (+) (+) (+) (+) 
PPP1CA 10 PCDH9 (+) (+) (-) (+) 
PPP1CB 13 PCDH11X (+) (+) (-) (-) 
PPP1CB 6 PCDH9 (+) (+) (-) (+) 
PPP1CC 20 PCDH11X (+) (+) (-) (+) 
PPP1CC 6 PCDH9 (+) (?) (-) (+) 
PPP1R7 82 PCDH11X 
PRIM2 8 PCDH10 
PRKCZ 65 PCDH9 
PRKRA 76 PCDH10 (+) (+) (?) (+) 
PRKRIR 41 PCDH10 
PSMC1 39 PCDH10 (?) (?) (?) (+) 
PSPH 84 PCDH9 
PSTPIP1 54 PCDH9 
PTPN3 37 PCDH9 
PYCR1 64 PCDH10 
RAB34 87 PCDH11X (+) (-) (?) (+) 
RAB7L1 56 PCDH10 
RAB9A 31 PCDH10 
RALYL 79 PCDH9 
RAP1GDS1 74 PCDH10 (+) (+) (?) (-) 
RARS2 41 PCDH11X 
RASGEF1B 67 PCDH9 
RASL11B 70 PCDH10 
RBM34 84 PCDH11X 
RFTN1 1 PCDH11X 
RFTN2 3 PCDH11X (+) (-) (-) (+) 
RGS20 87 PCDH10 (+) (-) (+) (-) 
RLIM 79 PCDH10 
RNF113A 71 PCDH10 
RNF115 17 PCDH10 (+) (-) (+) (-) 
RNF20 84 PCDH10 
RNMTL1 63 PCDH11X 
RPA1 10 PCDH11X 
RPP30 3 PCDH9 
RRAGC 7 PCDH9 
RRAGC 85 PCDH10 (+) (-) (+) (-) 
SCEL 35 PCDH9 (+) (+) (-) (+) 
SCRN2 43 PCDH9 
SETD2 77 PCDH9 
SH3D19 83 PCDH9 (+) (+) (+) (+) 
SH3GL2 90 PCDH11X 
SKIL 11 PCDH11X (+) (-) (-) (+) 
SNF8 65 PCDH10 
SORBS3 38 PCDH10 
SPDYE2 96 PCDH9 
SPDYE2 20 PCDH10 (+) (-) (-) (+) 
SSFA2 64 PCDH11X 
STAU1 82 PCDH10 (+) (+) (+) (+) 
SULT1A3 76 PCDH11X (+) (-) (-) (+) 
SYT14 95 PCDH9 
SYTL2 81 PCDH11X (+) (-) (-) (+) 
TAOK3 65 PCDH11X 
TAS2R46 63 PCDH9 
TBC1D23 72 PCDH9 
TBCEL 28 PCDH10 
TBK1 57 PCDH11X 
TBRG1 53 PCDH9 
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TBX20 76 PCDH9     
TGDS 48 PCDH10     
TGFBR2 9 PCDH9 (+) (-) (-) (-) 
THAP11 30 PCDH11X     
TNNI2 91 PCDH10     
TP53I11 86 PCDH9     
TPP2 80 PCDH10     
TRIM23 93 PCDH11X (+) (-) (?) (-) 
TRIM23 1 PCDH9 (+) (+) (+) (+) 
TRIM23 33 PCDH10 (+) (+) (?) (+) 
TRIT1 68 PCDH9 (+)    
TROVE2 42 PCDH10     
TSC1 62 PCDH9     
TTLL1 58 PCDH11X (+) (-) (-) (+) 
TUBGCP3 52 PCDH10     
TXNRD2 54 PCDH10     
U2AF1 53 PCDH10     
UBASH3B 4 PCDH11X     
UBC 59 PCDH9     
UBE2E2 69 PCDH10     
UBL3 92 PCDH11X     
UBTD2 21 PCDH11X (+) (-) (?) (+) 
USP12 55 PCDH11X (+) (-) (-) (+) 
USP21 60 PCDH9     
USP33 13 PCDH9 (+) (+) (-) (-) 
USP46 5 PCDH11X (+) (-) (-) (+) 
VDR 88 PCDH10     
VGLL4 49 PCDH10 (+) (-) (+) (+) 
VHL 48 PCDH11X     
VPS45 25 PCDH10 (+) (+) (?) (+) 
WDR76 28 PCDH9     
XAGE1D 31 PCDH11X     
YME1L1 83 PCDH10 (+) (-) (-) (+) 
ZBTB7A 79 PCDH11X     
ZBTB7B 12 PCDH9 (+) (-) (-) (-) 
ZBTB7B 4 PCDH10 (+) (+) (-) (+) 
ZIC4 70 PCDH9     
ZNF16 86 PCDH11X     
ZNF202 9 PCDH10 (+) (+) (-) (+) 
ZNF296 43 PCDH10 (+) (?) (?) (+) 
ZNF341 78 PCDH9 (+)    
ZNF341 45 PCDH10     
ZNF548 89 PCDH9     
ZNF711 82 PCDH9 (+) (-) (-) (-) 
 
 ???????????????????????????????
Array Mappit was performed for 3 different PCDHs and gave a list of 96 top candidates for each 
bait. All these candidates were re-tested in a binary MAPPIT experiment for confirmation. 
Numbers of confirmed candidates are listed in Table 12. The cross test was used for two 
purposes: as an extra re-test for the bait of reference (“Cross test” in the Table) and to identify 
extra partners for the other baits (“Cross test other Pcdhs” in the Table). Each PCDH received a 
small number of extra candidate interactors when analyzed in the cross test experiment, and 
these were added to the confirmed list obtained after the re-tests.  
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Table 12 Summary of positives in different test for the analyzed PCDHs 
Array MAPPIT Re test Cross test Cross test other Pcdhs 
PCDH11X 96 29 25 38 
PCDH10 96 25 12 15 
PCDH9 96 34 19 21 
Finally, we selected a priority list of candidate interactors. The challenge was then to prioritize 
putative interaction partners to be confirmed by biochemical methods. To this end deep 
literature search and IPA analysis were performed to find links and connections between 
candidates. At the time of this analysis we were particularly focused on the roles that different 
PCDHs could play in cancer. Different shortlists have been created. Table 13 shows for each PCDH 
cytoplasmic domain the definitive selection of candidate interactors .This selection takes into 
account: the original array-MAPPIT, the re-tests, the cross-interactions and the literature 
selection. 
Table 13 Common candidates, interesting partners on the basis of literature indications and interactors 
already identified in previous experiments have been selected and listed  
PCDH9 PCDH10 PCDH11X 
CUL5 
 
+ - + 
DMRTC1 + + + 
FHL3 - - + 
KNIP4 - + - 
GGN - - + 
MAX + + + 
MXD3 (MAD3) + - + 
MXD4 + - + 
MXI1 + + - 
PDLIM7 + - + 
TRIM23 - + + 
USP12 - - + 
USP33 + - - 
USP46 - - + 
ZBTBT7 + + +
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From this table we made a first priority list for biochemical studies including MAX, MXD3(MAD3) and 
MXI1, all three belonging to the same pathway, and also CUL5, FHL3, PDLIM7. On the basis of 
literature indications, we added in our following experiments also some other candidates from the 
MAPPIT list that were not included in the top scores. This selection comprised PSMC1, USP family 
members and actin-related proteins. Before proceeding with CoIP experiments, a confirmation of 
those latter candidates in a binary MAPPIT assay was warranted. For the USP family we obtained a 
short list of candidate interactors for each PCDH (Table 14). In this confirmation experiment, we 
used as bait constructs, either plasmids encoding full-size cytoplasmic domains of PCDH11X and 
PCDH10, or encoding progressive truncations of these cytoplasmic domains. For details see Figure 
53. Results are shown in Figure 54 and summarized in Table 15 and Table 16.  
Table 14 list of Ubiquitin related putative interaction partner 
 
 
 
 
Figure 53 Full length and N-and C- terminally truncated constructs for the cytoplasmic domain of PCDH10 
and PCDH11X.  
Conserved motives are represented with colored boxes. CM, conserved motif; TM, transmembrane domain 
PCDH11X PCDH10 PCDH9 
UBL3 PSMC1 USP33 
UBASH3B U2AF1 MEF2A 
UBTD2 UBE2E2 UBC 
USP12  USP21 
CUL5  CUL5 
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Figure 54 One-to-one MAPPIT test for PCDH10cyt, PCDH11Xcyt and truncated vertions 
Different constructs were screened with relevant preys such as USPs (and related) proteins, MAX and 
MXD3(MAD3).  
Luciferase Activity (Fold Induction)
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Table 15 Confirmed (Grey) candidates for interaction with different constructs of PCDH11X and PCDH10 
cytoplasmic domains 
 
  USP21 USP46 CUL5 USP21 USP33 USP15 UBC MAX MAD3 
PCDH11X          
PCDH11X C-terminal          
PCDH10          
PCDH10 845-1041          
PCDH10 904-1041          
PCDH10 904-958          
 
Table 15 only shows confirmed candidates for interaction with different constructs of PCDH11X and 
PCDH10 cytoplasmic domains. An additional binary MAPPIT experiment was finally performed with 
the same protocol in order to test for interaction with two additional PCDH11X fragment constructs 
and for additional candidate interactions of the priority list. These results are shown in Table 16. 
 
Table 16 Confirmed (Grey) candidates for interaction with different constructs of PCDH11X and PCDH10 
cytoplasmic domains 
 
 MAX MXD1 PDLIM7 MDM2 FHL3 
PCDH11X      
PCDH11X CM3      
PCDH11X C-terminal      
PCDH11X CM3 MUT      
 
Based on literature suggestion, a binary MAPPIT assay was performed to specifically confirm the 
results obtained from the Array MAPPIT screens concerning actin related proteins. The one-to one 
experiment was performed for 7 different PCDH baits: PCDH9cyt, PCDH11Xcyt, PCDH11Xcyt T 
TERMINAL, PCDH11Ycyt, PCDH-PCcyt, PCDH18cyt and PCDH19cyt and 24 preys plasmids: 21 putative 
interaction partner, 1 empty prey and 2 positive controls (Figure 55). 
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Figure 55 One-to-One MAPPIT test for actin related 
protein as preys and different PCDHs as baits.  
On the left, list of preys. On the right the results. Y 
axis: Luciferase activity (fold induction) 
Luciferase Activity (Fold Induction) 
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From these results we could confirm some candidates suggested from the screens. In conclusion 
KLF4 is positive for PCDH9 and PCDH19, and ARL13B for PCDH11Y, PCDH18 and PCDH19. Kruppel-
like factor 4 is a member of the KLF family of transcription factors and regulates proliferation, 
differentiation, apoptosis and somatic cell reprogramming. 
 ?????????????????????????????????
The Ingenuity Pathway Analysis (IPA) software has been developed to analyze and understand 
complex 'omics’ data. Different kinds of data can be loaded and analyzed. We used the system to 
identify the relationship between the candidates of the obtained lists, checking for interactions but 
also for common functions. Each list was studied independently from the others concerning 
interactions and belonging to the same common pathway. Figure 56, 57 and 58 show the 
involvement of different candidates from the MAPPIT lists in canonical relevant pathways.  
 
 
Figure 56 Canonical pathway related to PPP1CB,PPP1CA,PPP1CC, GNA14, HSP8 ans USP46 and USP 12 
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Figure 57 Canonical pathway related to MAX,MXI1, PDE18. 
 
 
Figure 58 Canonical pathways related to TGFBR2, HDAC11, MEF2A, PP1CA, PP1CB, PP1CC, MAX and MXI1. 
 
Next, the complete list of candidates was analyzed for already known interactions with PCDHs but 
no known link were identified. IPA has been used then to identify relationship between the family of 
PCDHs and the list of candidates including the shortest path which can connect two molecules of the 
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group. Only one node was added. The Figure 59 shows the relationships. The nodes are listed in 
Table 17.   
 
Figure 59 IPA Path Explorer. Candidates (pink) and PCDHs (green) relations in the shortest pathway 
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Table 17 PCDHs and candidates relations. List of protein of the shortest path. (IPA analysis) 
Symbol Synonym(s) Location Family 
ABI1 Abelson interactor 1, Abl binding protein 4, abl-
interactor 1, ABLBP4, E3B1, Eps8 binding, NAP1, Nap1 
binding, NAP1BP, SSH3BP1, SSH3BP 
Cytoplasm Other 
AHR Ah, AH receptor, Ahh, Ahre, aryl-hydrocarbon receptor, 
bHLHe76, DIOXIN receptor, In 
Nucleus ligand-dependent nuclear 
receptor 
AR AIS, Andr, androgen receptor, AW320017, DHTR, 
HUMARA, HYSP1, KD, NR3C4, SBMA, SMAX1, 
Testosterone receptor, TFM 
Nucleus ligand-dependent nuclear 
receptor 
BCL6 B cell leukaemia/lymphoma 6, B cell 
leukemia/lymphoma 6, B-cell CLL/lymphoma 6, BCL5, 
BCL6A, LAZ3, ZBTB27, zinc finger protein 51, ZNF51 
Nucleus transcription regulator 
CREB1 2310001E10Rik, 3526402H21RIK, AV083133, CAMP 
RESPONSE ELEMENT binding protein 1, cAMP responsive 
element binding protein 1, Cbp, CREB 
Nucleus transcription regulator 
CTNNB1 armadillo, Beta-cat, Beta-catenin, beta-Ctnn, Bfc, catenin 
(cadherin associated protein), beta 1, catenin (cadherin 
associated protein), ? 1, catenin (cadherin-associated 
protein), beta 1, 88kDa, catenin (cadherin-associated 
protein), ? 1, 88kDa, CATENIN beta, CATENIN ?, CATNB, 
CTNN beta, CTNN ?, CTNNB, Mesc, MRD19, ?-cat, ?-
catenin, ?-Ctnn 
Nucleus transcription regulator 
DMRTC1/DMRTC1B DMRT-like family C1, DMRT-like family C1B, DMRTC1, 
DMRTC1B 
Other Other 
ELAVL1 2410055N02Rik, DKFZP667b083, ELAV1, ELAV 
(embryonic lethal, abnormal vision)-like 1 (Hu antigen R), 
ELAV like RNA binding protein 1, Hu antigen R, Hua, HUR, 
MelG, RGD:731215, RNA binding protein HuR, W91709 
Cytoplasm Other 
EPAS1 bHLHe73, ECYT4, endothelial PAS domain protein 1, Hif2, 
HIF-2alpha, Hif1alpha related factor, HIF2 ?, HIF2A, HLF, 
HRF, MOP2, PASD2 
Nucleus transcription regulator 
EZH2 EHZ2, enhancer of zeste 2 polycomb repressive complex 
2 subunit, enhancer of zeste homolog 2 (Drosophila), 
ENX-1, Enx1h, EZH1, EZH2b, KMT6, KMT6A, mKIAA4065, 
WVS2, WVS 
Nucleus transcription regulator 
FHL3 four and a half LIM domains 3, SLIM2 Plasma Membrane Other 
GGN AI593290, gametogenetin Nucleus Other 
HIF1A AA959795, bHLHe78, HIF1, HIF-1alpha (hydroxylated), 
HIF-1?, HIF-1? (hydroxylated), HIF1-ALPHA, Hypoxia 
inducible factor 1 alpha subunit, Hypoxia inducible factor 
1 ? subunit, hypoxia inducible factor 1, alpha subunit, 
hypoxia inducible factor 1, ? subunit, hypoxia-inducible 
factor 1, alpha subunit (basic helix-loop-helix 
transcription factor), hypoxia-inducible factor 1, ? 
subunit (basic helix-loop-helix transcription factor), 
MOP1, PASD8 
Nucleus transcription regulator 
IFNG IFG, IFI, IFN gamma, IFN type II, IFN-?, IFNG2, INF-?, 
interferon gamma, Interferon ?, interferon, gamma, 
interferon, ?, type II INTERFERON, ? interferon, ?-ifn 
Extracellular Space Cytokine 
IKBKG 1110037D23Rik, AI848108, AI851264, AMCBX1, 
AW124339, FIP-3, Fip3p, I Kappa B Gamma, I ? B ?, IkB ?, 
Nucleus Kinase 
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IKK-gamma, IKK-?, IKK[g], IKKAP1, IKKG, IMD33, inhibitor 
of kappa light polypeptide gene enhancer in B-cells, 
kinase gamma, inhibitor of kappaB kinase gamma, 
inhibitor of kappaB kinase ?, inhibitor of ? light 
polypeptide gene enhancer in B-cells, kinase ?, IP1, IP2, 
IP, IPD2, NEMO, NEMO RELATED, ZC2HC9 
KCNIP4 AV032399, Calp250, CALP, KCHIP4, KChIP4a, Kv channel 
interacting protein 4 
Plasma Membrane ion channel 
KLF4 EZF, GKLF, Kruppel-like factor 4 (gut), Zie Nucleus transcription regulator 
MAX AA960152, AI875693, bHLHd4, bHLHd5, bHLHd6, 
bHLHd7, bHLHd8, Max protein, MYC associated factor X, 
Myn 
Nucleus transcription regulator 
MXD3 4631412E13Rik, BHLHC13, MAD3, MAX dimerization 
protein 3, MYX 
Nucleus transcription regulator 
MXD4 2810410A03RIK, bHLHc12, MAD4, MAX dimerization 
protein 4, MST149, MSTP149 
Nucleus transcription regulator 
MXI1 bHLHc11, ENSMUSG00000067085, Gm10197, 
LOC100360898, MAD2, Max inter 1, Max interacting 
protein 1, MAX interactor 1, MAX interactor 1, 
dimerization protein, MAXD2, MX11, MXD2, MXI, MXI-
WR 
Nucleus transcription regulator 
MYC AU016757, bHLHe39, C-MYC-P64, CMYC, mMyc, MRTL, 
Myc2, MYCC, myelocytomatosis oncogene, Niard, Nird, 
RNCMYC, v-myc avian myelocytomatosis viral oncogene 
homolog 
Nucleus transcription regulator 
NDN AI528698, HsT16328, NECDIN, necdin, melanoma 
antigen (MAGE) family member, Peg6, PWCR 
Nucleus Other 
PCDH1 2010005A06RIK, AI585920, AXIAL PROTOCADHERIN, Pc1, 
PC42, PCDH42, protocadherin 1 
Plasma Membrane Other 
PCDH10 6430521D13RIK, 6430703F07Rik, mKIAA1400, OL-pc, OL-
PCDH, PCDH19, protocadherin 10, RGD1565811 
Plasma Membrane Other 
PCDH11X A230092L07RIK, LOC100039461, LOC100046467, 
PCDH11, PCDH-X, PCDHX11, PPP1R119, protocadherin 
11 X-linked, RGD1562864 
Plasma Membrane Other 
PCDH11Y PCDH22, PCDH-PC, PCDHX, PCDHY, protocadherin 11 Y-
linked 
Other Other 
PCDH17 C030033F14RIK, Gm78, LOC144997, PCDH68, PCH68, 
protocadherin 17 
Plasma Membrane Other 
PCDH18 3110038E07Rik, BB095589, PCDH68L, protocadherin 18 Extracellular Space Other 
PCDH19 B530002L05Rik, EFMR, EIEE9, Gm717, LOC279653, 
mKIAA1313, protocadherin 19, RGD1565392 
Extracellular Space Other 
PCDH20 C630015B17RIK, PCDH13, protocadherin 20 Other Other 
PCDH7 BH-Pc, BHPCDH, PPP1R120, protocadherin 7 Plasma Membrane Other 
PCDH8 1700080P15Rik, ARCADLIN, PAPC, protocadherin 8 Plasma Membrane Other 
PCDH9 C530050I23RIK, LOC638275, protocadherin 9 Plasma Membrane Other 
PDLIM7 1110003B01RIK, AV007930, Enigma, LMP1, LMP3, LMP, 
PDZ and LIM domain 7, PDZ and LIM domain 7 (enigma) 
Cytoplasm Other 
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PPP1CA dism2, PP-1A, Pp-1c, PP1 ?, PP1 ? C, PP1alpha, PP1C 
alpha, PP1C ?, PPP1A, Ppp1c, Protein Phosphatase 1, 
protein phosphatase 1, catalytic subunit, alpha isoform, 
protein phosphatase 1, catalytic subunit, alpha isozyme, 
protein phosphatase 1, catalytic subunit, ? isoform, 
protein phosphatase 1, catalytic subunit, ? isozyme, 
Ser/Thr Phosphatase Type1 alpha, Ser/Thr Phosphatase 
Type1 ? 
Cytoplasm Phosphatase 
SMAD3 AU022421, DKFZP586N0721, hMAD-3, HSPC193, 
HsT17436, JV15-2, LDS3, LDS1C, MAD3, MADH3, SMAD 
family member 3 
Nucleus transcription regulator 
TNF AT-TNF, DIF, RATTNF, TMTNF, TNF-a, TNF-alpha, TNF-?, 
TNFSF2, Tnfsf1a, tumor necrosis factor, Tumor Necrosis 
Factor ?, tumor necrosis factor, ?, tumour necrosis 
factor, tumour Necrosis Factor Alpha, tumour Necrosis 
Factor ?, tumour necrosis factor, alpha, tumour necrosis 
factor, ? 
Extracellular Space Cytokine 
TP53 bbl, BCC7, bfy, bhy, LFS1, p44, P53, P53 cellular tumour 
antigen, p53 tumor suppressor, transformation related 
protein 53, TRP53, tumor protein p53, tumour protein 
p53 
Nucleus transcription regulator 
TRIM23 6330516O20Rik, AI450195, ARD1, ARFD1, RNF46, 
tripartite motif-containing 23 
Nucleus enzyme 
UBC 2700054O04Rik, AI194771, HMG20, Polyubiquitin, 
Rps27a, TI-225, Uba52, Ubb, UBIQUITIN C 
Cytoplasm enzyme 
UBQLN4 A1U, A1Up, AI663987, C1orf6, CIP75, RGD1308273, 
UBIN, ubiquilin 4 
Cytoplasm other 
USP12 LOC684318, UBH1, ubiquitin specific peptidase 12, 
USP12L1 
Cytoplasm peptidase 
USP33 9830169D19RIK, AA409780, ubiquitin specific peptidase 
33, VDU1 
Cytoplasm peptidase 
USP45 3110003C05Rik, 4930550B20RIK, AI843191, GCAP7, 
ubiquitin specific peptidase 45, ubiquitin specific 
petidase 45 
Other peptidase 
ZBTB7B C2H2-Type Domain Containing Protein, CKROX, hcKROX, 
45THPOK, ZBTB15, ZFP-67, zinc finger and BTB domain 
containing 7B, ZNF857B 
Nucleus transcription regulator 
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III.4 Conclusions 
Functions of the PCDHs family have not yet been described in detail. Our approach is based on 
the ‘guilt by association’ concept (introduced on Chapter II) implying a correlation between 
mutually interacting proteins and cooperation for the same function. Identifying interactor 
partners of different members of the ?-PCDH family might elucidate the involvement of these 
PCDHs in specific pathways.  
First, we performed a screening to identify a list of candidate interactors. After a few attempts 
with Yeast 2-hybrid and classical MAPPIT approaches, the array MAPPIT screening method turned 
out to be the most appropriate test for our research questions. Results from these screenings 
were confirmed in binary (one-to-one) MAPPIT experiments. Due to a significant background 
signal in case of PCDHs baits, the resulting list was not as precise as hoped for. Anyway, we could 
identify in the top of our ranking list both known interaction partners of PCDHs as well as hits 
from previous experiments, confirming the validity of at least some array MAPPIT results. This is 
the case for PP1CA, a known interactor of PCDH11X scoring in position 15 of the PCDH11X array, 
and for PDLIM7, listed second in the same experiment, and previously identified as new candidate 
interaction partner in binary MAPPIT experiments and co localization test. The final short list 
includes what has been considered the most reliable and interesting candidates to reach the 
scope. An example is represented by three proteins, belonging to the MAX-MAD pathway, which 
are highly associated with cancer. The analysis of the re-test experiments confirmed 71 of the 288 
candidates proposed by the array MAPPIT experiments (Identified by (+) in the column “retest”, 
table 11). After additional cross test experiments, we created a short list of candidate interactors, 
which were positive in confirmation test using the original PCDH as bait but often also being 
positive in interaction with other members of the ?PCDH family. 48 candidates were included in 
this final list (pink in table 11). 
The list of the 48 candidates was investigated for diseases and common functions (Ingenuity 
Pathway Analysis). We identify 12 different association groups where at least 15 molecules of the 
48 were involved. Details are shown in Table 18. Our results indicate that every group of 35 to 15 
molecules proposed to be interaction partner of PCDHs family member, play a role in cancer.  
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Table 18 Clusters of candidates interaction partners of PCDHs are involved in cancer. 
Diseases or Functions 
Annotation 
Molecules # Molecules 
Cancer ACOT8,CUL5,DPYSL5,DTX3L,EPB42,FHL3,GGN,GTPBP4,HEY1,HOXB7,KLF1
4,KLF4,MAX,MGA,MXD3,MXI1,NFIA,NKD2,PAX8,PDE1B,PDLIM7,RAB34,R
FTN2,SH3D19,SKIL,SP6,STAU1,SYT14,TRIM23,TTLL1,UBTD2,UNC13D,USP
12,USP33,USP46,ZBTB7B 
36 
tumorigenesis of tissue ACOT8,CUL5,DPYSL5,DTX3L,EPB42,GGN,GTPBP4,HEY1,HOXB7,KLF14,KLF
4,MAX,MGA,MXD3,MXI1,NFIA,NKD2,PAX8,PDE1B,PDLIM7,RAB34,RFTN2,
SH3D19,SKIL,SP6,STAU1,SYT14,TRIM23,TTLL1,UBTD2,UNC13D,USP12,US
P33,USP46,ZBTB7B 
35 
malignant solid tumor ACOT8,CUL5,DPYSL5,DTX3L,EPB42,FHL3,GGN,GTPBP4,HEY1,HOXB7,KLF1
4,KLF4,MAX,MGA,MXD3,MXI1,NFIA,NKD2,PAX8,PDE1B,PDLIM7,RAB34,R
FTN2,SKIL,SP6,STAU1,SYT14,TRIM23,TTLL1,UNC13D,USP12,USP33,USP46
,ZBTB7B 
34 
epithelial cancer ACOT8,CUL5,DPYSL5,DTX3L,EPB42,GGN,GTPBP4,HEY1,HOXB7,KLF14,KLF
4,MAX,MGA,MXD3,MXI1,NFIA,NKD2,PAX8,PDE1B,PDLIM7,RAB34,RFTN2,
SKIL,SP6,STAU1,SYT14,TRIM23,TTLL1,UNC13D,USP12,USP33,USP46,ZBTB
7B 
33 
digestive system cancer ACOT8,CUL5,DPYSL5,DTX3L,EPB42,GGN,GTPBP4,HOXB7,KLF14,KLF4,MAX
,MGA,MXD3,MXI1,NFIA,NKD2,PAX8,PDE1B,PDLIM7,RAB34,RFTN2,SKIL,S
P6,STAU1,SYT14,TRIM23,TTLL1,UNC13D,USP33,USP46,ZBTB7B 
31 
abdominal cancer ACOT8,CUL5,DPYSL5,DTX3L,EPB42,GGN,GTPBP4,HOXB7,KLF14,KLF4,MAX
,MGA,MXD3,MXI1,NFIA,NKD2,PAX8,PDE1B,PDLIM7,RAB34,RFTN2,SKIL,S
P6,STAU1,SYT14,TRIM23,TTLL1,UNC13D,USP33,USP46,ZBTB7B 
31 
Adenocarcinoma ACOT8,CUL5,DPYSL5,DTX3L,EPB42,GGN,GTPBP4,HOXB7,KLF14,KLF4,MAX
,MGA,MXD3,MXI1,NFIA,NKD2,PAX8,PDE1B,PDLIM7,RAB34,RFTN2,SKIL,S
P6,STAU1,SYT14,TRIM23,TTLL1,USP33,USP46,ZBTB7B 
30 
gastrointestinal tract 
cancer 
CUL5,DPYSL5,DTX3L,EPB42,GGN,GTPBP4,HOXB7,KLF14,KLF4,MAX,MGA,
MXD3,MXI1,NFIA,NKD2,PAX8,PDE1B,PDLIM7,RAB34,RFTN2,SP6,STAU1,T
RIM23,TTLL1,USP33,ZBTB7B 
26 
abdominal 
adenocarcinoma 
CUL5,DTX3L,EPB42,GGN,GTPBP4,HOXB7,KLF14,KLF4,MAX,MGA,MXD3,M
XI1,NKD2,PAX8,PDE1B,PDLIM7,RAB34,RFTN2,SKIL,STAU1,SYT14,TRIM23,
TTLL1,USP33,ZBTB7B 
25 
malignant neoplasm of 
large intestine 
CUL5,DPYSL5,DTX3L,EPB42,GGN,GTPBP4,HOXB7,KLF14,KLF4,MAX,MGA,
MXD3,MXI1,NFIA,NKD2,PAX8,PDE1B,PDLIM7,RFTN2,SP6,TRIM23,TTLL1,U
SP33,ZBTB7B 
24 
breast or colorectal 
cancer 
CUL5,DTX3L,EPB42,FHL3,GTPBP4,HOXB7,KLF14,KLF4,MAX,MGA,MXD3,M
XI1,NKD2,PAX8,PDE1B,PDLIM7,TRIM23,USP12,ZBTB7B 
19 
liver carcinoma ACOT8,CUL5,DTX3L,EPB42,GGN,HOXB7,KLF14,MGA,MXD3,NKD2,PDE1B,
SKIL,TRIM23,UNC13D,USP33 
15 
To further prioritize the members of this selection list, several Ingenuity Pathway analyses have 
been performed, and different lists (i.e. common or exclusive candidates) were compared to 
identify correlations and collaborations in specific pathways. Our results show that the candidate 
interactors in our priority list belong to different pathways and are involved in many biological 
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functions. At this stage we could not identify any strong indication concerning the function of 
PCDHs: our results only show that many mechanisms, involved in a variety of functions, might 
host members of the ?PCDH family, unfortunately without offering any firm conclusion 
concerning the roles that PCDHs might play in cells. 
Few candidates from the list were then selected for further molecular investigation. MAX, MXD3 
(MAD3) and MXI1, as already mentioned, belong to the same pathway strongly related to cancer. 
Our selection included also PDLIM7, a candidate previously identified and still to be confirmed 
independently; a small group of ubiquitin-related proteins; FHL3, an interactor of FHL2 previously 
proposed to interact with PCDH11Y in a pull down assay; DMRTC1 and ZBTB7, common 
candidates for the three PCDHs; a short list of actin-related proteins suggested by the PCDH 
literature; PSMC1, proposed but not always confirmed in MAPPIT but interesting given literature 
indications. These candidates form together what we call the priority list: the following 
experiments (Chapter IV) of confirmation in biochemical assays were performed on the basis of 
this priority list. 
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Chapter IV. BIOCHEMICAL CONFIRMATION AND 
PATHWAY ANALYSIS 
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IV.1 Biochemical pull down experiments 
?????? ???????????????????????????????????????
To confirm the results obtained from the MAPPIT assay (Chapter III), we performed biochemical 
pulldown experiments. Immunoprecipitation (IP) is the technique which allows the precipitation of a 
target protein from a solution, generally a cell lysate, using an antibody that is target-specific. We 
performed experiments using Dynabeads to capture the antibody. This tool allows simple, mild, but 
efficient washing steps and the resulting immunoprecipitate can be analyzed by western blotting or 
mass spectrometry directly after elution from the washed beads. To identify interacting proteins, 
plasmids encoding EYFP-tagged full-length ?PCDHs were transfected into Hek293T cells. Molecular 
complexes were then isolated by using a mouse anti-GFP antibody coupled to magnetic beads 
(Dynabeads M-280 Sheep anti-mouse IgG, Invitrogen), which acts as the solid support for binding Ig 
or target molecules. The aim was to identify by mass spectrometry (MS) the proteins pulled down 
together with EYFP tagged PCDHs. 
Before starting large scale experiments, we tested the Dynabead-based pulldown procedure on the 
confirmed interaction between PCDH11X and DYNLT1 (Uta Brunner, not published). Next, we 
performed a pull down experiment on PCDH11X. The primary antibody used was a commercial anti-
GFP (Invitrogen). Western blot data were promising as the GFP-fused PCDH11X was clearly 
detectable (Figure 60) although CBB (Coomassie Brilliant Blue) staining was uninformative. 
 
Figure 60 Pilot pull down experiment.  
Western blot with anti-GFP antibody for pull down experiments 
for PCDH11X-EYFP. TL=total lysate 
 
Full-length PCDH11X, PCDH11Y, PCDH10, PCDH18 and PCDH9, all EYFP tagged, were overexpressed 
by transient transfection in Hek293Tcells and localized by fluorescence microscopy. The membrane 
localization was not clear as expected, above all for PCDH10. Localization experiments of transiently 
overexpressed PCDH10 were performed also in other cell lines as shown in Figure 61. We noticed 
protein aggregates in the cytoplasm, indicating an unexpected localization of PCDHs. Our data 
indicate a possible localization of a subpopulation of PCDH10 at the perinuclear regions in HeLa cells, 
suggesting an internalization subsequent an interaction with a dynein motor complex, but this event 
upon ectopic overexpression can also be due to the fact that the transfected cells are not able to 
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manage such a high production of artificially induced protein. We also attempted to establish stable 
cell lines with more physiological expression levels of PCDHs in order to minimize possible 
overexpression artifacts. This stable cell line showed to be suitable for other experiments but didn’t 
perform well for CoIP which was then performed in Hek293Tcells transiently transfected for the 
different PCDHs and relevant candidates.  
Figure 61 PCDH10 accumulates in the cytoplasm if transiently transfected in various cell lines 
EYFP-PCDH10 was transiently overexpressed in a number of cell lines. The expected membrane localization was 
not clearly observed in every cell line where protein accumulations were noticed. (Picture by I. Kahr, not 
published). 
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?????? ??????????????????
CoImmunoprecipitation tests have been performed for different PCDHs and a short list of candidate 
interactors. As discussed in Chapter III, the long MAPPIT-based list of candidates was reduced to a 
rather short priority list. We performed experiments in Hek293T cells transiently transfected with 
EYFP tagged PCDHs.  
IV.1.2.1 Materials and methods 
CoImmunoprecipitation: CoIP experiments were performed in Hek293Tcells, cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) +10% fetal bovine serum. The day before transfection, 300.000 
cells were seeded in each standard 60 mm petri dish. To confirm interactions, GFP-tagged ?PCDHs 
were co-transfected with Flag-tagged candidates in Hek293T cells. Cells were transfected using CaP 
precipitation method as previously described. Medium was changed after 4/6 hours. Cells were 
lysed 24h after transfection in IP lysis buffer (150 mM NaCl, 2 mM EDTA, 25 mM Tris pH 7.4, 0.5 % 
Triton-X100, complete protease inhibitor mix); lysate was scraped off and transferred in a cold tube, 
incubated while rotating for 10 minutes and centrifuged for 20 minutes at 4°C at high speed. Protein 
concentration was determined with the DC protein assay (Bio-Rad) and 40 ?g per sample were kept 
as input.  CoIP was performed using Dynabeads M-280 Sheep anti-mouse IgG (Invitrogen) according 
to the manufacturer’s instructions. Dynabeads were re-suspended by vortexing and 50 ?l Dynabeads 
suspension per IP were transferred to a tube, placed on the magnet and the supernatant was 
removed. 1 ?g antibody diluted in 200 ?l PBS/ 0.02% Tween20 (PBS/T) was added and incubated 
with rotation for 10 min at RT or 2h at 4°C. The complexes were washed once and suspended in 200 
?l PBS. The Dynabeads were washed twice with IP lysis buffer and incubated with 1 mg cell lysate for 
10 minutes (up to 2 hours) at RT with rotation. The Dynabeads-antibody-antigen complex was 
washed three times using 1 ml IP lysis buffer. After the second wash, the beads were transferred to a 
new tube. After the final wash, the tube was placed on the magnet and the buffer was removed 
from the tube (without letting the beads dry out completely). 50 ?l of 1XSDS loading buffer (50 mM 
Tris pH 6.8, 2 % SDS, 0.1 % bromophenol blue, 10% glycerol, 100 mM ?-mercaptoethanol) were 
added and gently pipetted up and down to re-suspend the Dynabeads-antibody-antigen complex. 
After incubation for 10 min at 95°C, the tubes were placed onto the magnet and the eluate was 
loaded on an SDS-PAGE gel for Western blot analysis. 
SDS-PAGE and Western blotting: 40 ?g of total protein cell lysate and 50 ?l of eluate from the CoIP 
were loaded on a one-dimensional SDS-PAGE gel. Proteins were transferred to PVDF membranes 
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(Millipore) which was blocked with 5% non-fat dry milk in TBS -0.1 % Tween-20. Membranes were 
incubated with primary antibodies overnight at 4°C. After several washing steps in TBS-Tween and 
TBS, membranes were incubated for 1 hour with secondary horseradish peroxidase (HRP)-
conjugated antibodies. Detection was performed using the ECL detection system (Amersham GE 
healthcare). Primary Antibodies: for CoIP, Anti-GFP 3E6 Mouse Invitrogen, Cat.-No. A11120; for WB, 
Anti-GFP Mouse Roche, Cat.-No. 11814460001 1/1000 Anti-FLAG Mouse Sigma, Cat.-No. F3165 
1/1000. Secondary Antibodies: for WB, Anti-mouse HRP Sheep GE Healthcare, Cat.-No. NA931V 
1/3000. 
IV.1.2.2 Results
We initially performed experiments for PCDH10 and PCDH11X and co-transfected EYFP-tagged PCDH 
constructs with flag-tagged interaction candidates encoding plasmids. To start we optimized the 
protocol by testing a known interaction partner, DYNLT1 (Figure 62).  
We started the confirmation experiments with the MAX-MAD group of candidates as they have an 
established role in cancer. We could clearly show a strong interaction of the MAX protein with both 
PCDHs (Figure 63). Our blots confirmed also the interaction of PCDH10 with MAD3 (MXD3), and 
more modestly with MXI1. Surprisingly, we could not show the interaction with MAD3 and MXI1 for 
PCDH11, even though members of this MAX-MAD group turned out to be positive in all kinds of our 
PCDH-MAPPIT experiments, and were not identified in MAPPIT experiments with other baits 
(personal communication by Sam Lievens). Furthermore, we performed CoIP tests for PCDH1 and 
PCDH7 to investigate whether MAX could be a common interaction partner and this indeed turned 
out to be the case. The experiment was performed for the long (iso1) and the short (iso2) isoforms 
Figure 62 DYNLT1 coimmunoprecipitates with PCDH10 and 
PCDH11X 
DYNL1 flag-tagged and PCDH10-EYFP or PCDH11x-EYFP or 
EYFP alone (as control) were expressed in Hek293Tcells. IP 
was performed with ?GFP antibody and WB with ?flag 
antibody.   
DYNLT1 co-precipitates with PCDH10 and with PCDH11X as 
expected but not with EYPF.  
EYFP         PCDH10      PCDH11X 
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of MAX which were both indicated as putative interaction partners in MAPPIT experiment. A 
construct missing the gp130 (present in the MAPPIT plasmids) was used to exclude an aspecific 
interaction for iso1. The results of CoIP experiments together with our MAPPIT findings identified 
MAX as a candidate interaction partner for PCDH10, PCDH11X, PCDH9, PCDH1 and PCDH7. 
Interaction with MAD3 could be confirmed only for PCDH10 despite the positive MAPPIT results for 
PCDH11X and PCDH9 as well as PCDH10 (Figure 63). Both irrelevant antibody and EYFP antibody 
resulted in a precipitation of MAD3 and MXI1 for PCDH11X. Thus, given the aspecificity of the 
signals, these results are inconclusive and a different analysis system might be used to confirm the 
interactions suggested by our MAPPIT experiments. 
 
Figure 63 Coimmunoprecipitation of different PCDHs with putative interaction partners 
WB analysis of lysate from Hek293T cells transiently transfected with PCDH10-EYFP, PCDH11-EYFP, PCDH1-
EYFP or PCDH7-EYFP and MAX-flag, MAD3-flag, MXI1-flag, FHL2-flag and PDLIM7-flag. CoIP performed with 
antibody anti GFP to precipitate PCDHs EYFP tagged (IP) or with irrelevant antibody as control (IPc). TL=total 
lysate. Known interaction between PCDH10 and DYNLT1 has been used as positive control. WB performed with 
anti-flag antibody.   
 
Both PCDH10 and PCDH11X interact with FHL2 (Figure 63). FHL2 has been shown to interact with 
PCDH11Y and it has been found positive in our binary MAPPIT (details in Chapter III). PDLIM7, 
another of our high ranking interaction candidates, immunoprecipitates with PCDH11X but the 
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negative control (IP with irrelevant antibody) shows an equally strong signal which implies that the 
interaction seen in this CoIP can be aspecific. Beside those first priority candidates we checked the 
interaction of PCDHs also with a few more candidate interactors from the array.  
CUL5 and PSMC1 became interesting interaction candidates on the basis of literature. Indeed, a 
connection between PCDH10 and PSD-95 (post synaptic density protein 95) has been recently 
reported1. Tsai et al. showed that Pcdh10 plays a role in MEF2-induced synapse elimination and 
functions by delivering ubiquitinated PSD-95, a critical synaptic scaffolding molecule, to the 
proteasome. CUL5 is one of the proteins in the list of our interaction candidates and the Cullin 
protein family plays a role in the post-translational ubiquitin modification of cellular proteins. Our 
list of candidates included PSMC1, a proteome subunit, as well: we wanted to confirm these 
interactions to demonstrate any role of this protein in the binding of PCDH10 to the proteasome. 
CoIP experiments confirmed the interaction of CUL5 with PCDH10 but not with PCDH11X, while 
PSMC1 interacted with neither PCDH10 nor PCDH11X in CoIP experiments (Figure 64).   
 
Figure 64 Coimmunoprecipitation of PCDH10 or PCDH11X with PSMC1 and CUL5 
WB analysis of lysate from Hek293T cells transiently transfected with PCDH10-EYFP or PCDH11-EYFP and CUL5 
or PSMC1 flag tagged. Lysate CoIP performed with anti-GFP (IP) antibody or with an irrelevant antibody as 
control (IPc). TL=total lysate. WB performed with anti-flag antibody. 
 
CoIP experiments have been performed also for different members of the USP family with the same 
protocol. As it is shown in Figure 65 and in Figure 66, USP21 co-immunoprecipitates with the 3 
investigated PCDHs but only with PCDH9 in a specific way. PCDH9 interacts with USP33, and both 
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PCDH10 and PCDH11X co-immunoprecipitate with USP46. The interaction with CUL5, specific for 
PCDH10, was used as control. 
 
Figure 65 Coimmunoprecipitation experiments of PCDH10 with USP family members 
WB analysis of CoIP experiments performed in lysates of Hek293T cells transiently co-transfected with EYFP 
tagged PCDH10. IP=??GFP antibody, WB=??Flag or ??GFP antibody as indicated; TL, total lysate; X, empty line; 
C, negative-control antibody; IP, specific antibody (=??GFP). 
 
 
Figure 66 Coimmunoprecipitation experiments of PCDH11X and PCDH9 with USP family members 
WB analysis of CoIP experiments performed in lysates of Hek293T cells transiently co-transfected with EYFP 
tagged PCDH9, PCDH10 or PCDH11X together with flag tagged putative interaction partner belonging to USP 
family members as indicated on top. CoIP performed with anti-GFP antibody to precipitate PCDHs EYFP tagged 
(IP) or with irrelevant antibody as control (IPc). TL=total lysate. WB performed with anti-flag HRP-coupled 
antibody. 
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IV.2 Interaction candidates descriptions 
?????? ???????????????
MYC-associated protein X (MAX) is a ubiquitous and constitutively expressed protein, which plays a 
central role in the control of MYC. MYC is a very well-studied nuclear phosphoprotein involved in cell 
cycle progression, apoptosis and cellular transformation2. Together with MYCN and MYCL proteins, 
MYC is altered in function and expression in  most human cancers3. For this reason many studies 
have been carried out to investigate the functional relevance of MYC and to identify MYC interacting 
proteins. These studies first identified the presence at the extreme C terminus of a motif previously 
identified in many transcription factors, the basic-helix-loop-helix-leucine zipper (bHLHZip). This 
motif has been shown to be responsible for protein dimerization and DNA binding. To investigate if 
MYC behaves as the other transcription factors, PPIs studies were carried out, and, indeed, the 
prediction were confirmed: in this way MAX was identified as a MYC interaction partner2–5. MAX, as 
MYC, belongs to the bHLHZip protein family of transcriptor factor and is expressed in two isoforms 
which migrate as 21 and 22 kDa5. The short one is a 151 amino acid-long polypeptide while the long 
one is a 160 amino acid chain. The differential splicing occurs thanks to a sequence encoding nine 
amino acids in the N-terminus of MAX. Both isoforms are highly stable and independent from the 
cell cycle stage6. The short and the long 
isoforms take parts in the DNA binding, 
cell cycle progression, and apoptosis 
process in different ways. The strongest 
difference is the DNA binding capacity, 
which obviously has an impact on the 
protein’s effect on the target genes6. 
MAX was shown to interact with all 
MYC family proteins: the 
heterocomplex is able to recognize the 
DNA sequence CACGTG (an E-boxe 
sequence). The MYC network is very 
complex and requires many control 
mechanisms to coordinate all the 
cellular activities where it is involved. 
Figure 67 The Myc/Max/Mad network.  
The figure shows the components of the Myc/Max/Mad network. 
Known interactions (by the HLHZip dimerization domains) are 
shown with arrows. The network functions as regulator of many 
events of the cell cycle and metabolism and not all mechanisms 
have been elucidated yet. Figure from3. 
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An additional regulation is given by the interaction with MAX at the level of the formation of the 
heterodimers4. This regulation occurs due to a family of proteins which competes with MYC for the 
binding to MAX. The first component of the family to be described were MAD17 and MXI18. Both 
these proteins bind to MAX with the same affinity of MYC. Few years later, Hurlin and colleagues9 
identified other two member of the MAD family: MAD3 and MAD4. The four proteins behave as 
MYC: they only show a weak homodimerization and DNA binding ability. The MAD-MAX heterodimer 
act as a transcription repressor2, despite using the same binding site of MYC-MAX complex.  
Furthermore  MNT and MGA were described as MAX-interacting protein, but they are poorly related 
to the MAD family, even if they show some MAD-like functions3 (Figure 67).  
The MAPPIT assay carried out for PCDHs indicated some members of the MYC/MAX/MAD pathway 
as candidate interaction partners for different PCDHs. This was the only case in which different 
proteins of the same pathway turned out to be positive in our screening. Furthermore, as already 
mentioned, the deregulation of MYC/MAX/MAD pathway plays such an important role in the genesis 
of human cancer that it becomes the main focus of our further study. Interestingly, despite the 
consistent number of MAPPIT arrays performed in the lab of Prof. Tavernier, those candidates 
appear to be unique and specific for PCDHs. MAX turned out to be a candidate interaction partner 
for all the 3 studied PCDHs. The role of MAX in cancer has been shown in different studies. For 
example, MAX has been defined a tumor suppressor gene which causes hereditary 
pheochromocytoma (PPC)10: mutation in the gene were detected in patients and localized in most of 
the cases in the conserved amino acid of the bHLHZip region. If the ability of binding is lost, MAX 
cannot antagonize anymore the MYC dependent cell transformation11. This study, together with 
others, shows the importance of the MYC/MAX/MAD network in the development of neuronal crest 
tumor. The same has been shown for NMYC and his role in the development of neuroblastoma12. 
The members of the MAD family have been shown to suppress the development of cancer13, to 
promote differentiation in vivo and block cellular growth, while MNT can be considered a regulator 
of MYC and MGA is suggested to silence MYC responsive genes In quiescent cells14. It appears that 
despite some differences in action, the members and relatives of the MAD family, behave in the 
same way giving a putative functional redundancy even if it seems that they perform their functions 
in different timing due to differential expression induction11. MXI1 and MAD3 are generally 
expressed in the early phases of differentiation or in proliferating cells while MAD1 and MAD4 are 
expressed in the terminal stages of differentiation. Interestingly enough, the candidates belonging to 
the family which results positive in the MAPPIT experiments are involved in brain cancer. For 
examples MXI1 which is localized in chromosome 10q24-q25 (a cancer hotspot), shows a deletion 
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often found in brain cancer (i.e. 80% of glioblastoma multiforme and 15% of primary 
medulloblastoma). Furthermore the reintroduction of MXI1 in a MXI1 missing human glioblastoma 
cell line results in growth reduction and clonogenicity, and shows a high percentage of cells with 
DNA degradation with accumulation of cells in the G2-M phase. This light on the role in the 
pathogenesis of human glioblastoma, suggests that MXI1 can be considered a tumor suppressor 
gene, as expected15. Moreover, mutation in MXI1 was observed also in prostate cancer 16.  
MAD3 is a controversial and interesting candidate that MAPPIT proposed for PCDHs. If on the one 
hand it is similar to the other components of the family concerning structure and interaction with 
MAX, on the other hand it shows unique characteristics such as the expression profile during the 
different phases of the cell cycle. If MAX and MNT show a rather uniform expression and MAD1, 
MXI1, MAD4 are unregulated in quiescence and differentiation, MAD3 expression is associated with 
the last S-phase prior to terminal differentiation. This observation is surprising, given the role that 
MAD3 plays to inhibit proliferation and transformation. 
The most intriguing feature of MAD3, making it unique in the family, comes from a study challenging 
the switch model of MYC/MAX to MAD/MAX. Yun and colleagues17 demonstrated a new role of 
MAD3 in sonic hedgehog (shh)-dependent cerebellar granule neuron precursor (GNPs) proliferation 
and NMYC expression. The sonic hedgehog made by Purkinje neurons, regulates the vertebrate 
organogenesis and specifically controls the proliferations of GNPs (also) via NMYC during postnatal 
development. If Shh is over-activated, medulloblastoma can develop from the GNPs. They have 
shown that the inappropriate activation of MAD3 plays a role in tumor progression and stimulates 
proliferation. MAD3 is overexpressed in a mouse model of medulloblastoma and in many types of 
human brain tumors, including glioblastoma multiforme. In tumor, MAD3 is expressed during the 
complete cell cycle losing the S-phase exclusivity17,18. 
Considering our focus in cancer and the fact that PCDHs are mostly expressed in brain, those 
candidates look promising to be further investigated. The last member of the pathway which has 
been proposed as a candidate is MAD4. 
Ingenuity pathway analysis (IPA) was used to further process the list of candidates obtained from the 
screening and in particular for MYC/MAX/MAD pathway, in order to speculate on the role of the 
interaction between the MYC/MAX/MAD pathway and the ?PCDH family members. The analysis 
results in an even stronger confirmation of the role that the pathway plays in cancer, with a strong 
involvement in the nervous system functions. 
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?????? ??????????
Four and a half LIM domains (FHL) proteins belong to the LIM-only protein family, a group of 
proteins characterized by the presence of a LIM domain, a double zinc finger motif with a consensus 
amino acid sequence CX2CX16–23HX2 (C/H) X2CX2CX16–23CX2(C/H/D) which mediates PPIs19. FHL2 
proteins show an amino-terminal half LIM domain followed by a tandem of four full LIM domains20. 
FHL1, FHL2 and FHL3, three members of the family, show a homology of 50% in sequence identity 
and are mainly, but not exclusively, expressed in muscles. The family members regulate many 
transcription factors including SMAD proteins, ?-catenin, FOXO1, SRF, AP-1, NFAT, MyoD, and the 
androgen receptor21. FHL2 is the better described member of the family and, as the other members, 
plays a role in the regulation of a wide range of cell functions, including cell cycle, signal 
transduction, gene expression, apoptosis and cell proliferation21,22. It has been indicated as a critical 
inducer of the epithelial-to-mesenchymal transition (EMT) and invasion. 
Over 50 proteins have been shown to interact with FHL2. FHL2 homodimerizes and forms 
heterodimers with FHL3. Fimia and colleagues23 have shown the interaction between FHL2 and FHL3 
by Y2H technology, and independently Li et al.24 obtained the same result via Y2H and FRET. FHL3 
functions have not been well described yet, but an important role in the development and 
progression of breast cancer has been indicated25. Concerning the expression of FHL3, strong 
cytoplasmic staining has been shown in placental trophoblastic cells and smooth muscle cells. In 
male reproductive system, FHL3 is expressed in testis (cells of seminiferous ducts), prostate and 
epididymis glandular cells. Neuronal cells of hippocampus and lateral ventricles show moderate 
positivity in the nucleus. The clinical relevance of the FHL proteins is mostly due to their role in 
cancer. In a staining for 20 different types of cancer, FHL3 is positive in 27% of the cases and FHL2 in 
33% (data from the Human Protein Atlas http://www.proteinatlas.org/). FHL2 is overexpressed in 
hepatocellular carcinoma if compared with normal liver, in epithelial ovarian and breast cancer26,27, 
and in gastric and colon cancer28. Downregulation of FHL2 expression has been shown in 
rhabdomyosarcoma29 and in primary prostate cancer30, but another study reports that FHL2 
expression is increased in prostate adenocarcinoma cells31. TGF?1 stimulates Krüppel-like factor 
(KLF) 8, and KLF8-induced FHL2 activation has been recently identified as a critical mechanism 
underlying colorectal (and breast) cancer invasion and metastasis32. 
Expression of FHL2 in samples from patients operated for colorectal adenocarcinoma correlates with 
poor survival and nuclear expression of FHL2 in cancer cells associates with lymphatic metastasis in 
sporadic but not in HNPCC-associated colon cancer33–35. These results can be explained considering  
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the important role that FHL2 plays in EMT: FHL2 inhibits E-cadherin expression through interaction 
with Snail1 and promotes EMT in colon cancer36. 
The strong evidence for frequent epigenetic inactivation of PCDH10 in various human cancers, 
including gastric and prostate cancer, but not in matched normal tissues37–40, made FHL2 an 
interesting candidate for our project. In a patent application for a method to treat or prevent 
hormone resistant prostate cancer using a siRNA specific (or another inhibitor) of PCDH-PC 
(PCDH11y) expression or activity, Buttyan and colleagues demonstrated an interaction between 
FHL2 and PCDH11Y in a pull down assay and showed that expression of these two proteins 
correlates with prostate cancer prognosis and outcome. The mechanism linking FHL proteins and 
neoplasia is very intriguing but not clear yet. Different expression levels of family members in normal 
and tumor tissues have been observed41. Table 19 shows examples of FHL2 over-expressed or down-
regulated in different types of cancer. 
Table 19 FHL2 expression in cancer 
Tissue Normal tissue Cancer 
Breast - + 
Colon - + 
Lung - + 
Muscle + - 
Ovary - + 
Prostate + - 
Skin ? + 
FHL2 is a candidate PCDHs interaction partner, as shown from direct binary MAPPIT experiments for 
PCDH11X. Furthermore, FHL2 ranks in position 157 in the Array MAPPIT results for PCDH11X (25 as 
induction factor). FHL3 has been proposed as a candidate from the Array MAPPIT and confirmed in 
the retest, again for PCDH11X.   
?????? ??????
The structure of PDZ-LIM family members (or Enigma proteins) is characterized by the presence of 
an N-terminal PDZ domain and a series of C-terminal LIM domains. Enigma (PDLIM7), ENH, 
ZASP/Cypher, RIL, ALP, and CLP36 are members of the family and are cytoplasmic proteins. PDZ 
domain gets the name from the proteins where the domain was identified first (postsynaptic 
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density-95, discs large, and zo1 tight junction protein)42. It is a small, modular domain, which binds 
the consensus sequence (Ser/Thr)-X-(Val/Leu/Ile) of the target at the carboxyl terminus but also, for 
example, internal consensus sites and LIM domains43–45. Proteins which include the domain are often 
found in complexes at the cell-cell junctions. In particular, PDLIM7 is a 470 amino acid protein 
containing one PDZ and three LIM domains46; biologically it is considered an adapter: the PDZ 
domain can localize the LIM binding proteins to actin filaments. Most of the normal tissues are 
negative for PDLIM7 except a medium level expression in glial cells in cerebellar cortex, 
hippocampus and lateral ventricle. A medium level expression has been shown also in the heart 
myocytes. In a subcellular level, PDLIM7 is expressed at the actin filaments, but also in the nucleus 
and at the focal adhesion sites. The Human Proteomic Atlas includes staining for PDLM7 in 20 
different kinds of cancer and positive signaling has been observed in 17% of the cases. The strongest 
signal is shown in glioma cells, but a clear signal was noticed also in some breast and endometrial 
cancers.  
The interaction between PDLIM7 and ?PCDHs has not been published yet but this candidate appears 
to be recurrent in our assays. PDLIM7 was first confirmed in a binary MAPPIT assay and in co-
localization experiments for PCDH11X (Figure 68). The Array MAPPIT confirmed the interaction with 
PCDH11X: PDLIM7 is the second stronger candidate of the array MAPPIT list with a fold induction 
value of 119.  
PDLIM7 is known to negatively regulate p53 through MDM2 and has been shown to promote tumor 
cell survival in mice47. In the light of this report, PDLIM7 was considered an intriguing candidate for 
our cancer related list. Furthermore, PDLIM7 interacts with the Receptor Tyrosine Kinase RET to 
 
 
Figure 68 Co-localization of PCDH11X and PDLIM7 
Hek293T cells transiently transfected with a plasmid encoding PCHD11X-EYFP and Flag-gp130-PDLIM7. Uta 
Brummer, not published. 
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trigger its function in mitogenic signalling48. It has been published that RET binds to clustered Pcdhs 
in differentiated neuroblastoma cells and it is required for stabilization and differentiation-induced 
phosphorylation of Pcdhs49. Actually, it appears that Ret and Pcdhs stabilize each other: while Ret 
regulates Pcdh-? and Pcdh-? tyrosine phosphorylation and protein level, Pcdhs stabilize Ret in 
mouse central nervous system catecholaminergic cell line (CAD cells) and sympathetic neurons 
(Figure 69). This interaction is localized to the growth cones and synapses of neurons with 
demonstrated implications in axonal path finding and neuronal survival50,51. In the light of this, we 
believed that the putative interaction between PDLIM7 and ?PCDHs was of great interest and we 
included the candidate in the short priority list. 
 
 
Figure 69 Model of Pcdh and Ret interaction and stabilization in CAD and sympathetic neurons49. 
Activation of Ret with GDNF/GFR?1 leads to ubiquitination and rapid degradation. Pcdhs not bound to Ret also 
undergo degradation. Activated Ret bound to Pcdh is stabilized. Pcdhs bound to activated Ret are stabilized and 
phosphorylated and might initiate downstream signaling.  
 
?????? ????????????
Almost any protein undergoes posttranslational modifications, as the key mechanisms to increase 
proteomic diversity. There are many possible modifications. Two of the most frequent and relevant 
posttranslational modifications are phosphorylation and ubiquitination. Phosphorylation occurs on 
residues of serine, threonine or tyrosine and it is a reversible modification via phosphatases 
cleavage. Ubiquitination occurs on lysine residues, which are modified by the protein ubiquitin, a 76 
amino-acid polypeptide that is highly conserved and abundant in eukaryotic cells52,53. It is a tag 
process: ubiquitinated proteins are recognized by the 26S proteasome for degradation. 
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Figure 70 The enzymes and reactions of the UPS.  
The ubiquitination and degradation of substrate proteins is achieved by a series of reactions mediated by the 
enzymes of the ubiquitin–proteasome system (UPS). In the activation reaction, ubiquitin is ATP-dependently 
transferred to an E1 (step 1). The activated ubiquitin is then transferred to an E2 enzyme in the conjugating 
reaction (step 2). Then the E2 enzyme carries the ubiquitin to the E3 enzyme, which is also known as an 
ubiquitin ligase (step 3). E3 is important not only because it covalently ligates ubiquitin to Lys residues on the 
substrate protein, but also because it mediates substrate specificity. This process of ubiquitin ligation may be 
repeated with a Lys of the ubiquitin protein itself serving as the substrate, which leads to the formation of a 
polyubiquitin chain on the target protein. Deubiquitinating enzymes may reverse substrate protein 
ubiquitination (step 4). Ligation of polyubiquitin has diverse biological consequences for the recipient protein. 
For example, Lys11- and Lys48-linked polyubiquitin chains serve as tags to target substrate proteins for 
proteasomal degradation (step 5). Conversely, linear, Lys63- and Lys11-linked chains promote the assembly of 
signaling complexes (step 6). X, Y and Z indicate ubiquitin-binding proteins. Pi, inorganic phosphate; PPi, 
inorganic diphosphate; Ub, ubiquitin. Image is modified from54. 
 
During the ubiquitination process (Figure 70), ubiquitin molecules are attached to the acceptor 
protein in a complex three-step reaction, in the so called ubiquitin-proteasome pathway (UPP). First, 
an E1 ubiquitin activated enzyme starts the process activating the ubiquitin and transferring it in the 
active site, the amino acid cysteine, in an ATP-dependent reaction with the production of an 
intermediate substance known as ubiquitin-adenylate. A second enzyme, E2 (ubiquitin-conjugating 
enzyme), takes part in the process in the conjugation step. But the key enzyme in the process is the 
E3 (Ub-protein ligase): it acts as an adaptor, which binds activated E2 and protein substrate to allow 
isopeptide bond formationd 52,54,55.  
 
                                                          
d Isopeptide linkage: An amide bond that forms between a side-chain carboxyl group and amino group 
and is not present on the main chain of a protein. In the case of ubiquitination, isopeptide linkages form 
between the ?-nitrogen of Lys side chains and the C-terminus of the incoming ubiquitin, and constitute the 
basis of polyubiquitin chains54. 
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There are three kinds of E3 Ub ligases distinguished on the basis of their E2-recruiting domains: 
RING,e U-box and HECT domains.  
The process connects the last amino acid, glycine 76, of the ubiquitin molecule to a lysine on the 
substrate protein and can be repeated several times to build in this way chains of Ub. In humans 
there are two E1 enzymes, 37 Ub conjugating enzymes and more than 600 E3 Ub ligases52. When 
proteins undergo the ubiquitination modification they can have different biological destinies as it is 
shown in Figure 70, they can form complexes (20 types of Ub interaction domains have been 
identified and ubiquitin polymers can act as interaction site for proteins) or trigger proteasomal 
degradation. The UPP system is active for degradation in all tissues and for the majority of 
intracellular proteins. Another process is responsible for the degradation of extracellular and cell 
surface proteins and occurs in the lysosome55. 
There are about 100 human deubiquitinating enzymes (DUB) subdivided in 5 categories: ubiquitin C-
terminal hydrolases, ubiquitin-specific processing proteases (USPs), Machado-Joseph disease protein 
domain proteases, ovarian tumor proteases (OTUs) and JAMM (JAB1/MPN/Mov34 metalloenzyme) 
motif proteases56. 
The biggest and better characterized subgroup of DUBs with over 60 members is the one of the 
cysteine protease USPs (ubiquitin-specific proteases). Their catalytic domain shows the so called 
histidine and cysteine boxes and their specific action is to hydrolyze bonds involving the carboxyl 
group at the C-terminal glycine residue of ubiquitin53. The reversibility of the ubiquitination process 
is an important factor to conserve the balance. That may explain why mutations that affect the 
function of USPs have been shown to occur in many cancers as well as in other disorders involving 
inflammation and the regulation of cell death57.  
The Array MAPPIT experiments for ?PCDHs proposed some interaction candidates for different 
PCDHs which belong to the USPs family and these were confirmed in the binary assay and CoIP 
experiments. Between the candidates we could also identify CUL5 and PMSC1. 
e RING domain: it includes a catalytic zinc finger like domain (Cys3HisCys4) able to chelate two zinc ions. U-box 
domain: a derived version of the RING-finger domain that lacks the hallmark metal-chelating residues of the 
latter 5 and 6 but is likely to function similarly to the RING-finger in mediating ubiquitin-conjugation of protein 
substrates78. HECT domain: it contains a catalytic Cys residue able to accept the charged Ub from E254. 
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?????? ????? ???????
The Cullin family is a group of seven (CUL1, 2, 3, 4A, 4B, 5 and 7) hydrophobic proteins, which are 
used as scaffold proteins for the E3 ubiquitin ligase enzyme. The combination with RING proteins 
produces the so called Cullin-RING ubiquitin ligase (CRL). Cullins are then needed for ubiquitin-
dependent protein degradation as already described in this dissertation. 
 
 
Figure 71 CUL5: relevant functions and diseases (Ingenuity® Systems, www.ingenuity.com) 
 
In particular, Cullin5 (CUL5) is part of the SCF-like ECS (Elongin-Cullin 2/5-SOCS-box protein) E3 
ubiquitin-protein ligase complexes. CUL5 has different functions beside protein degradation, 
including receptor activity and calcium channel activity58 and it is involved in many biological 
activities including proliferation and migration of neuronal and cancer cells (Figure 71). Cul5 is 
defined as a cancer related gene. The expression in many different tissues (including the male and 
female reproductive systems and the brain) and, above all, the important role played in many types 
of cancer, make CUL5 an interesting candidate partner for PCDHs. In our MAPPIT studies, CUL5 ranks 
in position 9 in the ARRAY list for PCDH11X and retests clearly confirmed this interaction. Cross test 
experiments showed a positive signal also for PCDH9. An interaction of CUL5 with PCDH10 was also 
seen but not always confirmed in MAPPIT, although PCDH10 can clearly pull down CUL5 in CoIP 
experiments.   
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PMSC1 (Proteasome 26S subunit, ATPase, 1) is 
another degradation-related candidate interactor, 
which was proposed by the Array MAPPIT 
experiments. Two complexes are cooperating to 
build the proteasome system: 4 rings of 28 non-
identical subunits called the 20S core and the 
regulator 19S formed by a 9-subunit base that 
binds to the ring of the 20S core, and a 10-subunit 
lid. PMSC1 is one of the 19 essential subunits of a 
19S proteasome complex59. It is a 49-kDa protein 
comprised of 440 amino acids60. In 2012, Tsai et 
al.1 have shown the interaction of PCDH10 with 
PDS-95 (Figure 72): PSD-95 is ubiquitinated by the 
ubiquitin E3 ligase murine double minute 2 
(Mdm2) and then binds to Pcdh10, which links it 
to the proteasome for degradation. This 
degradation is responsible for synapse 
elimination. This study convinced us to include the 
candidate in the priority list to understand if it 
could play a role in this interaction since PMSC1 
resulted to be candidate number 39 in the Array 
for PCDH10. Despite some inconclusive MAPPIT 
confirmation data, we included the candidate in 
further MAPPIT tests and CoIP experiments. The 
observation of this interaction could indicate a 
role of PCDHs in dendrite development and/or 
dendritic spine function: so far little evidence has 
been shown for this role (Table 20). 
 
 
 
Figure 72 PCDH10 is required for synapse 
elimination. 
Working model of MEF2-induced synapse 
elimination in WT neurons and the molecular 
basis of the deficit in synapse elimination 
in Fmr1 KO neurons. Figure modified after1. 
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Table 20?Pcdh Dendritic Roles 
 
Name Reported Dendritic Role Ref. 
Protocadherin 7, NF-
protocadherin (Xenopus) 
Pcdh7 promotes retinal ganglion cell dendrite 
arborisation, possibly through TAF1. 
61 
Protocadherin 8, Arcadlin 
(mammals), paraxial  
Pcdh8 causes a decrease in spine number by 
activation of a MAPK pathway resulting in Pcdh8/N-
cadherin endocytosis. Consequently, neurons cultured 
from Pcdh8 knockout mice have increased dendritic 
spines, but only   in the presence of N-cadherin. 
62 
Protocadherin 10, Ol-
protocadherin 
Pcdh10 knockdown prevented MEF2-induced synapse 
elimination. Pcdh10 is necessary for ubiquitination 
and proteasomal degradation of PSD-95, leading to 
spine loss. 
1 
 
?????? ???????????????????????
In a screen for novel PCDH10 interaction partners in lysates of newborn mouse brain, Nakao et al. 
identified NAP1 as a cytoskeleton-related protein63. Recently DYNLT1, also cytoskeleton-related, has 
been identified by MAPPIT and CoIP experiments as an interaction partner of PCDH10 and PCDH11X 
(I.Kahr and U. Fuchs, not published) and preliminary studies have also suggested an interaction with 
several other ?PCDHs (our unpublished data).  
The cytoskeleton is a very dynamic and adaptable network of cytoplasmic protein filaments and 
tubules, and is responsible for the proper cell functioning: it guarantees the correct cell shape, the 
ability to move and to organize the internal components and to interact mechanically with other 
cells and with the environment. It is responsible for the constitution of the mitotic division 
machinery, and in neural cells it is the support for dendrites and axon structure64. 
The cytoskeleton comprises three different kinds of proteic filaments: actin filaments or 
microfilaments, microtubules (formed by heterodimers of ? and?? tubulin) and a group of polymers 
called intermediate filaments65. The intermediate filaments show a number of different protein 
subunits, are the less dynamic filaments, are often assembled in response to mechanical stress and 
are involved in stability rather than movement. Microtubules instead are important mediators of cell 
movement, are the largest fibers and are formed of tubulin heterodimers which assemble to create 
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protofilaments, which in turn can assemble to form the microtubules. Microtubule-associated 
proteins or MAPs are proteins that bind to the microtubules and that can mediate the interaction 
between microtubules and other cell components. Motor proteins are proteins that can associate 
with the polarized fibers of cytoskeleton and that convert chemical energy in the form of ATP to 
mechanical energy. In case of microtubules there are two major classes of motor proteins: kinesins 
and dyneins. Kinesins are responsible for the fast anterograde axonal transport which is the 
movement of vesicles and organelles outward, from the cell body (also called soma) to the synapse 
or cell membrane while dyneins participate in the movement in the opposite direction, i.e. the 
retrograde axonal transport. The elaborate cytoskeletal structures of neurons are shown in Figure 
73.  
Dyneins are divided in cytoplasmic or axonemal. The cytoplasmic dyneins are responsible for the 
microtubule-mediated transport processes. They are large multisubunit complexes made of two 
heavy chains with the motor domain in combination with associated subunits such as intermediate 
(IC), light intermediate (LIC) and light chains (LC). Cytoplasmic dynein needs to associate with a large 
protein complex called dynactin in order to translocate organelles. The 74-kDa intermediate chain 
(IC74) mediates the binding while the other subunit is responsible for the direct binding to the cargo. 
DYNLT, DYNLL and DYNLRB are three distinct families of LCs. DYNLT1, one of the members of DYNLT 
family, has been shown to interact with several molecules and it has been suggested to play a role in 
the internalization of many cargos; in contrast, it has been shown to also have several dynein-
independent functions. Our results show that PCDH10 interacts with DYNLT1, but not with the 
dynein-independent form, suggesting a role of the interaction in the motor complex (I. Kahr, not 
published). Our data indicate that PCDH10 might recruit DYNLT1 to the cell cortex for cell-cell 
migration or for initialization of the cell-cell contact process. Otherwise, it is possible that in different 
conditions PCDH10 is transported by DYNL1 to the perinuclear region, maybe for degradation. 
Anyway, the function of this interaction has not been clarified yet. 
Finally, the third kind of protein filaments of the cytoskeleton is the microfilament. Microfilaments 
are formed of globular (G) actin: each monomer interacts head-to-tail with two other actin 
monomers, forming in this way filaments (filamentous (F) actin). The filaments of actin localize 
beneath the plasma membrane and are anchored to the plasma membrane at the adherents 
junctions. This contact is cadherin-mediated through the binding to catenins, able to associate with 
actin filaments.  
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Figure 73 Neurons have elaborate cytoskeletal structures. 
(A, B) Neurons are specialized eukaryotic cells that extend long processes to form connections in the nervous 
system. Like other eukaryotic cells, neurons have a cytoskeleton that consists of three main polymers: 
microtubules (green), intermediate filaments (purple) and actin filaments (red). Microtubules emanate from 
the axon, and actin-filament networks form sheet-like structures and filopodial protrusions at the leading edge. 
Scale bar, 20 ?m. (C) The neuronal axon is a long membrane-bounded extension, in which neurofilaments (a 
class of intermediate filament in neurons) form a structural matrix that embeds microtubules, which transport 
materials from the cell body to the axon terminals at the synapse. (D) The growth cone contains dendritic actin 
filament networks and parallel actin filament filopodia. (E) Microtubules consist of 13 protofilaments of tubulin 
dimers arranged in a hollow tube. (F) Neurofilaments have flexible polymer arms that repel neighboring 
neurofilaments and determine the radius of the axon. (G) Actin filaments are arranged into networks. These 
networks can have many architectures, including the branched structures depicted here, which are formed by 
the Arp2/3 complex (blue). The diameters of microtubules, intermediate filaments, and actin filaments are 
within a factor of three of each other; the diagrams in E, F, and G are drawn approximately to scale. However, 
the relative flexibilities of these polymers differ markedly, as indicated by their persistence lengths: from least 
to most flexible, microtubules (5,000 ?m), actin filaments (13.5 ?m) and intermediate filaments (0.5 ?m). 
Figure from65. 
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Microfilaments, similar to microtubules, associate with motor proteins, in this case with myosin, 
responsible for contraction in the skeletal muscles. Networks of actin filaments constitute 
lamellipodia, protrusive actin structure localized at the leading edge of migrating cells, and filopodia, 
thin cytoplasmic projections that extend beyond the leading edge of lamellipodia66,67. Migrating cells 
show a fast turn-over of the actin cytoskeleton with lamellipodial protrusion boosted by actin 
polymerization. In cells, the major initiator of new actin filaments is the Arp2/3 complex68. Wiskott–
Aldrich syndrome protein (WASP) and WASP-family verprolin-homologous protein (WAVE) family 
proteins are responsible for the activation of Arp2/3 complex. Wave protein is incorporated in a 
large complex (WAVE regulatory complex, WRC) together with PIR121, Nap1, Abi and HSPC30069. 
The WRC is activated by Rac, which directly binds to Sra1 causing the release of VCA, a conserved C-
terminal sequence of the WASP protein responsible for the activation of Arp2/370. Different (classes 
of) ligands have been identified for WRC activation, including PCDH10 and PCDH19. The conserved 
WAVE regulatory complex (WRC)-interacting receptor sequence (WIRS) mediates the interaction. 
Indeed, studies have demonstrated that PCDH10 and PCDH19 enhance activation of the WRC by 
Rac1 and consequently the production of new actin filaments71. 
PCDH10 was identified as a Nap1 interaction partner72 and it was shown to pull down WAVE1 and 
ABI63. Nap1 (Nck associated protein 1) is an adaptor protein expressed in the cortical plate region of 
the developing cortex and it seems to play a role in the final steps of neuronal migration and 
differentiation73. Neurons have an elaborate cytoskeletal structures. 
Studies conducted in astrocytoma have shown that PCDH10 can recruit NAP1 and WAVE1 to the cell-
cell contact: no effect was noticed on the motility of single cells but the movement was accelerated 
in case of cell-cell contacts because of a reorganization of the assembly of F-actin and N-cadherin. 
Nakao and colleagues suggested a direct interaction of Nap1 and a region at the C-terminal of 
Pcdh10, downstream the CM2. This region was named Nap1-binding fragment (NBF). Recently the 
binding site of PCDH10 with WRC has been identified as a 9 residue sequence included in the NBF, 
which is necessary and sufficient for the binding. This motif has been named WIRS74. WIRS binds a 
surface of WRC composed by SRA1 and ABI2: this surface is created only when the complex is 
complete. These data are in contrast with a direct interaction of PCDH10 and Nap1 which seems to 
be indirect and related to a common partner such as Sri174. Chicken Pcdh19 was shown to interact 
with Nap1 as well and the same study suggested an interaction also for Nap1 with Pcdh1 and 
Pcdh975. 
221 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 74 Pcdh17 recruits the WAVE complex, lamellipodin and Ena/Vas proteins at the cell-cell contact 
Via recruiting of actin polymerization regulators to the contact site between neurons, Pcdh17 maintains the 
migration of the growth cones in neurons. The growth cones are in contact with other axons and are 
responsible for the fasciculation growth of axons from the same functional group of neurons. (Modified after76). 
 
Recently, PCDH17 was shown to recruit actin regulator complexes to regulate a (selective) 
fasciculation in mammalian axons76. Using amygdala neurons of Pcdh17 KO mice, it has been 
demonstrated that Pcdh17 is required for normal axon extensions. Pcdh17 recruits the WAVE 
complex, lamellipodin and Ena/Vas proteins at the cell-cell contact. 
If Pcdh17 forms homophilic interactions via its extracellular domain, the cytoplasmic domain seems 
to associate with the WAVE complex to create a motility machine and sustains cell migration 
process. In mouse brain lysate, Pcdh17 coimmunoprecipitates with Nap1, but also with Wave1 and 
Abi1. Taken together, Pcdh17 induces cell-cell contact by its extracellular domain and stimulates 
motility at the cell contact site by binding actin regulator molecules in the cytoplasm.  
To summarize, ?2PCDHs have been shown to play a role in cell motility and to bind to WRC to 
influence actin cytoskeletal dynamics. WRC is involved in the regulation of actin polymerization, 
responsible for the movement of the cells. In view of this, we performed experiments and analyses 
focused on identification of novel relevant Pcdh interactions to elucidate how this complex 
mechanism is regulated. 
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IV.3 Conclusions 
PCDH9, PCDH10 and PCDH11X were selected to investigate the PCDHs family. An Array MAPPIT 
screening was performed and results were confirmed in binary MAPPIT assay. After analysis and 
selection, a priority list was proposed to be further investigated. Coimmunoprecipitation has been 
used in this study as the prime confirmation test. In this way, I could confirm a molecular interaction 
of PCDH10 with MAX, MAD3, FHL2, CUL5, USP21 and USP46. For PCDH11X we confirmed the 
interaction with MAX, FHL2, USP21 and USP46. PDLIM7 was also considered a confirmed partner, 
despite problems with an aspecific signal in CoIP, as it is positive both in several MAPPIT screens and 
in a co-localization experiment.  
The confirmed candidates belong to different pathways involved in many different biological 
mechanisms, proposing multiple interesting roles for PCDHs. We mainly focused on cancer related 
mechanisms to further investigate the identified novel interactions and their putative roles in 
cancer. For instance, candidates belonging to the MAX-MAD family (see chapter IV.2.1) play an 
important role in cell development and cell cycle. The c-Myc protein induces cell proliferation by 
targeting transcriptional expression of genes (including cyclin D1) leading to G0–G1 cell cycle 
progression. C-Myc promotes cell cycle progression through heterodimerization with MAX. If MAD 
proteins are present, MAX heterodimerizes with MAD and represses gene transcription: it associates 
with the mSin3 co-repressor complex via histone deacetylation77. The balance of the two MAX 
complexes is strictly regulated and disturbing events can lead to tumorigenesis and development, 
miss regulation of differentiation and cell growth. Since the pathway is responsible for gene 
regulation, any mutation might interfere with transcription. As described (IV.2.1), our results 
indicated MAX, MXD3 and MXD1 as putative interaction partners of different members of the 
?PCDH family. The candidates are mutated in brain cancer and are defined as tumor suppressor 
genes.  
Also CUL5 (section IV.2.5), which mediates ubiquitination and subsequent proteasomal degradation 
of targeted proteins, is a tumor suppressor gene that inhibits cell proliferation. Together with PMSC1 
and USPs proteins (section IV.2.4), CUL5 belongs to the ubiquitination pathway responsible for 
protein degradation. The ubiquitin-proteasome system is responsible for the regulation of cyclin-
dependent kinases (CDKs) and of other cell cycle components but also for other pathways that 
interfere with the cell cycle program such as stress responses or checkpoint systems. This 
demonstrates the enormous impact of the ubiquitin-proteasome system on cell proliferation. Our 
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investigation identified various member of this pathway as PCDHs interaction partners. PCDH10 is 
required for synapse elimination and this is an interesting indication of the role that PCDHs might 
play in the degradation system: the mechanism has been not completely elucidated yet. In this 
context PMSC1 was a top candidate: we suggested that it could be responsible for the connection 
between PCDH10 and the proteasome. Unfortunately, it was not possible to confirm this interaction 
in CoIPs and further investigations with different techniques should be performed to better 
investigate this putative interaction.  
Migration and proliferation events are regulated also by FHL2/3, which are additional candidates on 
the priority list (section IV.2.2). FHL2/3 is known to be an important inducer of the EMT process. Our 
CoIP experiments confirmed the interaction of FHL2 with both PCDH10 and PCDH11X, suggesting 
again a role of different members of the ?PCDH family in cell proliferation. Furthermore, ?2PCDHs 
have been shown to play a role in the reorganization of actin cytoskeleton, as occurring in migrating 
cells (section IV.2.6). By MAPPIT technology, our group identified DYNLT1 as an interaction partner 
of PCDH10 and PCDH11X and confirmed this by CoIP. The MAPPIT array indicated a list of novel 
candidate interactors which are all actin-cytoskeleton related. Considering the indications 
concerning cell migration being influenced by ?PCDHs, as obtained by our and published studies, this 
class of molecules deserves to be further studied in relation to the ?PCDH family members. 
To summarize, the selected candidate interactors are cancer-related (and/or play a role in 
neurological diseases), as they mostly regulate cell cycle, proliferation and transcription. Different 
evidence indicates that ?PCDHs are involved in tumorigenesis and tumor progression and are mainly 
expressed in brain: in view of this, the confirmed proteins of the candidate list of interactors appear 
to be promising and interesting candidates. Since ?PCDH functions are largely unknown, some 
functional experiments were performed on the basis of the reported properties and functions of the 
interaction candidates (described in Chapter V). 
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Chapter V. FUNCTIONAL STUDIES f 
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RNA Seq analyses were done by Eleonora Billi, Pieter De Bleser and Frans van Roy. 
 
Quantitative analyses of cell properties of cell lines with induced protocadherin isoform 
expression were performed by Eleonora Billi and Marleen van Troys. 
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V.1 Introduction 
Despite the steadily growing interest in investigating the functions of ?PCDH family members, mostly 
due to their possible clinical impact, many details still remain obscure. Pcdhs are probably 
communicative rather than adhesive proteins and functional differences may exist between long and 
short isoforms. In this study we first identified and confirmed different candidates for ?PCDHs, and 
then tried to investigate the role of the confirmed interactions. It was difficult to determine ex ante 
how to proceed best in terms of functional characterization. Since the functions of ?PCDHs are 
largely unknown, functional characterization was much dependent on the identity of the candidates. 
Functional implications of the observed molecular interactions for normal morphogenesis as well as 
for tumorigenesis and tumor progression were the targets of the investigation with contemporary 
molecular tools.  
Different candidate interactors were analyzed with different techniques according to the known 
specific functions they might play in health or disease, and we focused on their putative or proven 
roles in the central neural system and cancer. First, we studied expression levels for the candidate 
interactors by use of Pcdh10 KO mice, and then we proceeded with specific tests for protein 
ubiquitination, protein half-life and degradation, cell migration, proliferation and adhesion. 
This Chapter thus covers three different approaches to further investigate the functional indications 
obtained from the identification of novel interaction partners.  
In the first part, a comparison of the expression level between PCDH10 KO mice and WT mice is 
presented: RNA sequencing experiments for cerebellum and qRT-PCR tests for total brain transcripts 
of PCDH10 KO versus WT mice will be presented and analyzed. 
In the second part specific validation studies for novel PCDH interaction partners are described 
including effects of selected interaction partners on PCDH ubiquitination and effect of PCDH 
expression on Myc activity.  
In the third and last part of the results section of this dissertation, a comparative functional analysis 
of specific cellular properties of PCDH10 and PCDH11X expressing cell lines will be presented. We 
established an in vitro cell based assay with the aim to further investigate the role of different PPIs 
on these selected properties.  
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V.2 Expression Analysis
 ???????????????
Surprisingly, most of the candidate interaction partners of our priority list for different ?PCDHs were 
transcription factors. The first test we therefore decided to perform was gene expression analysis. 
Experiments were carried out in mouse brain RNA samples. 
To quantify RNA molecules, the classic technique has been the Northern blot, since 1977: the 
technique reveals RNA expression using molecular probes and uses the principle of nucleic acid 
hybridization1. With the time it has been defined an inconvenient technique since it is not very 
precise, it requires long experimental time and a large amount of RNA, a requirement which is not 
always easy to achieve. With the advent of RT-PCR (Reverse transcription polymerase chain reaction) 
thanks to the discovery of reverse transcriptase and PCR technology, the quantification of RNA 
found a new method of choice. 
We performed qRT-PCR (Reverse transcription quantitative real-time PCR) experiments on brain RNA 
samples from Pcdh10 WT and KO mice, defective for either all isoforms or only the long isoforms. 
The expression levels of the candidates and related genes have been studied. Gene expression was 
also studied by RNA sequencing (RNA Seq) experiments. 
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 ?????????????????
V.2.2.1 PCDH10 KO mice and genotyping 
Conditional Pcdh10 knockout mice were generated in the lab by Irene Kahr using the 
recombineering technology (Summarized in Figure 75). 
 
Figure 75 Outline of generation process of KO mice  
Mice generation and picture by Kahr I. not published 
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Two different Pcdh10 mouse models were generated: Pcdh10all KO mice, where all the isoforms are 
deleted, and Pcdh10long KO mice where the short isoform (lacking the CM motifs) is conserved. All 
mice models were hosted in the SPF facility of the Inflammation Research Centre (IRC-VIB, UGent). 
Breeding and experiments were performed in the SFP facility according to the regulation and 
guidelines of the Ethical Committee for care and use of laboratory animals of the University of Gent. 
Figure 76 shows the gene structure and the alternative transcripts for PCDH10/Pcdh10. Details on 
genomic organization of PCDH10 and of the other members of the family are described in paragraph 
I.3.1 of this dissertation.  
 
Figure 76 Gene structure and alternative transcripts of PCDH10/pcdh10 and Pcdh10 isoforms protein 
structure 
(A) In the gene: grey boxes represent exons, the intervening line represent introns. In the transcripts: black 
boxes are the coding sequences, white boxes represent 5’ or 3’ untranslated regions. CD, sequence encoding 
the membrane proximal part of the cytoplasmic domain; CM1 and CM2 are the conserved motifs; EC, region 
encoding the cadherin extracellular repeats; MPED, sequence encoding the membrane proximal extracellular 
domain; TM encodes the transmembrane domain. Exon 1 alone encodes the complete ectodomain, the TM 
domain and a large part of the cytoplasmic domain. If no splicing occurs in the transcript a short isoform 
lacking the CMs is produced. In case of long isoforms, a splice donor is used in exon #1, and a long transcript is 
formed comprising exons encoding CM1 and CM2.  (B) Schematic representation of Pcdh10 protein isoforms. 
Numbers on the right indicate the total size (number of amino acid residues) of each isoform. Dashed lines 
indicate the regions that were floxed in Pcdh10all fl/fl and Pcdh10long fl/fl mice, respectively. After the Cre 
mediated deletion of exon 1 as expected a complete Pcdh10 KO mice was obtained, while in the Pcdh10long 
fl/fl mice, the removal of exon 2 and 3 leads to a frame shift in exon 4, and therefore only the short isoform can 
be expressed. (Modified from Kahr I., not published)  
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Pcdh10all KO mice and Pcdh10long KO mice were genotyped using genomic DNA extracted from the 
tail. Tail tips were incubated overnight (O/N) at 55°C in 200 ?l of lysis buffer (GB 10x, 10% Triton x-
100, H2O), (stock 200 ml GB 10x stored at -20°C : 134ml 2M Tris pH 8.8, 33,2 ml 1M (NH4)2SO4, 21.4 
ml 0.5 M MgCl2 and 11,4 ml H2O) and 0.8 ?l proteinase K (10 mg/ml). Samples were then incubated 
for 10 min at 95°C. The genomic DNA was precipitated with isopropanol, washed with 70% ethanol, 
air-dried and dissolved in 300 ?l of H2O. The PCR reaction included: 0.2 ?l of each specific primer (25 
pmol), 2 ?l of template, 0.4 ?l dNTPs (10 mM), 2 ?l of 10X PCR buffer, 1?l MgCl2 (50 mM) 0.2 ?l Taq 
and 14 ?l H2O. Used primers were for Floxed allele: Pcdh10 all 5’ Forward CATGTACCTTCTTCCCACAC; 
Reverse  GGCATGTGTCAATCAAAGCT; product size of wild type allele 519 bp, of targeted allele 469 
bp. Pcdh10 Long 3’ Forward CTTCCATTGGTCACTGTGCT; Reverse CCACCTTTGGCCATTAGTTA; product 
size of wild type allele 330 bp, of targeted allele 428 bp. For Cre-mediated deleted alleles: Pcdh10 all 
Forward CATGTACCTTCTTCCCACAC, Reverse GGTCTCTCAACTAGATAGCT, product size 775 bp. 
Pcdh10 long Forward GCGTGTACCAGTAAGCAATA, Reverse CCACCTTTGGCCATTAGTTA, product size 
652 bp. The thermocycling conditions for PCR reactions forPcdh10 all were: 3 min at 94°C , 35 cycles 
of 94°C for 30 sec, 57°C for 30 sec and 72°C for 45 sec (1 min for pcdh10 long); 72°C for 10 min.    
Mice were also genotyped to confirm the gender, by performing PCRs for specific regions only found 
in the Y chromosome: DDX3Y and Eif2S3Y genes were used for this purpose. Primers: DDX3Y 
Forward TGTTAGTTGCCACACCAGGACG, Reverse TGGTGGCATTGTGTCCTGCTCA; Eif2S3Y Forward 
GTATGCTGCTCCAGGTGGTCTT, Reverse CTCAGGTAATGCTCCAACAGCAC. Sry was used as well to 
confirm: Forward AACAACTGGGCTTTGCACATTG , Reverse GTTTATCAGGGTTTCTCTCTAGC. 
V.2.2.2 Tissues and RNA extraction  
Brains were isolated from WT, Pcdh10all and Pcdh10long homo and heterozygous KO mice. All mice 
were 3 weeks old. Brains were dissected in 3 parts: the olfactory bulbs, the cerebellum (separated 
from the colliculus and the spinal cord) and the rest. Most of the experiments were performed in 
cerebellum because of the high expression of Pcdh10. 
 Dissected brains were quick frozen and conserved at -80°C.  
Total RNA was extracted in RNAse free conditions using the Aurum Total RNA mini Kit (Bio-Rad) 
according to the manufacturer’s protocol.  TRIzol (800 ?l )  was used for homogenation of the fatty 
brain tissue .160?l RNase free Chloroform were added to each sample: the Eppendorf tubes were 
inverted for 15 sec, incubated for 2-3 minutes and then centrifuged at  12000X g at 4°C for  10 
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minutes. The supernatant was transferred into a new tube, paying attention not to touch the 
interphase of proteins, and 60% RNase free ethanol was added to the supernatant in a 1:1 ratio. 
Columns from the Aurum Total RNA mini Kit were used and the sample was loaded in more times in 
a max amount of 600 ?l each time. The protocol from the company was then followed. At the end of 
the process, the eluate is the total RNA sample and this was used immediately for downstream 
applications or frozen for later use. Cerebellum was divided in two equal parts and used separately. 
Elution was done in 80 ?l of elution buffer from the kit. Sample concentrations and purity were 
checked with a Thermo Scientific NanoDrop™ Spectrophotometer. We used samples of cerebellum 
which were showing a concentration higher than 350 ng/ ?l and samples of the cerebrum (without 
cerebellum) higher than 1200 ng/ul. The RNA purity was determined as a 260/280 wavelength ratio; 
a pure sample has a ratio of 2.1. The ratio 260/230 pointed at contaminations of salt or rest of 
phenol or presence of proteins. We considered clean sample with the ratio equal or higher than 2. 
Samples not meeting those characteristics were not used.  
V.2.2.3 QRT-PCR
cDNA was prepared from brain RNA with the iScript cDNA synthesis kit according to the 
manufacturer's instructions (Bio-Rad). Quantitative RT-PCR mixes contained 20 ng template cDNA, 
Light Cycler 480 SYBR Green I Mastermix (Roche) and 300 nM forward and reverse primers. RT-PCR 
mixes for the 3 most stable reference genes, selected from a panel of reference genes by applying 
geNorm2, were prepared in the same way. Reactions were performed on a Light Cycler 480 (Roche) 
using the following protocol: incubation at 95°C for 5 min, then 50 cycles at 95°C for 10 sec, 60°C for 
30 sec, and 72°C for 1 sec. Specific primers were selected based on specificity (melting curve 
analysis) and efficiency (standard curve). List of primers: Table 21. 
Table 21 Quantitative RT-PCR primers 
Gene Name Forward primer sequence Reverse primer sequence 
5330417C22Rik CCTGAGTCTCTGTGGAAACCAG ACAACCTGGCAGACATAGGCTG
Abl1      TGAGCAGAAAGATGCGCCTGAC CGCTCATCTTCATTTAGGCTGCC 
Adcy1 CCTTCTCCAACGTGATGACCTG GCTGATGTACCTGTTGACGCGT
Basp1 CGAAGCGAGCGCCGAGAGCA GCTAGGTTTAGAGTCTGAAGCCG
Bax TCAGGATGCGTCCACCAAGAAG  TGTGTCCACGGCGGCAATCATC
Bid CCACAACATTGCCAGACATCTCG TCACCTCATCAAGGGCTTTGGC
Bmp3     TAACACGGTCCGCAGCTTCAGA TGTGGCTGACAAAATGTTCTCCG 
Brca1 CGAGGAAATGGCAACTTGCCTAG TCACTCTGCGAGCAGTCTTCAG
Cartpt TACTCTGCCGTGGATGATGCGT TCGGAATGCGTTTACTCTTGAGC
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Casp 1          GGCACATTTCCAGGACTGACTG GCAAGACGTGTACGAGTGGTTG 
Casp8 AGAAGAGGGTCATCCTGGGAGA TCAGGACTTCCTTCAAGGCTGC 
Cbln3 AGTGGTGCCATCTACTTCGACC CCTGGACAGTTTGGCGGTTGTA 
Ccnb1 AGAGGTGGAACTTGCTGAGCCT GCACATCCAGATGTTTCCATCGG 
Ccnd1 TCTACACCGACAACTCCATCCG TCTGGCATTTTGGAGAGGAAGTG 
Cdc2L1 GACTCTCCAGCACTGTCACCTA GTCCTTTGCTCTGTAGACCACC 
Cdh23 CACTGTCACCTATGCCATCGTG GGCAGTGACAATCAGGGTGTAG 
Cdon TGAAGGACAGCCTGCCATGCTT CCTGGAGGAATCCGTAAGCACA 
Ceb1 CTGTGACTATCAAGACCATGCTG AGGAGGGTCATCTTTGTGGTGG 
Cerkl CCTCTTGGCTTCATTCCAGCAG GCAGACATCCACTGACCGTATG 
Cetn4 GATGACGATGCTACGGGAAGCA CCGTCACGATCAGCTTCATCAAG 
C-Myc        TGAGCCCCTAGTGCTGCAT AGCCCGACTCCGACCTCTT 
Cst3 CATACAGGTGGTGAGAGCTCGT CTGGTCATGGAAAGGACAGTCAG 
Cul5          GTGTAAATGCGCTGGTGACCTC CTCCAAGTCCTTCAACATCGGC 
Cux1 CCAAGAACGGCATTTGCCAGAG CCTTTCTGGGTCAGTTTGCTCC 
Dact2 GCCTTGGATAGTGACAGCAGAC GGATAGACGGTCGCTGCAAACA 
Dkk3 GGAGGAAGCTACGCTCAATGAG TTGCCAGGTTCACCTCAGAGGA 
Dos GGTCAAGAAATGGAAGCTGGAGC TCCTGCTCCATGCTCTCACTGG 
Dusp1 CAACCACAAGGCAGACATCAGC GTAAGCAAGGCAGATGGTGGCT 
Eed AGTTGAGCAGCGACGAGAACAG TCCTTCCTGGTGCATTTGGCGT 
Ephb6 GGAACATCCTCGACTACCAGCT TCAACCGTGTCACAGTGGCAGT 
Exosc9 TCTCAGATGGCTGCTCCAGCTT CCTTTTCACCAGCGACAACACAG 
F2R TTTCCTCTCCGACAGTCCTGGT CAGCACAAGATGCTGTAGAGGTG 
Fas GGACCCAGAATACCAAGTGCAG GTTGCTGGTGAGTGTGCATTCC 
Fbl          GCAAGAGAGGAAACCAGTCAGG AGACTCTCCAGGGACCAGATTC 
Fhl1          GCTGCCTGAAGTGCTTTGACAAG ACTTGGCACAGCGGAAGCAGTT 
Fhl2          CCTGCTTCTGTGACTTGTACGC CAGTCGTTGTGCCATTGGCGTT 
Fhl3          ACCTGTCAGGACAGTGAGCTTC GCACAGAAAGCAGTGTTCATGCC 
Fndc9 CACGAACCTCGGTGGTCTTACA TCTTTCGTGGCAGTTCCTCCAG 
Fxyd7 CTATGCCACTGTGCAGACTGTG AGGAGGGCAGTTCCGACTTACA 
Galnt13 CTGGCGAGAATAAAGGAAGACAG TTGAGGGACAGGATACCATCGG 
Gapdh TGTGTCCGTCGTGGATCTGA TTGCTGTTGAAGTCGCAGGAG 
Gm5148 GTTTGTCATGCCACTTCTGGTCC AGATGGCTGGTGAGACTCCACA 
Gng4 TTGTGGTGTAGACGCTGGAGCA CCAGTGTTGTCAGACTTCTTGCC 
Grp AGGCACGGTCCTGGCTAAGATG CCGTCTCTGTCAGCCGCATAC 
Hprt AGTGTTGGATACAGGCCAGAC CGTGATTCAAATCCCTGAAGT 
Htr1B          TCACTGACCTGCTCGTGTCCAT TATCCGACGACAGCCAGAAGTC 
Il34 CAGGAGGTTCAGACATTGCTGG GCAGTTGTCCAGCAAGGCTTTG 
Irf4          GAACGAGGAGAAGAGCGTCTTC GTAGGAGGATCTGGCTTGTCGA 
Itga5          ACCTGGACCAAGACGGCTACAA CTGGGAAGGTTTAGTGCTCAGTC 
Jun CCTTGAAAGCTCAGAACTCGGAG TGCTGCGTTAGCATGAGTTGGC 
Kcna5 AGACTCTGCCTGAGTTCAGGGA GAATGGGTCAGCCAGTGTCCTA 
Klhl14 CTGCTGTTGGTTGGAGGATTGC CTACCTCTACAACGCAGTGGTG 
L Myc        ATGGACTTCGACTCGTATCAGC AGAAATCCTCTCCGCAGTCATA 
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Lhfpl5 GCTCCATCATCTGCTTCAGCCT CCCAACCATCTGGGTAGACTAG 
Lin7B GAGTCGCTTCTGCTCCGCCAT GCCGTGAAAGCAGCCACTGTG 
Ly6H CCACCGATACCGTTTGTGCCAG AGTGCCGCTTAACGAAGTCGCA 
Mad1        AGATGCCTTCAAACGGAGGAA GTGAGTTGATCTGCTACTGGTG 
Mad3        CCCGATACACTACACTAAGCCT  CAGCTTCTGGATATGCACCCT 
Mad4        GGCGACTTCGCAAGGAAGAA  GAGCCTGAGTTTAGCTCGTCT 
Mal          ACCTTCCCTGACTTGCTCTTCG GCCACAAAGCAGAACACAGACAC 
Mal2 CCGACATCCTAAGGACGTACTC CCATCCTTGGAGCAGAGGTAGA 
Max        AGCGAGGTTTCAATCTGCGG    ACGTTTTCGTTCCAGTGCATTAT 
Max          TGACCTCAAGCGGCAGAATGCT TTGGCGTTGGTGTAGAGGCTGT 
Mdm2          CCGAGTTTCTCTGTGAAGGAGC GTCTGCTCTCACTCAGCGATGT 
Mdm4          GCTCTCGCACAGGATCACACTA ATGTCGTGAGGTAGGCAGTGTG 
Mga        GAGGAGCACCTACCTTCTTTGT ACGGGCATCTCGATTAGTAACT 
Mgp AGGAACGCAACAAGCCTGCCTA CTGCCTGAAGTAGCGGTTGTAG 
Mlx        GGTCGAGTATGCCTACAGTGA  GACACTACACTCCCCTTGTGG 
Mnt CGGCTGAAGAAGCCAAATCCAG GATGTTGCGCTTCAGGGTCTCA 
Mnt        TCCTGTAGTGACCAATTCCCC  GGCTCCTTAATGCTGAGTCCA 
Msh2 GAACAAAGGCGAGTATGAAGAGG GCGTCTAAGTGAGCCAGCACAT 
Msh2 GTCTGTGCCAACAGAGATGCTC CCGTAACTGTCTGGAAAGCATGG 
Mxi1        AACATGGCTACGCCTCATCG CGGTTCTTTTCCAACTCATTGTG 
Myoc ACCCAGGAGCAAAGAAGGAGAC CAATCCTCCATGTGCTTTCCTGG 
Ndn CCTCTGGTTTCCAGACATGGTG ATGGTGTGGAGATTGGTCAGCC 
N-Myc        ACCATGCCGGGGATGATCT  AGCATCTCCGTAGCCCAATTC 
Nnat GTGGTGGAGGAAGAGGGTTAAG CACATTTTGGGGAGGGCTTTCG 
Nov GTCACCAACAGGAATCGCCAGT GTAGGTGGATGGCTTTCAGGGA 
Nptx2 GGCAAGCCAACGAGATTGTGCT TGCCATCACTGACAAACAGCGG 
Nrip2 GATTTCTGCTGGATGTCTCAGGC GCTGTTCTACCTGAGTTGGTGG 
Otof CGCCAAAGTCAAGACCCTCTTC CACAGGAAGTCCTTTCGCTGCT 
P21 AGGTGGACCTGGAGACTCTCAG TCCTCTTGGAGAAGATCAGCCG 
P27 GGAGCGGCAAGATCGCATCTC TCCTGACAAGCCACGCAGTAGA 
Pcdh1 CTGACGGCAGCATAGGTGAA AGTTTGAGGGCGCTGCTCTT 
Pcdh7 AACGATAACACGCCCACCTT GCCATTGCGACCAAAGTCAC 
Pcdh9 TTTGATCAACAGCCGCTTTC CTCCGGAGTTTCCACGATAT 
Pcdh10all GAGCAGGAACATGGCACTTT AGTAAGGGGTCCGTGAGTTG 
Pcdh10long ACAGTGGTCATGGAGACAGT TCCTCGGTGCAGTTGGAGAA 
Pcdh10short CCAAGTCAATTCTGCTCTGG GTGCCAGAGGAACTTCATTC 
Pcdh11 CGGAGAACTCGGCTATAAAC CAATGACATCAAGTCCGAAA 
Pcdh17 TCAGTGCCAGAGGAGCAAGG AGATGCGGTGCGGAGTTCTC 
Pcdh18 AGCATAGGGGCTAAAATTGA CAGCACGTCCACTTCAATGT 
Pcdh19 TTGACCGAGACCTGCTGTGC TGGGAGCATTGTCGTTCAGG 
Pcdh8 CTCAGTGGCCCAGAGCAAGA CCGGAGCAGAGAGCTGTTGA 
Pdlim7 CCTCCTGCTATGATGTGCGCTA  GCACAGGTGAAGCAATGGACGT 
Pdyn CTGTGTGCAGTGAGGATTCAGG GAGACCGTCAGGGTGAGAAAAG 
Pkp2          CAGGTGCTGAAGCAAACCAGAG GACACTCTCTGTCAAGGTGAGC 
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Pnck GCTGTCTCCTACCTTCATAGCC GCCTAGCATGTTGCCAGCTTGT 
Pou4F1 AGTACCCGTCGCTGCACTCCA GACACCGCGATGTCCACGGC 
Ralyl TGAGTGAGCGTCATGCAAGAGC GGGTCTCTTACTTCCAGGCTTTG 
Rest CATCTAACGCGACACATGCGGA CCCGTTGTGAACCTGTCTTGCA 
Rgag4 AGCCTCGCTCACTGGAGTTCAA GTCATGTGCTGCCTCTGATCCT 
Rgs10 CCTGGAGAATCTTCTGGAAGACC CTGCTTCCTGTCCTCCGTTTTC 
Rgs4 CTGAAGTCGGAATACAGCGAGG CTGGTGCAAGAGTCCAGGTTCA 
Rgs9 TACGGCGATCAGTCCAAGGTCA CTGCATCCAGTACATAGCGGTG 
Rnf152 AGATGAGGACCAGCCAGAAGGA GTGTGGTATGGCAATGACTGCC 
Rpl13a CCTGCTGCTCTCAAGGTTGTT TGGTTGTCACTGCCTGGTACTT 
Rpp25 TCCACGACAACTTGGCTACCAG CTTAGCGGTGCCTTCTTCAGCA 
Ruvbl2 GGATACCAAGCAGATTCTGCGC GTGATGAGCTGGATGGCATAGC 
Scfd2          CTTCCTGGCATTTGAAAGGCTCC GTTGAGGTCGTCACTGGTTCTC 
Scn3A TCCGAGCCTTATCCCGCTTTGA GAAGATGAGGCACACCAGTAGC 
Sdha CTTGAATGAGGCTGACTGTG ATCACATAAGCTGGTCCTGT 
Serpina3N CAACCAGAGACCCTGAGGAAGT AGGACATCCTCCAGGCTGTAGT 
Sfrp5 GAGATGCTGCACTGCCACAAGT TGCTCCATCTCACACTGGGCAC 
Slitrk6 GCTTCACTTGGGAAACAACCGC TGTGGAGACCAAGGAACATGCC 
Smco3 GACGGAGAAGATTGCCATCGTG TGCCAGTTGTGACACTTGAGCC 
Smg1 CTGCTCAGGTTGCTAGTGAAGC CGCACATACACTTCAGGGTGGT 
Srf          CTCACCTACCAGGTGTCGGAAT CTGCTGACTTGCATGGTGGTAG 
St8Sia6 CATGAGCTACGAGGTGGAAAGC GGATAGTCCACAAAAGGCTGCG 
Stk32B TGTTCAAGGTGGAGCGTGTCCA GGTAGGTCATGCTCTGGATGTC 
Svep1 CCAGATGGTTGGGAATCCTGTG GGCTGAGTAGAAGCCATTCTCC 
Syt16 AGTGACTCTGGTTCTGGAGCCA GAGACAGTGACTGCGTGGATGA 
Tmie CCAAGGAGACTGTGGTGTTCTG ATACCGAGCCTCGATCTCCTTC 
Ubc AGCCCAGTGTTACCACCAAG ACCCAAGAACAAGCACAAGG 
Usp1          AGTAGCGTCACACCTGTGGACA GCTTTCACATTCCAAACACCGAG 
Usp12         AACAGCACACCAGACCCAACCT TGTTCCACGTCAACAGAAAGGTC 
Usp15          CAGATGGACACCTACGTTGCTG TCATCTGGCTCGTCGGTTTCCA 
Usp21          TCCTGAATGCCGTGCTACAGTG AGAGGGCACCAATCACATCTGC 
Usp33          AACAGCCAGGAGACCGTCAAAG GGCTTGCTGATAACCGTGGACT 
Usp46          CACAGCATTGCCACGCAGAAGA AACTCGTGAGCATCCTGCTGCA 
Vip GATGCCGTTTGAAGGAGCAGGT GAAGTCTGCTGTAATCGCTGGTG 
Vstm2L GACTGGACTGACAAGCAGACGT AGCTTGTGGGAGATGTTGCTGC 
Vwa5B2 CCCTGGAGTTTATGAGGTGGCA GGAAGTAAGCCTGTCCTCTGCT 
Wdfy1 AGAGTGCAGTCACTGTGCTACC CTGCTCACACTTCTGACAGGAG 
Yb1 CAGGAGAGCAAGGTAGACCAGT TGCTGACCTTGGGTCTCATCTC 
Znf477 TTCCACCAGAGGAGCCTGCTAT TACACAGGAGGCAGCGGTAAGA 
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V.2.2.4 RNA Sequencing
RNA samples were prepared in the lab from cerebellum of 3 week old mice. After brain dissection, 
cerebellar tissue was used for RNA extraction using TRIzol/chloroform during homogenation of the 
fatty brain tissue. Subsequently, the Aurum Total RNA mini Kit (Bio-Rad) was used according to the 
manufacturer’s protocol. RNA dissolved in elution buffer was checked for quality and concentration, 
frozen to -80°C and shipped to the VIB Nucleomics Core (VIB, Belgium) for RNA sequencing by Next 
Generation Sequencing (NGS) technology, i.e. massive parallel sequencing using Illumina Truseq 
procedures on an Illumina Hi-Seq apparatus. Two experiments were run at different time points and 
an internal control was included in the second experiment to normalize and allow merging of the 
results with the first experiment. Samples were analyzed for purity and integrity and then used for 
the experiments. An Illumina system was used for the sequencing. (More info can be found at the 
company web site http://www.illumina.com/techniques/sequencing.html). To assess the accuracy of 
a sequencing platform, the Phred quality score (Q score) to accuracy was used. A value of Q has to 
be equal or higher than 20 to be used for next generation sequencing experiments. The relative A, C, 
G, T content has been checked and Diversity in Read Quality calculated by the ShortRead 1.20.0 
package from Bioconductor (http://www.bioconductor.org). Different controls were performed by 
the Nucleomics Core to confirm the efficiency of the samples to perform in the sequencing process. 
In the read pre-processing, the data were transferred in fastq-files and were first processed for 
technical artefacts: low quality ends (<Q20) were trimmed with FastX 0.0.13 
(http://hannonlab.cshl.edu/fastx_toolkit/index.html) and the reads that were shorter than 35 bp 
were excluded. Other reads were excluded after the cut of the adapter which are trimmed only at 
the end (at least 10 bp overlap and 90% match) with Cutadapt 1.2.13. PolyA-reads (more than 90% of 
the bases equal A), ambiguous reads (containing N), low quality reads (more than 50% of the bases < 
Q25) and artifact reads (all but 3 bases in the read equal one base type) were then filtered using 
FastX 0.0.13 and ShortRead 1.16.3. Extra contaminant was removed using Bowtie 2.1.0.  
The preprocessed data from the two experiments were aligned to the reference genome of Mus 
musculus (mus musculus GRCm38.73), for a total of 23 samples. The alignment to the reference 
genome was performed with Tophat v2.0.8b4. An extra filter for quality was added with Samtools 
0.1.19 able also to sort the reads from the alignment according to the chromosomes and to index 
the resulting bam-files.  
The annotation of genomic features required different steps: first, the unique transcript-related 
features associated with a gene were identified and selected from the Cufflinks v2.1.1 toolkit 
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resulting in gtf-format results5. Then the exon chains of transcripts of the same gene were merged 
with MergeBed from the Bedtools v2.17.0 toolkit6 for the identification.  Gffread from the Cufflinks 
v2.1.1 toolkit was used again this time to extract the genomic sequence of the identified transcripts: 
for each transcript the sequence length and percentage of G/C-content were described. The entire 
identified transcript group was compared with the reference transcripts. All the annotations were 
received in in gtf-format, fasta-format and tab-delimited text. 
Expression levels were defined by counting the reads that overlap specific genes in different steps. 
Htseq-count 0.5.4p3 was used to count the overlapping reads in the alignment and the results were 
merged with the reference gene annotation previously made. Genes with less than 1 counts-per-
million were excluded. Due to the relevance of the GC content in a sample, samples were normalized 
and corrected for this value using EDASeq package from Bioconductor7. Samples were normalized 
for library size and RNA composition as well in the same way. FPKM values are the rate of fragments 
per base multiplied by a number in proportion to the number of fragments sequenced ant is used to 
simplify the results. FPKM values were generated by dividing each normalized count by the total 
number of counts and then the scaled counts were divided for each gene by the gene length (in 
kbp). 
 ?????????????????????????
??????? ???????????????????????????????
Pcdh expression levels were tested in mice brain and in lung tissue. We performed qRT-PCR 
experiments for Pcdh1, Pcdh7, Pcdh9, Pcdh10, Pcdh11X, Pcdh18 and Pcdh19. Pcdh1 was highly 
expressed in lungs, together with Pcdh18. All Pcdhs were expressed in brain, as expected (Figure 77).  
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Figure 77 Pcdhs are expressed in mouse brain  
Each graph shows the expression of Pcdhs in relative quantities (Y axis). X axis shows the samples: brain on the 
right and lung on the left. 
 
V.2.3.2 Expression levels of the candidate ?Pcdh interactors 
Myc Target genes 
QRT-PCR experiments have been performed and repeated in different settings and samples to assess 
changes in RNA level of the candidate ?Pcdh interactors, in lysates of total brain tissue and/or 
cerebellum, from WT and Pcdh10 KO mice. Preliminary tests were conducted to optimize the 
experiments and select the most efficient primer pair to amplify each selected gene. Those first 
experiments, although only preliminary, already showed a tendency towards no or only little 
variation in expression levels in tissues with or without Pcdh10 (Figure 78). 
243 
 
 
Figure 78 qRT-PCR experiment in mouse brain for Pcdh10 and MAX related candidates  
qPCR Primer Pairs were designed for SYBR Green-based real-time qPCR. Total brain was used from 3 week old 
mice Pcdh10+/+, Pcdh10+/- and Pcdh10-/-. We used 1 mouse for each condition. The black bars show Pcdh10 
differential expression levels (in correspondence with the Pcdh10 genotypes of the mice analyzed, as indicated 
by +/+, +/- or -/-), the other bars represent expression levels of different genes in the brains of those mice. A 
differential expression level in function of the Pcdh10 genotypes was clear only for Mad4 and Mlx. 
 
Since many components of the MAX-MAD pathway were confirmed in a biochemical assay to be 
?Pcdh interactor candidates, expression level experiments were performed for an expanded list, 
including the MAX-MAD pathway genes and some Myc target genes. In 2008, Kim and colleagues 
identified over 1400 direct Myc target genes in HeLa cells and human primary fibroblasts, with 
different roles in cellular pathways and functions8. We selected a number of Myc target genes to 
form a list of candidates on the basis of two studies reporting genes to be involved in prostate and 
brain cancer9,10:  some were involved in cell cycle regulation such as CCNB1, CDC2L1 and CEB1, but 
also in transcription such as MNT and TIP48, and in DNA repair mechanisms (such as BRCA1, MSH2, 
YWHE)9. Finally, also direct MAD3 target genes with involvement in medulloblastoma were included 
in our selection, such as BMP3, FBL and SCFD210. 
The experiments were performed on RNA from total brain lysates from 3 week old mice, 3 wild type 
(+/+) and 3 homozygous (-/-) Pcdh10all mutant mice. Unfortunately, we could not confirm any up- or 
down-regulation.  
The same experiments but with an expanded list were performed on new RNA samples from 
cerebella lysates of 3 wild type (+/+), 4 homozygous (-/-) mutant Pcdh10all and 4 homozygous (-/-) 
mutant Pcdh10long mice. Results were analyzed with +QBase, represented via Graph-pad and 
shown in Figure 79, 80, 81. Only Ruvbl2 turned out to be downregulated, and this only in the 
Pcdh10long-/- mice samples (Figure 80).  
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Figure 79 PCDH10 mRNA expression levels in WT, PCDH10all KO mice and PCDH10long KO mice cerebellum 
Ns P value > 0.05, * P value ? 0.05, ** P value ? 0.01 
Figure 80 Ruvbl2 mRNA expression is downregulated in PCDH10long KO mouse cerebellum. 
Ns P value > 0.05, * P value ? 0.05, ** P value ? 0.01 
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Figure 81 mRNA expression levels of MYC-related genes in Pcdh10all and Pcdh10long KO mouse cerebellum. 
QRT-PCR analysis of cerebellum from Pcdh10all and Pcdh10long KO mice. None of the candidates showed 
differential expression compared with WT mice. X axis= samples, Y Axis= Normalized expression values 
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USPs related proteins 
Expression levels were investigated in 3 week old mouse cerebella. Ubiquitin-specific proteases 
(USPs) form a superfamily of deubiquitinating cysteine proteases and are responsible for the 
cleavage of ubiquitin molecules from proteins and other molecules11. Any change in their expression 
levels in cerebella with or without Pcdh10 could play a role in the homeostasis of the proteins. Since 
DUB inhibitors are considered as potential anti-cancer agents, we investigated whether Pcdh10 
levels are instrumental in the expression levels of USP proteins. QRT-PCR experiments were 
performed for USP1, USP12, USP15, USP21, USP33 and USP46 in the cerebella from 3 Pcdh10+/+all 
and 3 Pcdh10-/-all mice. We could not, however, show any difference in USP expression levels 
between the KO and the WT mice (not shown). 
FHL family members  
FHL1, FHL2 and FHL3 belong to the family of the ‘Four and a half LIM domain’ proteins. The 
expression levels of the three members of the family did not turn out to be influenced by the Pcdh10 
levels in mouse brain tissue (Figure 82). 
 
 
Other candidates 
The expression levels of a list of candidates have been checked, again without showing any 
difference between Pcdh10 KO and WT mice (examples shown in Figure 83). 
 
 
 
Figure 82 Expression levels of Fhl family members are not influenced by Pcdh10 
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V.2.3.3 Conclusions  
To investigate whether ?Pcdhs play a regulatory role in determining the expression level of the 
respective candidate interaction partners and related genes, qRT-PCR experiments were performed. 
Pcdh1, Pcdh7, Pcdh9, Pcdh10, Pcdh11X, Pcdh18 and Pcdh19 expression levels were first analyzed in 
brain and lungs of WT mice, and high expression was found in brain as expected.  Then, the gene 
expression levels of the different candidate interactors were investigated in total brain or 
cerebellum of WT, Pcdh10all KO and Pcdh10long KO mice. Deubiquitinating enzymes (DUBs) are 
proteases responsible for the cleavage of ubiquitin and are thus modulators of protein degradation. 
Considering their implication in the regulation of critical pathways such as DNA damage repair, gene 
transcription, cell cycle progression and apoptosis, the correlation of defective DUB expression with 
neurological disorders and cancer is not surprising. post-translational protein modifications(including 
phosphorylation and ubiquitination) are involved in cancer development, for example in breast 
cancer where such modifications are considered to be mediators of cancer signaling pathways12–20. 
USPs are a class of DUB proteins, which have been shown to play a role in regulated signaling 
pathways implicated in cancer: for example, USP15 has been found to be amplified in human breast 
cancer, ovarian and glioblastoma tumors and is an important regulator of cell cycle progression13. 
Therefore, we analyzed whether changes in the expression level of different members of the USP 
group can occur in mouse cerebellum as a function of Pcdh expression. Analysis of USP1, USP12, 
USP15, USP21, USP33, USP46 (all putative interaction partners of Pcdhs) were performed but 
showed no differences in expression in Pcdh10all KO or Pcdh10long KO mouse cerebellum in 
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Figure 83 mRNA expression level of Cul5 and Pdlim7 in Pcdh10all and Pcdh10long KO mice cerebellum 
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comparison with WT cerebellum. The gene expression of another candidate, CUL5, which is related 
to the ubiquitin system for protein degradation, was analyzed in the same experiment and did not 
show a significant difference between KO and WT cerebella either.  
PDLIM7 gene expression was studied as well: PDLIM7 is a member of the PDZ-LIM family and 
contains an N-terminal PDZ domain, three C-terminal LIM domains and a canonical PY (PPXY) motif. 
It is considered to be an adaptor to stabilize membrane-associated signaling complexes. The PDZ-
LIM family is involved in many biological functions such as cardiac and skeletal muscle development 
and maintenance, neuronal signaling, and tumor cell growth. PDLIM7 associates with actin filaments 
in fibroblasts via its PDZ domain. It has been shown to negatively regulate p53 through inhibition of 
MDM2 self-ubiquitination and has been shown to promote tumor cell survival in mice21. Evidence 
has been shown in different studies for the role of PDILM7 in cancer; for instance, its expression 
level is related to the survival rate of breast cancer patients22. Furthermore, PDLIM7 interacts with 
the receptor tyrosine kinase RET and is responsible for the activation of mitogenic signaling of Ret23. 
Since Ret binds to clustered Pcdhs in differentiated neuroblastoma cells and is required for 
stabilization and differentiation-induced phosphorylation of Pcdhs1124, PDLIM7 roles were 
investigated at different levels, including gene expression. QRT-PCR experiments, performed as 
previously explained, showed that Pcdh10 expression does not influence PDLM7 gene expression.  
Members of FHL family (FHL1, FHL2 and FHL3) are expressed in a cell- and tissue-specific manner 
and play flexible roles in different cellular systems: for instance, FHL proteins are involved in the 
regulation of cellular proliferation, differentiation, and adhesion/migration in different tissues and 
cell lines. Up- or down-regulation of FHL protein levels has been shown in a number of different 
kinds of cancer, indicating a role of the family in cancer-related pathways. For instance, FHL2, the 
better-studied member of the family, has been shown to induce EMT in colon cancer as it negatively 
regulates E-cadherin expression and hence also the formation of E-cadherin–?-catenin complexes25. 
The clinical relevance of the members of the family is apparent from the role that the members play 
in cancer but mechanisms that regulate those functions are still unclear. I investigated the gene 
expression levels of the FHL family with and without ablation of Pcdh10 and concluded that in 
cerebellum Pcdh10 does not play a role in regulation of the RNA levels of members of FHL2 family. 
Since most evidence for FHL-PCDH interactions has been found in relation to Pcdh11X/Y it would be 
interesting to investigate whether the silencing or the overexpression of Pcdh11X/Y can influence 
FHL family members at the RNA level. Studies in vivo have not been performed because of the 
difficulty in obtaining Pcdh11X KO mice (unpublished data by Dr. Uta Fuchs). 
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Expression of MAX-MAD pathway genes and some Myc target genes was studied as previously 
explained. The relevance of this pathway in cancer is nowadays obvious but all the related 
mechanisms behind this enormously branched influence in cancer are still not entirely clarified: MYC 
activation has been implicated in the pathogenesis of more than half types of human tumors; it is 
regulated at different levels but mostly via alterations in signaling pathways that induce or repress 
its transcription. On the other hand MYC inactivation has been shown to induce rapid apoptosis and 
also this function requires the binding to MAX. For instance, in lymphoma and in liver 
adenocarcinoma, MYC inactivation induces proliferative arrest, differentiation/senescence, and 
widespread apoptosis (reviewed in26). 
Gene expression experiments were performed to study the role of Pcdh10 in the regulation of RNA 
levels of members of the MAX-MAD pathways and Myc target genes. Preliminary tests showed an 
increase of the expression levels of MAD4 and MLX in total brain of Pcdh10all KO mice, but this 
could not be confirmed in cerebellum, where only RUVBL2 turned out to be influenced by the 
expression of Pcdh10. Reptin/RUVBL2 and the related protein Pontin/RUVBL1 belong to the AAA+ 
(ATPases Associated with various cellular Activities) family. They can heterodimerize and show 
ATPase and helicase activities. Myc binds specific sites in genomic DNA and induces histone 
acetylation and it has been shown to associates with TIP60 and recruits it to chromatin in vivo with 
four other components of the TIP60 histone acetyltransferase (HAT) complex: TRRAP, p400, RUVBL1 
and RUVBL227–30. RUVBL1/2 are involved in many important cellular processes, such as chromatin 
remodeling, transcription and mitosis, however, the mechanism mediating their function is still 
unclear. The both interact with ?-catenin and c-Myc. RuvBL1 is an essential mediator of c-Myc 
oncogenic transformation and the interaction between RUVBL1 and cMYC have been shown to 
influence important MYC functions. So far no functional role has been established for RUVBL2 in 
MYC functions. C-MYC recruits both RuvBL1 and RuvBL2 for transcriptional control of target genes 
critical for cell transformation.  
Upon Wnt signaling stimulation, the interaction of ?-catenin with RUVBL2 in the nucleus induces the 
transcription of a metastasis suppressor gene (KAL1). If RUVBL2 is sumoylated the transcription of 
KAL1 is inhibited leading to increased metastatic potential of the cell line. RT-PCR analysis performed 
on KAI1 mRNA using metastatic LNCap cells, showed that re-expression of RUVBL2 restores KAI1 
expression while downregulation persists in case of increased sumoylated Reptin/RUVBL2. RUVBL2 
interact also with ATF2, an important inhibitor of the cell cycle which induces apoptosis in response 
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to DNA damage. Both Reptin/RUVBL2 and Pontin/RUVBL1 expression has been found to be 
increased in a large number of cancer types showing their role in tumor biology. 
In our studies, performed in brain of WT, Pcdh10all KO and PCDH10long KO mice, RUVBL2 mRNA is 
downregulated in cerebrum of Pcdh10long KO mice indicating a role for the long isoform of Pcdh10 
in RUVBL2 expression. Pcdh10 is expected to function as a tumor suppressor gene and RUVBL2 
expression is found to be increased in a large number of cancers. A correlation between the known 
functions of the two candidates and the downregulation of RUVBL2 in absence of longPcdh10 
isoform is not clear. The delicate balance between opposite functions played by MYC might be 
relevant to understand the putative correlation between RUVBL2 and PCDHs. It would be interesting 
to investigate if the interactions between RUVBL2 and ?-catenin or c-MYC are influenced by PCDHs 
and if the mechanism correlates with the novel interaction partners from the MAX-MAD pathway. 
Studies of migration and proliferation might be use for this.  
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 ????????????????????
V.2.4.1 Report and raw data 
RNA samples were prepared in the lab and shipped to the Nucleomics Core facility in Leuven. Each 
sample was checked twice for quality and purity. The platform used was HiSeq (Illumina). The 
experiment included 17 samples in total (Table 22). The reference organism used was Mus musculus. 
From the preliminary tests, samples showed the required high quality. The mapping efficiency after 
the filtering of the mapped reads was higher than 97%.  
Table 22 Samples used for RNA Sequencing 
Samples were obtained from cerebellum of 3 weeks old Pcdh10KO and WT mice, specifically: 7 WT (3 males + 4 
females), 5 Pcdh10longKO (3 males + 2 females) and5 Pcdh10allKO (3 males + 2 females). Sex genotyping of 
mice was performed as previously described (MMRRC's genotyping protocol including Sry primers, 
www.mmrrc.org/strains/10318). 
 
 
 
 
To analyze expression levels a Relative log Expression (RLE) plot was generated using a normalized 
log2-scale count for each gene. The ratio between the expression level of a gene and the median 
Exp 1809 pcdh10_all_WTzaa1 WT MALE 
 pcdh10_long_KO_M8 LONG KO FEMALE 
 pcdh10_all_KO_a1 ALL KO MALE 
 Pcdh10_long_KO_I2.5 LONG KO MALE 
 Pcdh10_all_KO_zaa4 ALL KO MALE 
 Pcdh10_long_I13_WT WT FEMALE 
 Pcdh10_long_KO_M2 LONG KO FEMALE  
 Pcdh10_all_WT_a6 WT FEMALE 
 Pcdh10_long_WT_l1_3 WT FEMALE 
 Pcdh10_WT_zaa3 WT FEMALE 
 Pcdh10_all_KO_zaa6 ALL KO MALE 
Exp 1928 UFVR_07ZAA1C WT (CONTROL) MALE 
 UFVR_08ZAA5 WT MALE 
 UFVR_09I.2.6 LONG KO MALE 
 UFVR_10ZAA10 ALL KO FEMALE 
 UFVR_I1 3.9 ALL KO FEMALE 
 UFVR_12 I2.2 LONG KO MALE 
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expression of the same gene in every sample of the experiment was calculated. Only few genes are 
expected to have different expression levels, which is why, as expected, all the results are similar 
and in a range close to 0 after normalization. Computational analysis investigating the Spearman 
correlation and using normalized counts as expression levels produced a heat map of the correlation 
matrix (Figure 84).  
 
Figure 84 A heat map of the correlation matrix  
The columns and rows of the correlation matrix are reordered such that similar samples form clusters. The 
presence of clusters with a biological interpretation is an indication that normalization successfully removed 
technical artefacts. 
 
In the heat map, each row and column is associated with a sample and samples with a similar gene 
expression profile are located close to each other. Correlation between expression profiles is 
represented where rows and columns cross. This is shown on a color scale: red means high 
correlation, green means less correlation. The two repetitions of the WT.M sample (analyzed in both 
exp1809 and exp1928) cluster together: this indicates that the batch effect between the two 
experiments is probably negligible. This is further confirmed by the fact that samples from both 
experiments mix in the clustering as expected. Furthermore the heat map shows that samples from 
the same gender tend to cluster together. In the same way, samples from the same genotype cluster 
together. Anyway, clustering efforts are generally not perfect, but only show a tendency that 
samples from the same genotype or the same gender are more similar to each other. 
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In our investigation mouse gender was considered, and analysis of the results was conducted in 
gender-related groups. When we compared data from samples of different genders, we only found 
differences in gender-related genes as being highly significant.  
The results of the RNA sequencing were presented as raw data (before filtering and normalization) 
and as FPKM (fragments per kb of exon per million reads mapped), computed from filtered and 
normalized counts. Different analysis approaches were used to understand the meaning of the data. 
V.2.4.2 Pcdh10 exons in KO mice: validation of genotype in RNA Seq experiment 
The number of reads of each Pcdh10 exon in the RNA Seq experiment on Pcdh10allKO and 
Pcdh10longKO cerebella was analyzed as an extra control for the KO condition. Exon 1 (Figure 85) 
which contains the start codon was floxed in order to conditionally knockout all isoforms in 
Pcdh10allKO mice (see above). On the other hand, to preserve expression of the short isoform, 
exons 2 and 3 were floxed in Pcdh10longKO mice: this causes a frameshift in exons 4 and 5 resulting 
in expression of the short isoform only. As expected the number of reads for exon 1 demonstrated 
their absence in Pcdh10allKO mice and their conservation in Pcdh10longKO. 
 
Figure 85 Analysis of reads for exon 1 in Pcdh10all and Pcdh10long KO mouse cerebellum. 
Analysis of differential usage of exon 1 in PCDH10, by bam-files in IGV and visually comparing the coverage of 
the exons. As expected, Pcdh10allKO mice do not have reads for exon 1 (line 3) while the same exon is 
conserved in Pcdh10long KO mice 
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V.2.4.3 Software analyses
Data obtained from the sequencing were analyzed and studied for correlations, with Ingenuity® 
Pathway Analysis (IPA®) (http://www.ingenuity.com/) and MetaCore™ system 
(http://thomsonreuters.com/en/products-services/pharma-life-sciences/pharmaceutical-
research/metacore.html). Transcripts in cerebella from Pcdh10all KO mice didn’t show particularly 
significant differences to those of WT mice. Surprisingly, cerebellar transcripts of Pcdh10long KO 
mice showed many differences upon comparison to those of WT or Pcdh10all KO mice. 
Ingenuity® Pathway Analysis 
To start with, the eight first-ranked for differential expression transcripts (cut-off of data: FDR.tgw 
=0.05) in common for Pcdh10long KO compared withPcdh10all KO or WT were analyzed for 
molecular or functional relationships: RGAG4, POU4F1, SMCO3, MYOC, RGS10, RGS4, GM5148 and 
MGP. The complete list of transcripts that show a change in expression can be found in Table 23.  
Table 23 Complete list of the 27 transcripts found differentially expressed in Pcdh10long KO compared 
withPcdh10all KO or WT (Ingenuity® Systems, www.ingenuity.com) 
Gene.Name Description 
5330417C22Rik RIKEN cDNA 5330417C22 gene  
C130046K22Rik RIKEN cDNA C130046K22 gene  
Cartpt CART prepropeptide  
Dkk3 dickkopf homolog 3 (Xenopus laevis)  
Etv1 ets variant gene 1  
Exosc9 exosome component 9 
Galnt13 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13  
Gm11637 predicted gene 11637  
Gm5148 predicted gene 5148  
Gpr88 G-protein coupled receptor 88
Hoxb5 homeobox  
Htr3a 5-hydroxytryptamine (serotonin) receptor 3A
Kcnd2 potassium voltage-gated channel, Shal-related family, member 2  
Klhl14 kelch-like 14 
Mgp matrix Gla protein  
Myoc myocilin  
Ndn necdin  
Pou4f1 POU domain, class 4, transcription factor 1 
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Ralyl RALY RNA binding protein-like  
Rgag4 retrotransposon gag domain containing 4  
Rgs10 regulator of G-protein signaling 10 
Rgs4 regulator of G-protein signaling 4  
Rgs9 regulator of G-protein signaling 9  
Rnf152 ring finger protein 152  
Smco3 single-pass membrane protein with coiled-coil domains 3  
Svep1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1  
Zcwpw2 zinc finger, CW type with PWWP domain 2  
 
From the 27 candidates of the complete list we selected the 8 more convincing in terms of reads and 
consistency. IPA did not show any direct interaction between the proteins encoded by the genes of 
this shortlist. An extended analysis was then performed to find connections including intermediate 
elements. Results are shown in Figure 86: Myc, Ubc and Bcl6 appear to be linkage molecules of the 
Top list of the RNA Seq results. Pcdh1, 8 and 9 are known to be related to these groups of molecules. 
Nothing is known about the other members of the Pcdh family, including Pcdh10, which relates 
them to the network 
.  
Figure 86 Shortest pathway analysis of the eight first ranked genes differently expressed in the RNA Seq 
analysis  
Only one node was added by the program to analysis to investigate putative correlations between the 
proposed molecules (red). The pathway is shown considering the subcellular localization. (Ingenuity® Systems, 
www.ingenuity.com). Only the molecules which show an interaction are shown. 
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Next, we investigated the role of those 8 molecules and whether they are related to known specific 
functionIn Figures 87, 88, and 89, their connections to carcinoma, cell movement, and 
differentiation are shown. 
.
Figure 87 Correlation of ?Pcdh family members and up/down regulated molecules in Pcdh10long KO mouse 
cerebellum with carcinoma pathways.  
?Pcdh are proposed to be proto-oncogenes and tumor suppressor genes. The identification of a carcinoma 
related pathway might help to elucidate the mechanisms involved in tumor development and progression. 
(Ingenuity® Systems, www.ingenuity.com). In red: the molecules from the top 8 list; in blue: Pcdhs. 
Figure 88 Cell movement related pathways and correlation with ?Pcdhs and up/down regulated molecules in 
Pcdh10long KO mouse cerebellum (Ingenuity® Systems, www.ingenuity.com) 
In red: the molecules from the top 8 list; in blue: Pcdhs. 
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Figure 89??Pcdhs and “top 8 list” molecules and cell differentiation related pathways (Ingenuity® Systems, 
www.ingenuity.com) 
 
Because of our focus in cancer, we analyzed the carcinoma related connections in detail. PCDH10 
has been proposed to be a tumor suppressor gene for nasopharyngeal, esophageal, colorectal, 
breast, cervical, prostate and other carcinomas, showing frequent methylation of the PCDH10 
gene31–34. Furthermore, PCDH10 is involved in inhibition of proliferation, apoptosis induction, and 
repression of invasion35. The IPA analysis found correlations with carcinoma mostly for MGP (Matrix 
gla protein). Published real-time RT-PCR experiments relate this protein to different epithelial 
ovarian cancer (EOC) subtypes including mucinous ovarian carcinoma, clear-cell ovarian carcinoma 
and serous ovarian carcinoma in humans36, while microarray analysis has shown that an 
upregulation of MGP mRNA in carcinoma-associated fibroblasts is associated with oral squamous cell 
carcinoma in human37. MGP interacts with BCL6 (B-cell lymphoma 6), a nuclear phosphoprotein 
related to RGS4 and RGS10, which belongs to our shortlist. Furthermore, BCL6 has been shown to 
interact with PCDH9 in humans38. BCL6 plays a role in carcinoma: for example, downregulation of 
human BCL6 mRNA in breast tumors is associated with triple-negative breast cancer in females39, 
and somatic missense mutations of the BCL6 gene are associated with adenocarcinoma in human 
colon40. Additionally, PCDH9 is related to carcinoma itself. For example, it has been shown that a 
somatic mutation of the PCDH9 gene is associated with adenocarcinoma in human esophagus41 and 
the Catalogue Of Somatic Mutations In Cancer (COSMIC) reports an association for PCDH9 mutations 
258 
with adenocarcinoma in human cecum, in human colon and human esophagus. BCL6 interacts with 
UBC,42 which is an interaction partner of PCDH1 (our findings).  
IPA software was used to compare the RNA levels for cerebella from Pcdh10long KO and WT mice, 
Pcdh10long KO and WT+Pcdh10all KO mice. In the comparison between Pcdh10long KO and WT, the 
first 100 higher ranked genes were uploaded and filtered for significant number of reads: only 73 
genes were in the filtered list. 41 of these genes are associated with connective tissue development 
and function, embryonic development and organ development pathways, and 32 with cell 
morphology, cellular assembly and organization and cellular function and maintenance pathways. 
With respect to the main diseases and functions in which the members of the list can be involved, 
the analysis showed that 20 molecules are involved in neurological diseases, 15 in hereditary 
disorders and 8 in cancer. 17 molecules are related to cellular development and 9 to cellular growth 
and proliferation. Many of them are related to physiological system development in embryos and 
adults. The list of upstream regulators of the pathways includes ARID4B, HOXB3, HTT and REST. REST 
(RE1-silencing transcription factor) is a transcriptional repressor which binds neuron-restrictive 
silencer element (NRSE) and represses neuronal gene transcription in non-neuronal cells; it is related 
to 4 relevant molecules for our study and interacts with UBC (Figure 90, Figure91 and Table 24). 
Figure 90 REST and PCDHs 
(Ingenuity® Systems,
www.ingenuity.com) 
IPA analysis of the shortest link 
between REST and PCDHs. Dark 
molecules= putative candidates 
from our results POU4F1, VIP, 
CARTPT and STX1A. 
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Figure 91 REST interaction partners. Obtained with 
STRING. 
Input: REST; Restricts the expression of neuronal genes 
by associating with two distinct corepressors, mSin3 and 
CoREST, which in turn recruit histone deacetylase to the 
promoters of REST-regulated genes. Mediates repression 
by recruiting the BHC complex at RE1/NRSE sites which 
acts by deacetylating and demethylating specific sites on 
histones, thereby acting as a chromatin modifier 
(1097 aa). (Homo sapiens) 
 
 
 
 
Table 24 REST predicted functional partners obtained with STRING 
 RCOR1 REST corepressor 1; Essential component of the BHC complex, a corepressor complex that 
represses essential component of the BHC complex, a corepressor complex that represses 
transcription of neuron-specific genes in non-neuronal cells. The BHC complex is recruited at 
RE1/NRSE sites by REST and acts by deacetylating and demethylating specific sites on histones, 
thereby acting as a chromatin modifier. (482 aa) 
  
 UBC ubiquitin C (685 aa)   
 BTRC beta-transducin repeat containing E3 ubiquitin protein ligase; Substrate recognition component 
Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase 
complex which mediates the ubiquitination and subsequent proteasomal degradation of target 
proteins. Recognizes and binds to phosphorylated target proteins. SCF (BTRC) mediates the 
ubiquitination of CTNNB1 and participates in Wnt signaling. (605 aa) 
  
 FBXW11 F-box and WD repeat domain containing 11; Substrate recognition component of a SCF (SKP1-
CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and 
subsequent proteasomal degradation of target proteins. Probably recognizes and binds to 
phosphorylated target proteins. SCF (FBXW11) mediates the ubiquitination of phosphorylated 
CTNNB1 and participates in Wnt signaling. (542 aa) 
  
 HDAC1 histone deacetylase 1; Responsible for the deacetylation of lysine residues on the N-terminal part 
of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic 
repression and plays an important role in transcriptional regulation, cell cycle progression and 
developmental events. (482 aa) 
  
 BDNF brain-derived neurotrophic factor (329 aa)   
 SIN3A SIN3 transcription regulator homolog A (yeast); Acts as a transcriptional repressor. Corepressor for 
REST. Interacts with MXI1 to repress MYC responsive genes and antagonize MYC oncogenic 
activities. Also interacts with MXD1-MAX heterodimers to repress transcription by tethering SIN3A 
to DNA (1273 aa) 
  
 SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 
4 (1679 aa) 
  
 SIN3B SIN3 transcription regulator homolog B (yeast); Acts as a transcriptional repressor. Interacts with 
MXI1 to repress MYC responsive genes and antagonize MYC oncogenic activities. Interacts with 
MAD-MAX heterodimers by binding to MAD. The heterodimer then represses transcription by 
tethering SIN3B to DNA. (1162 aa) 
  
 EHMT2 euchromatic histone-lysine N-methyltransferase 2 (1210 aa)   
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The same procedure and parameters were applied to compare Pcdh10long KO and Pcdh10all KO 
mice. Notably, the results were similar to the ones for the comparison with the WT so a final analysis 
was performed with Pcdh10long KO vs. WT + Pcdh10all KO. 
For this final analysis the first 300 molecules were uploaded (cutoff of logRatio=1 and FDR=0.05). 
Five main associated network functions were identified by the analysis:  
? Behavior, Cell-To-Cell Signaling and Interaction, Molecular Transport; 50 molecules 
? Behavior, Endocrine System Disorders, Organismal Injury and Abnormalities; 30 molecules 
? Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry; 29 molecules 
? Neurological Disease, Organismal Injury and Abnormalities, Dermatological Diseases and 
Conditions; 25 molecules 
? Hereditary Disorder, Neurological Disease, Psychological Disorders; 25 molecules 
Concerning diseases and disorders, not surprisingly, the analysis showed high impact in 
Psychological Disorders (41 molecules) and Neurological Diseases (48 molecules). Besides this the 
most represented function is Cell-To-Cell Signaling and Interaction and many molecules turned out 
to be involved in Nervous System Development and Function. The top up- and down- regulated 
molecules are listed and described in Table 25 and Table 26. 
Table 25 Up- regulated and down-regulated molecule top list obtained with IPA analysis system and ranked 
according to the expression value  
Pcdh10long KO vs. WT + Pcdh10all KO mice. The top 300 molecules were analyzed (cutoff of logRatio=1 and 
FDR=0.05). 
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Table 26 Description of up- and down-regulated molecules, obtained via STRING. 
Molecule        Description   
 TGM5 transglutaminase 5; Catalyzes the cross-linking of proteins and the conjugation of 
polyamines to proteins. Contributes to the formation of the cornified cell envelope of 
keratinocytes (720 aa) 
 COMP cartilage oligomeric matrix protein; May play a role in the structural integrity of cartilage 
via its interaction with other extracellular matrix proteins such as the collagens and 
fibronectin. Can mediate the interaction of chondrocytes with the cartilage extracellular 
matrix through interaction with cell surface integrin receptors. Could play a role in the 
pathogenesis of osteoarthritis. Potent suppressor of apoptosis in both primary 
chondrocytes and transformed cells. Suppresses apoptosis by blocking the activation of 
caspase-3 and by inducing the IAP family of survival proteins. (757 aa) 
 HOXB5 homeobox B5; Sequence-specific transcription factor which is part of a developmental 
regulatory system that provides cells with specific positional identities on the anterior-
posterior axis (269 aa) 
 PRPH peripherin; Class-III neuronal intermediate filament protein (470 aa) 
 CRHBP corticotropin releasing hormone binding protein; Binds CRF and inactivates it. May 
prevent inappropriate pituitary-adrenal stimulation in pregnancy (322 aa) 
 GABRA6 gamma-aminobutyric acid (GABA) A receptor, alpha 6; GABA, the major inhibitory 
neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the 
GABA/benzodiazepine receptor and opening an integral chloride channel (453 aa) 
 FZD7 frizzled family receptor 7; Receptor for Wnt proteins. Most of frizzled receptors are 
coupled to the beta-catenin canonical signaling pathway, which leads to the activation of 
disheveled proteins, inhibition of GSK- 3 kinase, nuclear accumulation of beta-catenin 
and activation of Wnt target genes. A second signaling pathway involving PKC and 
calcium fluxes has been seen for some family members, but it is not yet clear if it 
represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC 
seems to be required for Wnt-mediated inactivation of GSK-3 kinase. (574 aa) 
 CARTPT CART prepropeptide; Satiety factor closely associated with the actions of leptin and 
neuropeptide y; this anorectic peptide inhibits both normal and starvation-induced 
feeding and completely blocks the feeding response induced by neuropeptide Y and 
regulated by leptin in the hypothalamus. It promotes neuronal development and survival 
in vitro (116 aa) 
 CHRNA5 cholinergic receptor, nicotinic, alpha 5 (neuronal); After binding acetylcholine, the AChR 
responds by an extensive change in conformation that affects all subunits and leads to 
opening of an ion-conducting channel across the plasma membrane (468 aa) 
 GPR88 G protein-coupled receptor 88; Orphan receptor (384 aa) 
 CERKL ceramide kinase-like (558 aa) 
 HTR3A 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic; This is one of the several 
different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that 
functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-
gated ion channel, which when activated causes fast, depolarizing responses in neurons. 
It is a cation-specific, but otherwise relatively nonselective, ion channel (516 aa) 
 VIP vasoactive intestinal peptide; VIP causes vasodilation, lowers arterial blood pressure, 
stimulates myocardial contractility, increases glycogenolysis and relaxes the smooth 
muscle of trachea, stomach and gall bladder (170 aa) 
 CNR1 cannabinoid receptor 1 (brain) (472 aa) 
 POU4F1 POU class 4 homeobox 1; Probable transcription factor which may play a role in the 
regulation of specific gene expression within a subset of neuronal lineages. May play a 
role in determining or maintaining the identities of a small subset of visual system 
neurons (419 aa) 
 ZCWPW2 zinc finger, CW type with PWWP domain 2 (356 aa) 
 QRFPR pyroglutamylated RFamide peptide receptor; Receptor for the orexigenic neuropeptide 
QRFP. The activity of this receptor is mediated by G proteins that modulate adenylate 
cyclase activity and intracellular calcium levels (431 aa) 
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In the list of upstream regulators, together with POU4F1 and HTT, which were already included in 
the list of down- regulated molecules, as expected, we notice the presence of REST.  CACNA1H, 
CARTPT, EPHA10, POU4F1, STX1A, TAC1 and VIP are the target molecules in our dataset for REST and 
CARTPT, GAL, GPR64, HOXB5, NECAB2, POU4F1, PRPH, TAC1 are the targets of POU4F1. When 
analyzed for function and disease, as expected and previously anticipated from the Pcdh10long KO 
and WT comparison, the main roles played by the bigger fraction of differentially expressed 
molecules are related to neurological disorders. A few examples are listed in Table 27. 
Table 27 Diseases and functional annotations related to differentially expressed molecules (Ingenuity® 
Systems, www.ingenuity.com) 
 
Category Diseases or Functions 
Annotation 
Molecules 
Behavior behavior 
 
ADRA1B,BCL11B,CARTPT,CELF6,CHRNA5,CRHBP,DRD2,DRD5,EPHB6,GAL,GFRA1,G
PR26,GRP,LRRC7,NPTX2,OPRK1,PAK6,PCDH8,PDE11A,PDYN,POU4F1,RGS9,RXRG,
SLC30A3,SLITRK6,SSTR2,STX1A,TAC1,TRHR,VGF,VIP 
Neurological 
Disease 
Movement Disorders ADRA1B,BASP1,BCL11B,BID,CACNA1H,CARTPT,CHRNA5,DKK3,DRD2,DRD5,GABRA
3,GABRG3,GPR83,GPR88,HTR3A,KCNA5,MAL2,MYH7,OPRK1,PDYN,PTPN5,RGS4,R
GS9,RXRG,SCN3A,SCN3B,SCN5A,SERPINA3,TAC1 
Molecular 
Transport 
transport of molecule BCL11B,CACNA1H,CARTPT,CDH23,CNGB1,CPNE6,DRD2,F2R,FABP5,FXYD7,GABRA
3,GAL,GFRA1,GRIP2,GRP,KCNA5,LIN7B,NNAT,PDYN,RSPO1,SCN3B,SCN5A,SLC30A
3,SSTR2,STX1A,TAC1,VIP 
Neurological 
Disease 
dyskinesia ADRA1B,BASP1,BCL11B,CHRNA5,DKK3,DRD2,DRD5,GABRA3,GABRG3,GPR83,GPR
88,HTR3A,KCNA5,MAL2,MYH7,OPRK1,PTPN5,RGS4,RGS9,RXRG,SCN3A,SCN3B,SC
N5A,SERPINA3,TAC1 
Psychological 
Disorders 
Huntington's Disease ADRA1B,BASP1,BCL11B,DKK3,DRD2,DRD5,GABRA3,GABRG3,GPR83,GPR88,HTR3
A,KCNA5,MAL2,MYH7,OPRK1,PTPN5,RGS4,RGS9,RXRG,SCN3A,SCN3B,SCN5A,SER
PINA3,TAC1 
Neurological 
Disease 
Huntington's Disease ADRA1B,BASP1,BCL11B,DKK3,DRD2,DRD5,GABRA3,GABRG3,GPR83,GPR88,HTR3
A,KCNA5,MAL2,MYH7,OPRK1,PTPN5,RGS4,RGS9,RXRG,SCN3A,SCN3B,SCN5A,SER
PINA3,TAC1 
Hereditary 
Disorder 
Huntington's Disease ADRA1B,BASP1,BCL11B,DKK3,DRD2,DRD5,GABRA3,GABRG3,GPR83,GPR88,HTR3
A,KCNA5,MAL2,MYH7,OPRK1,PTPN5,RGS4,RGS9,RXRG,SCN3A,SCN3B,SCN5A,SER
PINA3,TAC1 
Skeletal and 
Muscular Disorders 
Huntington's Disease ADRA1B,BASP1,BCL11B,DKK3,DRD2,DRD5,GABRA3,GABRG3,GPR83,GPR88,HTR3
A,KCNA5,MAL2,MYH7,OPRK1,PTPN5,RGS4,RGS9,RXRG,SCN3A,SCN3B,SCN5A,SER
PINA3,TAC1 
Psychological 
Disorders 
Mood Disorders ADRA1B,ANKRD6,CACNA1H,CARTPT,CHRNA5,CRHBP,DRD2,DRD5,GABRA3,GABR
G3,HTR3A,OPRK1,PDE11A,PDYN,RGS4,SCN3A,SCN3B,SCN5A,SLC30A3,STX1A,TAC
1,VGF 
Cell-To-Cell 
Signaling and 
Interaction 
neurotransmission CARTPT,CHRNA5,CNGB1,CNIH3,CPNE6,CRHBP,DRD2,DRD5,F2R,GABRA3,GAL,HTR
3A,OPRK1,PCDH8,RGS4,SCN5A,SSTR2,STX1A,SYT5 
Nervous System 
Development and 
Function 
neurotransmission CARTPT,CHRNA5,CNGB1,CNIH3,CPNE6,CRHBP,DRD2,DRD5,F2R,GABRA3,GAL,HTR
3A,OPRK1,PCDH8,RGS4,SCN5A,SSTR2,STX1A,SYT5 
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Psychological 
Disorders 
Schizophrenia ADRA1B,CACNA1H,CHRNA5,CRHBP,DRD2,DRD5,GABRA3,GABRG3,GFRA1,GRIP2,L
IN7B,OPRK1,PCDH8,RGS4,RXRG,SCN5A,STX1A,TAC1,VGF 
Neurological 
Disease 
Schizophrenia ADRA1B,CACNA1H,CHRNA5,CRHBP,DRD2,DRD5,GABRA3,GABRG3,GFRA1,GRIP2,L
IN7B,OPRK1,PCDH8,RGS4,RXRG,SCN5A,STX1A,TAC1,VGF 
Hereditary 
Disorder 
Schizophrenia ADRA1B,CACNA1H,CHRNA5,CRHBP,DRD2,DRD5,GABRA3,GABRG3,GFRA1,GRIP2,L
IN7B,OPRK1,PCDH8,RGS4,RXRG,SCN5A,STX1A,TAC1,VGF 
Cardiovascular 
Disease 
Heart Disease ADRA1B,CACNA1H,CHRNA5,DRD2,DRD5,F2R,GABRA3,GABRG3,KCNA5,MGP,MYH
7,OPRK1,PDE11A,RGS4,SCN3B,SCN5A,TAC1,TIMP2,VIP 
Cellular Function 
and Maintenance 
organization of 
cytoskeleton 
ADRA1B,BASP1,BCL11B,CACNA1H,DKK3,DRD2,F2R,GAL,GFRA1,GRP,IGSF9,LRRC7,
PAK6,POU4F1,PRPH,SLITRK6,TAC1,VGF,VIP 
Cellular Assembly 
and Organization 
organization of 
cytoskeleton 
ADRA1B,BASP1,BCL11B,CACNA1H,DKK3,DRD2,F2R,GAL,GFRA1,GRP,IGSF9,LRRC7,
PAK6,POU4F1,PRPH,SLITRK6,TAC1,VGF,VIP 
Neurological 
Disease 
seizure disorder ADRA1B,ANKRD6,BID,CACNA1H,CHRNA5,DRD2,GABRA3,GABRG3,GAL,GFRA1,NPT
X2,PDYN,RGS4,SCN3A,SCN3B,SCN5A,SSTR2,TAC1 
Molecular 
Transport 
concentration of lipid ADRA1B,BCL11B,BID,CARTPT,DKK3,DRD2,EPHB6,F2R,FABP5,GAL,GRP,OPRK1,RGS
4,RXRG,SSTR2,TAC1,VGF,VIP 
Small Molecule 
Biochemistry 
concentration of lipid ADRA1B,BCL11B,BID,CARTPT,DKK3,DRD2,EPHB6,F2R,FABP5,GAL,GRP,OPRK1,RGS
4,RXRG,SSTR2,TAC1,VGF,VIP 
Lipid Metabolism concentration of lipid ADRA1B,BCL11B,BID,CARTPT,DKK3,DRD2,EPHB6,F2R,FABP5,GAL,GRP,OPRK1,RGS
4,RXRG,SSTR2,TAC1,VGF,VIP 
Nervous System 
Development and 
Function 
morphology of nervous 
system 
BID,CDH23,CNGB1,CRTAC1,DRD2,GAL,GFRA1,HOXB5,KCNA5,LRRC7,NRARP,OTOF,
PAK6,POU4F1,RGS11,RXRG,SLITRK6,TAC1 
Cellular Function 
and Maintenance 
microtubule dynamics BASP1,BCL11B,CACNA1H,DKK3,DRD2,F2R,GAL,GFRA1,GRP,IGSF9,LRRC7,PAK6,PO
U4F1,PRPH,SLITRK6,TAC1,VGF,VIP 
Cellular Assembly 
and Organization 
microtubule dynamics BASP1,BCL11B,CACNA1H,DKK3,DRD2,F2R,GAL,GFRA1,GRP,IGSF9,LRRC7,PAK6,PO
U4F1,PRPH,SLITRK6,TAC1,VGF,VIP 
Metabolic Disease glucose metabolism 
disorder 
ADRA1B,CARTPT,CNGB1,CPNE4,DRD2,DRD5,FABP5,GABRA3,GABRG3,GAL,GRP,H
TR3A,PDE11A,PDYN,SCN5A,SERPINA3,SSTR2,VIP 
Neurological 
Disease 
seizures ANKRD6,BID,CACNA1H,CHRNA5,DRD2,GABRA3,GABRG3,GAL,GFRA1,NPTX2,PDYN
,RGS4,SCN3A,SCN3B,SCN5A,SSTR2,TAC1 
Nutritional Disease obesity ADRA1B,CACNA1H,CARTPT,DRD2,FABP5,GABRA3,GABRG3,GAL,HTR3A,PDE11A,R
XRG,SCN3A,SCN3B,SCN5A,SSTR2,TIMP2,VGF 
Psychological 
Disorders 
bipolar disorder ADRA1B,ANKRD6,CACNA1H,CRHBP,DRD2,DRD5,GABRA3,GABRG3,HTR3A,OPRK1,
PDYN,RGS4,SCN3A,SCN3B,SCN5A,VGF 
Neurological 
Disease 
bipolar disorder ADRA1B,ANKRD6,CACNA1H,CRHBP,DRD2,DRD5,GABRA3,GABRG3,HTR3A,OPRK1,
PDYN,RGS4,SCN3A,SCN3B,SCN5A,VGF 
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MetaCore™ Analysis 
The IPA system offered a lot of information but definitive conclusions could not be reached. The 
indications given form the analysis might be useful in the future when new discoveries and 
information can be integrated. The same data were also analyzed with the Metacore system which 
calculates p-values for networks generated by the algorithms. P-value calculations are based on 
hypergeometric distributions and are used to evaluate network’s relevance to Gene Ontology (GO) 
biological process classification.  
112 genes from the RNA sequencing experiment were analyzed. The analysis for canonical pathways 
offered a set of signaling and metabolic maps, which are created by Thomson Reuters scientists by a 
process based on published peer?reviewed literature (Figure 92).  
Figure 92 Significance of Pathway Maps.  
Sorting is done for the 'Statistically significant Maps'. (MetaCore™ Analysis, Thomson Reuters). 
The maps identified by the analysis mainly points to the nicotine signaling including different 
pathways. Nicotine works by the binding to nAChR receptor: in the brain this is responsible for the 
adaptation effect that occurs in response to chronic exposure. The main responsible of nicotine 
addiction is dopamine release. Dopamine binds to the receptor and activates a feedback loop 
regulation. DARPP-32, dopamine and cyclic AMP-regulated phospho-protein, is one of the key 
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players in the dopamine signaling: when phosphorylated in a specific threonine residues, it inhibits 
PPP1CA causing the inhibition of dopamine secretion. Recently several evidence (in vitro studies on 
cell cultures and in vivo studies on rodents ) indicate a role of nicotine in cancer development43,44. 
Data from the analysis are visualized in Figure 93 where different nicotine related signaling pathways 
are shown, including the nicotine signaling in cholinergic neurons which is indicated to be the most 
significant map from the analysis. Details of this pathway are shown in Figure 94. 
 
 
Figure 93 Nicotine signaling. General scheme 
Experimental data from all files is linked to and visualized on the maps as thermometer-like figures. Up-ward 
thermometers have red color and indicate upregulated signals and down-ward (blue) ones indicate 
downregulated expression levels of the genes. MetaCore™ Analysis, Thomson Reuters 
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Figure 94 The top scored map (map with the lowest p-value) based on the enrichment distribution sorted by 
'Statistically significant Maps' set.  
 Experimental data from all files is linked to and visualized on the maps as thermometer-like figures. Up-ward 
thermometers have red color and indicate upregulated signals and down-ward (blue) ones indicate 
downregulated expression levels of the genes. MetaCore™ Analysis, Thomson Reuters. 
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MetaCore use the Gene Ontology (GO) classification to investigate the functions of molecules of 
interest. The GO project aims to describe and correlate genes across different databases in 
association with biological processes, cellular components and molecular functions in a species-
independent manner (Figure 95).  
 
Figure 95 The significance of 
GO Processes associated 
with the network  
The GO Processes tab is used 
to see the top 10 functional 
processes associated with 
the network.  Sorting is done 
for 'Statistically significant 
Processes'. MetaCore™ 
Analysis, Thomson Reuters 
 
 
We analyzed the data using the Diseases tab function to identify the top 10 diseases associated with 
the network. The list includes bipolar disorders, affective disorders and psychotic ones, trigeminal 
neuralgia and nerve diseases and gastrointestinal related diseases (vomiting, constipation and 
digestive diseases). Three specific networks were proposed to be related to the obtained data. The 
gene list used as the input data generated a biological network using the Analyze Networks (AN) 
algorithm: the obtained networks were prioritized based on the number of fragments of canonical 
pathways on the network (details in Table 28). 
Table 28 MetaCore™ Analysis, Thomson Reuters
??? ????????????? ?????????? ????? ???????
1 Galpha(i)-specific peptide GPCRs, GRP, 
Galpha(q)-specific peptide GPCRs, 
Substance P, Thyroliberin 
cell surface receptor signaling pathway (89.1%), signal 
transduction (97.8%), response to organic cyclic 
compound (63.0%), response to oxygen-containing 
compound (69.6%), response to endogenous stimulus 
(69.6%) 
55 5 
2 Substance P extracellular region, CART, 
CREB1, Neurokinin-2 receptor, LRCH4 
behavior (61.2%), feeding behavior (40.8%), micturition 
(26.5%), behavioral response to nicotine (24.5%), 
regulation of amine transport (34.7%) 
50 12 
3 BHMT2, Guanine deaminase, DPY19L2, 
GRP, INDOL1 
synaptic transmission (58.0%), transmission of nerve 
impulse (58.0%), multicellular organismal signaling 
(58.0%), cell-cell signaling (58.0%), neuropeptide 
signaling pathway (28.0%) 
50 11 
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In summary, two analysis steps in MetaCore™ (Enrichment Analysis Workflow and Analyze Network) 
led us to the identification of processes which are differently regulated in the cerebellum of 
Pcdh10long KO mice. Enrichment analysis and network construction allowed us to evaluate 
statistically significant genes, which distinguish WT and KO brains. In addition, we examined the 
implicated disease pathways.  
V.2.4.4 QPCR experiments on RNA Seq results
QRT-PCR experiments were performed in cerebrum of WT, Pcdh10All KO and Pcdh10Long KO mice: 
molecules of interest were selected from the RNA Sequencing experiment and analysis. A list of 
about 67 genes was compiled. From the list of significant hits obtained by RNA Seq analysis, we 
selected candidates based on the ranking starting from the highest significance of differential 
expression. This list of selected transcripts is shown in Table 29. 
Table 29 List of genes analyzed on qRT-PCR experiments 
5330417C22Rik Ephb6 Myoc Rpp25 
Adcy1 Exosc9 Ndn Scn3a 
Basp1 F2r Nnat Sfrp5 
Bid Fndc9 Nov Slitrk6 
Cartpt Fxyd7 Nptx2 Smco3 
Cbln3 Galnt13 Nrip2 Smg1 
Cdh23 Gm5148 Otof St8sia6 
Cdon Gng4 Pdyn Stk32b 
Cerkl Gpr88 Pnck Svep1 
Cetn4 Il34 Pou4f1 Syt16 
Cst3 Kcna5 Ralyl Tmie 
Cul5 Klhl14 Rest Vip 
Cux1 Lhfpl5 Rgag4 Vstm2l 
Dact2 Lin7b Rgs10 Vwa5b2 
Dkk3 Ly6h Rgs4 Wdfy1 
Dos Mal2 Rgs9 Yb1 
Eed Mgp Rnf152 
In these experiments, as expected we could not identify statistically significant differences in the 
expression of the genes (except for Pcdh10) in total KO mice when compared with WT, while the 
knock out for the long isoform of Pcdh10 showed again some examples of up- and down-regulation 
when compared with Pcdh10KOall and WT mice, as summarized in Table 30. Graphpad software is 
here used to show the two most significant results as an example to highlight the following 
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conclusions: in accordance with the RNASeq data, WT brain and Pcdh10all KO brain do not show 
transcriptional differences, while Pcdh10long KO brain shows statistically significant (*/**) 
differences when compared with either WT or Pcdh10all KO brain (Figure 96).  In this experiment we 
obtained relative quantities of expression for three mice for each condition. 
 
Table 30 Up- and down-regulated molecules in Pcdh10Long KO mice in qRT-PCR experiments 
 
+ Ccnd Cyclin D1 
- Cetn4 Centrin 4 
- Dos Protein Dos 
- Epn Epyphycan 
- Exosc9 Exosome complex 9 
- Fas TNF Receptor Superfamily, Member 6 
- Gm5184 Pseudogene 
- Mgp Matrix Gla Protein 
- Pnck Pregnancy Up-Regulated Nonubiquitous CaM Kinase 
- Rgs4 Schizophrenia Disorder 9 
- St8sia6 ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-Sialyltransferase 6 
- Stk32b Serine/Threonine Kinase 32B 
- Syt16 Synaptotagmin XVI 
- Tmie Transmembrane Inner Ear Expressed Protein 
- Vip vasoactive intestinal polypeptide 
- Wdfy1 WD Repeat And FYVE Domain Containing 1 
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Figure 96 Examples of Downregulation in Pcdh10Long KO mice:  Exosc9 and Gm5182 analyzed with Graph 
Pad. 
Gm5184 is a mouse pseudogene otherwise not further described. Exosc9 encodes a component of the RNA 
exosome which is responsible for processing and degradation of RNA in the nucleus and cytoplasm.  
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V.2.4.5 Conclusions and discussion  
RNA-Seq experiments were performed to identify mRNA expression changes in the cerebellum of 
Pcdh10all KO mice and Pcdh10long KO mice in comparison with WT mice. Results of those 
experiments were not easy to interpret.  
Cerebellum from WT mice and from Pcdh10all KO mice did not show significant changes in mRNA 
expression when compared. Surprisingly the comparison of Pcdh10long KO mice with either WT or 
Pcdh10all KO mice resulted in a long list of up- and down- regulated transcripts. Quite a few of those 
differences seem to be significant, consistent and reproducible. IPA and Metacore analyses were 
used to analyze the results and to identify common pathways.  
WT vs Pcdh10long KO mice and Pcdh10all KO vs Pcdh10long KO mice analyses were performed, 
common differently expressed molecules were selected, and these were: Gm5148, Gpr88, Mgp, 
Myoc, Pou4f1, Rgag4 Rgs10 and Rgs4 mRNAs. Mgp is connected to Rgs4 and Rgs10 through Bcl6 
(Figure 97). Mgp and Bcl6 correlate with carcinoma in different studies. PCDH1 and PCDH9 interact 
or correlate with Bcl6. Is not clear how Pcdh10 can play a role in this context.  
In conclusion, we have shown that a complicated and difficult to explain change in RNA expression 
profile occurs in Pcdh10long KO mouse cerebella but not in Pcdh10allKO cerebella.  In Pcdh10long 
KO mice the long isoforms of Pcdh10 are deleted while the short one is conserved. The short isoform 
does not include the CMs.  
 
Figure 97 Connections between different expressed molecules indicated from RNA-Seq experiments and 
PCDHs. 
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To explain why the total KO mice show the same RNA expression profile as the WT mice, we 
speculate that other ?Pcdhs may compensate as they show redundant functions.  
QRT-PCR experiments were performed in total brain of Pcdh10allKO mice for ?Pcdh family members. 
Statistically significant upregulation was shown for Pcdh7, Pcdh8, Pcdh11, Pcdh17 and Pcdh18 
transcripts. When the same experiment was performed in brains of Pcdh10long KO mice, none of 
these ?Pcdh showed a change in mRNA expression level (I. Kahr, PhD thesis Ghent University). These 
results indicate that if Pcdh10 is lost in the very early stages of development, a compensation 
mechanism occurs based on upregulation of several other members of the protein family. In 
contrast, it seems that the preserved presence of the short isoform of Pcdh10 does not induce the 
upregulation of other Pcdhs upon ablation of the long Pcdh10 isoforms; apparently, the short 
isoform is then upregulated at the RNA level. Western blot analysis in brain lysates of heterozygous 
and homozygous Pcdh10long KO mice were carried out and as expected these revealed 
downregulation of long Pcdh10 isoforms in heterozygous mutant and complete absence of the long 
isoforms in the homozygous KO. Also at the protein level, homozygous Pcdh10long KO mice showed 
an upregulation of the short isoform. The total Pcdh10 expression level seemed to be similar to the 
level in the WT brain lysate. Intriguingly, in the RNA Seq analysis the upregulation of other Pcdhs in 
Pcdh10Long KO mice was not shown.  This discrepancy with the QRT-PCR data is puzzling. A possible 
although rather unlikely explanation might be that on the one hand total brain including cerebellum 
and on the other hand cerebellum only was used for these two different experiments. It could 
therefore be interesting to perform extra RNA Seq analyses on total-brain lysate to address this 
discrepancy. 
 ?????????????????????????
Considering the nature of the identified interaction candidates (mostly transcription factors) and of 
PCDHs (transmembrane proteins) we considered the possible localization of the interaction: can 
PCDHs migrate to the nucleus?  
Since the localization of a protein is closely related to the specific function of the same protein, many 
different ways to predict a protein's subcellular localization have been developed. Here we show the 
results of  8 different computational approaches to study the possibility of PCDH nuclear localization: 
CELLO2.5,45,46 Multiloc,47 PSORTII (http://psort.hgc.jp/form2.html), WoLF PSORT,48 Hum-mPLoc,49 
NLStradamus,50 SCLpred51 and BaCelLO52. PCDH sequence was analyzed as full protein, cytoplasmic 
domain (CD) only or extracellular domain (EC) only, with the aim of identifying the presence of a 
nuclear localization signal (NLS). An NLS is a sequence which allows the translocation of the protein 
(or part of it) to the nucleus. The so-called classical nuclear import pathway is the best described 
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mechanism of transport of protein between cytoplasm and nucleus53,54. As shown in Figure 98, 
PCDH11X particularly shows the signs of an NLS in its CDs.  
 
Figure 98 PCDHs showing an NLS, required for nuclear translocation.  
8 computational approaches were used to investigate the possibility of nuclear localization for PCDH family 
members. 
 
Since the separated PCDHs’ cytoplasmic domain could display nuclear localization we speculated 
that these TM proteins could be subject to cleavage phenomena. Some studies have shown that 
Pcdhs are indeed involved in nuclear signaling. For example, Xenopus Pcdh7/NF-Pcdh interacts with 
chromatin, as well as with TAF1/set, but this last interaction appears to occur in the cytoplasm55. 
Clustered PCDHs have been shown to be cleaved by ? secretase in order to produce fragments which 
can transport information to the nucleus, mostly during development56. Further experiments need 
to be done to investigate the cleavage occurrence in ?PCDHs and to identify the localization of the 
interactions with the candidates. For instance, a strong transcription activator such as VP16 could be 
used, fused to the full length PCDH protein, to show if events of specific cleavage occur indeed in the 
CD. 
V.3 USP Family Experiments   
USP proteins and CUL5 are involved in the proteasome mediated degradation of ubiquitinated 
proteins. The presence of certain candidates in the list of confirmed interactors for PCDHs required 
further analysis to study the role of the interaction in the process. We performed different tests to 
study the possible roles of the interactions.  
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 ?????????????? ????????????
Ubiquitination assays were performed in HEK293T cells. On day 1 cells were seeded: 2 400 000 
HEK293T cells mid-petri dish and transfected after 24h with CaP transfection method as previously 
described (with 2??g of total DNA). The day after cells were first washed with PBS and then were 
incubated over night with MG132 (proteasomal inhibitor, 1/4000) + chloroquine (lysosomal 
inhibitor, 1/2000) in OPTIMEM medium. The day after cells were washed with PBS, lysed in 250ul 2% 
SDS gel laemmli buffer (2% SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 8) with 2mM sodium 
orthovanadate, 50 mM sodium fluoride, NEM and protease inhibitors and sonicated (20 cycles, 10’’ 
on, 5’’ off)  using the Bioruptor Plus (Diagenode). After boiling for 10’, 30 ?l are kept aside for total 
lysate, 2250?l of dilution buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton) were 
added to the rest. After 1h incubation and 30’ of centrifugation, samples were divided concerning 
the experimental plan and incubated with ab anti-GFP and beads or anti-flag beads. 
Immunoprecipitation was performed with Dynabeads as previously described. Elution was done in 
2X laemmli buffer and samples were boiled 10’ before being loaded on SDS-PAGE. 
For Lysosome & Proteasome Inhibitor assay 200 000 HEK293T cells were seeded in 12 well plates, 
transfected, washed, incubate overnight with MG132 OR chloroquine, lysate and sonicated as for 
ubiquitination assay.  After boiling, cell lysates were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes (Amersham Biosciences). Blotting efficiency was checked by Ponceau S 
staining (Sigma). Blots were blocked in StartingBlock blocking buffer (Pierce), when using Odyssey 
infrared imaging (LICOR) or in 5% milk upon enhanced chemiluminescence (ECL) detection. ?-actin, 
HA-tagged, Flag-tagged and E-tagged proteins were revealed using a rabbit or mouse anti-?-actin 
(1:5000, Sigma), monoclonal rat anti-HA (3F10) (1:5000, Roche), rabbit anti-Flag (1:5000, Sigma) and 
mouse anti-E-tag (1:10000, Phadia) antibody, respectively, followed by an anti-rabbit or anti-mouse 
DyLight 800- or DyLight 680-conjugated antibody (1:15000, Pierce) or an anti-rat Alexa Fluor 680-
conjugated antibody (1:5000, Molecular Probes), diluted in Odyssey blocking buffer (Li-Cor) + 0.1% 
Tween-20. Rabbit anti-RNF41 A300-048A (1:20000, Bethyl) or rabbit anti-ASB6 HPA004341 (1:200, 
Sigma) were revealed by SuperSignal West Pico Chemiluminescent Substrate (Pierce) using 
peroxidase-conjugated anti-rabbit antibodies (1:5000, Jackson ImmunoResearch). 
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 ?????????????
There is no current evidence of the regulation of PCDHs via ubiquitination so first PCDH 
ubiquitination was checked.  PCDH10, PCDH11x, PCDH7 and PCDH1 were transiently transfected in 
HEK293T cells. To be able to detect the ubiquitination as a smear in the gel, it is necessary to 
counteract protein degradation by adding MG132 (proteasomal inhibitor) and chloroquine 
(lysosomal inhibitor). IP experiments were performed as previously described. Results are shown in 
Figure 99. 
 
 
Figure 99 PCDHs appear to be ubiquitinated 
In presence of proteasomal and lysosomal inhibitors, different PCDHs show that they undergo an ubiquitination 
process as evidenced by the smear in presence of ubiquitin (+) pMet7-sol Il5R is used as control plasmid. GFP 
antibody has been used to pull down EYFP tagged PCDHs. Antibody anti HA has been used in the Western Blot.  
 
To investigate the role of different USPs on the ubiquitination level, the same experiment was 
performed including USP8, USP21 or USP46. Preliminary data show that the tested USPs do not 
interfere with the ubiquitination of PCDHs (not shown). Extra experiments with a larger panel of 
USPs are required to confirm this indication.   
We performed experiments to analyze the stability of PCDHs and to see if the interaction with USPs 
could interfere with it. The experiment was performed for PCDH10 and PCD11X with and without 
USPs at 6 different time points from 0 to 46 hours. In the first 16 hours PCDHs are stable, and then 
the expression is reduced.  We could define a time point of approximately 20 hours where the 
protein starts to be degraded but this can be due to cellular stress after an extended time post-
transfection (Figure 100).  
0 M    
1(C) pMet7-sol IL-5R   
2 PCDH10-EYFP pMet7-sol IL-5R  
3 PCDH10-EYFP pMet7-sol IL-5R pcDNA3-HA-ubiquitin 
4 PCDH11X-EYFP pMet7-sol IL-5R  
5 PCDH11X-EYFP pMet7-sol IL-5R pcDNA3-HA-ubiquitin 
6 PCDH1-EYFP pMet7-sol IL-5R  
7 PCDH1-EYFP pMet7-sol IL-5R pcDNA3-HA-ubiquitin 
8 PCDH7-EYFP pMet7-sol IL-5R  
9 PCDH7-EYFP pMet7-sol IL-5R pcDNA3-HA-ubiquitin 
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Figure 100 PCDHs show a half-life of about 
20 hours 
Protein stability experiments for PCDH10, 
PCDH11X and PCDH9 at 7 different time 
points. Experiments were performed in 
transiently transfected HEK293T cells. 
Incubation with Chloroquine (lysosomal 
inhibitor, 1/2000). 
 
 
 
 
 
We performed the same experiment for the first 16 hours to study the role of USPs in the protein 
degradation. As shown in Figure 101, USP8 and USP21 do not interfere with the process.  This 
preliminary experiment will need to be performed again at a bigger scale including different USPs, 
extra time points (i.e. 20, 36 and 42 hours) and extra positive and loading controls.  
 
   
Figure 101 USPs do not interfere with PCDH stability  
Experiments were performed in transiently transfected 
HEK293T cells. Incubation with Chloroquine (lysosomal 
inhibitor, 1/2000) : first line T0,0h; second line T1,8; third 
line T2,16h. 404= pMet-sol IL-5R, C= control transfection 
with 404. 
 
 
 
 
 
In conclusion, different PCDHs seem to undergo ubiquitination but we could not show any role 
played by different USP proteins in the process. More experiments are needed to confirm this 
indication. A more complete panel of USPs should be used, perhaps in the inducible FlpIn Trex HEK 
293T PCDHs stable cell lines.  
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V.4 MAX-MAD pathway  
MAX functions as the center of a transcription factor network that includes the MYC family of 
oncoproteins and the tumor suppressor MAD family. To study the interplay between PCDHs and Myc 
pathway we used a Cignal Lenti Myc reporter assay. Cignal Lenti Myc reporter kit (SA Biosciences) is 
designed to monitor the activity of Myc-regulated signal transduction pathways in cultured cells. The 
reporter kit consists of a Myc-responsive firefly luciferase construct and a construct constitutively 
expressing Renilla luciferase. 
Following the manual guidelines, experiments were performed on inducible HEK293T Flp In TRex 
PCDH10 EYFP and HEK293T Flp In Trex PCD11X-EYFP cell lines. Induced and not induced cells were 
transfected with the reporter construct or with controls. The negative control is a mixture of a not 
inducible reporter construct, which encodes firefly luciferase under the control of a basal promoter 
element (TATA box) and constitutively expressing Renilla luciferase construct. This was used to 
measure the reporter background. The positive control was as well taken from the kit and is a 
constitutively expressing GFP construct together with a constitutively expressing firefly luciferase 
construct and a constitutively expressing Renilla luciferase construct. This is a control for successful 
transfection. The Cignal reporter is again a mixture, but this time of an inducible transcription factor 
responsive construct and the constitutively expressing Renilla luciferase construct. This experiment 
was rather preliminary as it was performed only in duplicate for each condition, and replicated only 
once. However, the same result was obtained twice: about no signal of Myc activity for any 
condition and, consequently, no difference could be demonstrated under the influence of PCDHs.  
 
Figure 102 PCDH10 and PCD11X do not interfere with Myc activity in a reporter assay.  
Experiments showed that the Myc activity was not regulated by PCDH10 or PCDH11X in a Myc 
reporter assay (Figure 102). The same set up could be used to repeat the experiment after Myc 
pathway activation, for example by doxorubicin. Furthermore it might be interesting to investigate 
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the endogenous effects of Pcdh loss on MYC signaling. Pcdh10 KO mice (or cells from there mice) or 
siRNA against PCDH11 might be use for the purpose. For instance, myc signaling is required for some 
forms of p53-dependent apoptosis. Specific tests might elucidate the role of this mechanism: if 
PCDHs activate Myc, apoptosis might increase while If PCDH inactivates MYC, cells may become 
more resistant to apoptosis. Since Myc is related to many pathways, different studies can still be 
performed. 
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V.5 Migration proliferation and adhesion  
 ??????????????????
Morphogenetic processes are the foundations of organs and tissue formation during the embryonic 
development phases and they occur due to the ability of the cells to recognize each other and build 
stable interactions with other cells and with the extracellular matrix. Generally, in health and 
disease, these processes, including migration, proliferation and adhesion play important roles for 
physiologic development and in occurrence and progression of diseases. Due to the presence of EC 
domains, the first identified function of the ?PCDHs subfamily was cell-cell adhesion. On the other 
hand, considering that the unique intracellular domain of ?PCDHs lacks the catenin-interacting 
motifs which are playing a role in the adhesion function in classical cadherins, this ability has been 
shown to be weak. Furthermore, some regions of the cytoplasmic domain of ?2PCDHS even show 
adhesion suppressing functions: for instance, in a fibroblastic cell line, the expression of a mutated 
PCDH19, which lacks part of the CD results in larger cell aggregates when compared with full-length 
PCDH19 expressing cells57. More recently, a similar behavior has been shown for PCDH17 if 
expressed in a mutated form in neurons: the lack of the CD induces lateral clumping of axons in 
embryonic brain58. Recent studies have shown that ?PCDHs can promote focal cell motility58–62, while 
in zebrafish Pcdh18 has been shown to play a role in the reduction of cell migration, maybe due to 
an enhanced cell adhesion activity63. To understand how ?PCDHs can play a role in cell motility, 
different studies have been performed and some hypotheses have been formulated but the exact 
mechanism is still to be clarified. ?2PCDHs bind different components of the WASP family verprolin-
homologous protein (WAVE) complex57,58,60,61. This binding occurs via a specific motif, called WIRF 
and being present in the CD of ?2PCDHs64. The WAVE protein is part of a WAVE receptor complex 
(WRC) formed by Sra1/Cyfip1 (or the orthologue PIR121/Cyfip2), Nap1/Hem2/Kette (or the 
orthologue Hem1), Abi2 (or the orthologues Abi1 and Abi3), HSPC300/Brick1, and WAVE1/SCAR (or 
the orthologues WAVE2 and WAVE3)65: this complex is responsible for strong actin nucleating 
activity. Different mechanisms are involved, showing on the one hand the influence of the activation 
of Arp2/3 (actin-related protein 2/3)66 or, on the other hand, the role of Abi proteins67 which allow 
the binding with lamellipodin (Lpd), a known interaction partner of actin polymerization regulators 
such as Ena/VASP family proteins. Hayashi and colleagues recently have shown that if the WAVE 
complex binds Pcdh17, regulation of actin dynamics occurs preferably via the interaction with 
lamellipodin and Ena/VASP family proteins58. In the same study they have shown that in confluent 
U251 cells the expression of PCDH17, but also of PCDH10, increases the migration of single cells. 
Those observations brought the authors to the conclusion that Pcdh17 recruits the WAVE-complex, 
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Lpd and Ena/VASP at cell-cell contact sites and in this way plays a role in the motility of the 
membrane and thereby promotes cell migration59. 
Interestingly, some of the interaction partners that we identified for different members of the 
?PCDH family have been shown to play a role in the same mechanisms, such as growth and 
migration. For example, as it is known and already mentioned, the MAX-MAD pathway is responsible 
for a delicate balance of the oncogene Myc: while the dimers Myc-Max are involved in cell 
proliferation and oncogenesis due to their transcription activation function, the Max-Mad dimers act 
as transcriptional repressor: hence, Mad and Myc are in competition for the binding of Max and the 
result of the switch from Myc–Max to Mad–Max dimers is a decrease in cell growth and 
proliferation. In this way the members of the Mad family can inhibit cellular growth and 
transformation and work as antagonists of the activity of Myc. For example, a role of MAD1 has 
been shown in suspended or semi solid cultures of the human macrophage cell line U-937: 
compared to non-expressing MAD1 cells, the sample showed a reduced, almost completely inhibited 
proliferation, suggesting a role of MAD1 in growth and proliferation of U-937 human monoblast68.  
Concerning another protein family identified as likely interaction partners of ?PCDHs, the FHL family, 
it is known that the proteins of this group play a role in a large number of cellular processes and they 
take part to the regulation of cell growth, adhesion and migration69–75. Furthermore, members of the 
FHL family have been shown to participate in carcinogenesis and to facilitate the association of 
proteins with the actin cytoskeleton in the cytoplasm. FHL2 plays a shown role in proliferation but its 
activity is intriguing since it can have both a positive and a negative effect on cell cycle related 
processes, depending on the tissues analyzed76. Furthermore as already presented in Chapter IV, our 
experiments indicates actin related protein as potential interaction partners of PCDHs and member 
of the WRC complex have been already shown to interact with different PCHDs. This class of 
partners is implicated in cell movement, above all for the role played in the axonal cones and it 
became of major interest for growth and migration studies. 
Given the nature of the identified candidates and based on published data on PCDHs and/or the 
selected partners, we decided to investigate PCDH dependent effects on cell migration, cell growth 
and cell adhesion with the final aim of investigating quantitatively the role played by the different 
novel interactions in various cell properties. We explored functional effects of increasing the level of 
PCDH10 or PCDH11x in a number of cell-based assays in order to establish a workflow to test the 
effect of the identified candidate interactors on different PCDHs. The cell-based assay provided a set 
of tools to address in the future the effect of disturbing the interactions between PCDHs and a 
selected partner by downregulating this partner by siRNA. 
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V.5.2.1 Methodology 
V.5.2.1.1 Cells 
HEK293T cell lines expressing EYFP-tagged PCDH10, PCDH11X and PCDH11Y upon doxycycline 
addition were generated (HEK293T-FlpInTRex PCDH 10-EYPF, HEK293T-FlpInTRex PCDH 11X-EYPF) 
using the Flp-In™ TRex™ System (Life Technologies) (Figure 103). Briefly, the Flp-inTM TRexTM 
HEK293T host cell line by Invitrogen was used to directly generate Flp-In™ TRex™ expression cell 
lines. The host cell line has been co-transfected with pcDNA™5/FRT/TO and pOG44 Flp recombinase 
expression. In this way the gene of interest included in the expression vector is integrated in a Flp 
recombinase-dependent manner into the genome. pcDNA™5/FRT/TO is a inducible expression 
vector from Invitrogen and it contains an hybrid human cytomegalovirus (CMV)/TetO2 promoter, a 
FLP Recombination Target (FRT) site and a Hygromycin resistance gene. These cells were grown in 
DMEM growth medium supplemented with Glutamax I (Invitrogen) and 10 % fetal bovine serum 
(FBS, HyClone) at 37°C in 5% CO2. Doxycycline (Sigma) was added to 2?g/ml, 48 h before start of a 
functional assay. Where indicated, epidermal growth factor (EGF, Invitrogen) was added to 5 nM. 
HeLa cells stably expressing either PCDH10 tagged to far-red fluorescent protein mKate2, or only 
mKate2 (control) were grown under the same conditions. These stable cell lines were established by 
Irene Kahr: HEK293T cells were transiently co-transfected with the pLenti6 (puro)-PCDH10-EYFP 
construct and packaging plasmids pMD.G and pCMV Delta R8.9 in order to produce the requested 
lentivirus. The viral supernatant was collected after 48 h, filtered (0.45?m filter by Millipore) and 
added to HeLa cells. 1 ?g/ml Puromycin (Sigma) was added after 48 h for selection. Un-transduced 
control cultures were used as control: the complete eradication of those supported the 100% 
transduction of the surviving cells of transduced population. 
 
  
282 
Figure 103 The Flp-In™ Systemg 
It is used for generating stable mammalian expression cell lines by Flp recombinase-mediated integration while 
the T-Rex systemh is a Tetracycline-Regulated Expression system for mammalian cells: The Flp-inTM T-RexTM 
System merges the properties and the protocols of the Flp-In and the T-Rex Systems to obtain a host cell line 
which contains a single FRT site (introduced by transfection of the pFRT/lacZeo plasmid) and expresses the Tet 
repressor (introduced by transfection of the pcDNA6/TR plasmid). 
g Briefly, a Flp In target site vector, pFRT/lacZeo, is used to create the host cell line. An SV40 early promoter controls the 
expression of the fusion gene which is included in the vector, together with a FRT site (as binding and cleavage site for the 
Flp recombinase) just after its start codon; mammalian cells transfected with the vector can then be first selected for 
ZeocinTM resistance and then screened for those containing only one integrated FRT site. Once this host cell line is 
isolated, it can be co-transfected with an expression vector, pcDNATM5/FRT in which we cloned the gene of interest and 
which carries an FRT site linked to a (defective) hygromycin resistance gene, and with pOG44, a plasmid which 
constitutively expresses the Flp recombinase. The introduction of the expression vector at the FRT site activates a range of 
events which ends with the foundation of stable Flp-In™ expression, cell lines, which can be selected for hygromycin 
resistance, Zeocin™ sensitivity, lack of ?-galactosidase activity, and construction of the recombinant protein of interest 
h The main component of the system is an inducible expression plasmid, in which the gene of interest is cloned in the 
multiple cloning site and whose expression is regulated by the strong CMV promoter. Two copies of the Tet operating 2 
(TetO2) sequence have been inserted in the promoter as a binding site for the Tet repressor. The other component of the 
system is the pcDNA™6/TR regulatory vector which expresses high levels of the Tet repressor (TetR) gene under the control 
of the human CMV promoter. Both plasmids are transfected into mammalian cells with a standard method of choice. 
In non-induced condition, the transcription of the gene of interest is repressed by the high affinity binding of the repressor 
to the TetO2 region of the promoter. If tetracycline is added a change of conformation on the homodimers which the 
repressor form to bind the promoter occurs, with consequent dissociation from it. This allows the initiation of transcription 
of the factor of interest. (More details can be found on the company website: http://www.lifetechnologies.com). 
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V.5.2.1.2 Cell exclusion zone migration assay and data analysis 
The experimental set-up is shown in Figure 104. A 96-well plate (NUNC; Thermo Fisher Scientific) 
were coated with monomeric rat tail collagen type I (BD Biosciences) by incubating for 1 h at room 
temperature with 100 ?l of 40?g/ml collagen in Ca2+ and Mg2+ containing Dulbecco’s Phosphate-
Buffered Saline (D-PBS; Gibco). Fifty-five thousand cells were seeded per well in growth medium in 
presence or absence of doxycycline and a cell-free area was simultaneously generated in the middle 
of the well according to the ORIS cell invasion protocol (ORISTM; Plathypus Technologies). We note 
that the reproducibility of the onset of migration is strongly dependent on the level of confluency at 
start. After 16 h at 37°C and 5% CO2 allowing cell adhesion and spreading, the insert and medium 
was removed and replaced by 200 ?l medium containing doxycycline, 1 or 10 % FBS and, where 
indicated, EGF. For each condition, x-10 replicates (wells) were performed. Subsequently, the cells 
were allowed to migrate into the cell-free central zone for the indicated time. Phase-contrast time-
lapse movies were recorded with a time interval of 20 min using a 10 x UPlanFL objective (N.A. 0.30) 
on a CellM live cell imaging system with temperature and CO2-control and an IX81 microscope 
(Olympus). Image and data analysis were done using CELLMIA, image processing software developed 
in the group Van Troys/Ampe (UGent, Faculty of Medicine, Dep. Biochemistry) that quantifies the 
area covered by the cells in time77, and using the data management and analysis software, 
CellMissy78. The latter derives the median velocity of the cells using linear regression of the area over 
time curves and statistically compares the different conditions using pair wise non-parametric tests 
(Wilcoxon) with Benjamin-Hochberg correction for multiple testing.    
 
Figure 104 Migration assay work flow. 
Migration of cells seeded as a confluent layer is followed in the central cell free zone in time followed by image 
and data processing. The velocity of the cell layer (median of velocity in replicates) is based on the evolution of 
the cell covered area in time. 4-6 conditions are tested in parallel with 10 replicates per condition. 
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V.5.2.1.3 Cell proliferation assay 
HEK293T-FlpInTRex PCDH 10-EYFP, HEK293T-FlpInTRex PCDH 11x-EYFP cells were either pre-treated 
with doxycycline (induction of expression of the fusion protein) or not (control) and seeded at 4500 
per well in a 96-wells tissue culture plate (6 replicates per condition per plate, number of plates 
equals number of time points) that was coated with monomeric collagen type I as described above. 
After overnight incubation, one plate (T0) was treated according to the procedure described in Cell 
Proliferation Kit II (Roche).  This assay is based on the cleavage of the tetrazolium salt XTT (2, 3-Bis-
(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt) in the presence of an 
electron-coupling reagent, producing a soluble formazan salt (Figure 105). Mitochondrial enzymes 
are inactivated shortly after cell death: only living mitochondria can reduce the XTT. 
The cells were incubated with the XTT labelling mixture for four hours and formazan production was 
quantitated using a scanning multi-well spectrophotometer (450 nm). The absorbance directly 
correlates to the number of viable, metabolically active cells. The measurement was repeated at 
different time points TX (e.g. T48). The ratio’s Tx/T0 (e.g. T48/T0) is indicative of cell growth. The 
different time points or conditions were statistically compared using a t-test. 
Figure 105 Cleavage of the tetrazolium salt XTT  
The tetrazolium salt of XTT (2, 3-Bis-(2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide salt) is 
an inner salt, that is cleaved to formazan by the succinate dehydrogenase system of the mitochondrial 
respiratory chain. The dehydrogenase is still active only in cells with an intact mitochondrial and cell 
membrane. In the shown example phenazine methosulfate (PMS) is the electron coupling agent which is 
necessary as an intermediate electron acceptor during the reaction. (Modified from 
https://www.applichem.com/literatur/applications/nr-12-zellproliferations-assay-xtt/)  
V.5.2.1.4 Cell adhesion assay 
Cell adhesion kinetics are measured in real time on the iCelligence instrument (ACEA, 
http://www.aceabio.com) (Figure 106), based on impedance when the cells adhere to and spread on 
the gold coating of the E-Plate L8 (ACEA) in normal growth medium. The wells were coated with 
collagen (10 ?g/ml) as described by the E-Plate manual (ACEA). HEK293T-FlpInTRex PCDH10-EYFP, 
HEK293T-FlpInTRex PCDH11X-EYFP cells that were pre-treated for 48 h with doxycycline or not 
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(control), were added at 20000 cells to the wells and measurement (every minute) is immediately 
started for up to 8 hours (four replicates/condition). Adhesion and spreading is mainly occurring in 
the first two hours. The assay is sensitive to small differences in the number of cells added at start, 
and thus to differences in cell number between the populations that are compared. Currently cell 
counting is done repeatedly in both concentrated and diluted cell suspensions to reduce errors in 
counting. 
The assay system expresses impedance in arbitrary Cell Index (CI) units (Rn-Rb)/4.6; where Rn is the 
cell-electrode impedance of the well when it contains cells and Rb is the background impedance of 
the well with the media alone, and the constant 4.6 is related to the voltage used. From average CI 
versus time (T, in minutes), curves ?CI/?T were determined for the time intervals indicated. 
 
Figure 106 iCELLigence principle 
 The system is based on 3 components: an electronic analyzer inside the cell culture incubator, an iPad able to 
run the needed software and electronic plates called E plates L8 with microelectrodes. The status of the cells is 
reflected by the changes on the electrical impedance, defined as the opposition of a system to the current if a 
voltage is applied: in presence of cells the electrode impedance is increased. The quantity of cells that interact 
and the kind of this interaction to the electrode influence the level of impedance. (http://www.aceabio.com) 
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V.5.2.2 Results
V.5.2.2.1 Properties of cell models used to investigate functional effects of PCDHs expression 
We established four stable cell lines expressing, respectively, EYFP tagged PCDH11X, PCDH11Y, or 
PCDH10 and also a mock cell line expressing EYFP alone. We used the Doxycycline-inducible Flp-inTM 
T-RexTM HEK293T cell line (Life Technologies) to generate these stable cell lines because it allows
single copy integration of the gene target. The Flp-inTM T-RexTM host cell line contains a single FRT
site and expresses the Tet repressor. More details about the Flp-In and the T-rex Systems can be
found in the methodology section.  As a result, the Flp-In™ T-Rex™ expression cell lines should
exhibit the following phenotype: hygromycin resistance, zeocin™ sensitivity, lack of ß-galactosidase
activity, blasticidin resistance and tetracycline-regulated expression of the gene of interest.
Foremost, the constructs were produced by cloning into the pcDNATM5/FRT plasmid different full-
length PCDH cDNAs, each time fused in frame to EYFP: PCDH11X-EYFP, PCDH11Y-EYFP, and PCDH10-
EYFP. Moreover, one construct contained EYFP alone (mock control). Each construct encodes also a
hygromycin resistance gene for selection of positive transfectants. After successful Flp-mediated
single copy integration, expression could be induced by Doxycycline. The stable cell line for
PCDH11X-EYFP and the mock cell line were the first ones to be established and the expression was
checked with and without induction (Figure 107 and Figure 108).
PCDH10 was expressed as well as a EYFP fusion protein in the Flp-In TRex HEK293T cells but also in 
non- inducible HeLa cells (Figure 109). The PCDH10-EYFP stable cell line was used to confirm the 
results obtained using the Flp-In TRex HEK293T PCDH10-EYFP cell line. After preliminary tests we 
decided to use only Flp-In TRex HEK293T PCDH10-EYFP and Flp-In TRex HEK293T PCDH11X-EYFP 
(with and without DOX) because of a stronger expression level.  
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Figure 107 Tetracycline inducible cell lines.  
Two cell lines expressing either EYFP alone (mock 
control, top panel) or PCDH11X-EYFP (lower panel) 
after induction by doxycycline, a clear plasma 
membrane staining can be observed for PCDH11X, 
whereas the mock control shows cytoplasmic staining 
(Uta Brunner, unpublished data).  
 
 
 
 
 
 
    Flp-In-TRex Hek293T PCDH11Y-YFP 
 
 Figure 108 Tetracycline inducible cell lines.  
Stable cell line expressing PCDH11Y-EYFP with or 
without induction by Doxycycline (36 h). Compared with 
the stable cell line for PCDH11X we obtained a very low 
expression level, despite correct protein localization. 
 
 
 
 
Figure 109 PCDH10-EYFP expressing stable cell lines 
A) HEK293T stably expressing PCDH10-EYFP. Before 
fixations cells were induced with Doxycycline for 24h 
(+Dox) or left untreated (-Dox). PCDH10 was observed 
at the plasma membrane. B) HeLa cells stably 
expressing PCDH10-EYFP generated with lentiviral 
transduction. PCDH 10 was enriched at cell-cell 
contacts and filopodia protrusions ( I.Kahr, personal 
communication)  
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V.5.2.2.2 Effect of PCDH expression on cell migration velocity 
In a 2D-cell exclusion zone assay77,79 and using time lapse microscopy, we compared the migration 
kinetics of the stable HEK293T-FlpInTRex cell line in which PCDH10-EYFP expression was induced 
using a 48 h doxycycline treatment, to that of uninduced cells, used as control. Figure 110A shows 
the extent of migration at selected time points based on the phase contrast images (top and middle 
panels) and also demonstrates the expression level of the fluorescent fusion protein in the induced 
cell population (Figure 110A, bottom panels). The evolution of the area covered by the confluent cell 
layer in time, as it migrates in the central free zone in normal growth medium (10% FBS), is plotted 
for both conditions in Figure 110B. The cells with PCDH10 migrated slightly, but significantly faster 
than the control cells (p<0.001, Figure 110C). The median migration velocity is derived from the 
slope of the linear part of the curve (0-25h). In these cells, the positive effect of PCDH10 was not 
observed from the in conditions in which the migration velocity is inherently lower: lower serum 
condition (1% FBS) or 1%FBS in combination with 5nM EGF.  
Based on the same assay, we showed that cells of a HeLa-derived cell line stably expressing a 
PCDH10-mKate2 fusion protein, also migrate significantly faster than cells of a control cell line 
(expressing only mKate2), both in 10 % serum and in 1% serum, 5nM EGF (Figure 111).  
A stable HEK293T-FlpInTRex cell line, in which PCDH11X-EYFP is induced by doxycycline treatment, 
was also tested. In contrast to the effect of PCDH10 described above, a change in migration 
properties was not observed for cells expressing PCDH11x at any of the tested conditions (Figure 
112). This may indicate specific differences between the two family members; however, we need to 
consider that the PCDH11X expression level seems to be lower than PCDH10 and this may also 
contribute to this difference. Further analyses are required. 
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Figure 110 Effect of PCDH10-EYFP expression on migration of inducible FlpIn-TRex HEK293T stable cell line.  
A. Images selected from time lapse sequence without (top) or with (middle) expression of PCDH10. The arrows 
indicate the direction of migration of the confluent cell layer in the central cell free zone; the dotted line 
delineates the cell layer and the cell-free zone. Bottom and middle panels: corresponding phase contrast and 
EYFP images. B. Mean cell covered area in time for control cells (9 replicate samples) and PCDH 10 cells (10 
replicates) in 10% FBS containing medium; error bars are SEM. C Mean velocity derived from plots as in B for 
control and PCDH10 cells tested under different conditions. Error bar is SEM, ***: p<0.01; n, number of 
replicates within experiment.   
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Figure 111 Effect of PCDH-10-MKate2 expression on migration of stable HeLa cell line.  
Mean cell velocity derived covered area in time for control cells (mKate2) and PCDH 10-mKate2 cells under 
different conditions; error bars are SEM. ***: p<0.01; n number of replicates within experiment.   
Figure 112 Effect of PCDH-11x-EYFP  expression on migration of inducible HEK-FlpIn-TRex stable cell line. 
A. Mean cell covered area in time for control cells (8 replicate samples) and PCDH 11x cells (7 replicates) in 
10% FBS containing medium; error bars are SEM. B. Mean velocity derived from plots as in B for control and 
PCDH 11x cells tested under different conditions. Error bar is SEM, n number of replicates within experiment.
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V.5.2.2.3 Effect of PCDH expression on cell growth 
The proliferation of the HEK293T-FlpInTRex cell lines with induced expression of either EYFP-tagged 
PCDH10 or PCDH11X was compared to that of the respective non-induced cells. Cell number was 
scored based on the level of metabolic activity (using XTT- proliferation assay producing a soluble 
colored formazan80 (see methods).  Beforehand, the linearity of the readout was tested in absence 
and presence of doxycycline by measuring formazan-based absorption for a cell number range of 
750-40000 cells per well (Figure 113A). The effect of different PCDHs expression on cell growth was 
measured (using a starting cell number of 4500 cells/well) at time zero and at three later time points 
with a maximum of 2.5 days (60h). The signal at each time point versus that at time zero is indicative 
of the fold change in proliferation under the different conditions. We note that at 60 h the signal 
slightly exceeded the maximal signal in Figure 113A suggesting the signal ratios at this time point 
could be an underestimation.  
 
Figure 113 Effect of PCDH10 or PCDH11X-EYFP expression on proliferation of inducible HEK293t stable cell 
lines using XTT-assay. 
 A. Linear response of signal for the cell number range 0-40.000 in absence or presence of doxycycline (dox). B, 
C. (left) Blanc corrected average absorption (A) ratio versus time zero (T0) at the time points indicated. (right) 
Average proliferation fold for the cells expressing PCDH10 (B) or PCDH11x (C) versus control cells (i.e. the 
corresponding cells without doxycycline treatment). In C, the control condition is set to 1 for each time point. 
Error bars are SEM; n=6; *, **, *** p < 0.1, 0.05 and 0.01 respectively. 
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Figure 113B shows that the signal ratio (left) at the different time points of the HEK293T-FlpInTRex 
PCDH10-EYFP cells and the corresponding fold change in proliferation (with ratio of control cells set 
to 1, right panel) are not significantly different from that of the control, at least at the induced level 
of PCDH10 and within the tested time period. In contrast, the presence of PCDH11X-EYFP, at the 
induced level, altered the ratio of the measured absorption values (left panel) and thus reduced the 
fold change of proliferation of the HEK293Tcells (right panel, control cells set to 1) by ~ 30 % after 48 
h to~50% at 60 h (Figure 113C) This effect on cell growth needs to be confirmed by repeating the 
current experiments and by using a complementary proliferation assay. 
V.5.2.2.4 Effect of expression of different PCDHs on cell adhesion on collagen 
Cells display integrin-dependent attachment to and spreading on the extracellular matrix protein 
collagen. We used the an impedance-based real-time cell analysis system (iCELLigence), which allows 
for label-free, dynamic monitoring of these cellular properties81. As described in the methods 
section, the impedance is expressed as Cell Index and the change in impedance ?CI in a given time 
interval ?T is used to compare adhesion and spreading kinetics between conditions. 
We compared the adhesion and spreading kinetics of HEK293T-FlpInTRex cells without or with 
induced expression of either EYFP-tagged PCDH10 or PCDH11X. As for the effects on migration and 
proliferation, the observed effect after induction is also determined by the level of expression of 
each PCDH. 
The comparison between the four conditions was independently performed three times up till now. 
Within each experiment, we evaluated the difference between the –Dox and + Dox condition. 
Interpretation across experiments was hampered by the fact the rate in CI increase and the plateau 
CI-value varies between biological replicates.  We here present data of one experiment (Figure 114). 
This shows no effect of PCDH10 expression (at the induced level) and a faster and/or more extensive 
spreading of the cells expressing PCDH11X at the induced level. This was consistent over two and 
three biological replicate experiments for PCDH10 and PCDH 11x, respectively. We note, however, 
that the differences induced by PCDH expression at the tested expression level are relatively small. 
Figure 114A, B shows the kinetics (CI versus time); Figure 114C, D the adhesion-spreading rates in 
different time intervals: 10- 30 minutes; 30-60 and 10-60 minutes. For the cells expressing PCDH11X 
the increased rate is mainly apparent early, in the first time interval. Additional experiments, 
preferably using imaging, need to confirm this and determine to which extend the cells already start 
spreading in this time interval.   
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Figure 114 Effect of PCDH10-EYFP or PCDH11X-EYFP expression on adhesion and spreading kinetics of 
inducible HEK-FlpIn-TRex stable cell lines. 
A, B. Real time monitoring of the impedance (expressed as cell index) increase upon attachment of a same 
amount of cells on the well surface of E8-plates for uninduced (control) and doxycycline-induced cells. Error is 
SEM, n=4 per condition. The time intervals used for graphs in C, D are indicated. At time 0, before the addition 
of cells, the signal in all cells is set to zero. The data shown are from one experiment and the observed relative 
effect was also observed in two and three independent experiments (out of three performed) for PCDH 10 and 
11x, respectively.  C, D Change of cell index CI in the indicated time intervals for the tested conditions. Error is 
SD, n=4. Note the increase in adhesion-spreading rate in the 10-30 minute interval for the protocadherin 11x 
expressing cells compared to control cells (D). C, D are based on the data of the experiment shown in A, B. 
 
V.5.2.3 Conclusions 
We explored cellular effects of expressing either PCDH10 or PCDH11X at a given level in a set of 
stable and/or inducible cell lines. The major goal was not so much to compare the differential effect 
of the different PCDHs but to establish in vitro cell based assays in which the PCDH10 or PCDH11X 
expression results in an effect that can be used in subsequent assays to test the effect of interactions 
with the candidate molecular partners that we identified.  
In summary we demonstrated that PCDH10 expressing cells displayed a moderate increase in cell 
migration speed on a 2D collagen-coated surface, but no effect on cell proliferation and no 
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consistent effect on the rate of cell attachment or spreading on collagen type I. We noted that the 
positive effect on cell migration speed was observed both in the inducible PCDH10-expressing 
HEKk293T cell line and in the stably transfected HeLa cell line. The PCDH11X expressing HEK293T 
cells displayed no significant effect on migration speed. However, the presence of PCDH11X 
significantly induced slower growth in vitro and seemed to induce the cells to attach more efficiently 
to and/or spread more quickly on a collagen coated surface. The effect of PCDH10 on cell migration 
and of PCDH11X on other characteristics are substantial and open possibilities to use these cell 
based effects for functionally validating a number of the partners identified previously using 
interactomics.  
Upregulation observed in cell migration in presence of PCDH10 is in contrast with the tumor 
suppressor role proposed for PCDH10 but can correlate with the recruitment of NAP1 to the cell 
membrane by interaction of PCDH10 and the WAVE complex (see below). 
For further investigations on migration, proliferation and adhesion using the assay we established 
will be important to consider the effect in different cell lines and to compare normalized expression 
level values in transiently and stable transfected cells.  
 ? ????????????????????? ?????????????
Actin polymerization is responsible for the movement of the cells and is regulated by nucleation 
promoting factors such as WASP, WAVE and Ena/VASP. Different ?PCDHs have been shown to play a 
role in the regulation of this delicate pathway by interacting with proteins of the complex. To 
elucidate better the mechanisms exploited by Pcdhs, we performed binary MAPPIT experiments on 
candidate PCDH interactors, previously indicated by Array MAPPIT. The results obtained could 
confirm some of these candidates. So, KLF4 (Kruppel-like factor 4) was identified as a confirmed 
interaction partner for PCDH9 and PCDH19, and ARL13B as an interaction partner for PCDH11Y, 
PCDH18 and PCDH19. KLF4 is a member of the KLF family of transcription factors and regulates 
proliferation, differentiation, apoptosis and somatic cell reprogramming. Interaction between PCDHs 
and NAP1 is indirect and cannot be shown with MAPPIT. As previously explained, Sra1 and Abi2 form 
an interface where PCDHs can bind in the WRC and the interaction cause the formation of the penta 
complex. This makes this interaction not suitable for this technique. It has been shown that (in 
apparent contradiction with its suggested tumor suppressor activity) PCDH10 enhances cell 
migration in astrocytoma cell lines as they recruit the WAVE complex from the lamellipodia to cell-
cell contacts. This may alter the F-actin organization leading to N-cadherin redistribution. In this way, 
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N-cadherin loses its ability to induce contact inhibition,  resulting in an uncooperative, accelerated 
cell movement60. Recently, a BioID experiment (unpublished data of van Roy’s lab) identified some 
of my MAPPIT hits as proximity partners for PCDH10: BAIAP2 (candidate interactor of PCDH9 and 
PCDH11X), CORO1B (candidate interactor of PCDH11X), DPYSL5 (candidate interactor of PCDH9), 
SH3D19 (candidate interactor of PCDH9) and TTLL1 (candidate interactor of PCDH11X). 
Our experiments have shown that PCDH10 expressing HEK293 and HeLa cells display a moderate 
increase in cell migration speed. Currently, plasmids encoding the candidate PCDH10 interactors 
identified by MAPPIT and BioID experiments are transfected in PCDH10 and PCDH11X expressing 
HEK293 cell line derivatives. These transfectants are then studied in migration experiments to 
elucidate if the interaction with PCDHs can influence the cell migration speed.  
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Protein-protein interactions are an essential part of most of biological processes and due to this 
relevance more and more methods to study them have been developed in the decades. Different 
methods offer different solutions: some can detect the interaction between two known proteins 
while others are suitable to identify a list of previously unknown interactors for a protein of interest. 
An overview of genetic and biochemical strategies is given in Chapter II of this thesis.  
The complete human proteome has been estimated to include about 400.000 protein-protein 
interactions (PPIs), indicating the complexity of this network; unravelling this complexity may 
provide answers to many unsolved questions in biology. The studies described in this Doctorate 
dissertation focused on ?-protocadherins (?Pcdhs), due to their relevance in many human biological 
events, both healthy and pathologic i.e. in many types of cancer1. Only a very limited number of 
studies describing ?Pcdhs interaction partners have been published to date. Protein phosphatase 1 ? 
(PP1???is a well-known interactor of the CM3 domain present in ??Pcdhs2. Moreover, different 
?Pcdhs have been observed to interact with the WASP-family verprolin homologous protein (WAVE) 
complex, confirming that these Pcdh family members share common binding mechanisms3,4. 
Furthermore, several studies have shown that ?Pcdhs can bind, directly or indirectly, to classical 
cadherins and influence their adhesive behaviour5–7.  
This dissertation investigates the ?Pcdh interactome and studies the modulation of ?Pcdh functions 
by the candidate interaction partners.   
In order to identify new intracellular interaction partners of the ?Pcdh family members, we carried 
out PPI screenings in yeast (yeast two-hybrid screen, Y2H) and in mammalian cells for different 
members of the family. We encountered limitations in the yeast system and in the first attempts to 
use a cDNA library screening on mammalian cells. We speculated that the Y2H screens failed 
because PCDHs and/or the prey clones were either unable to fold properly or were missing 
important post-translational modifications. For the MAPPIT (mammalian protein-protein interaction 
trap) cDNA library, limitations occurred because clones used in this technique may not represent the 
full length DNAs, causing incorrect folding, or because cDNA sub-domains might be cloned in the 
wrong frame. To overcome these limitations and provide a system closer to physiological conditions, 
the Array MAPPIT8 screening was developed and it was selected in this study as the most useful 
screening method for intracellular interaction partners of ?Pcdhs. Different elements in the Array 
MAPPIT procedure cooperate to create a near-optimal physiological context in which PCDHs and 
putative preys may interact, including: 
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? MAPPIT operates in mammalian cells 
? The PCDH cytoplasmic tail is fused to the C-terminus of a membrane receptor: the
interaction can occur in the natural cell compartment. 
? The physical separation of interactor and effector zone: the interactions occur at the
membrane, while the readout is in the nucleus. This avoids interference of the hybrid
proteins with the reporter activity. 
? An extra control is given by the signal being ligand-dependent. 
Taken together these characteristics indicate the Array MAPPIT a valid assay to identify interaction 
partners of PCDH family members. Nonetheless, some of our baits, especially PCDH10, showed a 
high background which makes the analysis less objective and precise than usual. A collection of 
10,000 open reading frames (ORFs) was used as a prey library to identify novel interaction partners. 
Confirmation using binary MAPPIT assays was performed with the aim to narrow down the long list 
of candidate interactors and to increase the stringency of the selection. In order to identify common 
intracellular binding partners among the ?Pcdhs tested we performed cross-tests. In this way, we 
obtained a priority list of candidate interactors, which needed independent confirmation. Next to 
MAPPIT-specified candidates, we considered other interaction candidates as suggested by literature 
studies. A priority list was made following an Ingenuity Pathway Analysis (IPA) to look for partners 
belonging to the same pathway, literature indications and our interest for specific or common 
cancer-related candidates. Our priority list for biochemical studies included myc-associated factor X 
(MAX), MAX dimerization protein 3 (MXD3) and MAX interactor 1 (MXI1), all three belonging to the 
same pathway; Cullin 5(CUL5), Four And A Half LIM Domains 3 (FHL3), PDZ And LIM Domain 7 
(Enigma, PDLIM7), Doublesex and mab-3 related transcription factor-like C 1 (DMRTC1) and tripartite 
motif-containing 23 (TRIM 23). Moreover, the MAPPIT data revealed other interesting candidates, 
including Proteasome 26S Subunit, ATPase 1 (PSMC1), ubiquitin-specific proteases (USP) family 
members and actin-related proteins.  
In this thesis we show that MAX interacts with PCDH1, PCDH7, PCDH9, PCDH10 and PCDH11X, while 
interaction with MXD3 could be confirmed in CoIP only for PCDH10. MAX is central in a transcription 
factor network that closely relates to the MYC family of oncoproteins and to a group of MYC 
antagonists (the MAD family). The MAD family has been demonstrated to have several different 
functions related to terminal differentiation, inhibition of cell cycle progression and tumor 
suppression9–19. We hypothesize that the interaction with PCDHs could boost the physiological 
functions of the MAD family components. To investigate this speculation in vitro, we performed a 
MYC reporter assay in HEK293T cells stably expressing PCDH10 or PCDH11X to monitor whether the 
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Myc-regulated signaling pathway activities in cells are influenced by the co-expression of PCDHs. The 
results, however, showed no differences between induced and non- induced HEK293T cells in case of 
expression of either PCDH. An interesting future follow-up experiment could involve a p53-
responsive construct in a similar set-up to test the effects of PCDH over-expression or silencing on 
the influence of Enigma/PDLIM7 in the context of the p53 pathway. Enigma/PDLIM7 is involved in 
neuronal signaling and tumor cell growth; it associates with actin filaments in fibroblasts via its PDZ 
domain and it has been shown to negatively regulate p53 through inhibition of MDM2 self-
ubiquitination20–22. The p53 protein has been shown to be destabilized by stress factors like DNA-
damaging agents (e.g., doxorubicin) due to a MDM2 binding-mediated degradation. The function of 
MDM2 is positively regulated by MDM4 (MDMX) and PDLIM7. Studies under doxorubicin treatment 
might lead to a better understanding of the mechanisms involved in the PDLIM7-dependent 
regulation of the p53 pathway. This evidence makes PDLIM7 an interesting candidate to understand 
PCDH functions. Finally, two more candidate interactors of PCDH10 and PCDH11X , FHL2 and FHL3, 
have also been shown to play a role in cancer as oncogenes and are involved in cell migration23–28. 
We were able to demonstrate that both PCDH10 and PCDH11X interact with FHL2. 
Migration, proliferation and adhesion are three critical mechanisms playing important roles in 
development and cancer. We established in vitro cell based assays in order to investigate the role of 
PCDHs, alone or influenced by the putative interaction partners identified in our study.  The effect of 
PCDH expression can be used in subsequent assays to investigate the roles played by the candidate 
molecular interaction partners identified in our experiments. A cell exclusion zone migration assay 
was established using inducible HEK293T cells expressing enhanced yellow fluorescent protein 
(EYFP)-tagged PCDH10 or PCD11x proteins. Our experiments show that PCDH10, but not PCDH11x, 
induces faster migration in HEK293T cells. We confirmed this observation in a PCDH10-EYFP 
expressing HeLa-derived cell line. Interestingly, this result is in apparent contrast with the tumor 
suppressor role proposed for PCDH10. PCDH10 has been shown to interact with the WAVE complex 
through a specific surface of the fully assembled wave regulatory complex (WRC), composed by 
Steroid Receptor RNA Activator 1 (SRA1) and Abl-Interactor 2 (ABI2)29. This interaction induces the 
recruitment of NAP1 at the membrane with alteration of F-actin organization and a N-cadherin 
redistribution. This results in an accelerated cell movement and can be an explanation for our 
observations. Both the HEK293T-FlpInTRex PCDH10-EYFP and the Hela-PCDH10-mKate2 cells express 
a long isoform of PCDH10. It might be interesting, in future experiments, to generate also similar cell 
lines expressing only the short isoform to investigate whether the latter plays a different role in the 
cells or has different interactions with specific candidates: an interaction partner influencing the 
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behavior of a cell line expressing the long isoform but not of a cell line expressing the short isoform 
could indicate specificity, especially in case the interactor is also found to bind to the cytoplasmic 
domain present only in the long isoform. In this context, MAPPIT experiments are planned for the 
short isoform of PCDH10. Our studies are at the moment focused on Pcdh10 because of specific 
reasons: PCDH10 exists only in two isoforms in humans, contrary to the numerous ones identified 
for PCDH11X/Y, allowing an easier and more straightforward analysis of the results. Furthermore, 
cell and cancer biology studies have been recently carried out specifically for Pcdh10. From an 
experimental point of view, one of the most relevant reasons of our focus on PCDH10 is the 
availability of conditional knock-out (KO) mice, generated in our own laboratory (I. Kahr, Ph.D. thesis, 
Ghent University).  
We applied also a proliferation assay based on the measurement of cell metabolic activity. Our 
preliminary results showed a slightly increased proliferation in cells expressing PCDH11X if compared 
with non- induced cells: these data agree with the proposed role of protoncogene for PCDH11X but 
this effect on cell growth needs to be confirmed by repeating the current experiments and by using a 
complementary proliferation assay. PCDH11X seems to be involved also in adhesion and spreading 
kinetics in a collagen based assay. Also in this case data are only preliminary since the attempt was 
to establish in vitro cell based assays for studying specific interactions between PCDHs and the 
candidate partners identified in our studies. In this experiment PCDH10 did not seem to induce 
changes in cell behavior if compared with non-induced cells, while PDCH11X apparently induced cells 
to attach more efficiently to and/or spread more quickly to a collagen-coated surface. Experiments 
were performed at different time points and this observation is mostly true at the earliest 
experimental interval. These experiments were carried out mainly with inducible HEK293T FlpIn 
TRex stable cell lines. The system used can of course influence the results; furthermore, we noticed 
that in migration and proliferation test the level of expression of the induced protein has a relevant 
effect. For this reason, efforts to standardize and/or normalize the protein expression will be made 
in further analyses and experiments.  
In conclusion, we established three assays to investigate the roles of specific molecular Pcdh 
interactions. Further experiments are planned and ongoing, as described. At this stage of the 
project, the most interesting experiment will involve an attempt to investigate the relation between 
PCDHs and actin-related proteins. Time-lapse experiments with fluorescent protein variants have 
shown convincing co-localization of PCDH10 with F-actin filaments, while overlap with microtubules 
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was not consistent (van Roy Unit, VIB-Ghent University, data not shown). In this context, the 
discrepancy between long and short isoforms could be indicative for specific roles of these isoforms. 
For example, a possible interaction of ?Pcdhs with the WAVE complex could happen in the context 
of F-actin re-organization. This could be validated in case the short Pcdh10 isoform was found not to 
be actin-associated. Moreover, the interaction of the short isoform of Pcdh10 with the WAVE 
complex would show that the indirect association with NAP1 is not the only form of interaction 
between the Pcdhs and the WRT, opening interesting perspectives for future investigations.  
In vitro experiments have shown that ectopic re-expression of PCDH10 in cell lines where the protein 
was silenced led to reduced cell migration, cell proliferation and invasive potential 30,31. In order to 
reproduce this silencing in vivo, and to study the function of Pcdh10 in living organisms, the van Roy 
Unit (VIB-Ghent University) lab has generated conditional KO mice either for all Pcdh10 isoforms or 
for its long isoform only (I. Kahr, PhD thesis, Ghent University). In contrast to a previously reported 
Pcdh10–null mouse, which showed an early lethal phenotype32, our mice did not show any evident 
phenotype. Most likely, this is due to differences in the experimental set-up of the study from 
Hirano, S. et al.3 (S. Hirano, personal communication to F. van Roy) although it could also depend on 
the different genetic background. Experiments to measure RNA expression levels were conducted in 
total brain or cerebellum of conditional Pcdh10all KO or Pcdh10long KO mice. QRT-PCR experiments 
were performed to analyze the expression of ?Pcdh family members in absence of PCDH10. These 
experiments showed that the complete loss of Pcdh10 in the early stages of development leads to 
up-regulations of the other members of the ?Pcdh family indicating compensation and an overlap in 
functions between different ?Pcdhs. Interestingly, the loss of the long isoform of Pcdh10 alone did 
not induce such an up-regulation of the other ?Pcdh, but instead triggered a compensatory increase 
of the short isoform. As the short isoform of PCDH10 lacks the two CM motifs this indirectly 
indicates that these CMs are not essentially required during early stage development. That 
compensation event could be the explanation of our intriguing transcriptome analysis conducted on 
cerebellum of Pcdh10all KO and Pcdh10long KO mice in comparison with wild type (WT) mice. RNA 
sequencing experiments showed no significant differences in the expression levels of in total KO 
versus WT mice. In contrast, different expression levels were seen for Pcdh10long KO mice. The 
analysis of these experiments is still not straightforward since in this particular experiment we could 
not appreciate up-regulations of the other ?Pcdhs family members. It would be interesting to 
perform these transcriptome experiments in total brain and in a larger data set in future follow-up 
experiments.  
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The fact that we could not observe the ‘spontaneous’ development of tumors in Pcdh10 KO mice 
might indicate that the loss of Pcdh10 alone is not sufficient for cancer formation, but rather it could 
boost another oncogenic event or a combination of different events. Since mouse Pcdh10 is 
expressed mainly in brain and because PCDH10 is a documented tumor suppressor candidate in 
medulloblastoma33, our lab has generated mouse Pcdh10 ablation models of medulloblastoma. To 
this end, we have been breeding conditional Pcdh10KO mice with mice undergoing GFAP-Cre-driven 
loss of p53 (required in many medulloblastoma models) and of retinoblastoma (Rb, which can lead 
to fast development of medulloblastoma in the external granule layer (EGL) of the cerebellum in 
combination with the loss of p53). Interestingly, the Pcdh10all KO medulloblastoma model mice 
(GFAP-Cre // p53 fl/fl or fl/+ // Rb fl/fl or +/+ // Pcdh10-all fl/fl) develop medulloblastoma more rapidly and 
more efficiently than a genetically-related mice with WT Pcdh10.  
The list of putative interaction partners proposed from our Array MAPPIT experiments includes 
many interesting candidates, for which a more thorough study would be relevant. These candidates 
include Kruppel-like factor 4 (KLF4)(resulted positive for interaction with PCDH9 and PCDH19) and 
the ADP ribosylation factor-like 13 B (ARL13B, interacting with PCDH11Y, PCDH18 and PCDH19). KLF4 
is a member of the Kruppel-like factor (KLF) family of transcription factors and regulates 
proliferation, differentiation, apoptosis and somatic cell reprogramming.ARL13B, instead, regulates 
cilia formation and maintenance and is involved in neuronal migration. Future experiments should 
involve further evaluation of these candidates in vitro as well as in vivo in mouse tumor models.  
Many studies have been performed to date to elucidate the biology of Pcdhs, mostly in non-cancer 
related experiments using model organisms such as rat and Xenopus laevis ( reviewed in 1). ?Pcdhs 
play a demonstrated and important role in neurological and neurodegenerative diseases. In 
particular, PCDH10 has been proposed to be an autism-spectrum disorder gene34. Recently, a study 
investigated the mechanism which relates PCDH10 to autism, and identified its role as being mostly 
dependent on elimination of excitatory synapses in the central nervous system35. This investigation 
revealed that Pcdh10 is an important protein mediating the transport of poly-ubiquitinated 
postsynaptic density protein 95 (PSD-95) to the proteasome. The authors identified a PIR 
(proteasome interacting region), involved in Pchd10 binding with the proteasome, in the cytoplasmic 
domain of Pcdh10. The location of this sequence corresponds to the one shared by both short and 
long isoforms of Pcdh10, i.e. upstream of the CMs. Our array MAPPIT study proposed PSMC1, a 
proteasome subunit, as Pcdh interaction partner. Therefore, we wanted to investigate this 
interaction with the aim to demonstrate a role for PSMC1 in the binding of PCDH10 to the 
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proteasome. Unfortunately, PSMC1 did not coimmunoprecipitate with PCDHs in HEK293Tcells co-
transfected with PCDH10 and PSMC1. Proteasomal degradation plays an important role in many 
processes related to tumor suppressor mechanisms as well. Considering these findings on the 
interactions involving PSD-95, we expected an increased proteasome-mediated degradation of 
specific (yet to be identified) target proteins upon Pcdh10 induction, rather than of protocadherins 
themselves. 
Finally, we identified several USPs proteins as potential interaction partners of ?Pcdhs. USP and 
other deubiquitinating enzymes (DUBs) can form multi-molecular complexes, with each other and 
with other proteins. For instance, USP15 interacts with more than 10 partners, including USP46 and 
USP12. Considering data available so far, the USPs that are able to interact with Pcdhs seem to be 
involved in signal transduction pathways rather than in other type of cellular events. We performed 
experiments on ubiquitination and protein degradation for different PCDHs in combination with 
different USPs in order to investigate the role of these interactions. Our preliminary results showed 
that the interaction of the USPs with Pcdhs does not influence these mechanisms. 
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Concluding remarks  
Cells control their functions and behavior mostly by the regulation of proteins. Proteins perform in 
networks but the mechanisms behind such regulations of complex correlations are still not 
completely elucidated. The “phenotype” of a cell is defined by the state of protein expression which 
is responsible for the cellular functions in normal development and in pathogenic conditions. Since 
the human genome was sequenced and many new technologies have been developed, our 
knowledge concerning the sophisticated cell regulation is exponentially growing. The family of 
?PCDHs has been shown to be involved in several kinds of cancer and in neurological diseases. 
Unfortunately, their functions in health are still poorly understood. In this study we identified a list 
of putative interaction partners, which might further a thorough investigation of the role of such 
interactions in various cellular mechanisms and signaling pathways. In the van Roy’s laboratory 
Pcdh10 KO mice were generated but we could not observe ‘spontaneous’ tumor formation in these 
mice so far, indicating that Pcdh10 defects alone are not sufficient for cancer formation. A Pcdh10all 
KO medulloblastoma mouse model shows an earlier appearance of the tumors indicating the 
requirement of a combination of events for cancer development. Identification of interaction 
partners and the characterization of mouse models for Pcdh-related cancers will be essential to 
elucidate the role played by PCDHs in signaling pathways and in diverse cellular functions. 
Elucidating those mechanisms will contribute to cancer research and might in the long run provide 
new targets for successful anti-tumor therapy development. 
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[From below comes the noise of a door slamming.] 
(Henrik Ibsen, A Doll's House) 
